PT J
AU Fontanesi, F
   Palmieri, L
   Scarcia, P
   Lodi, T
   Donnini, C
   Limongelli, A
   Tiranti, V
   Zeviani, M
   Ferrero, I
   Viola, AM
AF Fontanesi, F
   Palmieri, L
   Scarcia, P
   Lodi, T
   Donnini, C
   Limongelli, A
   Tiranti, V
   Zeviani, M
   Ferrero, I
   Viola, AM
TI Mutations in <i>AAC2</i>, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in <i>Saccharomyces cerevisiae</i> and affect mitochondrial DNA stability
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; adenine-nucleotide translocase; yeast mitochondria; adp/atp carrier; multiple deletions; escherichia-coli; proteins; gene; transformation; transport
AB Autosomal dominant and recessive forms of progressive external ophthalmoplegia (adPEO and arPEO) are mitochondrial disorders characterized by the presence of multiple deletions of mitochondrial DNA in affected tissues. Four adPEO-associated missense mutations have been identified in the ANT1 gene. In order to investigate their functional consequences on cellular physiology, we introduced three of them at equivalent positions in AAC2, the yeast orthologue of human ANT1. We demonstrate here that expression of the equivalent mutations in aac2-defective haploid strains of Saccharomyces cerevisiae results in (a) a marked growth defect on non-fermentable carbon sources, and (b) a concurrent reduction of the amount of mitochondrial cytochromes, cytochrome c oxidase activity and cellular respiration. The efficiency of ATP and ADP transport was variably affected by the different AAC2 mutations. However, irrespective of the absolute level of activity, the AAC2 pathogenic mutants showed a significant defect in ADP versus ATP transport compared with wild-type AAC2. In order to study whether a dominant phenotype, as in humans, could be observed, the aac2 mutant alleles were also inserted in combination with the endogenous wild-type AAC2 gene. The heteroallelic strains behaved as recessive for oxidative growth and petite-negative phenotype. In contrast, reduction in cytochrome content and increased mtDNA instability appeared to behave as dominant traits in heteroallelic strains. Our results indicate that S. cerevisiae is a suitable in vivo model to study the pathogenicity of the human ANT1 mutations and the pathophysiology leading to impairment of oxidative phosphorylation and damage of mtDNA integrity, as found in adPEO.
C1 Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
   Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy.
   Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
   CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy.
C3 University of Parma; Universita degli Studi di Bari Aldo Moro; Fondazione IRCCS Istituto Neurologico Carlo Besta; Consiglio Nazionale delle Ricerche (CNR)
RP Univ Parma, Dept Genet Anthropol Evolut, Parco Area Sci 11-A, I-43100 Parma, Italy.
EM iferrero@unipr.it
FU Telethon [GGP030039] Funding Source: Medline
CR ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626
   APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024
   AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2, P0
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   BULDER CJE, 1964, ANTON VAN LEE J M S, V30, P442, DOI 10.1007/BF02046758
   Capobianco L, 1996, BIOCHEMISTRY-US, V35, P8974, DOI 10.1021/bi960258v
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   CHEN YS, 1981, BIOCHEMISTRY-US, V20, P7557, DOI 10.1021/bi00529a034
   Darley-Usmar VM, 1987, MITOCHONDRIA PRACTIC, V0, P0
   DAUM G, 1982, J BIOL CHEM, V257, P3075
   DEFONTAINE A, 1991, NUCLEIC ACIDS RES, V19, P185, DOI 10.1093/nar/19.1.185
   DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   FERRERO I, 1981, A VAN LEEUW J MICROB, V47, P11, DOI 10.1007/BF00399063
   Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7
   HAIDKAMPER D, 1996, BIOCHEMISTRY-US, V35, P16144
   Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8
   HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4
   ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   KLINGENBERG M, 1979, TRENDS BIOCHEM SCI, V4, P249, DOI 10.1016/0968-0004(79)90215-9
   KOLAROV J, 1990, J BIOL CHEM, V265, P12711
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2
   KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAWSON JE, 1988, J BIOL CHEM, V263, P14812
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119
   OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928
   Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   SCHERER B, 1974, BIOCHEMISTRY-US, V13, P161, DOI 10.1021/bi00698a025
   Sherman F, 1986, LAB COURSE MANUAL ME, V0, P0
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   SLONIMSKI PP, 1968, BIOCHEM BIOPH RES CO, V30, P232, DOI 10.1016/0006-291X(68)90440-3
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200
   TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896
   Zara V, 1996, MOL CELL BIOL, V16, P6524
   ZEVIANI M, 1989, NEUROL CLIN, V7, P123, DOI 10.1016/S0733-8619(18)30832-6
NR 51
TC 64
Z9 67
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2004
VL 13
IS 9
BP 923
EP 934
DI 10.1093/hmg/ddh108
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 813GW
UT WOS:000220896600003
PM 15016764
DA 2024-11-01
ER

PT J
AU Nobuhara, Y
   Nakahara, K
   Higuchi, I
   Yoshida, T
   Fushiki, S
   Osame, M
   Arimura, K
   Nakagawa, M
AF Nobuhara, Y
   Nakahara, K
   Higuchi, I
   Yoshida, T
   Fushiki, S
   Osame, M
   Arimura, K
   Nakagawa, M
TI Juvenile form of Alexander disease with <i>GFAP</i> mutation and mitochondrial abnormality
SO NEUROLOGY
LA English
DT Article
AB The authors report a 29-year-old woman with marked atrophy of the cerebellum, medulla oblongata, and spinal cord, dementia, diffuse white matter abnormality on MRI, ragged-red fibers, and R88C mutation in the human glial fibrillary acidic protein (GFAP). Mitochondria DNA ( mtDNA) analysis showed a rare polymorphism at A8291G. This mtDNA polymorphism, which has been associated with limb-girdle type mitochondrial myopathy, may modify the clinical symptoms of this juvenile form of Alexander disease with GFAP mutation.
C1 Kyoto Prefectural Univ Med, Dept Neurol & Gerontol, Res Inst Neurol dis & Geriatr, Kamigyo Ku, Kyoto 6020841, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, Kagoshima 890, Japan.
   Miyazaki Prefectural Hosp, Div Neurol, Miyazaki, Japan.
   Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pathol & Appl Neurobiol, Kyoto 602, Japan.
C3 Kyoto Prefectural University of Medicine; Kagoshima University; Kyoto Prefectural University of Medicine
RP Kyoto Prefectural Univ Med, Dept Neurol & Gerontol, Res Inst Neurol dis & Geriatr, Kamigyo Ku, Kawaramachi Hirokoji 465, Kyoto 6020841, Japan.
EM mnakagaw@koto.kpu-m.ac.jp
CR Castellani RJ, 1998, BRAIN RES, V787, P15, DOI 10.1016/S0006-8993(97)01224-9
   Gingold MK, 1999, J CHILD NEUROL, V14, P325, DOI 10.1177/088307389901400510
   Gorospe JR, 2002, NEUROLOGY, V58, P1494, DOI 10.1212/WNL.58.10.1494
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   Kinoshita T, 2003, NEUROSCI LETT, V350, P169, DOI 10.1016/S0304-3940(03)00900-5
   Okamoto Y, 2002, J NEUROL SCI, V195, P71, DOI 10.1016/S0022-510X(01)00687-6
   Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
NR 8
TC 16
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 12
PY 2004
VL 63
IS 7
BP 1302
EP 1304
DI 10.1212/01.WNL.0000140695.90497.E2
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 861HV
UT WOS:000224408000033
PM 15477559
DA 2024-11-01
ER

PT J
AU Pich, MM
   Raule, N
   Catani, L
   Fagioli, ME
   Faenza, I
   Cocco, L
   Lenaz, G
AF Pich, MM
   Raule, N
   Catani, L
   Fagioli, ME
   Faenza, I
   Cocco, L
   Lenaz, G
TI Increased transcription of mitochondrial genes for Complex I in human platelets during ageing
SO FEBS LETTERS
LA English
DT Article
DE mitochondrial mRNA; ageing; oxidative phosphorylation system; gene expression
ID oxidative stress; skeletal-muscle; senescent rat; dna; liver; heart; age; expression; mutation; diseases
AB We studied the effect of ageing on the mRNA levels of mitochondria-encoded polypeptides in human platelets. We used quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate the expression of selected cytochrome c oxidase (COX) genes (subunits I and III) and Complex I genes (subunits reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase (ND)1 and ND5) in platelets from young and aged healthy subjects. Northern blot analysis confirmed the PCR results. COX I expression is higher than that of COX III in both young and aged platelets. A significant increase of transcripts for Complex I was found during ageing. On the contrary, the mRNA levels of the two COX subunits did not significantly vary during ageing. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Bologna, Dept Biochem G Moruzzi, I-40126 Bologna, Italy.
   Univ Bologna, Inst Hematol & Med Oncol Le A Seragnoli, I-40126 Bologna, Italy.
   Univ Bologna, Inst Anat, Cellular Signalling Lab, I-40126 Bologna, Italy.
C3 University of Bologna; University of Bologna; University of Bologna
RP Lenaz, G (corresponding author), Univ Bologna, Dept Biochem G Moruzzi, Via Irnerio 48, I-40126 Bologna, Italy.
EM lenaz@biocfarm.unibo.it
CR Andreu AL, 1998, BIOCHEM BIOPH RES CO, V252, P577, DOI 10.1006/bbrc.1998.9703
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Catani L, 2002, LEUKEMIA, V16, P1773, DOI 10.1038/sj.leu.2402597
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   DAurelio M, 2001, MECH AGEING DEV, V122, P823, DOI 10.1016/S0047-6374(01)00239-1
   Drouet M, 1999, EXP GERONTOL, V34, P843, DOI 10.1016/S0531-5565(99)00058-3
   Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508
   GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x
   Grossman LI, 1998, ELECTROPHORESIS, V19, P1254, DOI 10.1002/elps.1150190805
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C
   HOLMSEN H, 1987, HEMOSTASIS THROMBOSI, V0, P631
   KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x
   Lenaz G, 1998, BIOFACTORS, V8, P195, DOI 10.1002/biof.5520080305
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Ozawa T, 1999, J BIOENERG BIOMEMBR, V31, P377, DOI 10.1023/A:1005479920097
   Pich MM, 1996, FEBS LETT, V380, P176, DOI 10.1016/0014-5793(96)00037-3
   Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P99, DOI 10.1016/S0005-2728(98)00160-1
   Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8
   Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x
NR 23
TC 14
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD JAN 30
PY 2004
VL 558
IS 1-3
BP 19
EP 22
DI 10.1016/S0014-5793(03)01520-5
PG 4
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 772AJ
UT WOS:000188817900005
PM 14759509
DA 2024-11-01
ER

PT J
AU Naviaux, RK
   Nguyen, KV
AF Naviaux, RK
   Nguyen, KV
TI <i>POLG</i> mutations associated with Alpers' syndrome and mitochondrial DNA depletion
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; neuronal degeneration; polymerase-gamma; thymidine kinase; mtdna depletion; gene; deletions; disease; deficiency; childhood
AB Alpers' syndrome is a fatal neurogenetic disorder first described more than 70 years ago. It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease. In two unrelated pedigrees of Alpers' syndrome, each affected child was found to carry a homozygous mutation in exon 17 of the POLG locus that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein. In addition, each affected child was heterozygous for the G1681A mutation in exon 7 that led to an Ala467Thr substitution in POLG, within the linker region of the protein.
C1 Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA.
   Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.
   Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
C3 University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego
RP Naviaux, RK (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 214 Dickinson St,Bldg CTF,Room C-103, San Diego, CA 92103 USA.
EM naviaux@ucsd.edu
FU NCRR NIH HHS [M01 RR00827] Funding Source: Medline
CR Alam SL, 1999, J MOL BIOL, V288, P837, DOI 10.1006/jmbi.1999.2713
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   BOHNERT B, 1974, ARCH PSYCHIAT NERVEN, V218, P353, DOI 10.1007/BF00342578
   Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Heath EM, 2001, ARCH PATHOL LAB MED, V125, P127
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.3.CO;2-S
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANCUSO M, 2002, J NEUROL SCI, V0, P199
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   NAVIAUX RK, 1998, ATLAS METABOLIC DIS, V0, P314
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Robinson DN, 1997, DEVELOPMENT, V124, P1405
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SANDBANK U, 1972, J NEUROL NEUROSUR PS, V35, P749, DOI 10.1136/jnnp.35.6.749
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   TAANMAN JW, 2000, P 11 EUR BIOEN C EBE, V0, P0
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
NR 29
TC 329
Z9 349
U1 0
U2 20
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0364-5134
EI 
J9 ANN NEUROL
JI Ann. Neurol.
PD MAY 15
PY 2004
VL 55
IS 5
BP 706
EP 712
DI 10.1002/ana.20079
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 816NE
UT WOS:000221115800014
PM 15122711
DA 2024-11-01
ER

PT J
AU Shanske, S
   Pancrudo, J
   Kaufmann, P
   Engelstad, K
   Jhung, S
   Lu, JS
   Naini, A
   DiMauro, S
   De Vivo, DC
AF Shanske, S
   Pancrudo, J
   Kaufmann, P
   Engelstad, K
   Jhung, S
   Lu, JS
   Naini, A
   DiMauro, S
   De Vivo, DC
TI Varying loads of the mitochondrial DNA A3243G mutation in different tissues: Implications for diagnosis
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
ID stroke-like episodes; lactic-acidosis; point mutation; melas syndrome; blood; encephalomyopathy; encephalopathy; myopathy; subtype; muscle
AB Testing for common mutations in mitochondrial DNA (mtDNA), including the A3243G MELAS (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes) mutation, is routinely done in DNA isolated from blood. Since the blood level of the A3243G mutation may be low in probands and even lower in asymptomatic or oligosymptomatic maternal relatives, we assessed the proportion of A3243G mutant genomes in other accessible tissues. We studied five tissues (leukocytes, skin fibroblasts, hair roots, urinary sediment, and cheek mucosa) in 61 individuals from 22 families harboring the A3243G mutation. Although mutational loads varied widely among these tissues, as a rule DNA from urinary sediment had the highest and blood the lowest proportion of mutant genomes; individual hair roots differed markedly from one another; fibroblasts and cheek mucosa tended to have higher mutation loads than blood but lower than urinary sediment. In all individuals in whom the mutation was detectable in blood, it was also detected in other tissues. Conversely, in some individuals the mutation was undetectable in blood but clearly present in other tissues. We conclude that urinary sediment and cheek mucosa are tissues of choice for the diagnosis of mtDNA mutations, as they are easy to obtain and the mutation load is almost always greater than in blood. (C) 2004 Wiley-Liss, Inc.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   POULTON J, 1993, ANN NEUROL, V34, P116, DOI 10.1002/ana.410340124
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
NR 14
TC 94
Z9 101
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD OCT 1
PY 2004
VL 130A
IS 2
BP 134
EP 137
DI 10.1002/ajmg.a.30220
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 858HV
UT WOS:000224183800004
PM 15372523
DA 2024-11-01
ER

PT J
AU Miró, O
   López, S
   de la Concepción, MR
   Martínez, E
   Pedrol, E
   Garrabou, G
   Giralt, M
   Cardellach, F
   Gatell, JM
   Vilarroya, F
   Casademont, J
AF Miró, O
   López, S
   de la Concepción, MR
   Martínez, E
   Pedrol, E
   Garrabou, G
   Giralt, M
   Cardellach, F
   Gatell, JM
   Vilarroya, F
   Casademont, J
TI Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE peripheral blood mononuclear cells; mitochondrial DNA; cytochrome c oxidase subunit II; nucleoside reverse transcriptase inhibitors; stavudine; didanosine; DNA gamma-polymerase
ID blood mononuclear-cells; hiv-infected patients; skeletal-muscle; adipose-tissue; toxicity; myopathy; marker; drugs
AB Nucleoside analogue use is often related to mitochondrial DNA (mtDNA) depletion, but mitochondrial function is preserved in most asymptomatic patients. We determined whether homeostatic mechanisms are able to compensate for this mtDNA depletion in patients receiving stavudine plus didanosine (d4T + ddI), an antiretroviral combination with great in vitro and in vivo capacity to decrease mtDNA. We included 28 asymptomatic HIV-infected individuals: 17 subjects (cases) on a first-line antiretroviral regimen consisting of d4T + ddI as the nucleoside backbone plus nevirapine or nelfinavir for at least 6 months (mean: 16 +/- 8 months) and 11 naive subjects (controls). We assessed the following in peripheral blood mononuclear cells: mitochondrial mass by citrate synthase activity, mtDNA content by real-time polymerase chain reaction, cytochrome c oxidase subunit II (COX-II) expression by Western blot analysis, and COX activity by spectrophotometry. The mitochondrial mass and mtDNA content of cases decreased when compared with controls, whether normalized per cell or per mitochondrion. Conversely, COXII expression and COX activity were similar in cases and controls. COX-II expression was constant and independent of the mtDNA content, whereas it was closely related to COX activity. We concluded that treatment with dd4T + ddI is associated with decreased mitochondrial mass and mtDNA content but that COX-II expression and COX activity remain unaltered. These data suggest that upregulatory transcriptional or posttranscriptional mechanisms compensate for mtDNA depletion caused by d4T + ddI before profound mtDNA depletion occurs.
C1 Hosp Clin Barcelona, Dept Internal Med, Muscle Res Unit, Mitochondrial Res Lab,Inst Invest Bioued August P, E-08036 Barcelona, Spain.
   Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain.
   Hosp Clin Barcelona, Dept Infect Dis, Inst Invest Bioued August P, E-08036 Barcelona, Spain.
   Fdn Hosp Asil Granollers, Dept Internal Med, HIV Unit, Granollers, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona
RP Hosp Clin Barcelona, Dept Internal Med, Muscle Res Unit, Mitochondrial Res Lab,Inst Invest Bioued August P, Villarroel 170, E-08036 Barcelona, Spain.
EM omiro@clinic.ub.es
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113
   Cossarizza A, 2001, BIOESSAYS, V23, P1070, DOI 10.1002/bies.1152
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Gerschenson M, 2003, ANTIVIR THER, V8, P261
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   López S, 2004, ANTIVIR THER, V9, P47
   Miró O, 2003, ANTIVIR THER, V8, P0
   Miró O, 1998, J NEUROSCI METH, V80, P107, DOI 10.1016/S0165-0270(97)00204-5
   Miró O, 2003, AIDS RES HUM RETROV, V19, P1027, DOI 10.1089/088922203322588387
   Miró O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176
   Miró O, 2003, ANTIVIR THER, V8, P333
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7
   Polo R, 2003, JAIDS-J ACQ IMM DEF, V34, P32, DOI 10.1097/00126334-200309010-00004
   Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916
   Rodríguez-Santiago B, 2001, EUR J HUM GENET, V9, P279, DOI 10.1038/sj.ejhg.5200629
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002
   White AJ, 2001, SEX TRANSM INFECT, V77, P158, DOI 10.1136/sti.77.3.158
   Yerroum M, 2000, ACTA NEUROPATHOL, V100, P82, DOI 10.1007/s004010051196
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 31
TC 37
Z9 40
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 15
PY 2004
VL 37
IS 5
BP 1550
EP 1555
DI 
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 881FY
UT WOS:000225850000002
PM 15577406
DA 2024-11-01
ER

PT J
AU Jesina, P
   Tesarová, M
   Fornusková, D
   Vojtísková, A
   Pecina, P
   Kaplanová, V
   Hansíková, H
   Zeman, J
   Houstek, J
AF Jesina, P
   Tesarová, M
   Fornusková, D
   Vojtísková, A
   Pecina, P
   Kaplanová, V
   Hansíková, H
   Zeman, J
   Houstek, J
TI Diminished synthesis of subunit a (ATP6) and altered function of ATP synthase and cytochrome <i>c</i> oxidase due to the mtDNA 2 bp microdeletion of TA at positions 9205 and 9206
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE ATP6; ATP synthase; COX3; cytochrome c oxidase; mitochondrial disease; mitochondrial DNA (mtDNA)
ID blue-native-electrophoresis; mitochondrial-dna mutation; respiratory-chain; cells; gene; fibroblasts; disease; deficiency; complexes; protein
AB Dysfunction of mitochondrial ATPase (F1F0-ATP synthase) due to missense mutations in ATP6 [mtDNA (mitochondrial DNA)encoded subunit a] is a frequent cause of severe mitochondrial encephalomyopathies. We have investigated a rare mtDNA mutation, i.e. a 2 bp deletion of TA at positions 9205 and 9206 (9205DeltaTA), which affects the STOP codon of the ATP6 gene and the cleavage site between the RNAs for ATP6 and COX3 (cytochrome c oxidase 3). The mutation was present at increasing load in a three-generation family (in blood: 16%/82%/>98%). In the affected boy with severe encephalopathy, a homoplasmic mutation was present in blood, fibroblasts and muscle. The fibroblasts from the patient showed normal aurovertin-sensitive ATPase hydrolytic activity, a 70% decrease in ATP synthesis and an 85% decrease in COX activity. ADP-stimulated respiration and the ADP-induced decrease in the mitochondrial membrane potential at state 4 were decreased by 50%. The content of subunit a was decreased 10-fold compared with other ATPase subunits, and [15 S] methionine labelling showed a 9-fold decrease in subunit a biosynthesis. The content of COX subunits 1, 4 and 6c was decreased by 30-60%. Northern Blot and quantitative real-time reverse transcription-PCR analysis further demonstrated that the primary ATP6-COX3 transcript is cleaved to the ATP6 and COX3 mRNAs 2-3-fold less efficiently. Structural studies by Blue-Native and two-dimensional electrophoresis revealed an altered pattern of COX assembly and instability of the ATPase complex, which dissociated into subcomplexes. The results indicate that the 9205DeltaTA mutation prevents the synthesis of ATPase subunit a, and causes the formation of incomplete ATPase complexes that are capable of ATP hydrolysis but not ATP synthesis. The mutation also affects the biogenesis of COX, which is present in a decreased amount in cells from affected individuals.
C1 Acad Sci Czech Republ, Dept Bioenerget, Inst Physiol, Prague 14220, Czech Republic.
   Acad Sci Czech Republ, Ctr Integrated Genom, Prague 14220, Czech Republic.
   Charles Univ Prague, Fac Med 1, Dept Pediat, Prague 12000, Czech Republic.
   Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 12000, Czech Republic.
C3 Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Charles University Prague; Charles University Prague
RP Acad Sci Czech Republ, Dept Bioenerget, Inst Physiol, Videnska 1083, Prague 14220, Czech Republic.
EM houstek@biomed.cas.cz
FU NINR NIH HHS [P20 NR007790] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BARACCA A, 1989, BIOCHIM BIOPHYS ACTA, V976, P77, DOI 10.1016/S0005-2728(89)80191-4
   Bentlage HACM, 1996, NEUROLOGY, V47, P243, DOI 10.1212/WNL.47.1.243
   Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983
   Carrozzo R, 2000, FEBS LETT, V486, P297, DOI 10.1016/S0014-5793(00)02244-4
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Chowdhury SKR, 2000, CLIN CHIM ACTA, V298, P157, DOI 10.1016/S0009-8981(00)00300-4
   Chrzanowska-Lightowlers ZMA, 2004, BIOCHEM J, V377, P725, DOI 10.1042/bj20031556
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dubot A, 2004, BIOCHEM BIOPH RES CO, V313, P687, DOI 10.1016/j.bbrc.2003.12.013
   El Meziane A, 1998, NAT GENET, V18, P350
   Ellis TP, 2004, J BIOL CHEM, V279, P15728, DOI 10.1074/jbc.M314162200
   FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4
   FISCHER JC, 1986, CLIN CHIM ACTA, V155, P263, DOI 10.1016/0009-8981(86)90246-9
   Floryk D, 1999, BIOSCIENCE REP, V19, P27, DOI 10.1023/A:1020193906974
   Fornuskova D, 2003, CAS LEK CESK, V142, P313
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117
   Hoffbuhr KC, 2000, J BIOL CHEM, V275, P13994, DOI 10.1074/jbc.275.18.13994
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689
   HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A
   Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798
   KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523
   MAKINEN MW, 1968, ARCH BIOCHEM BIOPHYS, V126, P75, DOI 10.1016/0003-9861(68)90561-4
   Mili S, 2003, MOL CELL BIOL, V23, P4972, DOI 10.1128/MCB.23.14.4972-4982.2003
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORADIAMELI M, 1983, P NATL ACAD SCI-BIOL, V80, P6167, DOI 10.1073/pnas.80.20.6167
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9
   Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776
   PANSINI A, 1978, EUR J BIOCHEM, V92, P545, DOI 10.1111/j.1432-1033.1978.tb12776.x
   Pecina P, 2003, BBA-MOL BASIS DIS, V1639, P53, DOI 10.1016/S0925-4439(03)00127-3
   Plasek J, 1996, J PHOTOCH PHOTOBIO B, V33, P101, DOI 10.1016/1011-1344(96)07283-1
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   Seneca S, 1996, J INHERIT METAB DIS, V19, P115, DOI 10.1007/BF01799407
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238
   WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8
   Wanders RJA, 1996, J INHERIT METAB DIS, V19, P133, DOI 10.1007/BF01799412
   Wharton DC, 1967, METHODS ENZYMOL, V10, P245, DOI 10.1016/0076-6879(67)10048-7
NR 49
TC 56
Z9 59
U1 0
U2 16
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD NOV 1
PY 2004
VL 383
IS 
BP 561
EP 571
DI 10.1042/BJ20040407
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 873KQ
UT WOS:000225279300019
PM 15265003
DA 2024-11-01
ER

PT J
AU Dupuis, L
   Oudart, H
   René, F
   de Aguilar, JLG
   Loeffler, JP
AF Dupuis, L
   Oudart, H
   René, F
   de Aguilar, JLG
   Loeffler, JP
TI Evidence for defective energy homeostasis in amyotrophic lateral sclerosis:: benefit of a high-energy diet in a transgenic mouse
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
ID cu/zn superoxide-dismutase; nutritional-status; mitochondrial-dna; skeletal-muscle; animal-model; als patients; mice; degeneration; sod1; disease
AB Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by selective loss of motor neurons and progressive muscle wasting. Growing evidence indicates that mitochondrial dysfunction, not only occurring in motor neurons but also in skeletal muscle, may play a crucial role in the pathogenesis. In this regard, the life expectancy of the ALS G93A mouse line is extended by creatine, an intracellular energy shuttle that ameliorates muscle function. Moreover, a population of patients with sporadic ALS exhibits a generalized hypermetabolic state of as yet unknown origin. Altogether, these findings led us to explore whether alterations in energy homeostasis may contribute to the disease process. Here, we show important variations in a number of metabolic indicators in transgenic ALS mice, which in all shows a metabolic deficit. These alterations were accompanied early in the asymptomatic phase of the disease by reduced adipose tissue accumulation, increased energy expenditure, and concomitant skeletal muscle hypermetabolism. Compensating this energetic imbalance with a highly energetic diet extended mean survival by 20%. In conclusion, we suggest that hypermetabolism, mainly of muscular origin, may represent by itself an additional driven force involved in increasing motor neuron vulnerability.
C1 Univ Strasbourg 1, EA3433, Fac Med, Lab Signalisat Mol & Neurodegenerescence, F-67085 Strasbourg, France.
   CNRS, Unite Propre Rech 9010, Ctr Ecol & Physiol Energet, F-67087 Strasbourg, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg
RP Univ Strasbourg 1, EA3433, Fac Med, Lab Signalisat Mol & Neurodegenerescence, 11 Rue Humann, F-67085 Strasbourg, France.
EM loeffler@neurochem.u-strasbg.fr
CR AlAdsani H, 1997, J CLIN ENDOCR METAB, V82, P1118, DOI 10.1210/jc.82.4.1118
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   Brooks BR, 2000, AMYOTROPHIC LATERAL, V0, P31
   Cameron A, 2002, CURR OPIN CLIN NUTR, V5, P631, DOI 10.1097/00075197-200211000-00005
   Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071
   Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565
   Curti D, 1996, NEUROLOGY, V47, P1060, DOI 10.1212/WNL.47.4.1060
   Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059
   Desport JC, 2001, AM J CLIN NUTR, V74, P328
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434
   Dupuis L, 2003, FASEB J, V17, P2091, DOI 10.1096/fj.02-1182fje
   Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522
   Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000
   Groeneveld GJ, 2003, ANN NEUROL, V53, P437, DOI 10.1002/ana.10554
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203
   Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x
   Kasarskis EJ, 1996, AM J CLIN NUTR, V63, P130, DOI 10.1093/ajcn/63.1.130
   Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568
   Kong JM, 1998, J NEUROSCI, V18, P3241
   Leclerc N, 2001, NEUROMUSCULAR DISORD, V11, P722, DOI 10.1016/S0960-8966(01)00240-1
   Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002
   Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527
   Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200
   Menzies FM, 2002, NEUROCHEM INT, V40, P543, DOI 10.1016/S0197-0186(01)00125-5
   Morrison BM, 1998, J COMP NEUROL, V391, P64, DOI 10.1002/(SICI)1096-9861(19980202)391:1<64::AID-CNE6>3.0.CO;2-P
   NAKANO Y, 1987, ARCH NEUROL-CHICAGO, V44, P103, DOI 10.1001/archneur.1987.00520130079022
   Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8
   Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001
   RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9
   Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339
   Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x
   Wiedemann FR, 1998, J NEUROL SCI, V156, P65, DOI 10.1016/S0022-510X(98)00008-2
   WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a
NR 38
TC 409
Z9 449
U1 0
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 27
PY 2004
VL 101
IS 30
BP 11159
EP 11164
DI 10.1073/pnas.0402026101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 842JM
UT WOS:000223000200057
PM 15263088
DA 2024-11-01
ER

PT J
AU Khan, SM
   Bennett, JP
AF Khan, SM
   Bennett, JP
TI Development of mitochondrial gene replacement therapy
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article; Proceedings Paper
DE mitochondria; mitochondrial DNA; protein transduction; mitochondrial genome
ID protein transduction domain; ischemic brain injury; transcription factor; fusion protein; basic domain; cell-death; in-vitro; calcium; vivo; dna
AB Many "classic" mitochondrial diseases have been described that arise from single homoplasmic mutations in mitochondrial DNA(mtDNA). These diseases typically affect nonmitotic tissues (brain, retina, muscle), present with variable phenotypes, can appear sporadically, and are untreatable. Evolving evidence implicates mtDNA abnormalities in diseases such as Alzheimer's, Parkinson's, and type II diabetes, but specific causal mutations for these conditions remain to be defined. Understanding the mtDNA genotype-phenotype relationships and developing specific treatment for mtDNA-based diseases is hampered by inability to manipulate the mitochondrial genome. We present a novel protein transduction technology ("protofection") that allows insertion and expression of the human mitochondrial genome into mitochondria of living cells. With protofection, the mitochondrial genotype can be altered, or exogenous genes can be introduced to be expressed and either retained in mitochondria or be directed to other organelles. Protofection also delivers mtDNA in vivo, opening the way to rational development of mitochondrial gene replacement therapy of mtDNA-based diseases.
C1 Univ Virginia, Ctr Study Neurodegenerat Dis, Dept Neurol, Charlottesville, VA 22908 USA.
   GENCIA Corp, Charlottesville, VA USA.
C3 University of Virginia
RP Univ Virginia, Ctr Study Neurodegenerat Dis, Dept Neurol, POB 800394, Charlottesville, VA 22908 USA.
EM bennett@virginia.edu
FU NINDS NIH HHS [NS 39788, NS39005] Funding Source: Medline
CR Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Choi YS, 2004, BIOCHEM BIOPH RES CO, V314, P118, DOI 10.1016/j.bbrc.2003.12.065
   Del Gaizo V, 2003, MOL GENET METAB, V80, P170, DOI 10.1016/j.ymgme.2003.08.017
   Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dolgilevich S, 2002, BIOCHEM BIOPH RES CO, V299, P505, DOI 10.1016/S0006-291X(02)02664-5
   FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496
   Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504
   Graff C, 2002, BEST PRACT RES CL OB, V16, P715, DOI 10.1053/beog.2002.0315
   Gray MW, 2001, GENOME BIOL, V2, P0
   Hajnóczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8
   Hajnóczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872
   Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023
   Ho A, 2001, CANCER RES, V61, P474
   Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1
   Kilic Ü, 2003, STROKE, V34, P1304, DOI 10.1161/01.STR.0000066869.45310.50
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lescuyer P, 2003, PROTEOMICS, V3, P157, DOI 10.1002/pmic.200390024
   Margulis L, 2001, ANN NY ACAD SCI, V929, P55
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951
   PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027
   Schapira AHV, 2000, CURR OPIN NEUROL, V13, P527, DOI 10.1097/00019052-200010000-00004
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004
   Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495
   Toborek M, 2003, J NEUROCHEM, V84, P169, DOI 10.1046/j.1471-4159.2003.01543.x
   Vandecasteele G, 2001, IUBMB LIFE, V52, P213, DOI 10.1080/15216540152846028
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 37
TC 40
Z9 62
U1 0
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145-479X
EI 1573-6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD AUG 15
PY 2004
VL 36
IS 4
BP 387
EP 393
DI 10.1023/B:JOBB.0000041773.20072.9e
PG 7
WC Biophysics; Cell Biology
SC Biophysics; Cell Biology
GA 854PR
UT WOS:000223916300022
PM 15377877
DA 2024-11-01
ER

PT J
AU Bai, RK
   Perng, CL
   Hsu, CH
   Wong, LJC
AF Bai, RK
   Perng, CL
   Hsu, CH
   Wong, LJC
TI Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease
SO MITOCHONDRIAL PATHOGENESIS: FROM GENES AND APOPTOSIS TO AGING AND DISEASE
LA English
DT Article; Proceedings Paper
DE mtDNA depletion; quantitative analysis of mtDNA; real-time PCR analysis; mitochondrial DNA copy number
AB Molecular diagnosis of mitochondrial DNA disorder is usually focused on point mutations and large deletions. In the absence of detectable mtDNA mutations, abnormal amounts of mtDNA, either depletion or elevation, can be indicative of mitochondrial dysfunction. The amount of mitochondrial DNA (mtDNA), however, varies among individuals of different ages and among different tissues within the same individual. To establish a range of mtDNA levels, we analyzed 300 muscle and 200 blood specimens from patients suspected of having a mitochondrial disorder by real-time quantitative polymerase chain reaction (PCR) method. Copy numbers were calculated from the standard curve and threshold cycle number using TaqMan probes; 6FAM 5'TTACCGGGCTCTGCCATCT3'-TAMRA and VIC-5'AGCAATAACAGGTCTGTGATG3'-TAMRA for mtDNA and 18S rRNA gene (nDNA), respectively. The copy number ratio of mtDNA to nDNA was used as a measure of mtDNA content in each specimen. The mtDNA content in muscle increases steadily from birth to about 5 years of age; thereafter, it stays about the same. On the contrary, the mtDNA content in blood decreases with age. The amount of mtDNA in skeletal muscle is about 5-20 times higher than that in blood. About 7% of patients had mtDNA levels in muscle below 20% of the mean of the age-matched group, and about 10% of patients had muscle mtDNA levels 2- to 16-fold higher than the mean of the age-matched group. Patients with abnormal levels of mtDNA, either depletion or proliferation, had significant clinical manifestations characteristic of mitochondrial disease in addition to abnormal respiratory enzymes and mitochondrial cytopathies. Cardiomyopathy, lactic acidosis, abnormal brain NW findings, hypotonia, developmental delay, seizures, and failure to thrive are general clinical pictures of patients with mtDNA depletion. The average age of patients with mtDNA depletion is 4.1 years, compared to 23.6 years in patients with mtDNA proliferation. Mutations in nuclear genes involved in mtDNA synthesis and deoxynucleotide pools are probably the cause off mtDNA depletion. Our results demonstrate that real time quantitative PCR is a valuable tool for molecular screening of mitochondrial diseases.
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, M4000,3800 Reservoir Rd,NW, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Wong LC, 2002, AM J HUM GENET, V71, P501
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
NR 9
TC 110
Z9 129
U1 0
U2 13
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2004
VL 1011
IS 
BP 304
EP 309
DI 10.1196/annals.1293.029
PG 6
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BAE70
UT WOS:000221896100029
PM 15126306
DA 2024-11-01
ER

PT J
AU McFarland, R
   Schaefer, AM
   Gardner, JL
   Lynn, S
   Hayes, CM
   Barron, MJ
   Walker, M
   Chinnery, PF
   Taylor, RW
   Turnbull, DM
AF McFarland, R
   Schaefer, AM
   Gardner, JL
   Lynn, S
   Hayes, CM
   Barron, MJ
   Walker, M
   Chinnery, PF
   Taylor, RW
   Turnbull, DM
TI Familial myopathy: New insights into the T14709C mitochondrial tRNA mutation
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID disordered oxidative-metabolism; diabetes-mellitus; trna(ser(ucn)) gene; point mutation; muscle fibers; acid mutation; dna mutation; deafness; sequence; patient
AB We have defined the genetic defect in a large family first described in one of the earliest reports of suspected mitochondrial myopathy, as the mutation T14709C in the mitochondrial transfer RNA(Glu) (mt-tRNA(Glu)) gene. Extraordinarily, this mutation has attained homoplasmy (100% mutated mt-tRNA(Glu)) on at least three independent occasions in this family and has done so in one individual who remains asymptomatic with no clinical evidence of disease. Heteroplasmy (dual populations of mutated and wild-type mtDNA) usually is regarded as one of the primary diagnostic criteria for pathogenicity and previous reports of the T14709C mutation detail heteroplasmy in a variety of tissues. In contrast, homoplasmy of mt-tRNA mutations generally has been regarded as evidence of a benign nature, with rare exceptions that result in organ-specific phenotypes. Discovering that T14709C, a common and severe mt-tRNA mutation, can attain homoplasmy without symptoms or clinical signs of disease has profound implications for the identification and prevalence of other pathogenic mt-tRNA mutations. Furthermore, variation in phenotype between homoplasmic individuals implies a crucial contribution from the nuclear genetic environment in determining the clinical outcome of mt-tRNA mutations.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
   Univ Newcastle Upon Tyne, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Stanford University; Newcastle University - UK
RP Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU MRC [G108/539] Funding Source: UKRI; Medical Research Council [G108/539] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   FAWCETT PRW, 1982, J NEUROL SCI, V53, P397, DOI 10.1016/0022-510X(82)90021-1
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   HUDGSON P, 1972, J NEUROL SCI, V16, P343, DOI 10.1016/0022-510X(72)90197-9
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MECHLER F, 1981, J NEUROL SCI, V50, P191, DOI 10.1016/0022-510X(81)90165-9
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rigoli L, 2001, DIABETIC MED, V18, P334, DOI 10.1046/j.1464-5491.2001.00429-2.x
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 1997, ORGANELLE DIS, V0, P0
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WORSFOLD M, 1973, J NEUROL SCI, V19, P261, DOI 10.1016/0022-510X(73)90090-7
NR 25
TC 53
Z9 56
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD APR 15
PY 2004
VL 55
IS 4
BP 478
EP 484
DI 10.1002/ana.20004
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 806ME
UT WOS:000220437200004
PM 15048886
DA 2024-11-01
ER

PT J
AU Smigrodzki, R
   Parks, J
   Parker, WD
AF Smigrodzki, R
   Parks, J
   Parker, WD
TI High frequency of mitochondrial complex I mutations in Parkinson's disease and aging
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Parkinson's disease; mitochondrial DNA mutations; complex I deficiency
ID dna mismatch correction; methyl-directed repair; transfer-rna genes; alzheimers-disease; respiratory-chain; skeletal-muscle; point mutations; sequence-analysis; escherichia-coli; overlap syndrome
AB Idiopathic Parkinson's disease (PD) involves a systemic loss of activity of complex I of the mitochondrial electron transport chain. This biochemical lesion plays a key pathogenic role. Transfer of PD mitochondrial DNA recapitulates this loss of activity and several other pathogenic features of PD suggesting that this lesion may arise, at least in part, from mitochondrial DNA. We investigated this possibility by an extensive clonal sequencing of the seven mitochondrial genes encoding complex I subunits in PD and age-matched control frontal cortex. Each gene was completely sequenced an average of 94.4 times for each subject. Aminoacid-changing mutations were found at the frequency of 59.3 per million bases in both PD and controls, corresponding to approximately 32% of the mitochondrial genomes in the average sample having at least one mutation in a complex I gene. Individual low frequency mutations had an abundance of 1-10%. Significant interindividual variation in mutation frequency was observed. Several aminoacid-changing mutations were identified and multiple PD brains but not in controls. Genetic algorithm analysis detected areas in ND genes with a higher mutation frequency in PD that allowed differentiation of PD from controls. Total mutational burden due to low-abundance heteroplasmy is high and may play a role in human disease. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA.
C3 University of Virginia
RP Univ Virginia, Dept Neurol, BNG1370,Res Lane, Charlottesville, VA 22908 USA.
EM dp8m@virginia.edu
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   ANDERSON JJ, 1993, J NEUROL NEUROSUR PS, V56, P477, DOI 10.1136/jnnp.56.5.477
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bhagwat AS, 2002, MOL MICROBIOL, V44, P1421, DOI 10.1046/j.1365-2958.2002.02989.x
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395
   Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714
   Gahan ME, 2001, J CLIN VIROL, V22, P241, DOI 10.1016/S1386-6532(01)00195-0
   García-Lozano JR, 2002, EUR NEUROL, V48, P34, DOI 10.1159/000064955
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   Hattori N, 1998, GENOMICS, V49, P52, DOI 10.1006/geno.1997.5192
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   JELLINGER KA, 1991, MOL CHEM NEUROPATHOL, V14, P153, DOI 10.1007/BF03159935
   JENSEN MA, 1993, PCR METH APPL, V3, P186
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kirchner SC, 2000, NEUROTOXICOLOGY, V21, P441
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Kösel S, 2000, NEUROGENETICS, V2, P227
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435
   MODRICH P, 1989, J BIOL CHEM, V264, P6597
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V176, P938, DOI 10.1016/S0006-291X(05)80276-1
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M
   PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   Parks JK, 1999, SOCIETY FOR NEUROSCIENCE ABSTRACTS, V25, P1337
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Pulkes T, 2000, ANN NEUROL, V47, P841
   REICHMANN H, 1994, EUR NEUROL, V34, P263, DOI 10.1159/000117053
   Richter G, 2002, J NEURAL TRANSM, V109, P721, DOI 10.1007/s007020200060
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Ruano G, 1992, PCR METHODS APPL, V2, P112
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Shults CW, 1998, MOV DISORD S2, V13, P217
   SIMON D, 2003, NEUROLOGY S, V0, P0
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Simon DK, 2001, GENOMICS, V73, P113, DOI 10.1006/geno.2001.6515
   Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605
   Suter M, 1999, BIOCHEMISTRY-US, V38, P459, DOI 10.1021/bi9811922
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Tanaka M, 2002, J NEUROSCI RES, V70, P347, DOI 10.1002/jnr.10444
   Tanaka Masashi, 2002, JOURNAL OF NEUROLOGY, V249, P11
   Thompson JR, 2002, NUCLEIC ACIDS RES, V30, P2083, DOI 10.1093/nar/30.9.2083
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Trimmer PA, 1999, SOCIETY FOR NEUROSCIENCE ABSTRACTS, V25, P1336
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   VIVESBAUZA C, 1908, BIOCHEM BIOPH RES CO, V290, P1593
   Wallace D C, 1997, THE MOLECULAR AND GENETIC BASIS OF NEUROLOGICAL DISEASE, V0, P237
   Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900
   Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218
   Xia X, 2002, MOL BIOL EVOL, V19, P58, DOI 10.1093/oxfordjournals.molbev.a003982
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
   Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4
NR 88
TC 123
Z9 136
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD NOV-DEC 15
PY 2004
VL 25
IS 10
BP 1273
EP 1281
DI 10.1016/j.neurobiolaging.2004.02.020
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 864UY
UT WOS:000224659600002
PM 15465623
DA 2024-11-01
ER

PT J
AU Mohamed, SA
   Wesch, D
   Blumenthal, A
   Bruse, P
   Windler, K
   Ernst, M
   Kabelitz, D
   Oehmichen, M
   Meissner, C
AF Mohamed, SA
   Wesch, D
   Blumenthal, A
   Bruse, P
   Windler, K
   Ernst, M
   Kabelitz, D
   Oehmichen, M
   Meissner, C
TI Detection of the 4977 bp deletion of mitochondrial DNA in different human blood cells
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE human peripheral blood cells; mitochondrial DNA; fluorescent-labelled primer; 4977 bp deletion; aging
ID oxidative stress; skeletal-muscle; common deletion; human tissue; human brain; disease; mutation; age; damage; pcr
AB As recently reported, it is possible to detect and quantify the amount of the deleted human mitochondrial DNA (mtDNA) in whole blood, platelets and peripheral blood mononuclear cells using real-time PCR. The aim of this study was to identify the cell types in human blood carrying the 4977 bp deleted mtDNA and their accumulation with regard to donor age. Whole blood from 10 healthy donors (five individuals aged from 19 to 22 years, five aged from 57 to 61 years) was separated in various cell populations such as granulocytes, B cells/monocytes and T cells. Purity of the cell isolates was determined by flow cytometry. Total DNA was extracted and 250 ng DNA of each cell type was subjected to PCR using fluorescent-labelled primer pairs. The specific PCR product of the 4977 bp deletion was quantified using an automated detection system. The accumulation of the 4977 bp deletion was more pronounced in T lymphocytes and granulocytes in comparison to B lymphocytes/monocytes. The amount of the 4977 bp deletion in whole blood varied from 0 to 0.00018%, in T lymphocytes from 0.00009 to 0.00160%, in granulocytes from 0 to 0.00162% and in the B lymphocyte/monocyte fraction from 0 to 0.00025%. The higher amount of the deletion in T lymphocytes may be due to a subset of lymphocytes with a longer lifespan thus facilitating the accumulation of mitochondrial damage. The higher amount in granulocytes could have the explanation in the higher release of free radicals for prevention of infectious diseases, because free radicals are supposed to damage the macromolecules of this cell type. The 10 donors displayed differences in the pattern of the accumulation with regard to the different cell types, but no age-dependent accumulation was observed. Differences of the accumulation pattern may be due to actual individual living behaviour or environmental factors. (C) 2003 Elsevier Inc. All rights reserved.
C1 Med Univ Lubeck, Dept Legal Med, D-23562 Lubeck, Germany.
   Univ Kiel, Dept Immunol, D-2300 Kiel, Germany.
   Dept Immunol & Cell Biol, Borstel, Germany.
C3 University of Lubeck; University of Kiel
RP Med Univ Lubeck, Dept Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.
EM meissner@rmed.mu-luebeck.de
CR BABIOR BM, 1990, SEMIN HEMATOL, V27, P247
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   Biagini G, 1998, MECH AGEING DEV, V101, P269, DOI 10.1016/S0047-6374(97)00181-4
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   GATTERMANN N, 1995, LEUKEMIA, V9, P1704
   Gershon D, 1999, EXP GERONTOL, V34, P613, DOI 10.1016/S0531-5565(99)00010-8
   HAMBLET NS, 1995, BIOCHEM BIOPH RES CO, V207, P839, DOI 10.1006/bbrc.1995.1262
   Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hou JH, 1996, BIOCHEM J, V318, P1065, DOI 10.1042/bj3181065
   ISHIHARA T, 1983, PROGR TOPICS CYTOGEN, V4, P475
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kanungo MS, 1994, GENES AGING, V0, P0
   Kim UK, 2000, BASIC RES CARDIOL, V95, P163, DOI 10.1007/s003950050178
   Korr H, 1998, BRAZ J MED BIOL RES, V31, P289, DOI 10.1590/S0100-879X1998000200012
   Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1159/000025424
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   LINNANE AW, 1990, BIOCHEM INT, V22, P1067
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   MARTINEZCAYUELA M, 1995, BIOCHIMIE, V77, P147, DOI 10.1016/0300-9084(96)88119-3
   Meissner C, 1997, INT J LEGAL MED, V110, P288, DOI 10.1007/s004140050089
   Meissner C, 1999, FORENSIC SCI INT, V105, P115, DOI 10.1016/S0379-0738(99)00126-7
   Meissner C, 2000, FORENSIC SCI INT, V113, P109, DOI 10.1016/S0379-0738(00)00249-8
   Merril CR, 1996, ARCH BIOCHEM BIOPHYS, V326, P172, DOI 10.1006/abbi.1996.0062
   MOHAMED SA, 1999, J CLIN FORENSIC MED, V6, P210
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   Pawelec G, 2002, FRONT BIOSCI-LANDMRK, V7, P0
   POULTON J, 1991, AM J HUM GENET, V48, P649
   Ray AJ, 2000, J INVEST DERMATOL, V115, P674, DOI 10.1046/j.1523-1747.2000.00092.x
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SMITH OP, 1995, BRIT J HAEMATOL, V90, P469, DOI 10.1111/j.1365-2141.1995.tb05178.x
   SOONG NW, 1992, NAT GENET, V2, P318
   TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494
   von Wurmb N, 1998, MUTAT RES-FUND MOL M, V422, P247, DOI 10.1016/S0027-5107(98)00205-X
   von Wurmb-Schwark N, 2002, FORENSIC SCI INT, V126, P34, DOI 10.1016/S0379-0738(02)00026-9
   WALLACE DC, 1990, PEDIATR RES, V28, P525, DOI 10.1203/00006450-199011000-00023
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   Wei YH, 1998, CURR SCI INDIA, V74, P887
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhang CF, 1996, BIOCHEM BIOPH RES CO, V223, P450, DOI 10.1006/bbrc.1996.0914
NR 50
TC 31
Z9 37
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD FEB 15
PY 2004
VL 39
IS 2
BP 181
EP 188
DI 10.1016/j.exger.2003.10.011
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 776PC
UT WOS:000189124100005
PM 15036410
DA 2024-11-01
ER

PT J
AU Tesarova, M
   Hansikova, H
   Kytnarova, J
   Houstkova, H
   Bohm, M
   Cerna, L
   Zeman, J
   Houstek, J
AF Tesarova, M
   Hansikova, H
   Kytnarova, J
   Houstkova, H
   Bohm, M
   Cerna, L
   Zeman, J
   Houstek, J
TI Clinical heterogeneity, tissue distribution, and intergenerational segregation of mtDNA mutation A3243G
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article; Proceedings Paper
DE intergenerational transmission; mtDNA mutation A3243G
ID transfer rnaleu(uur) gene; mitochondrial-dna; lactic-acidosis; point mutation; transfer-rna; encephalomyopathy; encephalopathy; heteroplasmy; myopathy; muscle
AB Tissue distribution and segregation and the functional consequences of heteroplasmic mitochondrial DNA mutation A3243G were studied in 30 carriers. The mutation load in hair follicles was higher in 20 patients with a broad spectrum of clinical symptoms than in 10 nonaffected carriers. The onset of the disease negatively correlated with the mutation load in blood and muscle. The activities of respiratory chain complexes in isolated muscle mitochondria did not decrease in all patients and were normal in isolated platelets. Changes in the heteroplasmy level between pairs of mothers and offspring suggest that random genetic drift is the mechanism associated with the intergenerational transmission of the A3243G mutation. In conclusion, detailed clinical investigations and mitochondrial DNA analyses in several tissues are of the highest diagnostic value for the prognosis of the disease in carriers of the A3243G mutation.
C1 Charles Univ, Fac Med, Dept Paediat, Ctr Integrated Genom, Prague 12000 2, Czech Republic.
   Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic.
C3 Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences
RP Zeman, J (corresponding author), Charles Univ, Fac Med, Dept Paediat, Ctr Integrated Genom, Ke Karlovu 2, Prague 12000 2, Czech Republic.
CR Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   DiMauro S, 2001, SEMIN CELL DEV BIOL, V12, P397, DOI 10.1006/scdb.2001.0277
   El Meziane A, 1998, NAT GENET, V18, P350
   FOX JEB, 1992, METHOD ENZYMOL, V215, P42
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hansrote S, 2002, J NEUROL SCI, V197, P63, DOI 10.1016/S0022-510X(02)00048-5
   Juvonen V, 1997, HUM MUTAT, V9, P412, DOI 10.1002/(SICI)1098-1004(1997)9:5<412::AID-HUMU6>3.3.CO;2-Q
   Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAKINE MW, 1968, NEUROLOGY, V18, P299
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Morovvati S, 2002, ACTA NEUROL SCAND, V106, P104, DOI 10.1034/j.1600-0404.2002.01172.x
   Olsson C, 1998, HUM MUTAT, V12, P52, DOI 10.1002/(SICI)1098-1004(1998)12:1<52::AID-HUMU8>3.0.CO;2-K
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Shoubridge E A, 2000, HUM REPROD, V15 Suppl 2, P229
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
NR 23
TC 0
Z9 0
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1537-6524
EI 
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD JAN-APR 15
PY 2004
VL 14
IS 1-2
BP 79
EP 84
DI 10.1080/15376520490257527
PG 6
WC Toxicology
SC Toxicology
GA 757FU
UT WOS:000187551000016
PM 20021128
DA 2024-11-01
ER

PT J
AU Marotta, R
   Chin, J
   Quigley, A
   Katsabanis, S
   Kapsa, R
   Byrne, E
   Collins, S
AF Marotta, R
   Chin, J
   Quigley, A
   Katsabanis, S
   Kapsa, R
   Byrne, E
   Collins, S
TI Diagnostic screening of mitochondrial DNA mutations in Australian adults 1990-2001
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE mitochondria; genome; mutation; polymerase chain reaction; restriction fragment length polymorphism
ID hereditary optic neuropathy; ragged-red fibers; myoclonic epilepsy; intramitochondrial fibers; gene; encephalomyopathy; myopathy; disease; melas; merrf
AB Background: Many diverse pathogenic mitochondrial DNA (mtDNA) mutations have been described since 1988. The Melbourne Neuromuscular Research Institute (MNRI) has undertaken diagnostic detection of selected mtDNA mutations since 1990. MtDNA mutations screened have included point mutations associated with Leber's hereditary optic neuropathy (LHON; G3460A, G11778A and T14484C), mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS; A3243G), myoclonus epilepsy and ragged red fibres (MERRF; A8344G) and Leigh's syndrome/neuropathy ataxia retinitis pigmentosa (LS/NARP; T8993C/G). Samples have also been screened for deletions/ rearrangements associated with Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO). Aims: To present an audit of the MNRI mtDNA diagnostic service between 1990 and 2001, encompassing 1725 referred patients. Methods: The detection techniques carried out included polymerase chain reaction amplification of mtDNA combined with restriction fragment length polymorphism analysis for mtDNA point mutation detection, supplemented with selected sequence analysis and Southern blots for the detection of deletions/ rearrangements. Tissues tested included blood, hair and skeletal muscle. Results: Of the 1184 patients screened for MELAS A3243G, 6.17% were positive for the mutation, whereas for MERRF A8344G, 2.21% carried the mutation and for LS/NARP T8993C/G, 0.32% carried the mutation. The outcomes for the LHON mutations were G11778A, 6.60%, T14484C, 5.76% and G3460A, 0.29%. Of the patients referred for KSS and CPEO, 17.72% had deletions/rearrangements. Conclusions: Overall, the detection rate of mtDNA point mutations was low. The protean clinical features of mitochondrial disorders and the frequency of partial phenotypes lead to requests for tests in many patients with a relatively low likelihood of mtDNA mutations. An improved algorithm could involve mutation screening appropriate to the phenotype using sequencing of selected mtDNA regions in patients with a high likelihood of mtDNA disease. Features increasing the likelihood of mtDNA mutations include the following: (i) a typical phenotype, (ii) a maternal inheritance pattern and (iii) histochemical evidence of mitochondrial abnormality in the muscle biopsy. Efficient laboratory diagnosis of mtDNA disease involves good communication between the physician and laboratory scientists, coupled with screening of the appropriate tissue.
C1 St Vincents Hosp, Dept Clin Neurosci, Melbourne Neuromuscular Res Inst, Mitochondrial DNA Diagnost Lab, Fitzroy, Vic 3065, Australia.
   Peter MacCallum Canc Inst, Melbourne, Vic, Australia.
   Univ Melbourne, Ctr Neurosci Victoria, Melbourne, Vic, Australia.
C3 St Vincent's Health; St Vincent's Hospital Melbourne; NSW Health; St Vincents Hospital Sydney; Peter Maccallum Cancer Center; University of Melbourne
RP Marotta, R (corresponding author), St Vincents Hosp, Dept Clin Neurosci, Melbourne Neuromuscular Res Inst, Mitochondrial DNA Diagnost Lab, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.
EM marottr@svhm.org.au
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Brown MD, 2001, AM J MED GENET, V104, P331, DOI 10.1002/1096-8628(2001)104:4<331::AID-AJMG10054>3.0.CO;2-8
   BYRNE E, 1991, MED J AUSTRALIA, V154, P646, DOI 10.5694/j.1326-5377.1991.tb121246.x
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DIMAURO S, 1994, CURRENT DIAGNOSIS NE, V0, P340
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 2002, J NEURO-OPHTHALMOL, V22, P262, DOI 10.1097/00041327-200212000-00002
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   KOTSIMBOS N, 1994, HUM MUTAT, V4, P132, DOI 10.1002/humu.1380040207
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   LERTRIT P, 1992, HUM GENET, V90, P251
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   MCKELVIE PA, 1991, J NEUROL SCI, V102, P51, DOI 10.1016/0022-510X(91)90093-M
   NASS MMK, 1966, P NATL ACAD SCI USA, V56, P1215, DOI 10.1073/pnas.56.4.1215
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   NAVIAUX RK, 1999, SPECTRUM MITOCHONDRI, V0, P0
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Quigley A, 2001, J CLIN NEUROMUSCUL DIS, V3, P77, DOI 10.1097/00131402-200112000-00006
   ROSING HS, 1985, ANN NEUROL, V17, P228, DOI 10.1002/ana.410170303
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOFFNER JM, 1995, METABOLIC MOL BASIS, V1, P1535
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   STRYER L, 1988, BIOCHEMISTRY-US, V0, P823
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   VANBRUGGEN EFJ, 1963, BIOCHIM BIOPHYS ACTA, V119, P437
   VIKKI J, 1988, HUM GENET, V80, P317
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 36
TC 28
Z9 30
U1 0
U2 1
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1444-0903
EI 
J9 INTERN MED J
JI Intern. Med. J.
PD JAN-FEB 15
PY 2004
VL 34
IS 1-2
BP 10
EP 19
DI 10.1111/j.1444-0903.2004.t01-3-.x
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 768KB
UT WOS:000188541200004
PM 14748908
DA 2024-11-01
ER

PT J
AU Lindholm, H
   Löfberg, M
   Somer, H
   Näveri, H
   Sovijärvi, A
AF Lindholm, H
   Löfberg, M
   Somer, H
   Näveri, H
   Sovijärvi, A
TI Abnormal blood lactate accumulation after exercise in patients with multiple mitochondrial DNA deletions and minor muscular symptoms
SO CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING
LA English
DT Article
DE cardiopulmonary exercise test; lactate metabolism; mitochondrial myopathy; molecular genetics
ID magnetic-resonance spectroscopy; mcardles-disease; skeletal-muscle; work capacity; myopathy; responses; disorders; features
AB Study objectives: Muscle is one of the most commonly affected organs in mitochondrial disorders, and the symptoms are often exercise related. The cardiopulmonary exercise test with the determination of lactic acid formation could give supplementary information about the exercise-induced metabolic stress and compensatory mechanisms used in these disorders. The aim of this study was to evaluate the exercise capacity and lactate kinetics related to exercise in subjects with two genetically characterized mitochondrial disorders (multiple mitochondrial DNA deletions with PEO, MELAS) compared with lactate kinetics in subjects with metabolic myopathy (McArdle's disease) and in the healthy controls. Design: The subjects were consecutive, co-operative patients of Department of Neurology of Helsinki University Hospital. Molecular genetic analyses were used for group classification of the mitochondrial myopathy. Study subjects: The study groups consisted of 11 patients with multiple deletions (PEO) and five patients with a point mutation in the mitochondrial DNA (MELAS), four patients with a muscle phosphorylase enzyme deficiency (McArdle's disease) and 13 healthy controls. The clinical disease of the patients was relatively mild. Measurements and results: A graded exercise test with ventilatory gas analyses and venous blood lactic acid analyses was performed. The main finding was the prolonged accumulation of blood lactate after the exercise in the PEO and MELAS groups compared with the controls. An overcompensation in ventilation was found in the MELAS and PEO group. Conclusions: The blood lactate accumulation after exercise occurs in patients with multiple mitochondrial DNA deletions or MELAS even in patients with only mild exercise intolerance. Cardiopulmonary exercise can be used in the diagnostic process of patients with mitochondrial myopathies.
C1 Univ Helsinki Hosp, Div Clin Physiol, Dept Lab, Helsinki, Finland.
   Univ Helsinki Hosp, Dept Neurol, Helsinki, Finland.
   Univ Helsinki Hosp, Dept Med, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital
RP Finnish Inst Occupat Hlth, Dept Physiol, Topeliuksenkatu 41 A, Helsinki 00250, Finland.
EM harri.lindholm@ttl.fi
CR Argov Z, 1998, EUR NEUROL, V39, P65, DOI 10.1159/000007912
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   Haller RG, 1998, NEUROLOGY, V50, P37, DOI 10.1212/WNL.50.1.37
   HARKONEN M, 1982, ANN CLIN RES, V14, P20
   JEHENSON P, 1995, EUR J NUCL MED, V22, P1256, DOI 10.1007/BF00801609
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   LOWRY OH, 1964, J BIOL CHEM, V239, P18
   MCARDLE B, 1951, CLIN SCI, V10, P12
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   NORDESJO LO, 1975, SCAND J CLIN LAB INV, V35, P64
   PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802
   SELIGER V, 1978, EUR J APPL PHYSIOL, V39, P155, DOI 10.1007/BF00421342
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   SUE DY, 1991, CHEST, V99, P981, DOI 10.1378/chest.99.4.981
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   WASSERMAN K, 1975, AM REV RESPIR DIS, V112, P219
NR 27
TC 16
Z9 16
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1475-0961
EI 1475-097X
J9 CLIN PHYSIOL FUNCT I
JI Clin. Physiol. Funct. Imaging
PD MAR 15
PY 2004
VL 24
IS 2
BP 109
EP 115
DI 10.1111/j.1475-097X.2004.00531.x
PG 7
WC Physiology
SC Physiology
GA 805QN
UT WOS:000220380900007
PM 15056184
DA 2024-11-01
ER

PT J
AU Chinnery, PF
AF Chinnery, PF
TI New approaches to the treatment of mitochondrial disorders
SO REPRODUCTIVE BIOMEDICINE ONLINE
LA English
DT Article
DE gene therapy; mitochondrial disease; mitochondrial encephalomyopathy; mtDNA
ID c-oxidase deficiency; dilated cardiomyopathy; clinical-features; dna replication; gene-therapy; mutations; disease; sco2; mice; encephalomyopathy
AB Mitochondrial disorders are among the most common inherited metabolic diseases and the issue of treatment arises on a regular basis. There is no established treatment for mitochondrial disorders and current management is largely supportive, but recent advances in our understanding of the pathophysiology provide hope for novel treatments. Patients with mitochondrial myopathy due to mutations of mitochondrial DNA (mtDNA) may benefit from treatments that move normal mitochondrial genomes from the muscle satellite cells into skeletal muscle, but there are concerns about the long-term effects of this approach. A greater understanding of the pathophysiology of a number of nuclear genetic mitochondrial disorders suggests new avenues for treatment (such as copper-histidine in children with SCO2 gene mutations, and strategies modifying intra-mitochondrial nucleoside pools in the various disorders of mtDNA maintenance). A number of different strategies are also being explored at the molecular level, including the use of antigenomic molecules to mutated mtDNA and the allotropic expression of mutated mtDNA genes within the cell nucleus. Nuclear transfer techniques also provide hope for women at risk of transmitting pathogenic mtDNA mutations.
C1 Newcastle Univ, Sch Med, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Dept Neurol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
CR Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2002, MITOCHONDRION, V2, P149, DOI 10.1016/S1567-7249(02)00046-6
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHINNERY PF, 2003, IN PRESS NEUROMUSCUL, V0, P0
   Christodoulou J, 1998, AM J MED GENET, V76, P154, DOI 10.1002/(SICI)1096-8628(19980305)76:2<154::AID-AJMG9>3.3.CO;2-C
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DiMauro S, 2000, NEUROL SCI, V21, P0
   Eichenlaub-Ritter U, 2004, REPROD BIOMED ONLINE, V8, P45, DOI 10.1016/S1472-6483(10)60497-X
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   St John JC, 2004, REPROD BIOMED ONLINE, V8, P34, DOI 10.1016/S1472-6483(10)60496-8
   SUTHERLAND L, 1994, BIOCHEM SOC T, V22, PS413, DOI 10.1042/bst022413s
   Sutovsky P, 2004, REPROD BIOMED ONLINE, V8, P24, DOI 10.1016/S1472-6483(10)60495-6
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 1997, NEUROLOGY, V48, P28003
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor R W, 2000, HUM REPROD, V15 Suppl 2, P79
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
NR 50
TC 12
Z9 14
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1472-6483
EI 1472-6491
J9 REPROD BIOMED ONLINE
JI Reprod. Biomed. Online
PD JAN 15
PY 2004
VL 8
IS 1
BP 16
EP 23
DI 10.1016/S1472-6483(10)60494-4
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 879JN
UT WOS:000225714200003
PM 14759282
DA 2024-11-01
ER

PT J
AU Limongelli, A
   Schaefer, J
   Jackson, S
   Invernizzi, F
   Kirino, Y
   Suzuki, T
   Reichmann, H
   Zeviani, M
AF Limongelli, A
   Schaefer, J
   Jackson, S
   Invernizzi, F
   Kirino, Y
   Suzuki, T
   Reichmann, H
   Zeviani, M
TI Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA<SUP>ile</SUP> homoplasmic mutation in the mitochondrial genome
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID cytochrome-c-oxidase; dna; mtdna; translation; deletions; cells
AB Introduction: We present a family comprising a clinically normal mother and two daughters, each with severe encephalopathy with onset in late childhood. A third daughter had died previously of an earlier onset but neuropathologically similar disease. Methods: Sequence analysis of the entire mtDNA was carried out in muscle, fibroblasts, and lymphocytes of the affected daughters and unaffected mother. Biochemical analysis of individual respiratory chain enzymes was performed on the same tissues, and on several transmitochondrial cybrid clones containing the nucleus of a 143B.206 osteosarcoma cell line and the mutant mtDNA. Results: Genetic analyses revealed in both daughters and mother the presence of a novel mutation in the tRNAIle gene of mtDNA, which was homoplasmic in fibroblasts, lymphocytes, and skeletal muscle of the two patients. It was also homoplasmic in fibroblast and skeletal muscle samples of the mother, and approximately 97% heteroplasmic in her lymphocytes. Combined defects of complexes I and IV of the mitochondrial respiratory chain were found not only in fibroblasts of the two probands, but surprisingly also in those of their clinically unaffected mother. The respiratory chain defect segregated in transmitochondrial cybrids containing the nucleus of a 143B.206 osteosarcoma cell line and the mutant mtDNA, indicating that the latter was responsible for the biochemical phenotype. Discussion: Our results support the concept that homoplasmic mutations in tRNA genes can be responsible for mitochondrial disorders characterised by extremely variable penetrance. Albeit still unexplained, this phenomenon has important consequences in the nosological characterisation, clinical management, and genetic counselling of mitochondrial disorders.
C1 Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20133 Milan, Italy.
   Tech Univ Dresden, Sch Med, Neurol Clin, D-8027 Dresden, Germany.
   Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo, Japan.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Technische Universitat Dresden; University of Tokyo
RP Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20133 Milan, Italy.
EM zeviani@tin.it
FU Telethon [GGP030039] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, QJM-INT J MED, V90, P657, DOI 10.1093/qjmed/90.11.657
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Darley-Usmar VM, 1987, MITOCHONDRIA PRACTIC, V0, P0
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maassen JA, 2002, AM J MED GENET, V115, P66, DOI 10.1002/ajmg.10346
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221
   Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   Vu TH, 2002, NEUROL CLIN, V20, P809, DOI 10.1016/S0733-8619(01)00017-2
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 31
TC 42
Z9 44
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD MAY 15
PY 2004
VL 41
IS 5
BP 342
EP 349
DI 10.1136/jmg.2003.016048
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 817GI
UT WOS:000221165600005
PM 15121771
DA 2024-11-01
ER

PT J
AU De Block, CEM
   De Leeuw, IH
   Maassen, JA
   Ballaux, D
   Martin, JJ
AF De Block, CEM
   De Leeuw, IH
   Maassen, JA
   Ballaux, D
   Martin, JJ
TI A novel 7301-bp deletion in mitochondrial DNA in a patient with Kearns-Dayre syndrome, diabetes mellitus, and primary amenorrhoea
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE Kearns-Sayre syndrome; mitochondrial DNA mutations; diabetes mellitus
ID sayre syndrome; external ophthalmoplegia; trna(leu(uur)) gene; point mutation; hypoparathyroidism; encephalomyopathy; cytopathy; deafness; myopathy; muscle
AB We report a 27-year-old woman with a form of mitochondrial myopathy including chronic progressive external opthalmoplegia, retinal pigmentary dystrophy, cerebellar ataxia, and cardiac conduction block (Kearns-Sayre syndrome). At age 13 years a cardiac pacemaker was implanted. She also had sensineural hearing loss, delayed puberty, and primary amenorrhoea. She was weelchair-bound since the age of 20 years. At age 27, insulin-dependent diabetes mellitus and osteoporosis were diagnosed. Insulin treatment was started and associated endocrinopathies were investigated. DNA analysis identified a novel 7301-bp deletion in mitochondrial DNA, ranging from position 6530 to 13831 corroborating the diagnosis of Kearns-Sayre syndrome.
C1 Univ Hosp Antwerp, Dept Endocrinol Diabetol, B-2650 Edegem, Belgium.
   Leiden Univ, Ctr Med, Sect Signal Transduct, Dept Mol Cell Biol, Leiden, Netherlands.
   Vrije Univ Amsterdam, Leiden, Netherlands.
   Univ Hosp Antwerp, Dept Neurol, Edegem, Belgium.
C3 University of Antwerp; Leiden University - Excl LUMC; Leiden University; Vrije Universiteit Amsterdam; University of Antwerp
RP Univ Hosp Antwerp, Dept Endocrinol Diabetol, Wilrijkstr 10, B-2650 Edegem, Belgium.
EM christophe.deblock@ua.ac.be
CR Abramowicz MJ, 1996, J INHERIT METAB DIS, V19, P109, DOI 10.1007/BF01799405
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BURNS EC, 1982, ACTA PAEDIATR SCAND, V71, P693, DOI 10.1111/j.1651-2227.1982.tb09504.x
   COULTER DL, 1981, ARCH NEUROL-CHICAGO, V38, P247, DOI 10.1001/archneur.1981.00510040073013
   EGGER J, 1981, ARCH DIS CHILD, V56, P741, DOI 10.1136/adc.56.10.741
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KARPATI G, 1973, J NEUROL SCI, V19, P133, DOI 10.1016/0022-510X(73)90158-5
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   KISHIMOTO M, 1995, DIABETOLOGIA, V38, P193, DOI 10.1007/s001250050270
   KURIYAMA M, 1984, NEUROLOGY, V34, P253, DOI 10.1212/WNL.34.2.253
   Maassen JA, 2002, AM J MED GENET, V115, P66, DOI 10.1002/ajmg.10346
   MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McDonald W I, 1972, TRANS OPHTHALMOL SOC U K, V92, P179
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Oexle K, 1996, EXP CLIN ENDOCR DIAB, V104, P212, DOI 10.1055/s-0029-1211445
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   PELLOCK JM, 1978, ANN NEUROL, V3, P455, DOI 10.1002/ana.410030519
   QUADE A, 1992, CLIN INVESTIGATOR, V70, P396
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Tengan CH, 1998, J CLIN ENDOCR METAB, V83, P125, DOI 10.1210/jc.83.1.125
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
   vandeCorput MPC, 1997, J HISTOCHEM CYTOCHEM, V45, P55
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   WALLACE DC, 1995, BIOCHIM BIOPHYS ACTA, V1271, P1411
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 30
TC 14
Z9 14
U1 0
U2 5
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0947-7349
EI 1439-3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD FEB 15
PY 2004
VL 112
IS 2
BP 80
EP 83
DI 10.1055/s-2004-815754
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 807BO
UT WOS:000220477200003
PM 15031771
DA 2024-11-01
ER

PT J
AU Hirano, M
   Nishigaki, Y
   Martí, R
AF Hirano, M
   Nishigaki, Y
   Martí, R
TI Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE):: A disease of two genomes
SO NEUROLOGIST
LA English
DT Article
DE mitochondria; mitochondrial DNA; MNGIE; mitochondrial encephalomyopathy
ID cell growth-factor; chronic intestinal pseudoobstruction; familial visceral myopathy; kearns-sayre syndrome; mouse l-cells; thymidine phosphorylase; multisystem disorder; tissue distribution; multiple deletions; rectal biopsy
AB Background: Mitochondrial encephalomyopathies are clinically and genetically heterogeneous because mitochondria are the products of 2 genomes: mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Among the mendelian-inherited mitochondrial diseases are defects of intergenomic communication, disorders due to nDNA mutations that cause depletion and multiple deletions of mtDNA. Review Summary: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder of intergenomic communication and is defined clinically by 1) severe gastrointestinal dysmotility; 2) cachexia; 3) ptosis, ophthalmoparesis, or both; 4) peripheral neuropathy; and 5) leukoencephalopathy. Skeletal muscle biopsies of patients have revealed abnormalities of mtDNA and mitochondrial respiratory chain enzymes. The disease is caused by mutations in the thymidine phosphorylase (TP) gene. TP protein catalyzes phosphorolysis of thymidine to thymine and deoxyribose 1-phosphate. In MNGIE patients, TP enzyme activity is reduced drastically, and plasma thymidine and deoxyuridine are elevated dramatically. We have hypothesized that alterations of nucleoside metabolism cause an imbalanced mitochondrial nucleotide pool that leads to depletion and deletions of mtDNA. Conclusions: MNGIE is a recognizable clinical syndrome caused by mutations in TP. The diagnosis can be confirmed by measuring TP activity in buffy coat or plasma levels of thymidine and deoxyuridine. Reduction of circulating thymidine and deoxyuridine in MNGIE patients may be therapeutic.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.
EM mh29@columbia.edu
CR ANURAS S, 1983, GASTROENTEROLOGY, V84, P346
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   BAN S, 1992, ACTA PATHOL JAPON, V42, P818
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   BERK AJ, 1973, J BIOL CHEM, V248, P2722
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2
   Brown NS, 1998, BIOCHEM J, V334, P1
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   CERVERA R, 1988, GUT, V29, P544, DOI 10.1136/gut.29.4.544
   COLLIER TG, 1996, ANN NEUROL, V40, P545
   CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Debouverie M, 1997, REV NEUROL, V153, P547
   ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4
   FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125
   Hamano H, 1997, RINSHO SHINKEIGAKU, V37, P917
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT I, 1988, NATURE, V331, P34
   IONASESCU V, 1983, AM J MED GENET, V15, P103, DOI 10.1002/ajmg.1320150114
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kuroiwa T, 1998, ACTA NEUROPATHOL, V96, P86, DOI 10.1007/s004010050863
   LESTIENNE P, 1988, LANCET, V1, P885
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   LI V, 1992, DIGEST DIS SCI, V37, P456, DOI 10.1007/BF01307743
   LOWSKY R, 1993, GUT, V34, P279, DOI 10.1136/gut.34.2.279
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X
   Mueller LA, 1999, GASTROENTEROLOGY, V116, P959, DOI 10.1016/S0016-5085(99)70080-6
   NICHOLL JA, 1993, CLIN NEUROPATHOL, V12, P38
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OKAMURA K, 1976, J NEUROL SCI, V27, P79, DOI 10.1016/0022-510X(76)90236-7
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Perez-Atayde AR, 1998, AM J SURG PATHOL, V22, P1141, DOI 10.1097/00000478-199809000-00014
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   ROWLAND LP, 1992, HDB CLIN NEUROLOGY, V0, P287
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SCHON EA, 2001, MITOCHONDRIAL DISORD, V2, P0
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STEINER I, 1987, NEUROLOGY, V37, P1046, DOI 10.1212/WNL.37.6.1046
   UNCINI A, 1994, MUSCLE NERVE, V17, P667, DOI 10.1002/mus.880170616
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X
   Zelnik N, 1996, PEDIATR NEUROL, V14, P251, DOI 10.1016/0887-8994(96)00046-X
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 59
TC 130
Z9 142
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1074-7931
EI 
J9 NEUROLOGIST
JI Neurologist
PD JAN 15
PY 2004
VL 10
IS 1
BP 8
EP 17
DI 10.1097/01.nrl.0000106919.06469.04
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 768GE
UT WOS:000188534600002
PM 14720311
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, S
TI Mitochondrial medicine
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; skeletal-muscle; paternal inheritance; complex-i; severe hypermetabolism; carnitine deficiency; mtdna depletion; t7511c mutation; frequent cause
AB After reviewing the history of mitochondrial diseases, I follow a genetic classification to discuss new developments and old conundrums. In the field of mitochondrial DNA (mtDNA) mutations, I argue that we are not yet scraping the bottom of the barrel because: (i) new mtDNA mutations are still being discovered, especially in protein-coding genes; (ii) the pathogenicity of homoplasmic mutations is being revisited; (iii) some genetic dogmas are chipped but not broken; (iv) mtDNA haplotypes are gaining interest in human pathology; (v) pathogenesis is still largely enigmatic. In the field of nuclear DNA (nDNA) mutations, there has been good progress in our understanding of disorders due to faulty intergenomic communication. Of the genes responsible for multiple deletions and depletion of mtDNA, mutations in POLG have been associated with a great variety of clinical phenotypes in humans and to precocious aging in mice. Novel pathogenetic mechanisms include alterations in the lipid milieu of the inner mitochondrial membrane and mutations in genes controlling mitochondrial motility, fission, and fusion. (C) 2004 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg 4 420, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ, Coll Phys & Surg 4 420, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   BLASS J P, 1970, JOURNAL OF CLINICAL INVESTIGATION, V49, P423, DOI 10.1172/JCI106251
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Carelli V, 2002, MITOCHONDRIAL DISORD, V0, P115
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   DIMAURO S, 1973, SCIENCE, V182, P929, DOI 10.1126/science.182.4115.929
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DIMAURO S, 2003, IN PRESS BASIC APPL, V13, P0
   ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695
   GONATAS NK, 1965, P 5 INT C NEUR EXC M, V100, P606
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   NAINI A, 2004, IN PRESS ARCH NEUROL, V0, P0
   NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Neuwald AF, 1997, CURR BIOL, V7, P0
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schon EA, 2003, GENETICS MITOCHONDRI, V0, P111
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHY GM, 1966, BRAIN, V89, P133, DOI 10.1093/brain/89.1.133
   SHY GM, 1964, SCIENCE, V145, P493, DOI 10.1126/science.145.3631.493
   SKUDER P, 1995, INTELLIGENCE, V21, P1, DOI 10.1016/0160-2896(95)90035-7
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 93
TC 41
Z9 49
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD DEC 6
PY 2004
VL 1659
IS 2-3
BP 107
EP 114
DI 10.1016/j.bbabio.2004.08.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 882KT
UT WOS:000225938500002
PM 15576041
DA 2024-11-01
ER

PT J
AU Capaldi, RA
   Murray, J
   Byrne, L
   Janes, MS
   Marusich, MF
AF Capaldi, RA
   Murray, J
   Byrne, L
   Janes, MS
   Marusich, MF
TI Immunological approaches to the characterization and diagnosis of mitochondrial disease
SO MITOCHONDRION
LA English
DT Article; Proceedings Paper
DE monoclonal antibodies; pyruvate dehydrogenase; mitochondrial DNA; OXPHOS; respiratory chain
ID pyruvate-dehydrogenase complex; c-oxidase deficiency; respiratory-chain; skeletal-muscle; immunocapture; disorders; mutations; defects; tissue
AB Monoclonal antibodies (mAbs) are important tools in the diagnosis and characterization of mitochondrial diseases. They can be used in immunohistochemical and/or Western blotting approaches to identify misassembled OXPHOS complexes or pyruvate dehydrogenase deficiencies where the intact complex is not formed which is the great majority of cases. The advantage of antibody based approaches is that they can be quantitative, require very small amounts of tissue sample and are fast, simple and relatively cheap to perform. Here we provide details of the mAbs currently available and describe optimized protocols for both immunohistochemistry using patient fibroblasts as well as Western blotting using either cell culture or biopsy material. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
   Mol Probes Inc, Eugene, OR 97402 USA.
   Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
C3 University of Oregon; Thermo Fisher Scientific; Molecular Probes, Inc.; University of Oregon
RP Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
EM rcapaldi@oregon.uoregon.edu
CR Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Davey GP, 1997, J NEUROCHEM, V69, P2564
   Hanson BJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1281, DOI 10.1177/002215540205001001
   Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461
   Huang CC, 1999, ACTA NEUROL SCAND, V99, P125, DOI 10.1111/j.1600-0404.1999.tb00670.x
   JANES MS, 2003, UNPUB J HISTOCHEM CY, V0, P0
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   JOHNSON MA, 1988, J NEUROL SCI, V87, P75, DOI 10.1016/0022-510X(88)90056-1
   Lib M, 2003, ANAL BIOCHEM, V314, P121, DOI 10.1016/S0003-2697(02)00645-0
   Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.3.CO;2-B
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   MATTHEWS PM, 1994, BRAIN, V117, P435, DOI 10.1093/brain/117.3.435
   Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Scheffler IE, 1999, MITOCHONDRIA, V0, P0
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Schon EA, 2003, CURR MED CHEM, V10, P2523, DOI 10.2174/0929867033456503
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200
   von Kleist-Retzow JC, 1999, BBA-MOL BASIS DIS, V1455, P35, DOI 10.1016/S0925-4439(99)00050-2
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Williams SE, 1994, J BIOL CHEM, V0, P0
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 26
TC 29
Z9 31
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD SEP 15
PY 2004
VL 4
IS 5-6
BP 417
EP 426
DI 10.1016/j.mito.2004.07.006
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 885QS
UT WOS:000226172600008
PM 16120403
DA 2024-11-01
ER

PT J
AU Schwartz, M
   Vissing, J
AF Schwartz, M
   Vissing, J
TI No evidence for paternal inheritance of mtDNA in patients with sporadic mtDNA mutations
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mtDNA; paternal inheritance; mitochondria
ID mitochondrial-dna; sequence
AB With the publication of a patient with severe exercise intolerance, in whom the mutated mtDNA in muscle was shown to be paternally inherited, the strict maternal inheritance of mtDNA was challenged. Paternal mtDNA inheritance may have gone unrecognized in cases of mitochondrial disease with no clear maternal pattern of inheritance because mitochondrial haplotypes are rarely investigated in diagnostic analyses. To find further evidence for a paternal inheritance of mtDNA, we reinvestigated 12 patients with mitochondrial myopathy, in whom the pathogenic mutation was known to be sporadic. We compared the mtDNA haplotypes from the patient's muscle with that of the mtDNA haplotypes in blood from either the mother or the patient. No evidence of Paternal inheritance of mtDNA was found in this small study. Although these findings indicate that the Paternal inheritance of mtDNA is rare, they do not rule out that the phenomenon may occur at a rate that could still affect genetic counselling and anthropological research. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Copenhagen, Natl Hosp, Rigshosp, Dept Clin Genet 4062, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet
RP Schwartz, M (corresponding author), Univ Copenhagen, Natl Hosp, Rigshosp, Dept Clin Genet 4062, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM Schwartz@rh.dk
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   Bromham L, 2003, TRENDS ECOL EVOL, V18, P2, DOI 10.1016/S0169-5347(02)00009-5
   Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889
   Eyre-Walker A, 2001, J MOL EVOL, V53, P430, DOI 10.1007/s002390010232
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   JACOBS H, 2002, TRENDS GENET, V18, P551
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Macaulay V, 1999, P ROY SOC B-BIOL SCI, V266, P2037, DOI 10.1098/rspb.1999.0883
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   STONEKING M, 1991, AM J HUM GENET, V48, P370
   Vissing J, 2002, NEW ENGL J MED, V347, P2081
NR 12
TC 25
Z9 30
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2004
VL 218
IS 1-2
BP 99
EP 101
DI 10.1016/j.jns.2003.11.008
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 775WW
UT WOS:000189084500016
PM 14759640
DA 2024-11-01
ER

PT J
AU Uusimaa, J
   Finnilä, S
   Remes, AM
   Rantala, H
   Vainionpää, L
   Hassinen, IE
   Majamaa, K
AF Uusimaa, J
   Finnilä, S
   Remes, AM
   Rantala, H
   Vainionpää, L
   Hassinen, IE
   Majamaa, K
TI Molecular epidemiology of childhood mitochondrial encephalomyopathies in a Finnish population:: Sequence analysis of entire mtDNA of 17 children reveals heteroplasmic mutations in tRNA<SUP>Arg</SUP>, tRNA<SUP>Glu</SUP>, and tRNA<SUP>Leu(UUR)</SUP> genes
SO PEDIATRICS
LA English
DT Article
DE encephalomyopathy; mitochondrial DNA; tRNA mutation; conformation sensitive gel electrophoresis
ID sensitive gel-electrophoresis; stroke-like episodes; transfer-rna; point mutation; phylogenetic network; diabetes-mellitus; lactic-acidosis; coding-region; pcr products; dna
AB Objectives. Many heteroplasmic point mutations in tRNA genes of mitochondrial DNA ( mtDNA) have been associated with human diseases. We recently reported on a prospective 7-year study in which we enrolled 116 consecutive children with undefined encephalomyopathy. Seventeen of them were found to have both a defect in the mitochondrial respiratory chain and abnormal ultrastructure of muscle mitochondria, suggesting a clinically probable mitochondrial encephalopathy. Methods. We determined the frequency of mtDNA mutations in these 17 children by analyzing the entire sequence of mtDNA by conformation-sensitive gel electrophoresis and sequencing. Results. Three heteroplasmic tRNA mutations that were considered to be pathogenic were detected. Two of the mutations were novel transitions, 10438A>G in the tRNAArg gene and 14696A>G in the tRNAGlu gene, whereas the third one was 3243A>G, the common MELAS mutation. The mutant load was very high in the blood and skeletal muscle of the patients and markedly lower in the blood of asymptomatic maternal relatives. The 10438A>G mutation changes the nucleotide flanking the anticodon, whereas 14696A>G changes a nucleotide in the stem of the pseudouridine loop, creating a novel base pair and reducing the wobble. Conclusions. Our results emphasize that the analysis of the entire sequence of mtDNA is worthwhile in the diagnostic evaluation of patients with clinically probable mitochondrial encephalomyopathy. The frequency of pathogenic mtDNA mutations was found to be 18% among children with biochemically and histologically defined mitochondrial disease, suggesting that the likelihood of nuclear DNA mutations in such a group is several times higher than that of mtDNA mutations.
C1 Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Pediat, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland.
   Univ Oulu, Bioctr, FIN-90014 Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu
RP Univ Oulu, Dept Neurol, POB 5000, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   Brulé H, 1998, NUCLEIC ACIDS RES, V26, P537, DOI 10.1093/nar/26.2.537
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finnilä S, 1999, MUTAT RES-GENOMICS, V406, P109, DOI 10.1016/S1383-5726(99)00007-2
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Helm M, 1999, BIOCHEMISTRY-US, V38, P13338, DOI 10.1021/bi991061g
   Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   Körkkö J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260
   Meinilä M, 2001, HUM HERED, V52, P160, DOI 10.1159/000053372
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Servidei S, 2000, NEUROMUSCUL DISORD, V10, P0
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Torroni A, 1996, GENETICS, V144, P1835
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   WERLE E, 1994, NUCLEIC ACIDS RES, V22, P4354, DOI 10.1093/nar/22.20.4354
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
NR 30
TC 45
Z9 48
U1 1
U2 5
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD AUG 15
PY 2004
VL 114
IS 2
BP 443
EP 450
DI 10.1542/peds.114.2.443
PG 8
WC Pediatrics
SC Pediatrics
GA 842YG
UT WOS:000223040000016
PM 15286228
DA 2024-11-01
ER

PT J
AU Roy, MD
   Wittenhagen, LM
   Vozzella, BE
   Kelley, SO
AF Roy, MD
   Wittenhagen, LM
   Vozzella, BE
   Kelley, SO
TI Interdomain communication between weak structural elements within a disease-related human tRNA
SO BIOCHEMISTRY
LA English
DT Article
ID mitochondrial transfer-rna; phenylalanine transfer-rna; stroke-like episodes; crystal-structure; lactic-acidosis; dna mutations; aminoacylation; encephalopathy; resolution; myopathy
AB The structure of the human mitochondrial (hs mt) tRNA(Leu(UUR)) features several domains that are predicted to exhibit limited thermodynamic stability. An elevated frequency of disease-related mutations within these domains suggests a link between structural instability and the functional effects of pathogenic mutations. A series of tRNAs featuring mutations within the D and anticodon stems were prepared and investigated using nuclease probing. Structural mapping studies indicated that these domains were partially denatured for the wild type (WT) hs mt tRNA(Leu(UUR)) and were significantly stabilized by mutations introducing additional or stronger base pairs into the stem regions. In addition, trends in the aminoacylation activities of the D stem mutants suggested that the loose structure is required for function, with mutants displaying the most ordered structures exhibiting the lowest levels of aminoacylation activity. A pronounced interdependence of the structures of the anticodon and D stems was observed, with mutations strengthening the D stem stabilizing the anticodon stem and vice versa. The existence of strong interdomain communication was further elucidated with a mutant of hs mt tRNA(Leu(UUR)) containing a stabilized D stem and a pathogenic mutation that disrupted the anticodon stem. Strengthening the structure of the D stem completely restored the function of the disease-related mutant to WT levels, indicating that propagated structural weaknesses contribute to the functional deactivation of this tRNA by mutations.
C1 Boston Coll, Eugene F Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.
C3 Boston College
RP Boston Coll, Eugene F Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.
EM shana.kelley@bc.edu
FU NIGMS NIH HHS [R01 GM063890-01A2] Funding Source: Medline
CR Beuning PJ, 1999, ANAL BIOCHEM, V273, P284, DOI 10.1006/abio.1999.4223
   Bullard JM, 2000, BBA-GENE STRUCT EXPR, V1490, P245, DOI 10.1016/S0167-4781(99)00240-7
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dirheimer G, 1995, P93, V0, P0
   El Meziane A, 1998, NAT GENET, V18, P350
   *EM U, 2000, MITOMAP HUM MIT GEN, V0, P0
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   GAUSS DH, 1979, TRANSFER RNA STRUCTU, V0, P520
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   SCHIMMEL PR, 1979, TRANSFER RNA STRUCTU, V0, P297
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   *SCRIPPS RES I, 2000, OL EXT COEFF CALC, V0, P0
   SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964
   Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0
   Tsukuda K, 1997, DIABETIC MED, V14, P1032, DOI 10.1002/(SICI)1096-9136(199712)14:12<1032::AID-DIA504>3.0.CO;2-Y
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 30
TC 9
Z9 9
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
EI 
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 20
PY 2004
VL 43
IS 2
BP 384
EP 392
DI 10.1021/bi035711z
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 763RH
UT WOS:000188113900011
PM 14717592
DA 2024-11-01
ER

PT J
AU Crofts, AR
AF Crofts, AR
TI The cytochrome bc<sub>1</sub> complex:: Function in the context of structure
SO ANNUAL REVIEW OF PHYSIOLOGY
LA English
DT Review
DE antimycin; stigmatellin; myxothiazol; superoxide; mechanism
ID iron-sulfur protein; mitochondrial electron-transport; ubiquinone binding-capacity; forming hydrogen-bonds; scale domain movement; fe-s protein; rhodobacter-sphaeroides; q(o) site; quinol oxidation; bovine heart
AB The bc(1) complexes are intrinsic membrane proteins that catalyze the oxidation of ubihydroquinone and the reduction of cytochrome c in mitochondrial respiratory chains and bacterial photosynthetic and respiratory chains. The bc(1) complex operates through a Q-cycle mechanism that couples electron transfer to generation of the proton gradient that drives ATP synthesis. Genetic defects leading to mutations in proteins of the respiratory chain, including the subunits of the bc(1) complex, result in mitochondrial myopathies, many of which are a direct result of dysfunction at catalytic sites. Some myopathies, especially those in the cytochrome b subunit, exacerbate free-radical damage by enhancing superoxide production at the ubihydroquinone oxidation site. This bypass reaction appears to be an unavoidable feature of the reaction mechanism. Cellular aging is largely attributable to damage to DNA and proteins from the reactive oxygen species arising from superoxide and is a major contributing factor in many diseases of old age. An understanding of the mechanism of the bc(1) complex is therefore central to our understanding of the aging process. In addition, a wide range of inhibitors that mimic the quinone substrates are finding important applications in clinical therapy and agronomy. Recent structural studies have shown how many of these inhibitors bind, and have provided important clues to the mechanism of action and the basis of resistance through mutation. This paper reviews recent advances in our understanding of the mechanism of the bc(1) complex and their relation to these physiologically important issues in the context of the structural information available.
C1 Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
   Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign
RP Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
EM a-crofts@life.uiuc.edu
FU FIC NIH HHS [1 R03 TW01495] Funding Source: Medline; NIGMS NIH HHS [GM 62954, GM 35438] Funding Source: Medline
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   ANDREWS KM, 1984, PURIFICATION CHARACT, V0, P0
   Bartlett DW, 2002, PEST MANAG SCI, V58, P649, DOI 10.1002/ps.520
   Bartoschek S, 2001, J BIOL CHEM, V276, P35231, DOI 10.1074/jbc.C100365200
   BEAUTEMENT K, 1991, PESTIC SCI, V31, P499, DOI 10.1002/ps.2780310406
   BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Berry EA, 1999, BIOCHEM SOC T, V27, P565, DOI 10.1042/bst0270565
   Berry EA, 1999, J BIOENERG BIOMEMBR, V31, P177, DOI 10.1023/A:1005459426843
   Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005
   BOVERIS A, 1984, METHOD ENZYMOL, V105, P429
   BOWYER JR, 1980, BIOCHIM BIOPHYS ACTA, V592, P445, DOI 10.1016/0005-2728(80)90091-2
   BOWYER JR, 1982, J BIOL CHEM, V257, P8321
   BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x
   Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4
   BRANDT U, 1991, J BIOL CHEM, V266, P19958
   Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g
   Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   CLOUGH JM, 1995, CHEM BRIT, V31, P466
   Colbert CL, 2000, STRUCTURE, V8, P1267, DOI 10.1016/S0969-2126(00)00536-0
   Covián R, 2002, J BIOL CHEM, V277, P48449, DOI 10.1074/jbc.M208060200
   Covián R, 2001, EUR J BIOCHEM, V268, P5783, DOI 10.1046/j.0014-2956.2001.02521.x
   Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477
   Crofts AR, 1985, ENZYMES BIOCLOGICAL, V4, P347
   Crofts AR, 1999, PHOTOTROPHIC PROKARY, V0, P229
   Crofts AR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1481
   Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15827, DOI 10.1021/bi990963e
   Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m
   CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6
   Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u
   Crofts AR, 2003, J BIOL CHEM, V278, P36191, DOI 10.1074/jbc.M305461200
   Crofts AR, 2002, BBA-BIOENERGETICS, V1555, P48, DOI 10.1016/S0005-2728(02)00253-0
   Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2
   CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768
   CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2
   Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021
   Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5
   Crofts AR, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P493
   CROFTS AR, 2002, P C PHOT RES 12 BRIS, V0, P0
   CROFTS AR, 2003, IN PRESS BIOCH BIOPH, V0, P0
   CROFTS AR, 2003, IN PRESS PHOTOSYNTH, V0, P0
   Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337
   Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567
   Darrouzet E, 2003, BIOCHEMISTRY-US, V42, P1499, DOI 10.1021/bi026656h
   Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200
   Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7
   Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p
   DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N
   DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8
   Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085
   DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X
   DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5
   DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0
   DEVRIES S, 1982, FUNCTION QUINONES EN, V0, P235
   DEVRIES S, 1983, THESIS AMSTERDAM U T, V0, P0
   Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012
   DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015
   Dutton P L, 1978, METHODS ENZYMOL, V54, P411
   DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x
   Engstrom G, 2002, J BIOL CHEM, V277, P31072, DOI 10.1074/jbc.M202594200
   Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x
   Fivelman Quinton L, 2002, MALAR J, V1, P1
   Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814
   Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p
   Garland PB, 1975, ELECTRON TRANSFER CHAINS AND OXIDATIVE PHOSPHORYLATION, V0, P351
   GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5
   GLASER EG, 1984, FEBS LETT, V178, P336, DOI 10.1016/0014-5793(84)80629-8
   Graige MS, 1999, BIOCHEMISTRY-US, V38, P11465, DOI 10.1021/bi990708u
   GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014
   Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+
   HACKER B, 1994, BIOCHEMISTRY-US, V33, P13022, DOI 10.1021/bi00248a011
   HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033
   HACKER B, 1994, THESIS U ILLINOIS UR, V0, P0
   Hansen KC, 2000, BBA-BIOENERGETICS, V1456, P121, DOI 10.1016/S0005-2728(99)00107-3
   Harman D, 1992, EXS, V62, P1
   Hoek TLV, 1997, J MOL CELL CARDIOL, V29, P2441
   Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931
   Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0
   Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0
   Hunte C, 2002, BBA-BIOENERGETICS, V1555, P21, DOI 10.1016/S0005-2728(02)00249-9
   Hunte C, 2001, FEBS LETT, V504, P126, DOI 10.1016/S0014-5793(01)02744-2
   IWATA M, 2001, THESIS UPPSALA U SWE, V0, P0
   Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64
   Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0
   Jordan DB, 1999, PESTIC SCI, V55, P105, DOI 10.1002/(SICI)1096-9063(199902)55:2<105::AID-PS879>3.0.CO;2-D
   Jünemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603
   Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200
   Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026
   King TE, 1975, ELECTRON TRANSFER CHAINS AND OXIDATIVE PHOSPHORYLATION, V0, P105
   Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200
   Kresge AJ, 1999, METHODS ENZYMOL, V308, P276
   Kristal BS, 1997, FREE RADICAL BIO MED, V22, P823, DOI 10.1016/S0891-5849(96)00428-5
   Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591
   Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699
   LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584
   LINK TA, 1995, J BIOL CHEM, V270, P25001, DOI 10.1074/jbc.270.42.25001
   Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2
   Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X
   MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X
   MATSUURA K, 1983, J BIOL CHEM, V258, P1571
   Meinhardt S W, 1984, ADVANCES IN PHOTOSYNTHESIS RESEARCH, V1, P649
   MEINHARDT SW, 1983, BIOCHIM BIOPHYS ACTA, V723, P219, DOI 10.1016/0005-2728(83)90121-4
   MEINHARDT SW, 1982, FEBS LETT, V149, P217, DOI 10.1016/0014-5793(82)81104-6
   MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6
   MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7
   MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096
   Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e
   Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9
   Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160
   Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x
   Nitschke W, 1997, PHOTOSYNTHESIS: A COMPREHENSIVE TREATISE, V0, P285
   OHNISHI T, 1980, J BIOL CHEM, V255, P3278
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972
   Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200
   Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427
   Pines E, 1997, CHEM PHYS LETT, V281, P413, DOI 10.1016/S0009-2614(97)01245-1
   Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398
   RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E
   RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V592, P506, DOI 10.1016/0005-2728(80)90095-X
   RICH PR, 1981, BIOCHIM BIOPHYS ACTA, V637, P28, DOI 10.1016/0005-2728(81)90206-1
   RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X
   Roberts JA, 1997, INORG CHIM ACTA, V263, P395, DOI 10.1016/S0020-1693(97)05668-5
   ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758
   Rose MR, 1998, ARCH NEUROL-CHICAGO, V55, P17, DOI 10.1001/archneur.55.1.17
   SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006
   SALERNO JC, 1989, J BIOL CHEM, V264, P15398
   Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200
   Sauter H, 1996, CROP PROTECTION AGENTS FROM NATURE, V0, P50
   Schröter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x
   Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23
   Sharp RE, 1999, BIOCHEMISTRY-US, V38, P3440, DOI 10.1021/bi982639+
   Sharp RE, 1999, BIOCHEMISTRY-US, V38, P14973, DOI 10.1021/bi9914863
   Shinkarev VP, 2002, BIOCHEMISTRY-US, V41, P14372, DOI 10.1021/bi026198c
   Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j
   Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795
   Slater EC, 1981, CHEMIOSMOTIC PROTON CIRCUITS IN BIOLOGICAL MEMBRANES, V0, P69
   SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5
   Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8
   Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209
   Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535
   Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x
   Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409
   Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146
   Tian H, 2000, J BIOL CHEM, V275, P9587, DOI 10.1074/jbc.275.13.9587
   Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953
   Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6
   TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X
   TSAI AL, 1983, J BIOL CHEM, V258, P2122
   TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0
   Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8
   Ullmann GM, 2002, J BIOL INORG CHEM, V7, P632, DOI 10.1007/s00775-002-0342-6
   VANARK G, 1977, BIOCHIM BIOPHYS ACTA, V459, P119, DOI 10.1016/0005-2728(77)90014-7
   VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253
   WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987
   Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60
   Xiao KH, 2003, J BIOL CHEM, V278, P11419, DOI 10.1074/jbc.M211620200
   Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200
   Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3
   Yu CA, 2002, BBA-BIOENERGETICS, V1555, P65, DOI 10.1016/S0005-2728(02)00256-6
   Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7
   YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017
   Zhang HM, 2003, P NATL ACAD SCI USA, V100, P5160, DOI 10.1073/pnas.0931431100
   Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656
   Zhang Z, 2000, SUBCELL BIOCHEM, V35, P541
   Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612
   ZU Y, 2003, IN PRESS BIOCHEMISTR, V0, P0
   ZWECK A, 1989, EUR J BIOCHEM, V183, P199, DOI 10.1111/j.1432-1033.1989.tb14913.x
NR 172
TC 360
Z9 436
U1 4
U2 61
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4278
EI 1545-1585
J9 ANNU REV PHYSIOL
JI Annu. Rev. Physiol.
PD JUN 15
PY 2004
VL 66
IS 
BP 689
EP 733
DI 10.1146/annurev.physiol.66.032102.150251
PG 49
WC Physiology
SC Physiology
GA 812GK
UT WOS:000220827800027
PM 14977419
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Mancuso, M
   Naini, A
AF DiMauro, S
   Mancuso, M
   Naini, A
TI Mitochondrial encephalomyopathies - Therapeutic approach
SO MITOCHONDRIAL PATHOGENESIS: FROM GENES AND APOPTOSIS TO AGING AND DISEASE
LA English
DT Article; Proceedings Paper
DE encephalomyopathies; mitochondria
ID kearns-sayre syndrome; progressive external ophthalmoplegia; systemic carnitine deficiency; nadh-quinone oxidoreductase; complex-iii deficiency; stroke-like episodes; skeletal-muscle; coenzyme q(10); lactic-acidosis; in-vitro
AB Therapy for mitochondrial diseases is woefully inadequate. However, lack of cure does not equate with lack of treatment. In this review, we consider sequentially several different therapeutic approaches. Palliative therapy is dictated by good medical practice and includes anticonvulsant medication, control of endocrine dysfunction, and surgical procedures. Removal of noxious metabolites is centered on combating lactic acidosis, but it extends to other metabolites, such as thymidine in patients with the mitochondrial neurogastrointestinal encephalomyopathy syndrome. Attempts to bypass blocks in the respiratory chain by administration of artificial electron acceptors have not been successful, but this concept may be amenable to genetic engineering. Administration of metabolites and cofactors is the mainstay of real-life therapy and includes both components of the respiratory chain and other natural compounds. There is increasing interest in the administration of reactive oxygen species scavengers both in primary mitochondrial diseases and in neurodegenerative diseases directly or indirectly related to mitochondrial dysfunction. Aerobic exercise and physical therapy prevent or correct deconditioning and improve exercise tolerance in patients with mitochondrial myopathies due to mtDNA mutations. Gene therapy is a challenge because of polyplasmy and heteroplasmy, but interesting experimental approaches are being pursued and include, for example, decreasing the ratio of mutant to wild-type mitochondrial genomes (gene shifting), converting mutated mtDNA genes into normal nDNA genes (allotropic expression), importing cognate genes from other species, or correcting mtDNA mutations with specific restriction endonucleases. Germline therapy raises ethical problems but is being seriously considered to prevent maternal transmission of mtDNA mutations. Preventive therapy through genetic counseling and prenatal diagnosis is still limited for mtDNA-related disorders but is becoming increasingly important for nDNA-related disorders.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St,4-420, New York, NY 10032 USA.
EM sd12@Columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ALLEN RJ, 1983, ANN NEUROL, V13, P679, DOI 10.1002/ana.410130620
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   Beal MF, 2002, MITOCHONDRIAL DISORD, V0, PP17, DOI 10.1007/978-2-8178-0929-8_3
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BRESOLIN N, 1988, NEUROLOGY, V38, P892, DOI 10.1212/WNL.38.6.892
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Buyse G, 2003, NEUROLOGY, V60, P1679, DOI 10.1212/01.WNL.0000068549.52812.0F
   Chang SC, 1998, INT J ANTIMICROB AG, V10, P245, DOI 10.1016/S0924-8579(98)00040-5
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DEVIVO DC, 1990, ANN NEUROL, V28, P437
   DEVIVO DC, 1999, PEDIAT NEUROLOGY PRI, V1, P494
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DIMAURO S, 2002, MITOCHONDRIAL DISORD, V0, P307
   Dubern B, 2001, TRANSPLANTATION, V71, P633, DOI 10.1097/00007890-200103150-00009
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   Filla A, 2003, NEUROLOGY, V60, P1569, DOI 10.1212/01.WNL.0000067492.13062.DC
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   HAYES S, 2000, AMYOTROPH LATERAL S3, V3, P119
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Ikejiri Y, 1996, NEUROLOGY, V47, P583, DOI 10.1212/WNL.47.2.583
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   KENNAWAY NG, 1984, PEDIATR RES, V18, P991
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kuroda Y, 1997, J PEDIATR-US, V131, P450, DOI 10.1016/S0022-3476(97)80075-3
   Lamhonwah AM, 1998, BIOCHEM BIOPH RES CO, V252, P396, DOI 10.1006/bbrc.1998.9679
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Lodi R, 2001, ANN NEUROL, V49, P590
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mariotti C, 2003, NEUROLOGY, V60, P1676, DOI 10.1212/01.WNL.0000055872.50364.FC
   MATSUOKA T, 1992, NEUROMUSCULAR DISORD, V1, P443
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030
   Nishino I, 2000, ANN NEUROL, V47, P792
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Puoti G, 2003, J MED GENET, V40, P858, DOI 10.1136/jmg.40.11.858
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   RUBENSTEIN DS, 1995, CAMB Q HEALTHC ETHIC, V4, P316, DOI 10.1017/S0963180100006071
   Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Santorelli FM, 2002, NEUROMUSCULAR DISORD, V12, P56, DOI 10.1016/S0960-8966(01)00248-6
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167
   SERVIDEI S, 2002, MITOCHONDRIAL DISORD, V0, P37
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHERWOOD G, 1989, J INHERIT METAB DIS, V12, P393, DOI 10.1007/BF03335432
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   STANLEY CA, 1991, ANN NEUROL, V30, P709, DOI 10.1002/ana.410300512
   Sue CM, 2000, BRAIN PATHOL, V10, P442
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   TABRIZI SJ, 2002, MITOCHONDRIAL DISORD, V2, P143
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020
   TEIN I, 1993, PEDIATR RES, V34, P281, DOI 10.1203/00006450-199309000-00008
   Thorburn DR, 2001, MITOCHONDRION, V1, P123, DOI 10.1016/S1567-7249(01)00013-7
   TRANCHANT C, 1993, NEUROMUSCULAR DISORD, V3, P561, DOI 10.1016/0960-8966(93)90116-2
   White SL, 1999, PRENATAL DIAG, V19, P1165, DOI 10.1002/(SICI)1097-0223(199912)19:12<1165::AID-PD719>3.3.CO;2-4
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   YAMAMOTO M, 1987, J NEUROL NEUROSUR PS, V50, P1475, DOI 10.1136/jnnp.50.11.1475
NR 91
TC 44
Z9 50
U1 0
U2 6
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2004
VL 1011
IS 
BP 232
EP 245
DI 10.1196/annals.1293.023
PG 14
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BAE70
UT WOS:000221896100023
PM 15126300
DA 2024-11-01
ER

PT J
AU McFarland, R
   Taylor, RW
   Chinnery, PF
   Howell, N
   Turnbull, DM
AF McFarland, R
   Taylor, RW
   Chinnery, PF
   Howell, N
   Turnbull, DM
TI A novel sporadic mutation in cytochrome <i>c</i> oxidase subunit II as a cause of rhabdomyolysis
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; tRNA mutations; cytochrome c oxidase; myoglobinuria; DNA sequencing
ID human mitochondrial-dna; recurrent myoglobinuria; exercise intolerance; nonsense mutation; b gene; patient
AB Disorders of the mitochondrial genome are an important cause of neurological disease, with patients presenting a variety of different phenotypes. Exercise induced muscle pain and myoglobinuria have been described with a number of metabolic defects, but because of the enormous variability of the mitochondrial genome identifying causative mitochondrial DNA mutations can be extremely difficult. Since mitochondrial tRNA genes were considered to be hot spots for mutation, sequencing was initially often confined to these genes. In a patient with symptoms and signs of exercise intolerance and myoglobinuria we originally ascribed pathogenicity to a mitochondrial-tRNA(Phe) mutation but here we show that the true pathogenic mutation was a novel mutation in the gene encoding subunit II of cytochrome c oxidase. We believe that this study demonstrates the importance of whole mitochondrial genome sequencing and of access to large sequence databases. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Newcastle Upon Tyne, Sch Med, Dept Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Mitokor, San Diego, CA USA.
   Univ Texas, Med Branch, Dept Radiat Oncol, Galveston, TX 77550 USA.
   Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77550 USA.
C3 Newcastle University - UK; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston
RP Univ Newcastle Upon Tyne, Sch Med, Dept Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
CR Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chapiro E, 2002, EUR J HUM GENET, V10, P851, DOI 10.1038/sj.ejhg.5200894
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   Finnilä S, 1999, MUTAT RES-GENOMICS, V406, P109, DOI 10.1016/S1383-5726(99)00007-2
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MCFARLAND R, 2003, IN PRESS ANN NEUROL, V0, P0
   *MITOMAP, 2003, HUM MIT GEN DAT, V0, P0
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
NR 17
TC 53
Z9 54
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD FEB 15
PY 2004
VL 14
IS 2
BP 162
EP 166
DI 10.1016/j.nmd.2003.10.011
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 771VA
UT WOS:000188805700007
PM 14733964
DA 2024-11-01
ER

PT J
AU Vallance, HD
   Jeven, G
   Wallace, DC
   Brown, MD
AF Vallance, HD
   Jeven, G
   Wallace, DC
   Brown, MD
TI A case of sporadic infantile histiocytoid cardiomyopathy caused by the A8344G (MERRF) mitochondrial DNA mutation
SO PEDIATRIC CARDIOLOGY
LA English
DT Article
DE cardiomyopathy; mitochondria disorder; MERRF; mtDNA defect
ID cytochrome-b; deficiency; sco2; gene
AB The A8344G mitochondrial DNA (mtDNA) mutation is best known for the MERRF phenotype (myoclonic epilepsy, myopathy, and ragged red fibers). We describe a sporadic case of an infant with the A8344G mtDNA mutation who presented with failure to thrive and sudden unexpected death at 11 months of age. The autopsy revealed a histiocytold cardiomyopathy, diffuse steatosis of the liver, and bilateral retinal hypoplasia. Electron micrographs of cardiac myocytes showed striking mitochondrial hyperplasia, dispersing the sarcomeres. Special stains of frozen heart muscle showed an absence of complex IV (cytochrome c oxidase) in many of the myocytes. Both complexes I and IV of the respiratory chain were reduced in cardiac muscle. The A8344G mtDNA mutation was detected in both liver and cardiac muscle tissue. To our knowledge, this is the first description of the A8344G mtDNA mutation presenting as a sporadic case of fatal infantile cardiomyopathy and the first occurence of this mutation associated with histiocytoid cardiomyopathy.
C1 Univ British Columbia, Childrens & Womens Hlth Ctr BC, Dept Pathol, Vancouver, BC V6H 3N1, Canada.
   Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA.
   Mercer Univ, Sch Med, Macon, GA 31207 USA.
C3 University of British Columbia; BC Women's Hospital & Health Centre; Emory University; Mercer University
RP Vallance, HD (corresponding author), Univ British Columbia, Childrens & Womens Hlth Ctr BC, Dept Pathol, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.
CR Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008
   Hirano M, 1996, HANDBOOK OF MUSCLE DISEASE, V0, P479
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   MALHOTRA V, 1994, AM HEART J, V128, P1009, DOI 10.1016/0002-8703(94)90601-7
   Marin-Garcia J, 2000, J INHERIT METAB DIS, V23, P625, DOI 10.1023/A:1005638231195
   OTANI M, 1995, PATHOL INT, V45, P774, DOI 10.1111/j.1440-1827.1995.tb03396.x
   PAPADIMITRIOU A, 1984, PEDIATR RES, V18, P1023, DOI 10.1203/00006450-198418100-00023
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   RUSZKIEWICZ AR, 1995, AM J FOREN MED PATH, V16, P74, DOI 10.1097/00000433-199503000-00017
   SCHULZ MD, 1962, ARCHIVES PATHOLOGY, V74, P464
   Shehata BM, 1998, PEDIATR DEVEL PATHOL, V1, P56, DOI 10.1007/s100249900007
   Stratilova L, 1999, CAS LEK CESK, V138, P401
NR 12
TC 41
Z9 44
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0172-0643
EI 
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
PD SEP-OCT 15
PY 2004
VL 25
IS 5
BP 538
EP 540
DI 10.1007/s00246-003-0446-y
PG 3
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA 861ZR
UT WOS:000224459200018
PM 15164143
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Conforti, FL
   Rocchi, A
   Tessitore, A
   Muglia, M
   Tedeschi, G
   Panza, D
   Monsurrò, M
   Sola, P
   Mandrioli, J
   Choub, A
   DelCorona, A
   Manca, ML
   Mazzei, R
   Sprovieri, T
   Filosto, M
   Salviati, A
   Valentino, P
   Bono, F
   Caracciolo, M
   Simone, IL
   La Bella, V
   Majorana, G
   Siciliano, G
   Murri, L
   Quattrone, A
AF Mancuso, M
   Conforti, FL
   Rocchi, A
   Tessitore, A
   Muglia, M
   Tedeschi, G
   Panza, D
   Monsurrò, M
   Sola, P
   Mandrioli, J
   Choub, A
   DelCorona, A
   Manca, ML
   Mazzei, R
   Sprovieri, T
   Filosto, M
   Salviati, A
   Valentino, P
   Bono, F
   Caracciolo, M
   Simone, IL
   La Bella, V
   Majorana, G
   Siciliano, G
   Murri, L
   Quattrone, A
TI Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis?
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE ALS; mtDNA; haplogroups
ID dna haplogroups; skeletal-muscle; neuron disease; gene-mutations; als patients; locus; impairment; transport; risk; form
AB Mitochondrial impairment has been implicated in the pathogenesis of the amyotrophic lateral sclerosis (ALS). Furthermore, mitochondrial-specific polymorphisms were previously related to other neurodegenerative diseases, such as Parkinson, Friedreich and Alzheimer disease. To investigate if specific genetic polymorphisms within the mitochondrial genome (mtDNA) could act as susceptibility factors and contribute to the clinical expression of sporadic ALS (sALS), we have genotyped predefined European mtDNA haplogroups in 222 Italian patients with sALS and 151 matched controls. Individuals classified as haplogroup I demonstrated a significant decrease in risk of ALS versus individuals carrying the most common haplogroup, H (odds ratio 0.08, 95% confidence interval 0.04-0.4, p < 0.01). Further stratification of the dataset by sex, age and site of onset of disease and survival failed to reach significance for association. Our study provides evidence of the contribution of mitochondrial variation to the risk of ALS development in Caucasians. Further it may help elucidate the mechanism of the mitochondrial dysfunction detectable in ALS, and may be of relevance in development of strategies for the treatment of this disease. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Pisa, Neurol Clin, Dept Neurosci, I-56126 Pisa, Italy.
   CNR, Inst Neurol Sci, Cosenza, Italy.
   Univ Naples 2, Div Neurol 2, Naples, Italy.
   Univ Modena, Dept Neurosci, I-41100 Modena, Italy.
   Univ Verona, Dept Neurol Sci & Vis, Sect Clin Neurol, I-37100 Verona, Italy.
   Univ Magna Graecia, Neurol Inst, Catanzaro, Italy.
   Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy.
   Univ Palermo, Dept Neurol & Psychiat, Palermo, Italy.
   Univ Messina, Dept Neurosci Psychiat & Anaesthesiol Sci, Messina, Italy.
C3 University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Neurologiche (ISN-CNR); Universita della Campania Vanvitelli; Universita di Modena e Reggio Emilia; University of Verona; Magna Graecia University of Catanzaro; Universita degli Studi di Bari Aldo Moro; University of Palermo; University of Messina
RP Mancuso, M (corresponding author), Univ Pisa, Neurol Clin, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.
EM mmancuso@inwind.it
CR Abalkhail H, 2003, AM J HUM GENET, V73, P383, DOI 10.1086/377156
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Chen YZ, 2004, AM J HUM GENET, V74, P1128, DOI 10.1086/421054
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   deBelleroche J, 1996, J NEUROPATH EXP NEUR, V55, P747
   Dhaliwal GK, 2000, NEUROREPORT, V11, P2507, DOI 10.1097/00001756-200008030-00032
   Echaniz-Laguna A, 2002, ANN NEUROL, V52, P623, DOI 10.1002/ana.10357
   Gajewski CD, 2003, EXP NEUROL, V179, P229, DOI 10.1016/S0014-4886(02)00022-5
   Giacchetti M, 2004, J MED GENET, V41, P293, DOI 10.1136/jmg.2003.015289
   Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166
   Hand CK, 2002, AM J HUM GENET, V70, P251, DOI 10.1086/337945
   Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052
   Mancuso M, 2002, AMYOTROPH LATERAL SC, V3, P215, DOI 10.1080/146608202760839007
   Menzies FM, 2002, NEUROCHEM INT, V40, P543, DOI 10.1016/S0197-0186(01)00125-5
   Nishimura AL, 2004, J MED GENET, V41, P315, DOI 10.1136/jmg.2003.013029
   Orrell RW, 2000, NEUROMUSCULAR DISORD, V10, P63, DOI 10.1016/S0960-8966(99)00071-1
   Ro LS, 2003, MUSCLE NERVE, V28, P737, DOI 10.1002/mus.10504
   ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204
   Sambrook J, 2001, MOLECULAR CLONING: A LABORATORY MANUAL, V3rd, P6
   Sapp PC, 2003, AM J HUM GENET, V73, P397, DOI 10.1086/377158
   Sasaki S, 1996, NEUROLOGY, V47, P535, DOI 10.1212/WNL.47.2.535
   Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866
   Torroni A, 1996, GENETICS, V144, P1835
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339
   Wiedemann FR, 1998, J NEUROL SCI, V156, P65, DOI 10.1016/S0022-510X(98)00008-2
NR 32
TC 59
Z9 65
U1 0
U2 13
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND
SN 0304-3940
EI 
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD NOV 23
PY 2004
VL 371
IS 2-3
BP 158
EP 162
DI 10.1016/j.neulet.2004.08.060
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 872JP
UT WOS:000225203800015
PM 15519748
DA 2024-11-01
ER

PT J
AU Smeitink, JAM
   van den Heuvel, LWPJ
   Koopman, WJH
   Nijtmans, LGJ
   Ugalde, C
   Willems, PHGM
AF Smeitink, JAM
   van den Heuvel, LWPJ
   Koopman, WJH
   Nijtmans, LGJ
   Ugalde, C
   Willems, PHGM
TI Cell biological consequences of mitochondrial NADH: Ubiquinone oxidoreductase deficiency
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Review
DE mitochondria; cell biology; oxidative phosphorylation; Leigh disease; complex I; mitochondrial medicine
ID complex-i deficiency; hereditary optic neuropathy; quinone oxidoreductase; ndufs4 gene; triacylglycerol infusion; prenatal-diagnosis; nonsense mutation; encoded subunits; reactive oxygen; dna-damage
AB Human complex I (NADH:ubiquinone oxidoreductase; EC 1.6.5.3) is the first and largest multi-protein assembly of the mitochondrial oxidative phosphorylation (OXPHOS) system; the final biochemical cascade of events leading to the production of ATP. The complex consists of 46 subunits, 7 encoded by the mitochondrial DNA and the remainder by the nuclear genome. In recent years, numerous gene mutations leading to an isolated complex I deficiency have been characterized in both genomes. Disorders associated with complex I deficiency (OMIM 252010) mostly lead to multi-system disorders affecting brain, skeletal muscle and the heart. Of these, Leigh syndrome, a progressive fatal encephalopathy symmetrically affecting specific areas of the brain, brainstem and myelin, is the most frequently observed phenotype. Here, we review the current understanding of the cell biological consequences of isolated complex I deficiencies and propose further directions the field needs to take in order to develop rational treatment strategies for these devastating disorders.
C1 Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen
RP Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, Geert Grooteplein 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM J.Smeitink@cukz.umcn.nl
CR Ahlers PM, 2000, BBA-BIOENERGETICS, V1459, P258, DOI 10.1016/S0005-2728(00)00160-2
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ANTONICKA H, 2003, J BIOL CHEM, V0, P0
   Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210
   Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2
   BIA Y, 2001, J BIOL CHEM, V276, P38808
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Chung RS, 2003, J NEUROSCI, V23, P3336
   CLEETER MWJ, 1992, J NEUROCHEM, V58, P786, DOI 10.1111/j.1471-4159.1992.tb09789.x
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200
   FARRANTS GW, 1988, MUSCLE NERVE, V11, P45, DOI 10.1002/mus.880110109
   Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200
   Filosto M, 2003, NEUROPATH APPL NEURO, V29, P52, DOI 10.1046/j.1365-2990.2003.00411.x
   Filosto M, 2002, ACTA NEUROPATHOL, V103, P215, DOI 10.1007/s004010100455
   Gabaldón T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463
   Galante Y M, 1978, METHODS ENZYMOL, V53, P15
   GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1
   Guarente L, 2000, GENE DEV, V14, P1021
   Halliwell B, 1991, AM J MED, V91, P14, DOI 10.1016/0002-9343(91)90279-7
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Janssen R, 2002, HUM GENET, V110, P264, DOI 10.1007/s00439-001-0673-3
   JAUSLIN ML, 2003, FASEB J, V0, P0
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Küffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114
   Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481
   Mannella CA, 2000, J BIOENERG BIOMEMBR, V32, P1, DOI 10.1023/A:1005562109678
   Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7
   Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7
   Molinero A, 2003, J NEUROPATH EXP NEUR, V62, P315, DOI 10.1093/jnen/62.3.315
   MORGANHUGHES JA, 1979, J NEUROL SCI, V43, P27, DOI 10.1016/0022-510X(79)90071-6
   Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107
   Munnich A, 1996, EUR J PEDIATR, V155, P262
   Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1
   Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8
   Niers LEM, 2001, PRENATAL DIAG, V21, P871, DOI 10.1002/pd.162
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   NOHL H, 1989, FREE RADICAL BIO MED, V6, P369, DOI 10.1016/0891-5849(89)90081-6
   OOSTRA RJ, 1995, BIOCHEM BIOPH RES CO, V215, P1001, DOI 10.1006/bbrc.1995.2563
   Papa S, 1996, FEBS LETT, V379, P299, DOI 10.1016/0014-5793(95)01532-9
   Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6
   Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   Pitkanen S, 1996, PEDIATR RES, V39, P513, DOI 10.1203/00006450-199603000-00021
   Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O
   Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4
   Roef MJ, 2002, PEDIATR RES, V51, P592, DOI 10.1203/00006450-200205000-00008
   Roef MJ, 2002, AM J CLIN NUTR, V75, P228, DOI 10.1093/ajcn/75.2.228
   Roef MJ, 2002, AM J CLIN NUTR, V75, P237, DOI 10.1093/ajcn/75.2.237
   Roef MJ, 2002, NEUROLOGY, V58, P1088, DOI 10.1212/WNL.58.7.1088
   Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297
   SCACCO S, 2003, J BIOL CHEM, V0, P0
   SCHOLTE HR, 1988, J BIOENERG BIOMEMBR, V20, P161, DOI 10.1007/BF00768393
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Schuelke M, 2002, CLIN CHEM, V48, P772
   Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200
   SENGERS RCA, 1984, EUR J PEDIATR, V141, P192, DOI 10.1007/BF00572761
   Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167
   Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674
   Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   SMEITINK J, 1992, NEUROMUSCULAR DISORD, V2, P35, DOI 10.1016/0960-8966(92)90024-Z
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Smeitink JAM, 2003, J INHERIT METAB DIS, V26, P199, DOI 10.1023/A:1024489218004
   Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   UGALDE C, 2003, IN PRESS IMPAIRED CO, V0, P0
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Vasconcelos MH, 2002, TOXICOL APPL PHARM, V182, P91, DOI 10.1006/taap.2002.9428
   Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553
   WALKER C, 1992, CARCINOGENESIS, V13, P25, DOI 10.1093/carcin/13.1.25
   WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488
   WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x
   Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200
   Yaffe MP, 2003, NAT CELL BIOL, V5, P497, DOI 10.1038/ncb0603-497b
   Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493
   Yagi T, 2001, J BIOENERG BIOMEMBR, V33, P233, DOI 10.1023/A:1010787004053
   You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2
   Zhang XJ, 2003, J BIOL CHEM, V278, P13503, DOI 10.1074/jbc.M300073200
   Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x
NR 108
TC 53
Z9 54
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD JAN 15
PY 2004
VL 1
IS 1
BP 29
EP 40
DI 10.2174/1567202043480224
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 902LB
UT WOS:000227357500005
PM 16181064
DA 2024-11-01
ER

PT J
AU Gellerich, FN
   Trumbeckaite, S
   Müller, T
   Deschauer, M
   Chen, Y
   Gizatullina, Z
   Zierz, S
AF Gellerich, FN
   Trumbeckaite, S
   Müller, T
   Deschauer, M
   Chen, Y
   Gizatullina, Z
   Zierz, S
TI Energetic depression caused by mitochondrial dysfunction
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Review
DE mitochondria; adenine nucleotides; compartmentation; mtDNA; mutations; genotype-phenotype relations; respiratory chain complexes
ID skeletal-muscle mitochondria; oxidative-phosphorylation; rat-heart; permeability transition; rabbit reticulocytes; adenine-nucleotides; outer-membrane; dynamic compartmentation; external ophthalmoplegia; intermembrane space
AB Mitochondria, providing most of ATP needed for cell work, realizing numerous specific functions as biosyntheses or degradations, contributing to Ca2+ signalling also play a key role in the pathways to cell death. Impairment of mitochondrial functions caused by mutations of mt-genome and by acute processes are responsible for numerous diseases. The relations between changes on the level of molecules and the clinical state are rather complex, and the prediction of thresholds is difficult. Therefore investigations on different levels of an organismus ( genome, metabolites, enzymes, mitochondrial function in vivo and in vitro) are necessary ( multi level approach). Metabolic control theory is a valuable tool for understanding the different effects of mutations on the level of enzyme activities and mitochondrial function. Decreased concentrations of adenine nucleotides, leaky outer and inner mitochondrial membranes, decreased rates of mitochondrial linked pathways and decreased activities of respiratory chain enzymes contribute to depression of cellular energy metabolism characterized by decreased cytosolic phosphorylation potentials as one of the most important consequences of mitochondrial impairments. This review regards classical bioenergetic mechanisms of mitochondrial impairment which contribute to energetic depression.
C1 Univ Halle Wittenberg, Muskellabor Neurol Klin, D-06097 Halle An Der Saale, Germany.
C3 Martin Luther University Halle Wittenberg
RP Univ Halle Wittenberg, Muskellabor Neurol Klin, Julius Kuhn Str 7, D-06097 Halle An Der Saale, Germany.
EM frank.gellerich@medizin.uni-halle.de
CR Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604
   ANDREWS PA, 1992, CANCER RES, V52, P1895
   AUGUSTIN W, 1981, EBEC SHORT REPORTS, V40, P603
   BANK W, 1994, ANN NEUROL, V36, P830, DOI 10.1002/ana.410360606
   Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x
   Bende S Jr, 1992, ACTA CHIR HUNG, V33, P197
   Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2
   Blachly-Dyson E, 2001, IUBMB LIFE, V52, P113
   BOHNENSACK R, 1986, BIOCHIM BIOPHYS ACTA, V850, P72, DOI 10.1016/0005-2728(86)90010-1
   Brand MD, 1998, MOL CELL BIOCHEM, V184, P13, DOI 10.1023/A:1006893619101
   BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R
   Brealey David, 2002, LANCET (NORTH AMERICAN EDITION), V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Brown GC, 1995, BIOENERGETICS: A PRACTICAL APPROACH, V0, P0
   CHEN Y, 2002, EBEC SHORT REPORTS, V12, P323
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Crouser ED, 1999, AM J RESP CRIT CARE, V160, P1347, DOI 10.1164/ajrccm.160.4.9810116
   Crouser ED, 2000, AM J RESP CRIT CARE, V161, P1705, DOI 10.1164/ajrccm.161.5.9907043
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   EVTODIENKO YV, 1994, CELL CALCIUM, V15, P439, DOI 10.1016/0143-4160(94)90108-2
   Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508
   FISCHER JC, 1985, CLIN CHIM ACTA, V145, P89, DOI 10.1016/0009-8981(85)90022-1
   Gallitelli MF, 1999, J PHYSIOL-LONDON, V518, P433, DOI 10.1111/j.1469-7793.1999.0433p.x
   Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47
   GELLERICH F, 1998, J NEUROL, V245, P425
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GELLERICH FN, 1987, BIOCHIM BIOPHYS ACTA, V890, P117, DOI 10.1016/0005-2728(87)90012-0
   GELLERICH FN, 1977, ACTA BIOL MED GER, V36, P571
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1554, P48, DOI 10.1016/S0005-2728(02)00212-8
   Gellerich FN, 2002, BIOSCIENCE REP, V22, P99, DOI 10.1023/A:1016017224003
   Gellerich FN, 2000, BIOCHEM SOC T, V28, P164, DOI 10.1042/bst0280164
   GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5
   GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1140, P327, DOI 10.1016/0005-2728(93)90073-O
   Gellerich FN, 1999, SHOCK, V11, P336, DOI 10.1097/00024382-199905000-00006
   GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R
   Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X
   GORI Z, 1988, BRIT J EXP PATHOL, V69, P639
   GROEN AK, 1982, J BIOL CHEM, V257, P2754
   HALANGK W, 1986, BIOMED BIOCHIM ACTA, V45, P331
   HALANGK W, 1985, BIOMED BIOCHIM ACTA, V44, P411
   Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5
   HALLER T, 1994, ANAL BIOCHEM, V218, P338, DOI 10.1006/abio.1994.1188
   HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x
   HEINRICH R, 1985, BIOMED BIOCHIM ACTA, V44, P913
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HURKO O, 1990, PEDIATR RES, V28, P542, DOI 10.1203/00006450-199011000-00026
   Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3
   Iotti S, 1996, NMR BIOMED, V9, P24, DOI 10.1002/(SICI)1099-1492(199602)9:1<24::AID-NBM392>3.0.CO;2-B
   Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010
   Jassem W, 2002, TRANSPLANTATION, V73, P493, DOI 10.1097/00007890-200202270-00001
   JENNINGS RB, 1975, AM J PATHOL, V81, P179
   JENNINGS RB, 1981, AM J PATHOL, V102, P241
   JENNINGS RB, 1969, LAB INVEST, V20, P548
   Joshi MS, 2000, ANAL CELL PATHOL, V21, P41, DOI 10.1155/2000/201406
   JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0
   KACSER H, 1981, GENETICS, V97, P639
   Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149
   KACSER H, 1983, BIOCHEM SOC T, V11, P35, DOI 10.1042/bst0110035
   KAMMERMEIER H, 1987, J MOL CELL CARDIOL, V19, P115, DOI 10.1016/S0022-2828(87)80550-3
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kay L, 1997, MOL CELL BIOCHEM, V174, P79, DOI 10.1023/A:1006884607272
   Kay L, 1997, CARDIOVASC RES, V34, P547, DOI 10.1016/S0008-6363(97)00058-8
   Kemp GJ, 2002, MOL BIOL REP, V29, P187, DOI 10.1023/A:1020325812680
   Knecht W, 2000, ADV EXP MED BIOL, V486, P267
   Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6
   KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017
   Kudoh A, 1998, CRIT CARE MED, V26, P138, DOI 10.1097/00003246-199801000-00029
   KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F
   Kunz WS, 2001, BBA-BIOENERGETICS, V1504, P12, DOI 10.1016/S0005-2728(00)00235-8
   KUSTER U, 1976, BIOCHIM BIOPHYS ACTA, V440, P391, DOI 10.1016/0005-2728(76)90073-6
   Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6
   Laterveer FD, 1997, MOL CELL BIOCHEM, V174, P43, DOI 10.1023/A:1006899621926
   Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, PH1544, DOI 10.1152/ajpheart.1997.273.3.H1544
   LETELLIER T, 1992, PEDIATR RES, V32, P17, DOI 10.1203/00006450-199207000-00004
   Loffler M, 1997, MOL CELL BIOCHEM, V174, P125, DOI 10.1023/A:1006859115450
   Lombardi A, 2000, FEBS LETT, V475, P84, DOI 10.1016/S0014-5793(00)01633-1
   Lubisch W, 2002, BIOORG MED CHEM LETT, V12, P1335, DOI 10.1016/S0960-894X(02)00176-2
   LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L
   LUFT R, 1995, J INTERN MED, V238, P405, DOI 10.1111/j.1365-2796.1995.tb01218.x
   LUFT R, 1992, MT SINAI J MED, V59, P140
   Manfredi G, 2000, BRAIN PATHOL, V10, P462
   Maragos WF, 1998, EXP NEUROL, V154, P637, DOI 10.1006/exnr.1998.6918
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Mazat JP, 1997, MOL CELL BIOCHEM, V174, P143, DOI 10.1023/A:1006875517267
   MITHOFER K, 1992, ARCH BIOCHEM BIOPHYS, V295, P132, DOI 10.1016/0003-9861(92)90498-L
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   MULLER T, 2001, EUR J MED RES S, V5, P12
   Opalka JR, 2002, BIOCHEM PHARMACOL, V63, P725, DOI 10.1016/S0006-2952(01)00867-X
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Pedersen P L, 1978, PROG EXP TUMOR RES, V22, P190
   Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7
   POSTON JM, 1992, ARCH BIOCHEM BIOPHYS, V295, P35, DOI 10.1016/0003-9861(92)90484-E
   RAPOPORT SM, 1983, BIOMED BIOCHIM ACTA, V42, P5
   Rasmussen HN, 1997, MOL CELL BIOCHEM, V174, P55, DOI 10.1023/A:1006851705996
   Rawls J, 2000, EUR J BIOCHEM, V267, P2079, DOI 10.1046/j.1432-1327.2000.01213.x
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Rustin P, 2002, EUR J HUM GENET, V10, P289, DOI 10.1038/sj.ejhg.5200793
   SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X
   Schild L, 1998, EUR J BIOCHEM, V252, P508, DOI 10.1046/j.1432-1327.1998.2520508.x
   SCHLAME M, 1981, ACTA BIOL MED GER, V40, P617
   Scholte HR, 1997, MOL CELL BIOCHEM, V174, P61, DOI 10.1023/A:1006803807814
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Schulte-Mattler WJ, 2003, ARCH NEUROL-CHICAGO, V60, P50, DOI 10.1001/archneur.60.1.50
   SCHULTZE M, 1972, EUR J BIOCHEM, V27, P43, DOI 10.1111/j.1432-1033.1972.tb01808.x
   SCHUMER W, 1971, SURG GYNECOL OBSTETR, V133, P433
   Selivanov VA, 1998, BIOPHYS CHEM, V72, P111, DOI 10.1016/S0301-4622(98)00127-6
   SIMONSON SG, 1994, CIRC SHOCK, V43, P34
   SINGH KK, 1998, MITOCHONDRIAL DNA MU, V0, P1
   Skulachev VP, 2000, IUBMB LIFE, V49, P365, DOI 10.1080/152165400410209
   Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743
   SPENGLER V, 1981, ACTA BIOL MED GER, V40, P973
   Sperl W, 1997, MOL CELL BIOCHEM, V174, P71, DOI 10.1023/A:1006880529195
   SUZUKI K, 1995, BIOL CHEM H-S, V376, P523
   Trumbeckaite S, 2003, BIOCHEM PHARMACOL, V65, P911, DOI 10.1016/S0006-2952(02)01610-6
   Trumbeckaite S, 2001, EUR J BIOCHEM, V268, P1422, DOI 10.1046/j.1432-1327.2001.02012.x
   TRUMBECKAITE S, 2000, THESIS M LUTHER U HA, V0, P0
   VANDEGAER KM, 1982, BIOCHEM BIOPH RES CO, V109, P442, DOI 10.1016/0006-291X(82)91741-7
   VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5
   VONARDENNE M, 1988, MED HYPOTHESES, V25, P163, DOI 10.1016/0306-9877(88)90054-0
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   WALLACE DC, 1994, EPILEPSIA, V35, PS43, DOI 10.1111/j.1528-1157.1994.tb05928.x
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1993, SCIENCE, V256, P128
   Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748
   WARBURG O, 1970, Z NATURFORSCH PT B, VB 25, P332, DOI 10.1515/znb-1970-0332
   Wasniewska M, 2001, BIOCHEM BIOPH RES CO, V283, P687, DOI 10.1006/bbrc.2001.4834
   WEINHOUSE S, 1972, CANCER RES, V32, P2007
   WISNIEWSKI E, 1993, J BIOL CHEM, V268, P9343
   Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361
   WU EY, 1990, ARCH BIOCHEM BIOPHYS, V282, P358, DOI 10.1016/0003-9861(90)90129-M
   Wussling MHP, 1999, FEBS LETT, V463, P103, DOI 10.1016/S0014-5793(99)01595-1
   Zhang CF, 1997, BIOCHEM BIOPH RES CO, V230, P630, DOI 10.1006/bbrc.1996.6020
   ZIERZ S, 1989, NERVENARZT, V60, P545
NR 137
TC 32
Z9 39
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN-FEB 15
PY 2004
VL 256
IS 1-2
BP 391
EP 405
DI 10.1023/B:MCBI.0000009885.34498.e6
PG 15
WC Cell Biology
SC Cell Biology
GA 757AA
UT WOS:000187516900034
PM 14977198
DA 2024-11-01
ER

PT J
AU Da Pozzo, P
   Cardaioli, E
   Radi, E
   Federico, A
AF Da Pozzo, P
   Cardaioli, E
   Radi, E
   Federico, A
TI Sequence analysis of the complete mitochondrial genome in patients with mitochondrial encephaloneuromyopathies lacking the common pathogenic DNA mutations
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondrial encephaloneuromyopathies; mtDNA; mutation; polymorphism; heteroplasmic; homoplasmic
ID mtdna; encephalomyopathy; cardiomyopathy; disorders
AB The purpose of this study was to identify novel mitochondrial deoxyribonucleic acid (mtDNA) mutations in a series of patients with clinical and/or morphological features of mitochondrial dysfunction, but still no genetic diagnosis. A heterogeneous group of clinical disorders is caused by mutations in mtDNA that damage respiratory chain function of cell energy production. We developed a method to systematically screen the entire mitochondrial genome. The sequence-data were obtained with a rapid automated system. In the six mitochondrial genomes analysed we found 20 variants of the revised Cambridge reference sequence [Nat. Genet. 23 (1999) 147]. In skeletal muscle nineteen novel mtDNA variants were homoplasmic, suggesting secondary pathogenicity or co-responsibility in determination of the disease. In one patient we identified a novel heteroplasmic mtDNA mutation which presumably has a pathogenic role. This screening is therefore useful to extend the mtDNA polymorphism database and should facilitate definition of disease-related mutations in human mtDNA. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Siena, Dept Neurol & Behav Sci, Unit Neurol & Neurmetab Dis, I-53100 Siena, Italy.
   Univ Siena, Ctr Res Therapy & Prevent Neurhandicap, I-53100 Siena, Italy.
   Associaz Anni Verdi, Rome, Italy.
C3 University of Siena; University of Siena
RP Univ Siena, Dept Neurol & Behav Sci, Unit Neurol & Neurmetab Dis, Via Laterina 8, I-53100 Siena, Italy.
EM federico@unisi.it
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Fauser S, 2002, BIOCHEM BIOPH RES CO, V295, P342, DOI 10.1016/S0006-291X(02)00672-1
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Marchington DR, 1996, HUM MOL GENET, V5, P473, DOI 10.1093/hmg/5.4.473
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286
   Simon DK, 1999, ANNU REV MED, V50, P111
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   TORRONI K, 1996, GENETICS, V144, P1835
   WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661
   Zeviani M, 1997, MOL HUM REPROD, V3, P133, DOI 10.1093/molehr/3.2.133
NR 17
TC 13
Z9 13
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 5
PY 2004
VL 324
IS 1
BP 360
EP 364
DI 10.1016/j.bbrc.2004.09.058
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 863WX
UT WOS:000224595300055
PM 15465027
DA 2024-11-01
ER

PT J
AU Singh, B
   Low, PS
   Yeo, JF
AF Singh, B
   Low, PS
   Yeo, JF
TI MELAS: A case report
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Article
DE general anaesthesia; MELAS; mitochondrial DNA mutations; oral cavity; preventive dentistry
ID mitochondrial myopathy; lactic-acidosis; episodes melas; clinical-features; point mutation; encephalopathy
AB Introduction: Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is a rare, neurodegenerative and fatal disease caused by mutations in the mitochondrial DNA. Multiple systems of the body, including the oral cavity, can be affected by this disease. An electronic search of Medline spanning the years 1985 to 2003 was carried out using the key words "MELAS, Dentistry." It yielded no literature on the dental aspects of MELAS. Clinical Picture: This report documents the case of a 6-year-old Chinese boy diagnosed with MELAS and highlights problems encountered in the multidisciplinary management of MELAS patients, including its dental management. Treatment and Outcome: Dental management was successfully performed under general anaesthesia with close medical supervision by paediatrician and anaesthetist. Conclusions: There is no known treatment of the underlying disease and the clinical course is usually unpredictable. Preventive dental care is important in this group of patients as concurrent medical conditions can complicate dental care.
C1 Nalt Univ Hosp, Dept Oral & Maxillofacial Surg, Singapore 119074, Singapore.
   Natl Univ Singapore Hosp, Dept Pediat, Singapore 117548, Singapore.
C3 National University of Singapore
RP Nalt Univ Hosp, Dept Oral & Maxillofacial Surg, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
EM BaldevS@nuh.com.sg
CR BURNS AM, 1989, ANAESTHESIA, V44, P975, DOI 10.1111/j.1365-2044.1989.tb09200.x
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   CRAWFORD JS, 1981, ANAESTHESIA, V36, P821, DOI 10.1111/j.1365-2044.1981.tb08826.x
   Fang W, 1996, NEUROLOGY, V46, P1494, DOI 10.1212/WNL.46.5.1494
   Finsterer J, 1998, CAN J ANAESTH, V45, P781, DOI 10.1007/BF03012149
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   OHTANI Y, 1985, BRAIN DEV-JPN, V7, P249
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041
NR 12
TC 6
Z9 7
U1 1
U2 4
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
EI 
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD JUL 15
PY 2004
VL 33
IS 4
BP 69
EP 71
DI 
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 856DJ
UT WOS:000224023700013
PM 15389312
DA 2024-11-01
ER

PT J
AU Mayr, JA
   Paul, J
   Pecina, P
   Kurnik, P
   Förster, H
   Fötschl, U
   Sperl, W
   Houstek, J
AF Mayr, JA
   Paul, J
   Pecina, P
   Kurnik, P
   Förster, H
   Fötschl, U
   Sperl, W
   Houstek, J
TI Reduced respiratory control with ADP and changed pattern of respiratory chain enzymes as a result of selective deficiency of the mitochondrial ATP synthase
SO PEDIATRIC RESEARCH
LA English
DT Article
ID dna mutation; gene; muscle; electrophoresis; identification; heteroplasmy; f-1-atpase; complexes; defects; disease
AB The F0F1-ATPase, a multisubunit protein complex of the inner mitochondrial membrane, produces most of the ATP in mammalian cells. Mitochondrial diseases as a result of a dysfunction of ATPase can be caused by mutations in mitochondrial DNA-encoded ATPase subunit a or rarely by an ATPase defect of nuclear origin. Here we present a detailed functional and immunochemical analysis of a new case of selective and generalized ATPase deficiency found in an Austrian patient. The defect manifested with developmental delay, muscle hypotonia, failure to thrive, ptosis, and varying lactic acidemia (up to 12 mmol/L) beginning from the neonatal period. A low-degree dilated cardiomyopathy of the left ventricle developed between the age of 1 and 2 y. A >90% decrease in oligomycin-sensitive ATPase activity and an 86% decrease in the content of the ATPase complex was found in muscle mitochondria. It was associated with a significant decrease of ADP-stimulated respiration of succinate (1.5-fold) and respiratory control with ADP (1.7-fold) in permeabilized muscle fibers, and with a slight decrease of the respiratory chain complex I and compensatory increase in the content of complexes III and IV. The same ATPase deficiency without an increase in respiratory chain complexes was found in fibroblasts, suggesting a generalized defect with tissue-specific manifestation. Absence of any mutations in mitochondrial ATP6 and ATP8 genes indicates a nuclear origin of the defect.
C1 Acad Sci Czech Republ, Inst Physiol, Dept Bioenerget, CZ-14220 Prague 4, Czech Republic.
   Gen Hosp Salzburg, Dept Pediat, A-5020 Salzburg, Austria.
   Gen Hosp Klagenfurt, Dept Pediat, A-9020 Klagenfurt, Austria.
C3 Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences
RP Acad Sci Czech Republ, Inst Physiol, Dept Bioenerget, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
EM houstek@biomed.cas.cz
CR ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bentlage HACM, 1996, NEUROLOGY, V47, P243, DOI 10.1212/WNL.47.1.243
   Berger A, 2003, ACTA NEUROPATHOL, V105, P245, DOI 10.1007/s00401-002-0638-1
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Chowdhury SKR, 2000, CLIN CHIM ACTA, V298, P157, DOI 10.1016/S0009-8981(00)00300-4
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   Gnaiger E, 2000, LIFE IN THE COLD, V0, P431
   HOLME E, 1992, PEDIATR RES, V32, P731, DOI 10.1203/00006450-199212000-00022
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Houstek J, 1999, HUM MOL GENET, V8, P1967
   HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A
   Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9
   PUDDU P, 1993, BRIT J OPHTHALMOL, V77, P84, DOI 10.1136/bjo.77.2.84
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sperl W, 1997, MOL CELL BIOCHEM, V174, P71, DOI 10.1023/A:1006880529195
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   Tatuch Yuriy, 1994, EUROPEAN JOURNAL OF HUMAN GENETICS, V2, P35
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8
   Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200
NR 34
TC 27
Z9 28
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD JUN 15
PY 2004
VL 55
IS 6
BP 988
EP 994
DI 10.1203/01.pdr.0000127016.67809.6b
PG 7
WC Pediatrics
SC Pediatrics
GA 822NX
UT WOS:000221548000015
PM 15155867
DA 2024-11-01
ER

PT J
AU Pons, R
   Andreu, AL
   Checcarelli, N
   Vilá, MR
   Engelstad, K
   Sue, CM
   Shungu, D
   Haggerty, R
   De Vivo, DC
   DiMauro, S
AF Pons, R
   Andreu, AL
   Checcarelli, N
   Vilá, MR
   Engelstad, K
   Sue, CM
   Shungu, D
   Haggerty, R
   De Vivo, DC
   DiMauro, S
TI Mitochondrial DNA abnormalities and autistic spectrum disorders
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID thymidine kinase; melas; gene; depletion; mutation
AB Objectives To further characterize mtDNA defects associated with autistic features, especially the A3243G mtDNA mutation and mtDNA depletion. Study design Five patients with autistic spectrum disorders and family histories of mitochondrial DNA diseases were studied. We performed mtDNA analysis in all patients and magnetic resonance spectroscopy in three. Results Three patients manifested isolated autistic spectrum features and two had additional neurologic symptoms. Two patients harbored the A3243G mutation. In two others, the A3243G mutation was not found in accessible tissues but was present in tissues from their mothers. The fifth patient had 72% mtDNA depletion in skeletal muscle. Conclusions Autistic spectrum disorders with or without additional neurologic features can be early presentations of the A3243G mtDNA mutation and can be a prominent clinical manifestation of mtDNA depletion. Mitochondrial dysfunction should be considered in patients who have autistic features and associated neurologic findings or who have evidence of maternal inheritance.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
   Hosp Gen Valle Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Spain.
C3 Columbia University; Columbia University; Columbia University; Hospital Universitari Vall d'Hebron
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
CR Bailey A, 1998, BRAIN, V121, P889, DOI 10.1093/brain/121.5.889
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chugani DC, 1999, PROG NEURO-PSYCHOPH, V23, P635, DOI 10.1016/S0278-5846(99)00022-6
   DeLong GR, 1999, NEUROLOGY, V52, P911, DOI 10.1212/WNL.52.5.911
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1998, NEUROSCIENTIST, V4, P53, DOI 10.1177/107385849800400113
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Filiano JJ, 2002, J CHILD NEUROL, V17, P435, DOI 10.1177/088307380201700607
   Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   Kaufmann P, 2002, NEUROLOGY, V58, P0
   Kemper TL, 2002, MOL PSYCHIATR, V7, PS12, DOI 10.1038/sj.mp.4001165
   LASZLO A, 1994, CLIN CHIM ACTA, V229, P205, DOI 10.1016/0009-8981(94)90243-7
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marin-Garcia J, 1999, PEDIATR NEUROL, V21, P538, DOI 10.1016/S0887-8994(99)00038-7
   MINSHEW NJ, 1993, BIOL PSYCHIAT, V33, P762, DOI 10.1016/0006-3223(93)90017-8
   Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Piven J, 1997, CURR OPIN NEUROBIOL, V7, P708, DOI 10.1016/S0959-4388(97)80093-1
   Rapin I, 1999, NEUROLOGY, V52, P902, DOI 10.1212/WNL.52.5.902
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
NR 28
TC 110
Z9 118
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JAN 15
PY 2004
VL 144
IS 1
BP 81
EP 85
DI 10.1016/j.jpeds.2003.10.023
PG 5
WC Pediatrics
SC Pediatrics
GA 763MZ
UT WOS:000188091100015
PM 14722523
DA 2024-11-01
ER

PT J
AU Houshmand, M
   Gardner, A
   Hällström, T
   Müntzing, K
   Oldfors, A
   Holme, E
AF Houshmand, M
   Gardner, A
   Hällström, T
   Müntzing, K
   Oldfors, A
   Holme, E
TI Different tissue distribution of a mitochondrial DNA duplication and the corresponding deletion in a patient with a mild mitochondrial encephalomyopathy:: deletion in muscle, duplication in blood
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondria; mtDNA; duplication; deletion; long PCR
ID kearns-sayre syndrome; marrow-pancreas syndrome; c-oxidase deficiency; tandem duplication; diabetes-mellitus; rearrangements; myopathy; maintenance; mtdna; scale
AB Large-scale heteroplasmic mtDNA rearrangements were identified in a 57-year-old woman with chronic depressive disorder, hearing-loss, diabetes mellitus and a slowly progressive encephalomyopathy. A high percentage of a 24.2 kb duplicated molecule was found in lymphocytes whereas the corresponding deletion dimer dominated in muscle. PCR and Southern blot analyses were used to identify a 7658 bp duplication/deletion fragment. The duplicated mtDNA disrupted the cytochrome oxidase subunit I and cytochrome b genes at a position where there were no direct repeats. Duplicated mtDNA was not observed in the mother and brother of the patient. Histochemical analysis of skeletal muscle demonstrated pathological accumulation of mitochondria in cytochrome c oxidase negative fibers. In situ hybridization demonstrated only deleted mtDNA in cytochrome c oxidase negative fibres. We conclude that occurrence of deleted mtDNA correlates with phenotypic expression and that the duplicated mtDNA might serve as a generator of deletions, but is not directly pathogenic. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.
   Huddinge Univ Hosp, Karolinska Inst, Div Psychiat, NEUROTEC, Stockholm, Sweden.
   Univ Gothenburg, Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; University of Gothenburg; Sahlgrenska University Hospital
RP Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.
EM elisabeth.holme@clinchem.gu.se
CR BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   BROCKINGTON M, 1993, NAT GENET, V4, P67, DOI 10.1038/ng0593-67
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LESTIENNE P, 1988, LANCET, V1, P885
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   McCann BS, 2000, J NEUROPSYCH CLIN N, V12, P240, DOI 10.1176/appi.neuropsych.12.2.240
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NEGRIER MLM, 1988, AM J HUM GENET, V63, P1227
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   OLDFORS A, 1989, ACTA NEUROPATHOL, V77, P267, DOI 10.1007/BF00687578
   POULTON J, 1995, DIABETOLOGIA, V38, P868, DOI 10.1007/s001250050366
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   POULTON J, 1989, LANCET, V1, P236
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1989, NUCLEIC ACIDS RES, V17, P10223, DOI 10.1093/nar/17.24.10223
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   ROTIG A, 1989, LANCET, V1, P902
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Tang YY, 2000, MOL BIOL CELL, V11, P2349, DOI 10.1091/mbc.11.7.2349
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 26
TC 10
Z9 10
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR 15
PY 2004
VL 14
IS 3
BP 195
EP 201
DI 10.1016/j.nmd.2003.12.002
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 802FR
UT WOS:000220149900003
PM 15036329
DA 2024-11-01
ER

PT J
AU Taylor, RW
   Schaefer, AM
   Barron, MJ
   McFarland, R
   Turnbull, DM
AF Taylor, RW
   Schaefer, AM
   Barron, MJ
   McFarland, R
   Turnbull, DM
TI The diagnosis of mitochondrial muscle disease
SO NEUROMUSCULAR DISORDERS
LA English
DT Review
DE mitochondrial muscle disease; mitochondrial DNA; laboratory diagnosis; genetic testing; COX deficiency
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; respiratory-chain; mtdna mutation; lactic-acidosis; complex-i; point mutation; dna mutations; leigh-disease; exercise intolerance
AB Mitochondrial respiratory chain abnormalities are an important cause of neuromuscular disease and may be due to defects of either the mitochondrial or nuclear genome. On account of the clinical and genetic heterogeneity exhibited by the mitochondrial myopathies, their investigation and diagnosis remains a challenge, requiring a combination of techniques including muscle histochemistry, biochemical assessment of respiratory chain function and molecular genetic studies. Here, we describe a step-by-step approach to the clinical and laboratory diagnosis of mitochondrial muscle disease, highlighting the many potential problems that can hinder reaching the correct diagnosis. (C) 2004 Elsevier B.V. All rights reserved.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   BINDOFF LA, 1991, J NEUROL SCI, V102, P17, DOI 10.1016/0022-510X(91)90088-O
   Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, LANCET, V350, P560, DOI 10.1016/S0140-6736(97)05005-8
   CHINNERY PF, 1999, LANCET S1, V354, P17
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CHRETIEN D, 1994, CLIN CHIM ACTA, V228, P53, DOI 10.1016/0009-8981(94)90056-6
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Fromenty B, 1996, BBA-GENE STRUCT EXPR, V1308, P222, DOI 10.1016/0167-4781(96)00110-8
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   POULTON J, 1991, AM J HUM GENET, V48, P649
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Santorelli FM, 1998, ANN NEUROL, V44, P962, DOI 10.1002/ana.410440616
   Schaefer Andrew M, 2001, CURRENT OPINION IN PHARMACOLOGY, V1, P288
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   TASSIN S, 1980, NEUROPATH APPL NEURO, V6, P337, DOI 10.1111/j.1365-2990.1980.tb00670.x
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5
   Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Taylor RW, 2000, METH MOLEC MED, V38, P245, DOI 10.1385/1-59259-070-5:245
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Trijbels FJM, 1997, MOL CELL BIOCHEM, V174, P243, DOI 10.1023/A:1006868810424
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 88
TC 153
Z9 165
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR 15
PY 2004
VL 14
IS 4
BP 237
EP 245
DI 10.1016/j.nmd.2003.12.004
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 807LX
UT WOS:000220504100001
PM 15019701
DA 2024-11-01
ER

PT J
AU Bhat, HK
   Epelboym, I
AF Bhat, HK
   Epelboym, I
TI Quantitative analysis of total mitochondrial DNA: Competitive polymerase chain reaction versus real-time polymerase chain reaction
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE mitochondrial DNA; DNA quantification; real-time PCR; competitive PCR
ID induced cellular injury; oxidative stress; skeletal-muscle; nuclear-dna; damage; disease; pcr; quantification; antioxidants; depletion
AB An efficient and effective method for quantification of small amounts of nucleic acids contained within a sample specimen would be an important diagnostic tool for determining the content of mitochondrial DNA (mtDNA) in situations where the depletion thereof may be a contributing factor to the exhibited pathology phenotype. This study compares two quantification assays for calculating the total mtDNA molecule number per nanogram of total genomic DNA isolated from human blood, through the amplification of a 613-bp region on the mtDNA molecule. In one case, the mtDNA copy number was calculated by standard competitive polymerase chain reaction (PCR) technique that involves co-amplification of target DNA with various dilutions of a nonhomologous internal competitor that has the same primer binding sites as the target sequence, and subsequent determination of an equivalence point of target and competitor concentrations. In the second method, the calculation of copy number involved extrapolation from the fluorescence versus copy number standard curve generated by real-time PCR using various dilutions of the target amplicon sequence. While the mtDNA copy number was comparable using the two methods (4.92 +/- 1.01 X 10(4) molecules/ng total genomic DNA using competitive PCR vs 4.90 +/- 0.84 x 10(4) molecules/ng total genomic DNA using real-time PCR), both inter- and intraexperimental variance were significantly lower using the real-time PCR analysis. On the basis of reproducibility, assay complexity, and overall efficiency, including the time requirement and number of PCR reactions necessary for the analysis of a single sample, we recommend the real-time PCR quantification method described here, as its versatility and effectiveness will undoubtedly be of great use in various kinds of research related to mitochondrial DNA damage- and depletion-associated disorders. (c) 2004 Wiley Periodicals, Inc.
C1 Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
EM hb2009@columbia.edu
FU NIEHS NIH HHS [P30 ES09089] Funding Source: Medline
CR Abramova NE, 2000, FREE RADICAL BIO MED, V28, P281, DOI 10.1016/S0891-5849(99)00239-7
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Bhat HK, 1999, CIRCULATION, V99, P807, DOI 10.1161/01.CIR.99.6.807
   Bhat HK, 2002, J BIOCHEM MOL TOXIC, V16, P1, DOI 10.1002/jbt.10017
   Calabrese V, 1998, FREE RADICAL BIO MED, V24, P1159, DOI 10.1016/S0891-5849(97)00441-3
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   Crawford DR, 1997, FREE RADICAL BIO MED, V22, P551, DOI 10.1016/S0891-5849(96)00380-2
   Fernando LP, 2002, ANAL BIOCHEM, V306, P212, DOI 10.1006/abio.2002.5705
   FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6
   Goto Y, 2001, J INHERIT METAB DIS, V24, P181, DOI 10.1023/A:1010366917652
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059
   Kosaki R, 2003, JPN J OPHTHALMOL, V47, P240, DOI 10.1016/S0021-5155(03)00010-8
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002
   MaaswinkelMooij PD, 1996, J PEDIATR-US, V128, P679, DOI 10.1016/S0022-3476(96)80134-X
   Mansouri A, 2001, J PHARMACOL EXP THER, V298, P737
   Millson A, 2003, J MOL DIAGN, V5, P184, DOI 10.1016/S1525-1578(10)60471-0
   Motoori S, 2001, CANCER RES, V61, P5382
   MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x
   NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K
   Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Sauleda J, 1998, AM J RESP CRIT CARE, V157, P1413, DOI 10.1164/ajrccm.157.5.9710039
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Stevens SJC, 2002, J CLIN MICROBIOL, V40, P3986, DOI 10.1128/JCM.40.11.3986-3992.2002
   Stöcher M, 2002, J CLIN MICROBIOL, V40, P4547, DOI 10.1128/JCM.40.12.4547-4553.2002
   TRITSCHLER HJ, 1993, NEUROLOGY, V43, P280, DOI 10.1212/WNL.43.2.280
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wei Yau-Huei, 1998, PROCEEDINGS OF THE NATIONAL SCIENCE COUNCIL REPUBLIC OF CHINA PART B LIFE SCIENCES, V22, P55
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   ZHANG H, 1994, MOL PHARMACOL, V46, P1063
NR 35
TC 23
Z9 27
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD JUN 15
PY 2004
VL 18
IS 4
BP 180
EP 186
DI 10.1002/jbt.20024
PG 7
WC Biochemistry & Molecular Biology; Toxicology
SC Biochemistry & Molecular Biology; Toxicology
GA 912JR
UT WOS:000228074500002
PM 15452886
DA 2024-11-01
ER

PT J
AU Dimmick, J
AF Dimmick, J
TI Conjugated hyperbilirubinemia in infancy (mitochondrial DNA depletion syndrome, liver)
SO PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
LA English
DT Article
ID mtdna depletion; myopathy; diseases; kinase; gene
C1 Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
   British Columbia Childrens & Womens Hosp, Vancouver, BC V6T 2B5, Canada.
C3 University of British Columbia; University of British Columbia
RP Dimmick, J (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, 2211 Wesbrook Mall,UBC, Vancouver, BC V6T 2B5, Canada.
EM jdimmick@pathology.ubc.ca
CR Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MIERAU GW, 2004, IN PRESS PEDIAT DEV, V7, P0
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
NR 15
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1093-5266
EI 
J9 PEDIATR DEVEL PATHOL
JI Pediatr. Dev. Pathol.
PD NOV-DEC 15
PY 2004
VL 7
IS 6
BP 625
EP 628
DI 10.1007/s10024-004-5052-3
PG 4
WC Pathology; Pediatrics
SC Pathology; Pediatrics
GA 883QU
UT WOS:000226031600010
PM 15630532
DA 2024-11-01
ER

PT J
AU Dimauro, S
   Tay, S
   Mancuso, M
AF Dimauro, S
   Tay, S
   Mancuso, M
TI Mitochondrial encephalomyopathies - Diagnostic approach
SO MITOCHONDRIAL PATHOGENESIS: FROM GENES AND APOPTOSIS TO AGING AND DISEASE
LA English
DT Article; Proceedings Paper
DE mitochondria; encephalomyopathies
ID cytochrome-c-oxidase; spinal muscular-atrophy; stroke-like episodes; leigh-syndrome; dna depletion; succinate-dehydrogenase; thymidine phosphorylase; respiratory-chain; lactic-acidosis; gene-mutations
AB Mitochondrial diseases have extremely heterogeneous clinical presentations due to the ubiquitous nature of mitochondria and the dual genetic control of the respiratory chain. Thus, mitochondrial disorders can be multisystemic (mitochondrial encephalomyopathies) or confined to a single tissue, and they can be sporadic or transmitted by mendelian or maternal inheritance. Mendelian disorders are usually inherited as autosomal recessive traits, tend to present earlier in life, and usually "breed true" in each family. By contrast, mitochondrial DNA-related diseases usually start later and vary in their presentation within members of the same family. Precise diagnosis is often a challenge; we go through the traditional steps of the diagnostic process, trying to highlight clues to mitochondrial dysfunction in the family history, physical and neurological examinations, routine and special laboratory tests, and histochemical and biochemical results of the muscle biopsy. The ultimate goal is to reach, whenever possible, a definitive molecular diagnosis, which permits rational genetic counseling and a prenatal diagnosis.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St,4-420, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   ARGOV Z, 1991, ANN NEUROL, V30, P90, DOI 10.1002/ana.410300116
   Bank William, 1998, BIOFACTORS, V7, P243
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   BOUSTANY RN, 1983, ANN NEUROL, V14, P462, DOI 10.1002/ana.410140411
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   DiMauro S, 2003, BASIC APPL MYOL, V13, P145
   DIMAURO S, 2002, CLIN EVALUATION DIAG, V0, P535
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   HALL RE, 1993, J CLIN INVEST, V92, P2660, DOI 10.1172/JCI116882
   HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Lombes A, 1996, J INHERIT METAB DIS, V19, P286, DOI 10.1007/BF01799256
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mancuso M, 2003, ACTA NEUROPATHOL, V105, P621, DOI 10.1007/s00401-003-0699-9
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANCUSO M, 2003, BASIC APPL MYOL, V13, P22
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moraes Carlos T, 1993, P97, V0, P0
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033
   Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894
   Péquignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   SCHAPIRA AHV, 1990, NEW ENGL J MED, V323, P37, DOI 10.1056/NEJM199007053230107
   Schon EA, 2002, MITOCHONDRIA DISORDE, V2nd, P69
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SHUNGU DC, 1999, P INT SOC MAG RESON, V7, P49
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   VANCOSTER R, 1991, J NEUROL SCI, V104, P97, DOI 10.1016/0022-510X(91)90222-S
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Zeviani M, 2001, SEMIN CELL DEV BIOL, V12, P407, DOI 10.1006/scdb.2001.0278
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 61
TC 41
Z9 43
U1 0
U2 1
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2004
VL 1011
IS 
BP 217
EP 231
DI 10.1196/annals.1293.022
PG 15
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BAE70
UT WOS:000221896100022
PM 15126299
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Sembongi, H
   Bokori-Brown, M
   Granycome, C
   Ashley, N
   Poulton, J
   Jalanko, A
   Spelbrink, JN
   Holt, IJ
   Suomalainen, A
AF Tyynismaa, H
   Sembongi, H
   Bokori-Brown, M
   Granycome, C
   Ashley, N
   Poulton, J
   Jalanko, A
   Spelbrink, JN
   Holt, IJ
   Suomalainen, A
TI Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID mitochondrial transcription factor; progressive external ophthalmoplegia; dna-polymerase; factor-a; quantitative-analysis; multiple deletions; mutations; gene; subunit; protein
AB Mechanisms of mitochondrial DNA (mtDNA) maintenance have recently gained wide interest owing to their role in inherited diseases as well as in aging. Twinkle is a new mitochondrial 5'-3' DNA helicase, defects of which we have previously shown to underlie a mitochondrial disease, progressive external ophthalmoplegia with multiple mtDNA deletions. Mouse Twinkle is highly similar to the human counterpart, suggesting conserved function. Here, we have characterized the mouse Twinkle gene and expression profile and report that the expression patterns are not conserved between human and mouse, but are synchronized with the adjacent gene MrpL43, suggesting a shared promoter. To elucidate the in vivo role of Twinkle in mtDNA maintenance, we generated two transgenic mouse lines overexpressing wild-type Twinkle. We could demonstrate for the first time that increased expression of Twinkle in muscle and heart increases mtDNA copy number up to 3-fold higher than controls, more than any other factor reported to date. Additionally, we utilized cultured human cells and observed that reduced expression of Twinkle by RNA interference mediated a rapid drop in mtDNA copy number, further supporting the in vivo results. These data demonstrate that Twinkle helicase is essential for mtDNA maintenance, and that it may be a key regulator of mtDNA copy number in mammals.
C1 Univ Helsinki, Dept Neurol, Biomedicum Helsinki, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Dunn Human Nutr Unit, Cambridge CB2 2XY, England.
   John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   Natl Publ Hlth Inst, Dept Mol Med, Helsinki 00290, Finland.
   Inst Med Technol, Tampere 33014, Finland.
   Tampere Univ Hosp, Tampere 33014, Finland.
   Univ Helsinki, Cent Hosp, Dept Clin Chem, FIN-00290 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Oxford; Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital
RP Univ Helsinki, Dept Neurol, Biomedicum Helsinki, R C522B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU MRC [MC_U105663140] Funding Source: UKRI; Medical Research Council [MC_U105663140] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Gensler S, 2001, NUCLEIC ACIDS RES, V29, P3657, DOI 10.1093/nar/29.17.3657
   GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Kanki T, 2004, ANN NY ACAD SCI, V1011, P61, DOI 10.1196/annals.1293.007
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lefai E, 2000, MOL GEN GENET, V264, P37, DOI 10.1007/s004380000301
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200
   Meyer RG, 2003, GENE, V314, P181, DOI 10.1016/S0378-1119(03)00738-8
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 1998, METH MOL B, V86, P121
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Zhang LF, 2003, GENOMICS, V82, P660, DOI 10.1016/S0888-7543(03)00211-8
NR 34
TC 190
Z9 230
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2004
VL 13
IS 24
BP 3219
EP 3227
DI 10.1093/hmg/ddh342
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 883ZT
UT WOS:000226055100017
PM 15509589
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Filosto, M
   Oh, SJ
   DiMauro, S
AF Mancuso, M
   Filosto, M
   Oh, SJ
   DiMauro, S
TI A novel polymerase γ mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; mitochondrial complex i; polg mutations; genetic-heterogeneity; autosomal-dominant; dna; deletions; disease; deficiency; deafness
AB Background: Mutations in polymerase gamma cause progressive external ophthalmoplegia-and a variety of associated symptoms and signs, including neuropathy, ataxia, hypogonadism, hearing loss, muscle weakness, and psychiatric problems. Extrapyramidal signs have been rarely described. Objective: To describe a family with a novel polymerase gamma mutation and autosomal dominant transmission of. progressive external ophthalmoplegia, neuropathy, hypogonadism, and parkinsonism. Design: Case report. Patients: The proband, a 49-year-old woman with incipient parkinsonism,and her 59-year-old brother-with overt parkinsonian features. Main Outcome Measures: Mutation in the proband by sequencing the polymerase gamma gene and in affected relatives by restriction fragment length polymorphism analysis. Results: We found multiple mitochondrial DNA deletions in the proband's muscle and a novel missense mutation in the polymerase gamma gene (A2492G) in the proband and in her affected siblings. Conclusion: Parkinsonism was a prominent clinical feature in this family with autosomal dominant ophthalmoplegia, multiple mitochondrial DNA deletions, and a novel mutation in the polymerase gamma gene.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA.
C3 Columbia University; University of Alabama System; University of Alabama Birmingham
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01HD 32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Klopp N, 2003, OPHTHALMIC RES, V35, P71, DOI 10.1159/000069134
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 21
TC 78
Z9 83
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD NOV 15
PY 2004
VL 61
IS 11
BP 1777
EP 1779
DI 10.1001/archneur.61.11.1777
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 869EJ
UT WOS:000224965900017
PM 15534189
DA 2024-11-01
ER

PT J
AU Polisecki, EY
   Schreier, LE
   Ravioli, J
   Corach, D
AF Polisecki, EY
   Schreier, LE
   Ravioli, J
   Corach, D
TI Common mitochondrial DNA deletion associated with sudden natural death in adults
SO JOURNAL OF FORENSIC SCIENCES
LA English
DT Article
DE forensic science; sudden natural death; mitochondrial DNA; 4977 bp mitochondrial DNA deletion; aging
ID oxidative stress; cardiac death; tissue; disease; autopsy; damage; cardiomyopathy; population; mutations; increase
AB One of the most frequent causes of death in developed countries is sudden natural death (SND), which is the most common indication for medico-legal autopsies. Cardiac diseases are frequently detected among SND. Mitochondrial DNA (mtDNA) is easily damaged by reactive oxygen species, and it may cause dysfunction in tissues, leading to early events in cardiovascular disease. A specific mtDNA deletion of 4977 bp is associated to aging, myocardial dysfunction, and bioenergetic deficit. The potential link between mtDNA damage and SND has not been investigated before. Our aim was to evaluate the accumulation of the common mtDNA4977-deletion in cardiac muscle samples from autopsies of SND in adults (n = 14) in comparison to control samples from unnatural deaths (n = 12). Serial dilution-polymerase chain reaction method was performed to estimate the proportion of the total mtDNA harboring the mtDNA4977-deletion. Coefficient variation intra-assay was 8%, and inter-assay was 12%. MtDNA4977-deletion percentage was higher in samples obtained from victims of SND than in those from subjects who died of unnatural causes (p < 0.05). No differences in mtDNA4977-deletion were found between SND victims 39-51 years old, and no correlation was found between these samples and age, r = 0.30, p = 0.29 while it was significant among control samples, r = 0.68, p < 0.05. The association between mtDNA4977 deletion with SND victims might offer a tool to provide additional information to clarify complex SND investigations.
C1 Univ Buenos Aires, Serv Huellas Digitales Genet, Fac Farm & Bioquim, Catedra Genet & Biol Mol, Buenos Aires, DF, Argentina.
   Univ Buenos Aires, Dept Bioquim Clin, Fac Farm & Bioquim, Buenos Aires, DF, Argentina.
   Univ Buenos Aires, Fac Med, Catedra Med Legal, Buenos Aires, DF, Argentina.
C3 University of Buenos Aires; University of Buenos Aires; University of Buenos Aires
RP Corach, D (corresponding author), Univ Buenos Aires, Serv Huellas Digitales Genet, Fac Farm & Bioquim, Catedra Genet & Biol Mol, Junin 956,C113AAD, Buenos Aires, DF, Argentina.
CR Aizaki T, 1997, JPN CIRC J, V61, P1004, DOI 10.1253/jcj.61.1004
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Berdanier CD, 2001, MUTAT RES-FUND MOL M, V475, P169, DOI 10.1016/S0027-5107(01)00068-9
   Bogliolo M, 1999, MUTAGENESIS, V14, P77, DOI 10.1093/mutage/14.1.77
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   DIMAIO VJM, 1991, J FORENSIC SCI, V36, P17
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Doolan A, 2004, MED J AUSTRALIA, V180, P110, DOI 10.5694/j.1326-5377.2004.tb05830.x
   Escoffery CT, 2002, FORENSIC SCI INT, V129, P116, DOI 10.1016/S0379-0738(02)00268-2
   HIRSCH CS, 1984, ARCH PATHOL LAB MED, V108, P484
   KANNEL WB, 1990, CAN J CARDIOL, V6, P439
   Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Levitsky S, 2003, EUR J CARDIO-THORAC, V24, P777, DOI 10.1016/S1010-7940(03)00501-3
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Ruppert V, 2000, HERZ, V25, P161, DOI 10.1007/s000590050002
   SHEN WK, 1995, AM J CARDIOL, V76, P148, DOI 10.1016/S0002-9149(99)80047-2
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   World Health Organization, 1992, MAN INT STAT CLASS D, V1, P0
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 27
TC 7
Z9 8
U1 0
U2 0
PU AMER SOC TESTING MATERIALS
PI W CONSHOHOCKEN
PA 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959 USA
SN 0022-1198
EI 
J9 J FORENSIC SCI
JI J. Forensic Sci.
PD NOV 15
PY 2004
VL 49
IS 6
BP 1335
EP 1338
DI 
PG 4
WC Medicine, Legal
SC Legal Medicine
GA 868IY
UT WOS:000224908500026
PM 15568709
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Filosto, M
   Bellan, M
   Liguori, R
   Montagna, P
   Baruzzi, A
   DiMauro, S
   Carelli, V
AF Mancuso, M
   Filosto, M
   Bellan, M
   Liguori, R
   Montagna, P
   Baruzzi, A
   DiMauro, S
   Carelli, V
TI <i>POLG</i> mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness
SO NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; nucleotide translocator-1 gene; autosomal-dominant; mitochondrial-dna; multiple deletions; polymerase-gamma; twinkle; adpeo; ant1
AB The authors identified two novel heterozygous missense transitions in the gene for the mitochondrial polymerase gammaA subunit (POLG) in a family with an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders. These mutations were not detected in 120 healthy control subjects.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Univ Bologna, Dept Neurol Sci, I-40126 Bologna, Italy.
C3 Columbia University; University of Bologna
RP Columbia Univ Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01HD 32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 9
TC 66
Z9 72
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 27
PY 2004
VL 62
IS 2
BP 316
EP 318
DI 10.1212/WNL.62.2.316
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 767KT
UT WOS:000188439300036
PM 14745080
DA 2024-11-01
ER

PT J
AU Gambelli, S
   Malandrini, A
   Ginanneschi, F
   Berti, G
   Cardaioli, E
   De Stefano, R
   Franci, M
   Salvadori, C
   Mari, F
   Bruttini, M
   Rossi, A
   Federico, A
   Renieri, A
AF Gambelli, S
   Malandrini, A
   Ginanneschi, F
   Berti, G
   Cardaioli, E
   De Stefano, R
   Franci, M
   Salvadori, C
   Mari, F
   Bruttini, M
   Rossi, A
   Federico, A
   Renieri, A
TI Mitochondrial abnormalities in genetically assessed oculopharyngeal muscular dystrophy
SO EUROPEAN NEUROLOGY
LA English
DT Article
DE muscle biopsy; mitochondrial abnormality; intranuclear inclusions; oculopharyngeal muscular dystrophy
ID inclusion-body myositis; dna deletions; muscle-fibers; myopathy; gene
AB We report a family with a clinical diagnosis of oculopharyngeal muscular dystrophy in which muscle biopsy showed mitochondrial changes such as cytochrome-c-oxidasenegative fibers and aggregates of mitochondria containing paracrystalline inclusions. Molecular analysis demonstrated a GCG expansion in the poly( A)-binding protein 2 (PABP2) gene and failed to demonstrate multiple deletions of mtDNA. We hypothesize that mitochondrial abnormalities may be a secondary phenomenon. This observation may suggest that the PABP2 gene could interfere in the posttranscriptional regulation of genes involved in mitochondrial function. Copyright (C) 2004 S. Karger AG, Basel.
C1 Univ Siena, Dept Neurol & Behav Sci, IT-53100 Siena, Italy.
   Univ Siena, Inst Rheumatol, IT-53100 Siena, Italy.
   Univ Siena, Orthoped & Traumatol Clin, IT-53100 Siena, Italy.
C3 University of Siena; University of Siena; University of Siena
RP Univ Siena, Dept Neurol & Behav Sci, Viale Bracci 2, IT-53100 Siena, Italy.
EM malandrini@unisi.it
FU Telethon [E.1145] Funding Source: Medline
CR Andersson U, 2000, BIOCHEM J, V346, P33, DOI 10.1042/0264-6021:3460033
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   Kim YJ, 2001, HUM MOL GENET, V10, P1129, DOI 10.1093/hmg/10.11.1129
   Levine TD, 1998, MUSCLE NERVE, V21, P1724, DOI 10.1002/(SICI)1097-4598(199812)21:12<1724::AID-MUS15>3.0.CO;2-2
   Müller T, 2001, MUSCLE NERVE, V24, P120
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   PAUZNER R, 1991, MUSCLE NERVE, V14, P947, DOI 10.1002/mus.880141004
   Sambrook J, 1989, MOLECULAR CLONING, V0, P0
   SCHRODER JM, 1995, NEUROPATH APPL NEURO, V21, P68, DOI 10.1111/j.1365-2990.1995.tb01030.x
   Wong KT, 1996, NEUROMUSCULAR DISORD, V6, P163, DOI 10.1016/0960-8966(95)00039-9
NR 13
TC 11
Z9 14
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0014-3022
EI 1421-9913
J9 EUR NEUROL
JI Eur. Neurol.
PD JUN 15
PY 2004
VL 51
IS 3
BP 144
EP 147
DI 10.1159/000077070
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 818KT
UT WOS:000221244700004
PM 14988608
DA 2024-11-01
ER

PT J
AU Fetoni, V
   Briem, E
   Carrara, F
   Mora, M
   Zeviani, M
AF Fetoni, V
   Briem, E
   Carrara, F
   Mora, M
   Zeviani, M
TI Monomelic amyotrophy associated with the 7472insC mutation in the mtDNA tRNA<SUP>Ser(UCN)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
ID myopathy
AB We describe a 49-year-old male patient who experienced progressive amyotrophy with no sensorial abnormality in the left arm since 45 years of age. The neuromuscular syndrome was identical to that known as Hirayama disease, a rare form of focal lower motor neuron disease affecting the C7-C8-T1 metamers of the spinal cord. Asymmetric neurosensorial hearing loss was present since age 35 in the patient, and was also documented in an elder sister and in the mother. A muscle biopsy showed cytochrome c oxidase (COX) negative fibers but no ragged-red fibers, and mild reduction of COX was confirmed biochemically. The patient was found to have high levels of a known pathogenic mutation of mtDNA, the 7472insC in the gene encoding the tRNA(Ser(UCN)). Investigation on several family members showed a correlation between mutation load and clinical severity. This is the second report documenting the association of lower motor neurone involvement with a specific mtDNA. (C) 2004 Elsevier B.V. All rights reserved.
C1 Natl Neurol Inst Carlo Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20133 Milan, Italy.
   Publ Hlth Hosp, Neurol Unit, Milan, Italy.
   Natl Neurol Inst Carlo Besta, Unit Neuromuscular Disorders, I-20133 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Natl Neurol Inst Carlo Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20133 Milan, Italy.
EM zeviani@tin.it
FU Telethon [GGP030039] Funding Source: Medline
CR Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Darley-Usmar VM, 1987, MITOCHONDRIA PRACTIC, V0, P0
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   GUCUYENER K, 1991, PEDIATR NEUROL, V7, P220, DOI 10.1016/0887-8994(91)90089-4
   HIRAYAMA K, 1972, CLIN NEUROL TOKYO, V12, P13
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   SCHLEGEL U, 1987, J NEUROL SCI, V80, P351, DOI 10.1016/0022-510X(87)90169-9
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 14
TC 25
Z9 30
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV 15
PY 2004
VL 14
IS 11
BP 723
EP 726
DI 10.1016/j.nmd.2004.07.002
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 871FZ
UT WOS:000225116500003
PM 15482956
DA 2024-11-01
ER

PT J
AU Gokey, NG
   Cao, ZJ
   Pak, JW
   Lee, D
   McKiernan, SH
   McKenzie, D
   Weindruch, R
   Aiken, JM
AF Gokey, NG
   Cao, ZJ
   Pak, JW
   Lee, D
   McKiernan, SH
   McKenzie, D
   Weindruch, R
   Aiken, JM
TI Molecular analyses of mtDNA deletion mutations in microdissected skeletal muscle fibers from aged rhesus monkeys
SO AGING CELL
LA English
DT Article
DE aging; mtDNA; rhesus monkey; skeletal muscle
ID mitochondrial-dna deletions; cytochrome-c-oxidase; human tissue; abnormality; multiple; association; atrophy; disease; damage; heart
AB Mitochondrial DNA (mtDNA) deletion mutations colocalize with electron transport system (ETS) abnormalities in rhesus monkey skeletal muscle fibers. Using laser capture microdissection in conjunction with PCR and DNA sequence analysis, mitochondrial genomes from single sections of ETS abnormal fibers were characterized. All ETS abnormal fibers contained mtDNA deletion mutations. Deletions were large, removing 20-78% of the genome, with some to nearly all of the functional genes lost. In one-third of the deleted genomes, the light strand origin was deleted, whereas the heavy strand origin of replication was conserved in all fibers. A majority (27/39) of the deletion mutations had direct repeat sequences at their breakpoints and most (36/39) had one breakpoint within or in close proximity to the cytochrome b gene. Several pieces of evidence support the clonality of the mtDNA deletion mutation within an ETS abnormal region of a fiber: (a) only single, smaller than wild-type, PCR products were obtained from each ETS abnormal region; (b) the amplification of mtDNA from two regions of the same ETS abnormal fiber identified identical deletion mutations, and (c) a polymorphism was observed at nucleotide position 16103 (A and G) in the wild-type mtDNA of one animal (sequence analysis of an ETS abnormal region revealed that mtDNA deletion mutations contained only A or G at this position). Species-specific differences in the regions of the genomes lost as well as the presence of direct repeat sequences at the breakpoints suggest mechanistic differences in deletion mutation formation between rodents and primates.
C1 Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP 1656 Linden Dr, Madison, WI 53706 USA.
EM aiken@svm.vetmed.wisc.edu
FU NCRR NIH HHS [5P51 RR 000167] Funding Source: Medline; NIA NIH HHS [P01 AG11915, R01 AG11604] Funding Source: Medline
CR Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Dubowitz V, 1985, MUSCLE BIOPSY-A PRACTICAL APPROACH, VSecond, P19
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3
   LEE CM, 1993, J GERONTOL, V48, PB201, DOI 10.1093/geronj/48.6.B201
   LEE CM, 1994, MECH AGEING DEV, V75, P69, DOI 10.1016/0047-6374(94)90029-9
   LINNANE AW, 1990, BIOCHEM INT, V22, P1067
   Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   VanTuyle GC, 1996, MUTAT RES-FUND MOL M, V349, P95, DOI 10.1016/0027-5107(95)00165-4
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
NR 23
TC 74
Z9 81
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9726
EI 
J9 AGING CELL
JI Aging Cell
PD OCT 15
PY 2004
VL 3
IS 5
BP 319
EP 326
DI 10.1111/j.1474-9728.2004.00122.x
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 860FO
UT WOS:000224328100011
PM 15379855
DA 2024-11-01
ER

PT J
AU Bidooki, S
   Jackson, MJ
   Johnson, MA
   Chrzanowska-Lightowlers, ZMA
   Taylor, RW
   Venables, G
   Lightowlers, RN
   Turnbull, DM
   Bindoff, LA
AF Bidooki, S
   Jackson, MJ
   Johnson, MA
   Chrzanowska-Lightowlers, ZMA
   Taylor, RW
   Venables, G
   Lightowlers, RN
   Turnbull, DM
   Bindoff, LA
TI Sporadic mitochondrial myopathy due to a new mutation in the mitochondrial tRNA<SUP>Ser(UCN)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial myopathy; mtDNA; tRNA Serine
ID inherited hearing-loss; point mutation; sequence; family; merrf
AB We describe a young woman with a progressive mitochondrial myopathy that started with muscle weakness and went on to include deafness, dementia and ataxia. Skeletal muscle showed the histological and biochemical features of mitochondrial respiratory chain dysfunction. Genetic analysis identified a novel, heteroplasmic, A to G transition in tRNA(Ser(UCN)) at position 7480 affecting a highly conserved base in the anticodon loop. Single-fibre PCR showed highest levels of mutation in cytochrome c-oxidase-deficient fibres and quantification in two biopsies taken 5 years apart showed no change in percentage heteroplasmy. The mutation was present at lower levels in the patient's blood, but was not found in either her mother's or sister's blood and skeletal muscle, suggesting a sporadic occurrence. This is the eighth disease-causing mutation in this tRNA gene and confirms serine (UCN) as one of the most common sites for mtDNA mutation. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Bergen, Haukeland Univ Hosp, Inst Clin Med & Mol Med, Dept Neurol, N-5021 Bergen, Norway.
   Med Sch Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Sheffield Teaching Hosp NHS Trust, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England.
C3 University of Bergen; Haukeland University Hospital; Newcastle University - UK; University of Sheffield
RP Univ Bergen, Haukeland Univ Hosp, Inst Clin Med & Mol Med, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@helse-bergen.no
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BINDOFF LA, 1991, J NEUROL SCI, V102, P17, DOI 10.1016/0022-510X(91)90088-O
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Weber K, 1997, AM J HUM GENET, V60, P373
   YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 18
TC 18
Z9 20
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL 15
PY 2004
VL 14
IS 7
BP 417
EP 420
DI 10.1016/j.nmd.2004.03.004
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 838LQ
UT WOS:000222715200003
PM 15210164
DA 2024-11-01
ER

PT J
AU Chang, TM
   Chi, CS
   Tsai, CR
   Lee, HF
   Li, MC
AF Chang, TM
   Chi, CS
   Tsai, CR
   Lee, HF
   Li, MC
TI Paralytic ileus in MELAS with phenotypic features of MNGIE
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID stroke-like episodes; mitochondrial neurogastrointestinal encephalomyopathy; lactic-acidosis; rectal biopsy; encephalopathy; obstruction; myopathy; disorder
AB This report describes a child having the syndrome of overlapping phenotypic features of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Mitochondrial DNA analysis revealed a point mutation at position A3243G, whereas activity of thymidine phosphorylase and its corresponding gene analysis were normal. The most striking feature of this case was paralysis of one segment of the terminal ileum observed on laparotomy. The electron microscopic findings of the resected ileum and colon by limited right hemicolectomy disclosed accumulation of numerous enlarged mitochondria with ill-defined cristae which were similar to mitochondria reported in three previous MELAS cases and one MNGIE case with intestinal dysmotility. We emphasize that the MELAS and MNGIE phenotypes overlapped in this case and that the mechanism of acute ileus in MELAS was associated with functional paralysis of the intestine. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Taichung Vet Gen Hosp, Dept Pediat, Taichung 407, Taiwan.
   Taichung Vet Gen Hosp, Dept Pathol, Taichung 407, Taiwan.
   Taichung Vet Gen Hosp, Dept Neurol, Taichung 407, Taiwan.
C3 Taichung Veterans General Hospital; Taichung Veterans General Hospital; Taichung Veterans General Hospital
RP Chi, CS (corresponding author), Taichung Vet Gen Hosp, Dept Pediat, 160 Sec,3 Chung Kang Rd, Taichung 407, Taiwan.
CR Hiel JAP, 1998, NETH J MED, V53, P27, DOI 10.1016/S0300-2977(98)00018-7
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Kuroiwa T, 1998, ACTA NEUROPATHOL, V96, P86, DOI 10.1007/s004010050863
   Mori O, 2000, ACTA NEUROPATHOL, V100, P712, DOI 10.1007/s004010000209
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   Perez-Atayde AR, 1998, AM J SURG PATHOL, V22, P1141, DOI 10.1097/00000478-199809000-00014
   SCHUFFLER MD, 1980, ANN SURG, V192, P752, DOI 10.1097/00000658-198012000-00011
   Shimotake T, 1998, J PEDIATR SURG, V33, P1837, DOI 10.1016/S0022-3468(98)90301-3
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Vissing J, 2002, NEUROLOGY, V59, P926, DOI 10.1212/WNL.59.6.926
   YAMAMOTO M, 1987, J NEUROL NEUROSUR PS, V50, P1475, DOI 10.1136/jnnp.50.11.1475
NR 13
TC 26
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD NOV 15
PY 2004
VL 31
IS 5
BP 374
EP 377
DI 10.1016/j.pediatrneurol.2004.05.009
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 873WY
UT WOS:000225313400014
PM 15519124
DA 2024-11-01
ER

PT J
AU Chinnery, PF
   DiMauro, S
   Shanske, S
   Schon, EA
   Zeviani, M
   Mariotti, C
   Carrara, F
   Lombes, A
   Laforet, P
   Ogier, H
   Jaksch, M
   Lochmüller, H
   Horvath, R
   Deschauer, M
   Thorburn, DR
   Bindoff, LA
   Poulton, J
   Taylor, RW
   Matthews, JNS
   Turnbull, DM
AF Chinnery, PF
   DiMauro, S
   Shanske, S
   Schon, EA
   Zeviani, M
   Mariotti, C
   Carrara, F
   Lombes, A
   Laforet, P
   Ogier, H
   Jaksch, M
   Lochmüller, H
   Horvath, R
   Deschauer, M
   Thorburn, DR
   Bindoff, LA
   Poulton, J
   Taylor, RW
   Matthews, JNS
   Turnbull, DM
TI Risk of developing a mitochondrial DNA deletion disorder
SO LANCET
LA English
DT Article
ID progressive external ophthalmoplegia; human oocytes; duplications; mutations; myopathy; son
AB Background Pathogenic mitochondrial DNA (mtDNA) mutations are found in at least one in 8000 individuals. No effective treatment for mtDNA disorders is available, making disease prevention important. Many patients with mtDNA disease harbour a single pathogenic mtDNA deletion, but the risk factors for new cases and disease recurrence are not known. Methods We did a multicentre study of 226 families in which a single mtDNA deletion had been identified in the proband, including patients with chronic progressive external ophthalmoplegia, Kearns Sayre syndrome, or Pearson's syndrome. We studied the relation between maternal age and the risk of unaffected mothers having an affected child, and determined the recurrence risks among the siblings and offspring of affected individuals. Findings We noted no relation between maternal age and the risk of unaffected mothers having children with an mtDNA deletion disorder. None of the 251 siblings of the index cases developed clinical features of mtDNA disease. Risk of recurrence among the offspring of affected women was 4.11% (95% CI 0.86-11.54, or one in 117 to one in nine births). Only one of the mothers who had an affected child had a duplication of mtDNA in skeletal muscle. Interpretation Unlike nuclear chromosomal rearrangements, incidence of mtDNA deletion disorders does not increase with maternal age, and unaffected mothers are unlikely to have more than one affected child. Affected women were previously thought to have a negligible chance of having clinically affected offspring, but the actual risk is, on average, about one in 24 births.
C1 Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Dev, New York, NY 10032 USA.
   Natl Neurol Inst Carlo Besta, Pierfranco & Louisa Mariani Ctr Study Childrens M, Unit Mol Neurogenet, Milan, Italy.
   Hop La Pitie Salpetriere, Paris, France.
   Hop Robert Debre, F-75019 Paris, France.
   Metab Dis Ctr Munich Schwabing, Munich, Germany.
   Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   Univ Halle Wittenberg, Dept Neurol, Halle An Der Saale, Germany.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   Univ Oxford, Dept Obstet & Gynaecol, Oxford, England.
C3 Newcastle University - UK; Newcastle University - UK; Columbia University; Columbia University; Columbia University; Fondazione IRCCS Istituto Neurologico Carlo Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Robert-Debre - APHP; University of Munich; Martin Luther University Halle Wittenberg; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Bergen; Haukeland University Hospital; University of Oxford
RP Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU Telethon [1180] Funding Source: Medline
CR Barritt JA, 1999, MOL HUM REPROD, V5, P927, DOI 10.1093/molehr/5.10.927
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Brenner CA, 1998, MOL HUM REPROD, V4, P887, DOI 10.1093/molehr/4.9.887
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5
   CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x
   FERGUSONSMITH MA, 1983, BRIT MED BULL, V39, P355, DOI 10.1093/oxfordjournals.bmb.a071848
   HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   POULTON J, 1991, AM J HUM GENET, V48, P649
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1994, NAT GENET, V8, P313, DOI 10.1038/ng1294-313
   POULTON J, 1995, MUSCLE NERVE S, V3, P154
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SCHON EA, 1991, MOL GENETIC APPROACH, V0, P57
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 32
TC 131
Z9 145
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 14
PY 2004
VL 364
IS 9434
BP 592
EP 596
DI 10.1016/S0140-6736(04)16851-7
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 845WD
UT WOS:000223275100031
PM 15313359
DA 2024-11-01
ER

PT J
AU Szczepanowska, J
   Zablocki, K
   Duszynski, J
AF Szczepanowska, J
   Zablocki, K
   Duszynski, J
TI Influence of a mitochondrial genetic defect on capacitative calcium entry and mitochondrial organization in the osteosarcoma cells
SO FEBS LETTERS
LA English
DT Article
DE osteosarcoma; mitochondria; cytoskeleton; capacitative calcium entry; NARP
ID vascular endothelial-cells; atp synthase; oxidative-phosphorylation; endoplasmic-reticulum; mutation; ca2+; morphology; fusion; cytoskeleton; homeostasis
AB Effects of T8993G mutation in mitochondrial DNA (mtDNA), associated with neurogenical muscle weakness, ataxia and retinitis pigmentosa (NARP), on the cytoskeleton, mitochondrial network and calcium homeostasis in human osteosarcoma cells were investigated. In 98% NARP and rho(0) (lacking mtDNA) cells, the organization of the mitochondrial network and actin cytoskeleton was disturbed. Capacitative calcium entry (CCE) was practically independent of mitochondrial energy status in osteosarcoma cell lines. The significantly slower Ca2+ influx rates observed in 98% NARP and rho(0), in comparison to parental cells, indicates that proper actin cytoskeletal organization is important for CCE in these cells. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 M Nencki Inst Expt Biol, Dept Cellular Biochem, PL-02093 Warsaw, Poland.
C3 Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences
RP M Nencki Inst Expt Biol, Dept Cellular Biochem, Pasteura 3, PL-02093 Warsaw, Poland.
EM j.szczepanowska@nencki.gov.pl
CR Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200
   Baracca A, 2000, J BIOL CHEM, V275, P4177, DOI 10.1074/jbc.275.6.4177
   Barral MC, 1999, INORG CHEM COMMUN, V2, P153, DOI 10.1016/S1387-7003(99)00035-0
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Bishara NB, 2002, BRIT J PHARMACOL, V135, P119, DOI 10.1038/sj.bjp.0704465
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983
   Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616
   Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087
   DiMauro S, 2001, SEMIN CELL DEV BIOL, V12, P397, DOI 10.1006/scdb.2001.0277
   Dubot A, 2004, BIOCHEM BIOPH RES CO, V313, P687, DOI 10.1016/j.bbrc.2003.12.013
   Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200
   Friel DD, 2000, CELL CALCIUM, V28, P307, DOI 10.1054/ceca.2000.0172
   FRIESINGER G, 1994, APPL SUPERCOND, V2, P21, DOI 10.1016/0964-1807(94)90050-7
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221
   Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1
   HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P522, DOI 10.1042/bst0220522
   Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3
   Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157
   Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633
   Houstek J, 2004, BBA-BIOENERGETICS, V1658, P115, DOI 10.1016/j.bbabio.2004.04.012
   Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Knowles MK, 2002, P NATL ACAD SCI USA, V99, P14772, DOI 10.1073/pnas.232346999
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.e02-06-0330
   Lin T, 2003, NEUROGASTROENT MOTIL, V15, P277, DOI 10.1046/j.1365-2982.2003.00406.x
   Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200
   Mattenberger Y, 2003, FEBS LETT, V538, P53, DOI 10.1016/S0014-5793(03)00124-8
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   Minamikawa T, 1999, J CELL SCI, V112, P2419
   Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221
   Putney JW, 2001, J CELL SCI, V114, P2223
   Rappaport L, 1998, MOL CELL BIOCHEM, V184, P101, DOI 10.1023/A:1006843113166
   Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x
   Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527
   Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1
   Skulachev VP, 2004, MOL CELL BIOCHEM, V256, P341, DOI 10.1023/B:MCBI.0000009880.94044.49
   Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Territo PR, 2001, J BIOL CHEM, V276, P2586, DOI 10.1074/jbc.M002923200
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wasniewska M, 2001, BIOCHEM BIOPH RES CO, V283, P687, DOI 10.1006/bbrc.2001.4834
   Wasniewska M, 2000, FEBS LETT, V478, P237, DOI 10.1016/S0014-5793(00)01862-7
   WERTH JL, 1994, J NEUROSCI, V14, P348
   Zablocki K, 2003, CELL CALCIUM, V33, P91, DOI 10.1016/S0143-4160(02)00202-6
NR 58
TC 14
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD DEC 17
PY 2004
VL 578
IS 3
BP 316
EP 322
DI 10.1016/j.febslet.2004.11.022
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 882LH
UT WOS:000225939900021
PM 15589839
DA 2024-11-01
ER

PT J
AU Bertoni-Freddari, C
   Fattoretti, P
   Giorgetti, B
   Solazzi, M
   Balietti, M
   Meier-Ruge, W
AF Bertoni-Freddari, C
   Fattoretti, P
   Giorgetti, B
   Solazzi, M
   Balietti, M
   Meier-Ruge, W
TI Role of mitochondrial deterioration in physiological and pathological brain aging
SO GERONTOLOGY
LA English
DT Article
DE synaptic mitochondria; mitochondrial genetics; mitochondrial metabolic competence; mitochondrial structural dynamics; mitochondrial dysfunction; oxidative damage; mitochondrial therapeutics
ID cytochrome-oxidase; oxidative stress; neuronal death; dna; mutations; damage; consequences; pathogenesis; apoptosis; dynamics
AB Background: Mitochondria are widely reported to occupy a unique role in modulating cell viability, senescence and death. This is consistently supported by the multiple functions of these organelles. In addition to providing the energy for the myriad of cellular performances, mitochondria are involved in regulating thermogenesis, calcium buffering, integration of pro- and anti-apoptotic signals. Objective: To stress the significant importance of subtle, continuous and permanent mitochondrial alterations as key events in physiological aging and as unfavourable determinants of age-related neurodegenerative diseases. Results: Any dysfunction of these organelles may constitute a serious threat for cellular health status and survival, particularly of post-mitotic nerve and muscle cells. Mitochondrial deterioration may affect discrete features of the organelles (such as their structural dynamics, genetics and physiology) and lead to a progressive functional impairment. Conclusions: A variety of mitochondrial tasks, while hampering the possibility to recover the organelles' dysfunctions, offer different and reliable opportunities for therapeutic interventions. Copyright (C) 2004 S. Karger AG, Basel.
C1 INRCA Ancona, Res Dept, Neurobiol Aging Lab, IT-60121 Ancona, Italy.
   Univ Basel, Inst Pathol, Basel, Switzerland.
C3 IRCCS INRCA; University of Basel
RP INRCA Ancona, Res Dept, Neurobiol Aging Lab, Via Birarelli 8, IT-60121 Ancona, Italy.
EM c.bertoni@inrca.it
CR ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8
   BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202
   BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5
   Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8
   Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Bertoni-Freddari C, 1997, ANN N Y ACAD SCI, V826, P479, DOI 10.1111/j.1749-6632.1997.tb48508.x
   Bertoni-Freddari C, 2003, NATURWISSENSCHAFTEN, V90, P68, DOI 10.1007/s00114-002-0398-8
   Bertoni-Freddari C, 2002, J AM AGING ASSOC, V25, P101, DOI 10.1007/s11357-002-0008-x
   Bertoni-Freddari C, 2001, MICRON, V32, P405, DOI 10.1016/S0968-4328(00)00015-9
   BertoniFreddari C, 1996, GERONTOLOGY, V42, P170
   BERTONIFREDDARI C, 1993, BRAIN RES, V628, P193, DOI 10.1016/0006-8993(93)90955-M
   BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061
   Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   GARTNER LP, 1987, EXP GERONTOL, V22, P297, DOI 10.1016/0531-5565(87)90008-8
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342
   Karbowski M, 1997, BBA-LIPID LIPID MET, V1349, P242, DOI 10.1016/S0005-2760(97)00140-9
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883
   MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510
   Meier-Ruge WA, 1999, GERONTOLOGY, V45, P289, DOI 10.1159/000022104
   Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567
   Melov S, 2000, ANN NY ACAD SCI, V908, P219
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miquel J, 2000, METH MOLEC MED, V38, P221, DOI 10.1385/1-59259-070-5:221
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Salvioli S, 2001, FEBS LETT, V492, P9, DOI 10.1016/S0014-5793(01)02199-8
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   SINGH KK, 2003, ADV BASIC SCI DIAGNO, V0, P452
   SOLMI R, 1994, BIOCHEM MOL BIOL INT, V33, P477
   TAUCHI H, 1985, THRESHOLDS AGEING, V0, P91
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   White RJ, 1996, J NEUROSCI, V16, P5688
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 45
TC 25
Z9 25
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PD JUN 15
PY 2004
VL 50
IS 3
BP 187
EP 192
DI 10.1159/000076779
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 815UQ
UT WOS:000221067600011
PM 15114042
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, J
TI Mitochondriopathies
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Review
DE genetics; hereditary disease; multisystem; mutations; neuromuscular disease; skeletal muscle
ID respiratory-chain disorders; lethal metabolic-disorder; complex-i deficiency; multiple deletions; autosomal-dominant; external ophthalmoplegia; mtdna depletion; dna deletions; sideroblastic anemia; diagnostic-criteria
AB Mitochondriopathies (MCPs) are either due to sporadic or inherited mutations in nuclear or mitochondrial DNA located genes (primary MCPs), or due to exogenous factors (secondary MCPs). MCPs usually show a chronic, slowly progressive course and present with multiorgan involvement with varying onset between birth and late adulthood. Although several proteins with signalling, assembling, transport, enzymatic function can be impaired in MCP, most frequently the activity of the respiratory chain (RC) protein complexes is primarily or secondarily affected, leading to impaired oxygen utilization and reduced energy production. MCPs represent a diagnostic challenge because of their wide variation in presentation and course. Systems frequently affected in MCP are the peripheral nervous system (myopathy, polyneuropathy, lactacidosis), brain (leucencephalopathy, calcifications, stroke-like episodes, atrophy with dementia, epilepsy, upper motor neuron signs, ataxia, extrapyramidal manifestations, fatigue), endocrinium (short stature, hyperhidrosis, diabetes, hyperlipidaemia, hypogonadism, amenorrhoea, delayed puberty), heart (impulse generation or conduction defects, cardiomyopathy, left ventricular non-compaction heart failure), eyes (cataract, glaucoma, pigmentary retinopathy, optic atrophy), ears (deafness, tinnitus, peripheral vertigo), guts (dysphagia, vomiting, diarrhoea, hepatopathy, pseudo-obstruction, pancreatitis, pancreas insufficiency), kidney (renal failure, cysts) and bone marrow (sideroblastic anaemia). Apart from well-recognized syndromes, MCP should be considered in any patient with unexplained progressive multisystem disorder. Although there is actually no specific therapy and cure for MCP, many secondary problems require specific treatment. The rapidly increasing understanding of the pathophysiological background of MCPs may further facilitate the diagnostic approach and open perspectives to future, possibly causative therapies.
C1 Krankenanstalt Rudolfstiftung Wien, Dept Neurol, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Postfach 348, A-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Abe K, 1997, NEUROLOGY, V49, P837, DOI 10.1212/WNL.49.3.837
   Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Barrientos A, 1996, AM J HUM GENET, V58, P963
   Barrientos A, 1996, J CLIN INVEST, V97, P1570, DOI 10.1172/JCI118581
   Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814
   Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8
   Bénit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BOURGEOIS M, 1992, BRAIN DEV-JPN, V14, P404, DOI 10.1016/S0387-7604(12)80349-4
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chow C W, 2000, HUM REPROD, V15 Suppl 2, P68
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   ERNSTER L, 1959, NATURE, V184, P1851, DOI 10.1038/1841851a0
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   Fellman V, 2002, BLOOD CELL MOL DIS, V29, P444, DOI 10.1006/bcmd.2002.0582
   Finsterer J, 1999, CLIN NEUROPHYSIOL, V110, P1466, DOI 10.1016/S1388-2457(99)00090-5
   Finsterer J, 1997, AKTUEL NEUROL, V24, P231, DOI 10.1055/s-2007-1017815
   Finsterer J, 2002, CAN J NEUROL SCI, V29, P49, DOI 10.1017/S0317167100001712
   Finsterer J, 2002, AMYOTROPH LATERAL SC, V3, P219, DOI 10.1080/146608202760839008
   Finsterer J, 2002, METAB BRAIN DIS, V17, P41, DOI 10.1023/A:1014052330663
   Finsterer J, 2001, ACTA MED AUST, V28, P152, DOI 10.1046/j.1563-2571.2001.01036.x
   Finsterer J, 2001, J INHERIT METAB DIS, V24, P560, DOI 10.1023/A:1012415810881
   Finsterer J, 1998, CAN J ANAESTH, V45, P781, DOI 10.1007/BF03012149
   Finsterer J, 2000, METAB BRAIN DIS, V15, P163
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Hansen JJ, 2003, HUM GENET, V112, P71, DOI 10.1007/s00439-002-0837-9
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUCKRIEDE A, 1994, BBA-MOL BASIS DIS, V1227, P200, DOI 10.1016/0925-4439(94)90096-5
   IONASESCU V, 1983, AM J MED GENET, V15, P103, DOI 10.1002/ajmg.1320150114
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Kaukonen JA, 1996, AM J HUM GENET, V58, P763
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kirches EJF, 1998, J INHERIT METAB DIS, V21, P400, DOI 10.1023/A:1005306725644
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lev D, 2002, EUR J PAEDIATR NEUROL, V6, P121, DOI 10.1053/ejpn.2001.0558
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Lin DDM, 2003, AM J NEURORADIOL, V24, P33
   Lodi R, 2002, FREE RADICAL RES, V36, P461, DOI 10.1080/10715760290021324
   Lodi R, 2002, J NEUROL NEUROSUR PS, V72, P805, DOI 10.1136/jnnp.72.6.805
   Lodi R, 2001, ANN NEUROL, V49, P590
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Martínez-Fernández E, 2001, STROKE, V32, P2507, DOI 10.1161/hs1101.098328
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   *MIT DIS FDN, 2003, MIT DIS FDN, V0, P0
   *MITOMAP, 2003, HUM MIT GEN DAT, V0, P0
   Mitsui T, 2002, J NEUROL, V249, P1004, DOI 10.1007/s00415-002-0774-5
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORGANHUGHES JA, 1994, MYOLOGY, V0, P1610
   Moskowitz MA, 2003, STROKE, V34, P324, DOI 10.1161/01.STR.0000054047.14853.AD
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Niemann S, 2003, HUM GENET, V113, P92, DOI 10.1007/s00439-003-0938-0
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Parvari R, 2001, AM J HUM GENET, V69, P869, DOI 10.1086/323624
   Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   PESTRONK A, 2003, NEUROMUSCULAR DIS CT, V0, P0
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Schapira AHV, 2002, J NEUROL NEUROSUR PS, V72, P144, DOI 10.1136/jnnp.72.2.144
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHAPIRO AHV, 1994, MITOCHONDRIAL DISORD, V0, P1
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Siciliano G, 1999, NEUROMUSCULAR DISORD, V9, P411, DOI 10.1016/S0960-8966(99)00047-4
   Sperl W, 1997, WIEN KLIN WOCHENSCHR, V109, P93
   Stryer L, 1996, BIOCHEMIE, V0, P0
   Sue CM, 2000, BRAIN PATHOL, V10, P442
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   TSAIRIS P, 1973, NEUROLOGY, V23, P408
   Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Walker U A, 2002, PRAXIS (BERN 1994), V91, P2129
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Williams RS, 2002, NEW ENGL J MED, V347, P609, DOI 10.1056/NEJMe020083
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zeviani M, 1999, ITAL J NEUROL SCI, V20, P401
NR 133
TC 170
Z9 191
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR 15
PY 2004
VL 11
IS 3
BP 163
EP 186
DI 10.1046/j.1351-5101.2003.00728.x
PG 24
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 801AY
UT WOS:000220070000003
PM 15009163
DA 2024-11-01
ER

PT J
AU Challa, S
   Kanikannan, MA
   Jagarlapudi, MMK
   Bhoompally, VR
   Surath, M
AF Challa, S
   Kanikannan, MA
   Jagarlapudi, MMK
   Bhoompally, VR
   Surath, M
TI Diagnosis of mitochondrial diseases: Clinical and histological study of sixty patients with ragged red fibers
SO NEUROLOGY INDIA
LA English
DT Article
DE mitochondrial disease; ragged-red fiber; progressive external ophthalmoplegia; Kearns-Sayre syndrome; myoclonus epilepsy with ragged-red fibers; heart block
ID kearns-sayre-syndrome; atrioventricular-block; myoclonic epilepsy; dna; mutation; myopathy; gene; involvement; disorders; deletions
AB Background: Mitochondrial diseases are caused by mutations in mitochondrial or nuclear genes, or both and most patients do not present with easily recognizable disorders The characteristic morphologic change in muscle biopsy ragged-red fibers (RRFs) provides an important clue to the diagnosis. Materials and Methods: Demographic data, presenting symptoms, neurological features, and investigative findings in 60 patients with ragged-red fibers (RRFs) on muscle biopsy, seen between January 1990 and December 2002, were analyzed. The authors applied the modified respiratory chain (RC) diagnostic criteria retrospectively to determine the number of cases fulfilling the diagnostic criteria of mitochondrial disease. Results: The most common clinical syndrome associated with RRFs on muscle biopsy was progressive external ophthalmoplegia (PEO) with or without other signs, in 38 (63%) patients. Twenty-six patients (43%) had only external ophthalmoplegia, 5 (8%) patients presented with encephalomyopathy. Specific syndromes were the presenting feature in 8 (13%), Kearns-Sayre syndrome (KSS) in 4 and myoclonus epilepsy with, ragged-red fibers (MERRF) in 4. Myopathy was the presenting feature in 5 (8%) and 4 presented with infantile myopathy. Of the 60 patients, 18 (30%) had proximal muscle weakness. Two patients with KSS and one patient with myopathy had complete heart block necessitating pace making. When the modified RC diagnostic criteria were applied, only 26 (43%) patients had one other major criterion in addition to RRFs for the diagnosis of mitochondrial diseases. The remaining 34 (57%) patients with RRFs on Muscle biopsy had only some clinical features suggestive of RC disorder but did not fulfill the clinical criteria (of the modified diagnostic criteria) for the diagnosis of mitochondrial diseases. Conclusion: In patients with clinical features suggestive of RC disorder, demonstration of RRFs on muscle biopsy helps in confirming the diagnosis of mitochondrial disease in only a subgroup of patients.
C1 Nizams Inst Med Sci, Dept Pathol, Hyderabad 50082, Andhra Pradesh, India.
   Nizams Inst Med Sci, Dept Neurol, Hyderabad 50082, Andhra Pradesh, India.
   Care Hosp, Inst Neurol Sci, Hyderabad, Andhra Pradesh, India.
   LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical Sciences; L. V. Prasad Eye Institute
RP Challa, S (corresponding author), Nizams Inst Med Sci, Dept Pathol, Hyderabad 50082, Andhra Pradesh, India.
EM challa_sundaram@yahoo.com
CR ACHARYA JN, 1995, EPILEPSIA, V36, P429, DOI 10.1111/j.1528-1157.1995.tb00482.x
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DIMAURO S, 1990, PEDIATR RES, V28, P536, DOI 10.1203/00006450-199011000-00025
   DUBOWITZ, 1985, MUSCLE BIOPSY PRACTI, V0, P504
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Kakura H, 1998, JPN CIRC J, V62, P623, DOI 10.1253/jcj.62.623
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   RADHAKRISHNAN VV, 2000, NEUROSCIENCES TODAY, V4, P145
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SENGERS RCA, 1987, J INHERIT METAB DIS, V10, P98, DOI 10.1007/BF01812850
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1
   STANSBIE D, 1986, J INHERIT METAB DIS, V9, P105, DOI 10.1007/BF01799447
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   SWEENEY MG, 1993, Q J MED, V86, P709
   Taggart RT, 1999, HUM MUTAT, V13, P210
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Takeda K, 1989, RINSHO SHINKEIGAKU, V29, P643
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TORBERGSEN T, 1991, MUSCLE NERVE, V14, P35
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 20
Z9 22
U1 0
U2 3
PU NEUROL SOC INDIA
PI CHANDIGARH
PA C/O J S CHOPRA, PGIMER, DEPT NEUROLOGY, CHANDIGARH 160 012, INDIA
SN 0028-3886
EI 
J9 NEUROL INDIA
JI Neurol. India
PD SEP 15
PY 2004
VL 52
IS 3
BP 353
EP 358
DI 
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 865QE
UT WOS:000224716800011
PM 15472426
DA 2024-11-01
ER

PT J
AU Smith, PM
   Ross, GF
   Taylor, RW
   Turnbull, DA
   Lightowlers, RN
AF Smith, PM
   Ross, GF
   Taylor, RW
   Turnbull, DA
   Lightowlers, RN
TI Strategies for treating disorders of the mitochondrial genome
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE antigenomic hypothesis; mtDNA disease; treatment of mtDNA disease; alloptic expression; mithocondrial tRNA import
ID peptide nucleic-acids; mismatch repair activity; transfer-rna import; human-cells; saccharomyces-cerevisiae; mammalian mitochondria; dna heteroplasmy; skeletal-muscle; gene-therapy; restriction-endonuclease
AB Defects of the mitochondrial genome are a significant cause of disease. Patients suffer from a wide variety of clinical presentations, ranging from fatal infantile disease to mild muscle weakness. Most disorders, however, are characterized by inexorable progression: As mutations often cause defects in several components of the complexes that couple oxidative phosphorylation, this terminal state of oxidative metabolism cannot be readily bypassed by dietary means, leading to the search for novel therapies. In this article, we present the theory behind several concepts and report progress. We also discuss some of the recent difficulties encountered in the progress towards an antigenome approach to treating mtDNA disorders. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.n.lightowlers@nct.ac.uk
CR Bai YD, 2004, ANN NY ACAD SCI, V1011, P272, DOI 10.1196/annals.1293.026
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Bayona M, 2004, BBA-BIOENERGETICS, V1657, P89
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BOUGERON T, 1993, J BIOL CHEM, V268, P19369
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHRZANOWSKALIGHTOWLERS ZMA, 1995, GENE THER, V2, P311
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x
   Coulter CV, 2000, FREE RADICAL BIO MED, V28, P1547, DOI 10.1016/S0891-5849(00)00255-0
   DSouza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168-3659(03)00297-9
   Demidov VV, 2002, P NATL ACAD SCI USA, V99, P5953, DOI 10.1073/pnas.092127999
   DEVRIES S, 1988, EUR J BIOCHEM, V176, P377
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Glover KE, 2001, J BIOL CHEM, V276, P639, DOI 10.1074/jbc.M007708200
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Koulintchenko M, 2003, EMBO J, V22, P1245, DOI 10.1093/emboj/cdg128
   Kuhn H, 1999, J MOL BIOL, V286, P1337, DOI 10.1006/jmbi.1998.2578
   Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005
   LI K, 1994, J CELL BIOL, V124, P871, DOI 10.1083/jcb.124.6.871
   Liebling MR, 2003, MOL BIOTECHNOL, V25, P229, DOI 10.1385/MB:25:3:229
   Magalhaes PJ, 1998, MOL BIOL CELL, V9, P2375, DOI 10.1091/mbc.9.9.2375
   Mahoney DJ, 2002, CURR OPIN CLIN NUTR, V5, P619, DOI 10.1097/00075197-200211000-00004
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   Mason PA, 2003, FEBS LETT, V554, P6, DOI 10.1016/S0014-5793(03)01169-4
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091
   Oca-Cossio J, 2003, GENETICS, V165, P707
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   ONO A, 1994, BIOCHEMISTRY-US, V33, P4312, DOI 10.1021/bi00180a027
   Puranam RS, 2001, MOL CELL BIOL, V21, P548, DOI 10.1128/MCB.21.2.548-561.2001
   Ross GF, 2003, BIOCONJUGATE CHEM, V14, P962, DOI 10.1021/bc034050f
   ROSS MF, 2004, IN PRESS BIOCH J, V0, P0
   Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7
   Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200
   Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674
   SMITH PM, 2003, THESIS NEWCASTLE UPO, V0, P0
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Turnbull DM, 2002, NAT GENET, V30, P345, DOI 10.1038/ng0402-345
   VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0
   Weber K, 1997, AM J HUM GENET, V60, P373
   Weissig V, 1998, PHARMACEUT RES, V15, P334, DOI 10.1023/A:1011991307631
   Weissig V, 2001, ADV DRUG DELIVER REV, V49, P127, DOI 10.1016/S0169-409X(01)00131-4
NR 56
TC 22
Z9 29
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 0006-3002
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD DEC 6
PY 2004
VL 1659
IS 2-3
BP 232
EP 239
DI 10.1016/j.bbabio.2004.09.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 882KT
UT WOS:000225938500017
PM 15576056
DA 2024-11-01
ER

PT J
AU van den Bosch, BJC
   de Coo, IFM
   Hendrickx, ATM
   Busch, HFM
   de Jong, G
   Scholte, HR
   Smeets, HJM
AF van den Bosch, BJC
   de Coo, IFM
   Hendrickx, ATM
   Busch, HFM
   de Jong, G
   Scholte, HR
   Smeets, HJM
TI Increased risk for cardiorespiratory failure associated with the A3302G mutation in the mitochondrial DNA encoded tRNA<SUP>Leu(UUR)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial tRNA; point mutation; mitochondrial encephalomyopathy; cardiorespiratory failure; tRNA(Leut(UUR))
ID transfer rnaleu(uur) gene; a3243g mutation; diabetes-mellitus; melas mutation; cardiomyopathy; myopathy; disease; encephalomyopathy; disorders; deafness
AB Screening the mitochondrial DNA of a 64-year-old woman with mitochondrial myopathy revealed 76% of the tRNA(Leu(UUR)) A3302G mutation in muscle. Muscle of her affected son carried 96% mutated mitochondrial DNA. Both patients were biopsied twice, showing isolated complex I deficiency in the son's first biopsy, additional increased (within normal range) complex II+III activities in his second biopsy, combined complex I, II+III deficiency in mothers first biopsy and additional complex IV deficiency in her second biopsy. After a stay in the mountains, the son died of cardiac arrhythmia. The A3302G mutation has been reported before and is associated with mitochondrial myopathy and cardiorespiratory failure. Pathogenesis is explained by abnormal mtRNA processing, which was also reported for the adjacent C3303T mutation associated with cardiomyopathy and/or skeletal myopathy. Our findings suggest that a high mutation load of the A3302G mutation can lead to fatal cardiorespiratory failure, likely triggered by low environmental oxygen pressure and exercise. (C) 2004 Elsevier B.V. All rights reserved.
C1 Maastricht Univ, CARIM, Dept Genet & Cell Biol, NL-6200 MD Maastricht, Netherlands.
   Erasmus MC, Dept Child Neurol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus MC, Dept Neurol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus MC, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands.
   Erasmus MC, Dept Biochem, NL-3000 DR Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Maastricht Univ, CARIM, Dept Genet & Cell Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM bert.smeets@molcelb.unimaas.nl
CR BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   BUSCH HFM, 1981, MITOCHONDRIA MUSCULA, V0, P207
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Iwanaga R, 2001, ACTA NEUROPATHOL, V101, P179
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   JEANFRANCOIS MJB, 1994, AUST NZ J MED, V24, P188, DOI 10.1111/j.1445-5994.1994.tb00556.x
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Maassen JA, 2001, EXP CLIN ENDOCR DIAB, V109, P127, DOI 10.1055/s-2001-14834
   Marín-García J, 2002, J CARD FAIL, V8, P347, DOI 10.1054/jcaf.2002.127774
   Marín-García J, 2002, CARDIOVASC RES, V54, P516, DOI 10.1016/S0008-6363(01)00552-1
   Mongini T, 2002, CLIN NEUROPATHOL, V21, P72
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Santorelli F M, 2001, AM HEART J, V141, PE1, DOI 10.1067/mhj.2001.112088
   SCHOLTE HR, 1995, BBA-MOL BASIS DIS, V1271, P75, DOI 10.1016/0925-4439(95)00013-T
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Servidei Serenella, 2003, NEUROMUSCUL DISORD, V13, P848
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   WALLACE DC, 2003, MITOMAP HUMAN MITOCH, V0, P0
   WATMOUGH NJ, 1990, J CLIN INVEST, V85, P177, DOI 10.1172/JCI114409
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   ZEVIANI M, 1995, MUSCLE NERVE, V0, PS170
NR 32
TC 18
Z9 18
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT 15
PY 2004
VL 14
IS 10
BP 683
EP 688
DI 10.1016/j.nmd.2004.06.004
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 860HC
UT WOS:000224332100006
PM 15351426
DA 2024-11-01
ER

PT J
AU Miró, O
   López, S
   Martínez, E
   Pedrol, E
   Milinkovic, A
   Deig, E
   Garrabou, G
   Casademont, J
   Gatell, JM
   Cardellach, F
AF Miró, O
   López, S
   Martínez, E
   Pedrol, E
   Milinkovic, A
   Deig, E
   Garrabou, G
   Casademont, J
   Gatell, JM
   Cardellach, F
TI Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID lipid-peroxidation; undergo apoptosis; adipose-tissue; dna; toxicity; protein; zidovudine; depletion; myopathy; damage
AB To investigate the effects of HIV infection on mitochondrial DNA (mtDNA) content and other mitochondrial parameters, we used peripheral blood mononuclear cells (PBMCs) from 25 asymptomatic antiretroviral-naive human immunodeficiency virus (HIV)-infected patients and from 25 healthy control subjects. HIV-infected patients had significant decreases in mtDNA content (decrease, 23%; P<.05) and in the activities of mitochondrial respiratory chain (MRC) complex II (decrease, 41%; P<.001), MRC complex III (decrease, 38%; P<.001), MRC complex IV (decrease, 19%; P=.001), and glycerol-3-phosphate dehydrogenase (decrease, 22%; P<.001), along with increased lipid peroxidation of PBMC membranes (P=.007). Therefore, HIV infection is associated not only with mtDNA depletion, but also with extensive MRC disturbances and increased oxidative damage.
C1 Univ Barcelona, Sch Med,August Pi & Sunyer Biomed Res Inst, Hosp Clin, Infect Dis Unit, Barcelona, Spain.
   Univ Barcelona, Dept Internal Med, Muscle Res Unit, Mitochrondrial Res Lab, Barcelona, Spain.
   Fdn Hosp Asil de Granollers, Dept Internal Med, Granollers, Catalonia, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona
RP Hosp Clin Barcelona, Dept Internal Med, Muscle Res Unit, Villarroel 170, E-08036 Barcelona, Spain.
EM omiro@clinic.ub.es
CR Badley AD, 2003, TRENDS PHARMACOL SCI, V24, P298, DOI 10.1016/S0165-6147(03)00125-1
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Casademont J, 1996, BRAIN, V119, P1357, DOI 10.1093/brain/119.4.1357
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683
   Cherry CL, 2003, J CLIN VIROL, V26, P195, DOI 10.1016/S1386-6532(02)00118-X
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Cossarizza A, 1997, AIDS, V11, P19, DOI 10.1097/00002030-199701000-00004
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Hammond EL, 2003, J CLIN VIROL, V27, P97, DOI 10.1016/S1386-6532(02)00134-8
   HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704
   Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   Miró O, 1999, CARCINOGENESIS, V20, P1331, DOI 10.1093/carcin/20.7.1331
   Miró O, 2003, AIDS RES HUM RETROV, V19, P1027, DOI 10.1089/088922203322588387
   Miró O, 2003, ANTIVIR THER, V8, P333
   Muthumani K, 2002, J BIOL CHEM, V277, P37820, DOI 10.1074/jbc.M205313200
   Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7
   Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861
   Plymale DR, 1999, AIDS, V13, P1827, DOI 10.1097/00002030-199910010-00004
   Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Shiramizu B, 2003, JAIDS-J ACQ IMM DEF, V32, P370, DOI 10.1097/00126334-200304010-00004
   Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002
   Walker UA, 2004, HEPATOLOGY, V39, P311, DOI 10.1002/hep.20074
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   Wood E, 2002, J ACQ IMMUN DEF SYND, V30, P159, DOI 10.1097/01.QAI.0000014765.47046.5A
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 36
TC 126
Z9 143
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2004
VL 39
IS 5
BP 710
EP 716
DI 10.1086/423176
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 847CU
UT WOS:000223367500016
PM 15356787
DA 2024-11-01
ER

PT J
AU Simon, DK
   Lin, MT
   Zheng, LY
   Liu, GJ
   Ahn, CH
   Kim, LM
   Mauck, WM
   Twu, F
   Beal, MF
   Johns, DR
AF Simon, DK
   Lin, MT
   Zheng, LY
   Liu, GJ
   Ahn, CH
   Kim, LM
   Mauck, WM
   Twu, F
   Beal, MF
   Johns, DR
TI Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE mitochondria; Parkinson's disease; aging; somatic; oxidative stress; acquired mutations; neurodegeneration
ID complex-i deficiency; mtdna control region; oxidative damage; alzheimers-disease; point mutations; skeletal-muscle; human tissue; human-cells; human brain; accumulation
AB Oxidative damage to mitochondrial DNA (mtDNA) increases with age in the brain and can induce G:C to T:A and T:A to G:C point mutations. Though rare at any particular site, multiple somatic mtDNA mutations induced by oxidative damage or by other mechanisms may accumulate with age in the brain and thus could play a role in aging and neurodegenerative diseases. However, no prior study has quantified the total burden of mtDNA point mutation subtypes in the brain. Using a highly sensitive cloning and sequencing strategy, we find that the aggregate levels of G:C to T:A and T:A to G:C transversions and of all point mutations increase with age in the frontal cortex (FCtx). In the substantia nigra (SN), the aggregate levels of point mutations in young controls are similar to the levels in the SN or FCtx of elderly subjects. Extrapolation from our data suggests an average of 2.7 (FCtx) to 3.2 (SN) somatic point mutations per mitochondrial genome in elderly subjects. There were no significant differences between Parkinson's disease (PD) patients and age-matched controls in somatic mutation levels. These results indicate that individually rare mtDNA point mutations reach a high aggregate burden in FCtx and SN of elderly subjects. (C) 2003 Elsevier Science Inc. All rights reserved.
C1 Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY USA.
   Beth Israel Deaconess Med Ctr, Dept Ophthalmol, Boston, MA 02215 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cornell University; Weill Cornell Medicine; Harvard University; Beth Israel Deaconess Medical Center
RP Simon, DK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, 77 Ave Louis Pasteur,Room HIM-856, Boston, MA 02115 USA.
FU NIA NIH HHS [R01 AG20729, K08 AG00798] Funding Source: Medline; NINDS NIH HHS [K08 NS01971, K02 NS4311-01, K24 NS02239] Funding Source: Medline
CR Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P915
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Beckman KB, 1999, MUTAT RES-FUND MOL M, V424, P51, DOI 10.1016/S0027-5107(99)00007-X
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   BOWLING AC, 1993, J NEUROCHEM, V0, P60
   CHEN D, 1994, APPL COMPUT HARMON A, V1, P194
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI G, 1995, BBA-MOL BASIS DIS, V1271, P171, DOI 10.1016/0925-4439(95)00025-Y
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   DAurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200
   Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437
   Davis JN, 1998, BIOCHEM BIOPH RES CO, V244, P877, DOI 10.1006/bbrc.1998.8353
   Enríquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207
   Ferrante RJ, 1997, J NEUROCHEM, V69, P2064
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   Kubis N, 2000, BRAIN, V123, P366, DOI 10.1093/brain/123.2.366
   KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0
   Langston JW, 1996, NEUROLOGY, V47, PS153, DOI 10.1212/WNL.47.6_Suppl_3.153S
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1997, HUM MUTAT, V9, P265, DOI 10.1002/(SICI)1098-1004(1997)9:3<265::AID-HUMU8>3.3.CO;2-6
   Ma SY, 1999, NEUROPATH APPL NEURO, V25, P394
   Malyarchuk BA, 2002, HUM GENET, V111, P46, DOI 10.1007/s00439-002-0740-4
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416
   MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Perna NT, 1996, CURR BIOL, V6, P128, DOI 10.1016/S0960-9822(02)00441-4
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Simon DK, 2001, GENOMICS, V73, P113, DOI 10.1006/geno.2001.6515
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   van Orsouw NJ, 1998, GENOMICS, V52, P27, DOI 10.1006/geno.1998.5410
   Vielhaber S, 2000, BIOCHEM SOC T, V28, P159, DOI 10.1042/bst0280159
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5
NR 64
TC 94
Z9 102
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JAN 15
PY 2004
VL 25
IS 1
BP 71
EP 81
DI 10.1016/S0197-4580(03)00037-X
PG 11
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 759HT
UT WOS:000187732800012
PM 14675733
DA 2024-11-01
ER

PT J
AU Duncan, GE
   Perkins, LA
   Theriaque, DW
   Neiberger, RE
   Stacpoole, PW
AF Duncan, GE
   Perkins, LA
   Theriaque, DW
   Neiberger, RE
   Stacpoole, PW
TI Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID lactic-acidosis; oxidase deficiency; myopathy; intolerance; performance; endurance; mutations; index; drug; dna
AB We determined acute and chronic effects of dichloroacetate (DCA) on maximal (MAX) and submaximal (SUB) exercise responses in patients with abnormal mitochondrial energetics. Subjects (n = 9) completed a MAX treadmill bout 1 h after ingesting 25 mg/kg DCA or placebo (PL). A 15-min SUB bout was completed the next day while receiving the same treatment. After a 1-d washout, MAX and SUB were repeated while receiving the alternate treatment (acute). Gas exchange and heart rate were measured throughout all tests. Blood lactate (Bla) was measured 0, 3, and 10 min after MAX, and 5, 10, and 15 min during SUB. MAX and SUB were repeated after 3 months of daily DCA or PL. After a 2-wk washout, a final MAX and SUB were completed after 3 months of alternate treatment (chronic). Average Bla during SUB was lower (P < 0.05) during both acute (1.99 +/- 1.10 vs. 2.49 +/- 1.52 mmol/liter) and chronic (1.71 +/- 1.37 vs. 2.39 +/- 1.32 mmol/liter) DCA vs. PL despite similar exercise intensities between conditions (similar to 75 and 70% maximal exercise capacity during acute and chronic treatment). Thus, although DCA does not alter MAX responses, acute and chronic DCA attenuate the Bla response to moderate exercise in patients with abnormal mitochondrial energetics.
C1 Univ Washington, Dept Epidemiol, Nutr Sci Program, Seattle, WA 98195 USA.
   Univ Florida, Dept Med, Gainesville, FL 32610 USA.
   Univ Florida, Dept Pediat, Gainesville, FL 32610 USA.
   Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   Univ Florida, Gen Clin Res Ctr, Gainesville, FL 32610 USA.
C3 University of Washington; University of Washington Seattle; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida
RP Duncan, GE (corresponding author), Univ Washington, Dept Epidemiol, Nutr Sci Program, 305 Raitt Hall,Box 353410, Seattle, WA 98195 USA.
EM duncag@u.washington.edu
FU NCRR NIH HHS [RR-00082] Funding Source: Medline; NIEHS NIH HHS [ES-07355] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   CARRARO F, 1989, J APPL PHYSIOL, V66, P591, DOI 10.1152/jappl.1989.66.2.591
   DANDURAND RJ, 1995, CHEST, V108, P182, DOI 10.1378/chest.108.1.182
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DURKOT MJ, 1995, INT J SPORTS MED, V16, P167, DOI 10.1055/s-2007-972986
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   Fernández J, 2000, MED CLIN-BARCELONA, V114, P121, DOI 10.1016/S0025-7753(00)71216-4
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   Hatta Hideo, 1992, ANNALS OF PHYSIOLOGICAL ANTHROPOLOGY, V11, P339
   HENDERSON GN, 1994, DRUG DEV IND PHARM, V20, P2425, DOI 10.3109/03639049409042647
   Howlett RA, 1999, AM J PHYSIOL-ENDOC M, V277, PE18, DOI 10.1152/ajpendo.1999.277.1.E18
   KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915
   LUDVIK B, 1993, PFLUG ARCH EUR J PHY, V423, P251, DOI 10.1007/BF00374403
   MERRILL GF, 1980, J APPL PHYSIOL, V48, P427, DOI 10.1152/jappl.1980.48.3.427
   NAITO E, 1989, BRAIN DEV-JPN, V11, P195, DOI 10.1016/S0387-7604(89)80098-1
   POLLOCK ML, 1990, EXERCISE HLTH DIS EV, V0, P661
   SCHNEIDER SH, 1981, METABOLISM, V30, P590, DOI 10.1016/0026-0495(81)90137-2
   SLAUGHTER MH, 1988, HUM BIOL, V60, P709
   Stacpoole PW, 1997, ARCH DIS CHILD, V77, P535, DOI 10.1136/adc.77.6.535
   STACPOOLE PW, 1992, NEW ENGL J MED, V327, P1564, DOI 10.1056/NEJM199211263272204
   Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Thompson D, 1997, HOWLEY, V0, P0
   Vissing J, 1996, ANN NEUROL, V40, P655, DOI 10.1002/ana.410400416
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Westerblad H, 2002, NEWS PHYSIOL SCI, V17, P17
NR 34
TC 28
Z9 29
U1 0
U2 4
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR 15
PY 2004
VL 89
IS 4
BP 1733
EP 1738
DI 10.1210/jc.2003-031684
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 810OV
UT WOS:000220714500034
PM 15070938
DA 2024-11-01
ER

PT J
AU Takagi, K
   Yamada, Y
   Gong, JS
   Sone, T
   Yokota, M
   Tanaka, M
AF Takagi, K
   Yamada, Y
   Gong, JS
   Sone, T
   Yokota, M
   Tanaka, M
TI Association of a 5178C→A (Leu237Met) polymorphism in the mitochondrial DNA with a low prevalence of myocardial infarction in Japanese individuals
SO ATHEROSCLEROSIS
LA English
DT Article
DE mitochondrial DNA; single nucleotide polymorphism; myocardial infarction; association study; longevity; Japanese individuals
ID diabetic complications; genotype; longevity; mutations; pathogenesis; prediction; diseases; proteins; risk
AB Because mitochondria are the major sources of reactive oxygen species (ROS) in cells, certain alterations in mitochondrial functions can lead to metabolic perturbation in vascular endothelial cells and smooth muscle cells, resulting in vascular dysfunction. We previously demonstrated that a C --> A transversion in mitochondrial DNA (mtDNA) at nucleotide 5178 of the NADH dehydrogenase subunit 2 (ND2) gene, which results in a Leu --> Met substitution at amino acid 237, was found more frequently in Japanese centenarians than in controls. We also demonstrated that this Mt5178C --> A polymorphism has anti-atherosclerotic effects in diabetic subjects. We have now examined whether the Mt5178C --> A (Leu237Met) polymorphism in the mitochondrial ND2 gene is associated with a low prevalence of myocardial infarction (MI) in a case-control study. The genotype of ND2 gene was determined either with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or a colorimetry-based allele-specific DNA probe assay. Multivariate logistic regression analysis with adjustment for age, gender, body mass index, smoking status, hypertension, diabetes mellitus, hypercholesterolemia, and hyperuricemia revealed - that the frequency of the Mt5178A genotype was significantly higher in controls than in subjects with MI. These results suggest that the 5178A C Genotype of mitochondrial ND2 gene polymorphism is protective against MI; and this effect would explain, at least in part, its contribution to longevity. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Gifu Int Inst Biotechnol, Dept Gene Therapy, Kakamigahara, Japan.
   Ogaki Municipal Hosp, Dept Cardiol, Ogaki, Japan.
   Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi, Japan.
   Mie Univ, Life Sci Res Ctr, Dept Human Funct Genom, Tsu, Mie, Japan.
   Nagoya Univ, Grad Sch Med, Dept Clin Pathophysiol, Cardiovasc Div, Nagoya, Aichi, Japan.
C3 Ogaki Municipal Hospital; Nagoya University; Mie University; Nagoya University
RP Gifu Int Inst Biotechnol, Dept Gene Therapy, Kakamigahara, Japan.
EM mtanaka@giib.or.jp
CR Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   BRAND FN, 1992, J CLIN EPIDEMIOL, V45, P169, DOI 10.1016/0895-4356(92)90009-C
   BROWN MD, 1992, GENETICS, V130, P163
   BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835
   Florez-Duquet M, 1998, PHYSIOL REV, V78, P339, DOI 10.1152/physrev.1998.78.2.339
   Gong JS, 1998, J CLIN BIOCHEM NUTR, V24, P105
   GREENE DA, 1987, NEW ENGL J MED, V316, P599
   Hara H, 1996, DIABETIC MED, V13, P0
   Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   KING GL, 1997, KIDNEY INT S60, V51, P0
   Kokaze A, 2001, HUM GENET, V109, P521, DOI 10.1007/s004390100602
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Matsunaga H, 2001, DIABETES CARE, V24, P500, DOI 10.2337/diacare.24.3.500
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8
   TANAKA M, 1994, GENOMICS, V22, P327, DOI 10.1006/geno.1994.1391
   Tanaka M, 2000, MECH AGEING DEV, V116, P65, DOI 10.1016/S0047-6374(00)00149-4
   Umetsu K, 2001, ELECTROPHORESIS, V22, P3533, DOI 10.1002/1522-2683(200109)22:16<3533::AID-ELPS3533>3.0.CO;2-S
   Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445
   Yoshiike N, 1998, INT J OBESITY, V22, P684, DOI 10.1038/sj.ijo.0800651
NR 27
TC 78
Z9 91
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG 15
PY 2004
VL 175
IS 2
BP 281
EP 286
DI 10.1016/j.atherosclerosis.2004.03.008
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 843XT
UT WOS:000223121300011
PM 15262184
DA 2024-11-01
ER

PT J
AU Chen, CS
   Matsuoka, R
   Arai, S
   Momiyama, Y
   Murakami, H
   Kuno, S
   Ishikawa, K
   Nakada, K
   Tawata, M
   Hayashi, JI
AF Chen, CS
   Matsuoka, R
   Arai, S
   Momiyama, Y
   Murakami, H
   Kuno, S
   Ishikawa, K
   Nakada, K
   Tawata, M
   Hayashi, JI
TI Determination of normal ranges of mitochondrial respiratory activities by mtDNA transfer from 54 human subjects to mtDNA-less HeLa cells for identification of the pathogenicities of mutated mtDNAs
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE mtDNA-less HeLa cells; mtDNA transfer; mitochondrial diseases; pathogenic mtDNA mutations; respiratory function
ID protein-synthesis; dna mutation; variant; complementation; dysfunction; myopathy; defects; patient
AB To determine the pathogenicities of mutated mtDNAs in patients with respiration defects, the possible involvement of nuclear DNA mutations has to be excluded, since respiratory function is controlled by both nuclear DNA and mtDNA. This was achieved by showing that the mutated mtDNAs and respiration defects were co-transferred from patients to mtDNA-less human cells, and the resultant cybrid clones carrying mutated mtDNAs expressed respiration defects. To decide whether the cybrid clones expressed respiration defects, in this study the lowest limits of normal respiratory function were evaluated by transfer of mtDNAs from 54 normal subjects to mtDNA-less HeLa cells. The resultant cybrid clones showed that 71% respiratory function was the lowest limit of mtDNAs from normal subjects. On the other hand, cybrid clones carrying pathogenic mtDNAs from patients with mitochondrial diseases showed 0-64% respiratory function, suggesting that less than 71% respiratory function in cybrid clones should be a reliable indicator of whether the mutated mtDNAs of the patients were pathogenic.
C1 Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Inst Hlth & Sport Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan.
   Tokyo Womens Med Univ, Heart Inst Japan, Shinjuku Ku, Tokyo 1628666, Japan.
   Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Japan.
   Univ Ryukyus, Fac Med, Dept Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
C3 University of Tsukuba; University of Tsukuba; University of Tsukuba; Tokyo Women's Medical University; Japan Science & Technology Agency (JST); University of the Ryukyus
RP Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   MIYABAYASHI S, 1989, J INHERIT METAB DIS, V12, P373, DOI 10.1007/BF01799245
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Ohkubo E, 2000, BIOCHEM BIOPH RES CO, V278, P808, DOI 10.1006/bbrc.2000.3867
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Ruster B, 1996, BIOCHEM BIOPH RES CO, V219, P911, DOI 10.1006/bbrc.1996.0340
   Tawata M, 2000, DIABETES, V49, P1269, DOI 10.2337/diabetes.49.7.1269
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 20
TC 3
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021-924X
EI 1756-2651
J9 J BIOCHEM
JI J. Biochem.
PD FEB 15
PY 2004
VL 135
IS 2
BP 237
EP 243
DI 10.1093/jb/mvh028
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 813SP
UT WOS:000220927100011
PM 15047726
DA 2024-11-01
ER

PT J
AU Kirby, DM
   McFarland, R
   Ohtake, A
   Dunning, C
   Ryan, MT
   Wilson, C
   Ketteridge, D
   Turnbull, DM
   Thorburn, DR
   Taylor, RW
AF Kirby, DM
   McFarland, R
   Ohtake, A
   Dunning, C
   Ryan, MT
   Wilson, C
   Ketteridge, D
   Turnbull, DM
   Thorburn, DR
   Taylor, RW
TI Mutations of the mitochondrial <i>ND1</i> gene as a cause of MELAS
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID complex-i deficiency; hereditary optic neuroretinopathy; mtdna mutation; leigh-syndrome; dna; nadh; disease; subunit; binding; oxidase
AB Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes ( MELAS) is one of many clinical presentations associated with mutations in mitochondrial DNA ( mtDNA) and a biochemical deficiency of respiratory chain complex I. While the 'common' 3243A-->G mutation in the mitochondrial tRNA(Leu(UUR)) (MTTL1) gene is detected in approximately 80% of patients with MELAS, the aetiology of the remaining 20% is heterogeneous, with different causative mutations occurring in MTTL1, other mitochondrial tRNA (mt-tRNA) genes, and the MTND genes encoding subunits of complex I. We report three unrelated patients with MELAS in whom the 3243A-->G mutation could not be detected, but who expressed a specific deficiency of complex I activity in both skeletal muscle and cultured fibroblasts. Targeted sequencing of mt-tRNA and MTND genes revealed that each patient harboured a different novel mutation in the MTND1 subunit gene of complex I (3697G-->A, 3946G-->A, and 3949T-->C), each of which predicted an amino acid change. The failure to restore complex I activity upon fusion of patient cells with a cell line lacking mtDNA (rho(0) cells) confirmed pathogenicity for each of these mutations, all of which appear to perturb the assembly or turnover of complex I. Our finding of three novel mutations in the MTND1 gene causing MELAS is supportive of recent papers highlighting the importance of mtDNA mutations in the aetiology of childhood respiratory chain complex I deficiency and underlines the importance of a cohesive diagnostic strategy where molecular genetic investigations are shaped by the biochemical and histological findings.
C1 Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   Royal Childrens Hosp, Genet Hlth Serv Victoria, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.
   La Trobe Univ, Dept Biochem, Melbourne, Vic, Australia.
   Saitama Med Sch, Dept Paediat, Moroyama, Saitama 35004, Japan.
   Starship Childrens hosp, Metab Serv, Natl Testing Ctr, Auckland, New Zealand.
   Womens & Childrens Hosp, Dept Chem Pathol, Adelaide, SA, Australia.
C3 Newcastle University - UK; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; La Trobe University; Saitama Medical University; Starship Children's Hospital; Women's & Children's Hospital
RP Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6
   Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I
   Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kurki S, 2000, BIOCHEMISTRY-US, V39, P13496, DOI 10.1021/bi001134s
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221
   Procaccio V, 1999, J CLIN INVEST, V104, P83, DOI 10.1172/JCI6184
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   ROBINSON BH, 1987, J PEDIATR-US, V110, P216, DOI 10.1016/S0022-3476(87)80157-9
   Roth R, 2001, BBA-BIOENERGETICS, V1504, P352, DOI 10.1016/S0005-2728(00)00265-6
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541
   Zickermann V, 1998, BIOCHEMISTRY-US, V37, P11792, DOI 10.1021/bi9810555
NR 27
TC 145
Z9 165
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD OCT 15
PY 2004
VL 41
IS 10
BP 784
EP 789
DI 10.1136/jmg.2004.020537
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 858ZD
UT WOS:000224230500011
PM 15466014
DA 2024-11-01
ER

PT J
AU Gellerich, FN
   Mayr, JA
   Reuter, S
   Sperl, W
   Zierz, S
AF Gellerich, FN
   Mayr, JA
   Reuter, S
   Sperl, W
   Zierz, S
TI The problem of interlab variation in methods for mitochondrial disease diagnosis: enzymatic measurement of respiratory chain complexes
SO MITOCHONDRION
LA English
DT Article; Proceedings Paper
DE interlab variation; mitochondrial disease; respiratory chain complexes
ID oxidative-phosphorylation; energy-metabolism; assay; nadh; dna; dysfunction; myopathy; defects; baboons; rats
AB Due to the large importance of mitochondrial function for numerous diseases the detection of respiratory chain defects for diagnostic purposes is an important task of mitochondrial medicine. For comparing the methods, standard mitochondrial homogenate prepared from bovine skeletal muscle was sent on dry ice to 14 labs of 8 countries. Activities of complexes I, I+III, II, II+III, IV (cytochrome c oxidase) and V (F(0)F(1)ATPase) as well as of citrate synthase were measured. For all enzymes the results differed at more than one order of magnitude. From eight labs we were able to compare the results with their control values for human skeletal muscle. Four labs found normal activity of cytochrome-c-oxidase whereas three labs found higher and one lab found lower activities compared to the own controls. Since all labs used different temperatures (25, 30 and 37 degreesC) in one lab the temperature dependencies were measured experimentally. The temperature correction did not much reduce the divergence of the results. It is concluded that differences in the lab protocols are the reason for the large variation of results. Since the experimental results strongly depend on the used method a strict standardization is necessary. (C) 2004 Published by Elsevier B.V. on behalf of Mitochondria Research Society.
C1 Univ Halle Wittenberg, Muskellabor Neurol Klin & Poliklin, D-06097 Halle An Der Saale, Germany.
   Labor Univ Klin Kinder & Jugendheilkunde Salzburg, Osterreich, Germany.
C3 Martin Luther University Halle Wittenberg
RP Univ Halle Wittenberg, Muskellabor Neurol Klin & Poliklin, Julius Kuhn Str 7, D-06097 Halle An Der Saale, Germany.
EM frank.gellerich@medizin.uni-halle.de
CR Berger A, 2003, ACTA NEUROPATHOL, V105, P245, DOI 10.1007/s00401-002-0638-1
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brealey David, 2002, LANCET (NORTH AMERICAN EDITION), V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665
   ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J
   FISCHER JC, 1986, CLIN CHIM ACTA, V155, P263, DOI 10.1016/0009-8981(86)90246-9
   GELLERICH F, 1998, J NEUROL, V245, P425
   Gellerich FN, 2002, BIOSCIENCE REP, V22, P99, DOI 10.1023/A:1016017224003
   Gellerich FN, 1999, SHOCK, V11, P336, DOI 10.1097/00024382-199905000-00006
   GELLERICH FN, 2003, BIOCHIM BIOPHYS ACTA, V1556, P41
   GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105
   Hatefi Y, 1978, METHODS ENZYMOL, V53, P21
   KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4
   KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F
   LETELLIER T, 1992, PEDIATR RES, V32, P17, DOI 10.1203/00006450-199207000-00004
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L
   MAYR H, 2004, ERGEBNISSE RINDERMUS, V0, P132
   Mayr J, 2000, EUR J MED, V5, P47
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   Rubio-Gozalbo ME, 2000, NEUROPEDIATRICS, V31, P114, DOI 10.1055/s-2000-7491
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SCHAGGER H, 1996, METHOD ENZYMOL, V0, P555
   Scheubel RJ, 2002, J AM COLL CARDIOL, V40, P2174, DOI 10.1016/S0735-1097(02)02600-1
   Shepherd D, 1969, METHODS IN ENZYMOLOGY, V13, P11, DOI 10.1016/0076-6879(69)13006-2
   SHERRATT HSA, 1988, METHOD BIOCHEM ANAL, V33, P243
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Silva JP, 2002, BBA-BIOENERGETICS, V1555, P106, DOI 10.1016/S0005-2728(02)00263-3
   SINGER TP, 1976, METHOD BIOCHEM ANAL, V22, P123
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   SZCZESNAKACZMAREK A, 1984, INT J BIOCHEM, V16, P1231, DOI 10.1016/0020-711X(84)90221-0
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   TERVOORT MJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P245, DOI 10.1016/0005-2728(81)90163-8
   Tisdale HD, 1967, METHODS IN ENZYMOLOGY, V10, P213
   Trijbels FJM, 1997, MOL CELL BIOCHEM, V174, P243, DOI 10.1023/A:1006868810424
   TRIJBELS JMF, 1993, EUR J PEDIATR, V152, P178, DOI 10.1007/BF01956139
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Trumbeckaite S, 2001, EUR J BIOCHEM, V268, P1422, DOI 10.1046/j.1432-1327.2001.02012.x
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1
   Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZHENG XX, 1990, BIOCHIM BIOPHYS ACTA, V1019, P1, DOI 10.1016/0005-2728(90)90118-N
NR 49
TC 44
Z9 49
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP 15
PY 2004
VL 4
IS 5-6
BP 427
EP 439
DI 10.1016/j.mito.2004.07.007
PG 13
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 885QS
UT WOS:000226172600009
PM 16120404
DA 2024-11-01
ER

PT J
AU Shao, JY
   Li, YH
   Gao, HY
   Mai, HQ
   Zhang, Y
   Guo, XA
   Zeng, YX
AF Shao, JY
   Li, YH
   Gao, HY
   Mai, HQ
   Zhang, Y
   Guo, XA
   Zeng, YX
TI High frequency of common deletion (4981 bp) in mitochondrial DNA in nasopharyngeal carcinoma and its correlation with patient age and clinical stages
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE nasopharyngeal carcinoma; mitochondria; DNA; common deletion; real-time PCR
ID progressive external ophthalmoplegia; genome; mutations; disease; accumulation; genetics; smoking; plasma; tumors; damage
AB Mitochondrial DNA ( mtDNA) has a high mutation rate due at least in part to a lack of protective histones and an inefficient DNA repair system. The most frequently change in mtDNA is the so-called Common Deletion (CD), which accumulates in patients with heteroplasmic mtDNA mutations and in normal individuals during aging. In this study, wild type mtDNA (WT-mtDNA) and mitochondrial DNA with CD (CD-mtDNA) were quantitatively analyzed in different nasopharynx lesions. A novel type of CD-mtDNA (4981 bp) was detected significantly higher in nasopharyngeal carcinoma (NPC) (93%, 54/58) than in nasopharyngitis (60%, 28/47) and the paired white blood cells (WBC) (26%, 8/31). The ratio of CD-mtDNA to WT-mtDNA in NPC (0.000625, median) was ten times that in nasopharyngitis (0.000064, median) (P=0.003), and was significantly higher than that in paired WBC (0.000000, median) (P=0.000). The CD/WT-mtDNA ratio was 0.000564 (quartile range, 0.000184-0.000919) in late stage NPC, which was nearly three times the ratio in early stage NPC (0.000164, quartile range, 0.000042-0.000353) (P=0.015, Mann-Whitney Test). In NPC patients with ages < 48yrs (mean age), the ratio of CD-mtDNA to WT-mtDNA was 0.000625, which was nearly ten times that in NPC patients with ages < 48yrs (0.000064) (P=0.005, Mann-Whitney Test). This is the first quantitative study of CD-mtDNA mutations in NPC, which provides evidences that CD-mtDNA mutation might be involved in the development and progression of NPC.
C1 Sun Yat Sen Univ, Ctr Canc, Guangzhou 510060, Peoples R China.
C3 Sun Yat Sen University
RP Sun Yat Sen Univ, Ctr Canc, 651 Dong Feng Rd E, Guangzhou 510060, Peoples R China.
EM yxzeng@gzsums.edu.cn
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ballinger SW, 1996, CANCER RES, V56, P5692
   Carew Jennifer S, 2002, MOL CANCER, V1, P9, DOI 10.1186/1476-4598-1-9
   Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Feng BJ, 2002, NAT GENET, V31, P395, DOI 10.1038/ng932
   FUKUSHIMA S, 1995, HEPATOLOGY, V21, P1547
   GATTERMANN N, 1995, LEUKEMIA, V9, P1704
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Lee HC, 2001, MUTAT RES-GEN TOX EN, V493, P67, DOI 10.1016/S1383-5718(01)00160-7
   Lewis PD, 2000, J PATHOL, V191, P274
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Liu CS, 1997, ENVIRON MOL MUTAGEN, V30, P47, DOI 10.1002/(SICI)1098-2280(1997)30:1<47::AID-EM7>3.0.CO;2-9
   Máximo V, 2000, J PATHOL, V192, P561
   Máximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7
   Máximo V, 2001, GENE CHROMOSOME CANC, V32, P136, DOI 10.1002/gcc.1175
   MIN HQ, 1994, INT J RADIAT ONCOL, V30, P1037
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Nickander KK, 2002, J PERIPHER NERV SYST, V7, P96, DOI 10.1046/j.1529-8027.2002.02012.x
   Nomoto S, 2002, CLIN CANCER RES, V8, P481
   PANG CY, 1994, ARCH BIOCHEM BIOPHYS, V312, P534, DOI 10.1006/abbi.1994.1342
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Rogounovitch TI, 2002, CANCER RES, V62, P7031
   Shao JY, 2004, CANCER, V100, P1162, DOI 10.1002/cncr.20099
   Shao JY, 2000, INT J ONCOL, V17, P1267
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Tabaku M, 1999, GENET COUNSEL, V10, P285
   Wallace DC, 1997, SCI AM, V277, P40, DOI 10.1038/scientificamerican0897-40
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   YAMAMOTO H, 1992, BIOCHEM BIOPH RES CO, V182, P913, DOI 10.1016/0006-291X(92)91819-C
   Zhuang Z, 1998, CELL VIS, V5, P43
NR 38
TC 14
Z9 16
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD DEC 15
PY 2004
VL 3
IS 12
BP 1270
EP 1274
DI 10.4161/cbt.3.12.1243
PG 5
WC Oncology
SC Oncology
GA 918WJ
UT WOS:000228578000025
PM 15477759
DA 2024-11-01
ER

PT J
AU Casademont, J
   Perea, M
   López, S
   Beato, A
   Miró, O
   Cardellach, F
AF Casademont, J
   Perea, M
   López, S
   Beato, A
   Miró, O
   Cardellach, F
TI Enzymatic diagnosis of oxidative phosphorylation defects on muscle biopsy:: Better on tissue homogenate or on a mitochondria-enriched suspension?
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE mitochondria; respiratory chain; heteroplasmy; MELAS; enzymatic diagnosis
ID human skeletal-muscle; respiratory-chain; in-vivo; maintenance; disorders; diseases; mtdna
AB Background: The enzymatic analysis of mitochondrial respiratory chain (MRC) complexes of skeletal muscle is an important step in the diagnosis of mitochondrial disorders. Because of its lesser turbidity and increased sensitivity, mitochondrial fractionation has been increasingly considered the diagnostic method of choice compared with the more classical analysis of muscle homogenate. In circumstances in which mitochondria become abnormal in number, size or shape, the process of mitochondrial enrichment made by sequential centrifugation and washing may favor the selection of the most normal mitochondria, eliminating the most abnormal ones. In this situation, the study of muscle homogenate, paradoxically, may better reflect what happens in vivo. Case Report: To exemplify this situation we present a 60-year-old woman with a complete mitochondrial phenotype and a 70% heteroplasmic presence of the mtDNA A3243G mutation in muscle tissue. The respiratory and enzymatic activities from mitochondria-enriched muscle suspension were within normal control limits. In contrast, when muscle homogenate was studied, enzyme activities of complexes I, III, and V were found to be decreased. Conclusions: Although mitochondria-enriched muscle suspensions are usually more informative than muscle homogenates for studies of MRC, in some situations it may be necessary to study both to uncover the biochemical defect.
C1 Univ Barcelona, Hosp Clin Barcelona, Fac Med, Sch Med,Dept Med Grp Invest Muscular,IDIBAPS,Dept, E-08036 Barcelona, Catalonia, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Univ Barcelona, Hosp Clin Barcelona, Fac Med, Sch Med,Dept Med Grp Invest Muscular,IDIBAPS,Dept, UB,Villarroel 170, E-08036 Barcelona, Catalonia, Spain.
EM jordi@medicina.ub.es
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CARDELLACH F, 1992, ANN NEUROL, V31, P515, DOI 10.1002/ana.410310509
   CARDELLACH F, 1991, BIOCHEM J, V274, P565, DOI 10.1042/bj2740565
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   Fischel-Ghodsian N, 2000, MOL GENET METAB, V71, P93, DOI 10.1006/mgme.2000.3014
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOWELL N, 2000, HUM REPROD S, V2, P235
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Miró O, 1999, EUR J CLIN PHARMACOL, V55, P35, DOI 10.1007/s002280050589
   Miró O, 1998, J NEUROSCI METH, V80, P107, DOI 10.1016/S0165-0270(97)00204-5
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V
   Schaefer Andrew M, 2001, CURRENT OPINION IN PHARMACOLOGY, V1, P288
   SHAPIRA AHV, 1994, MITOCHONDRIAL DISORD, V0, P75
   SLINDE E, 1975, ANAL BIOCHEM, V66, P151, DOI 10.1016/0003-2697(75)90733-2
   Turnbull DM, 1998, NAT GENET, V18, P199, DOI 10.1038/ng0398-199
   Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006
NR 22
TC 12
Z9 12
U1 0
U2 0
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
EI 
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD SEP 15
PY 2004
VL 10
IS 9
BP CS49
EP CS53
DI 
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 867HR
UT WOS:000224833800016
PM 15328490
DA 2024-11-01
ER

PT J
AU Foury, F
   Hu, J
   Vanderstraeten, S
AF Foury, F
   Hu, J
   Vanderstraeten, S
TI Mitochondrial DNA mutators
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE base excision repair; mismatch repair; mitochondria; mutator; oxidative damage; PEO; Pol gamma; yeast
ID i klenow fragment; saccharomyces-cerevisiae; polymerase-gamma; mismatch repair; escherichia-coli; endonuclease-iii; human-cells; yeast; gene; mutations
AB In this article we review our current knowledge of the mechanisms by which point mutations arise in the mitochondrial DNA ( mtDNA) of Saccharomyces cerevisiae and discuss to what extent these mechanisms operate in human mtDNA mutagenesis. The 3'-5' exonuclease proofreading activity of Pol gamma ensures accuracy of mtDNA replication in both yeast and humans, while the role of base excision repair in mtDNA error avoidance remains debated. The mitochondrial mismatch repair Msh1 protein, which removes transitions in yeast, is absent in humans, a particularity that might cause accumulation of transitions, while the most frequent substitution in yeast mtDNA is A: T to T: A transversion. Proofreading-deficient mutator human cell lines and knockin mice have been created. They will be useful for studying the mechanisms by which mtDNA mutations accumulate in diseases, ageing, malignancy and drug therapy.
C1 Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium.
C3 Universite Catholique Louvain
RP Catholic Univ Louvain, Unite Biochim Physiol, Croix Sud 2-20, B-1348 Louvain, Belgium.
EM foury@fysa.ucl.ac.be
CR Alseth I, 1999, MOL CELL BIOL, V19, P3779
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bebenek K, 1995, METHOD ENZYMOL, V262, P217
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345
   BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0
   Bianchi NO, 2001, MUTAT RES-REV MUTAT, V488, P9, DOI 10.1016/S1383-5742(00)00063-6
   Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392
   Boiteux S, 2004, DNA REPAIR, V3, P1, DOI 10.1016/j.dnarep.2003.10.002
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787
   CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034
   Chatterjee A, 2001, NUCLEIC ACIDS RES, V29, P4935, DOI 10.1093/nar/29.24.4935
   CHI NW, 1994, J BIOL CHEM, V269, P29984
   Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000
   Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Dzierzbicki P, 2004, DNA REPAIR, V3, P403, DOI 10.1016/j.dnarep.2003.12.005
   EVANS MD, 2004, MUTATION RES, V0, P0
   Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7
   FOURY F, 1979, P NATL ACAD SCI USA, V76, P6529, DOI 10.1073/pnas.76.12.6529
   Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   FOURY F, 1989, J BIOL CHEM, V264, P20552
   Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213
   HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728
   HU J, 1999, THESIS CATHOLIC U LO, V0, P0
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Jacobs HT, 2001, TRENDS GENET, V17, P653, DOI 10.1016/S0168-9525(01)02480-5
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   JOHNSTON LH, 1979, MOL GEN GENET, V170, P327, DOI 10.1007/BF00267066
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693
   Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300
   Koprowski P, 2003, MOL GENET GENOMICS, V269, P632, DOI 10.1007/s00438-003-0873-8
   Koprowski P, 2002, MOL GENET GENOMICS, V266, P988, DOI 10.1007/s00438-001-0621-x
   KUNKEL TA, 1988, J BIOL CHEM, V263, P4450
   KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011
   LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s
   Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   Mason PA, 2003, FEBS LETT, V554, P6, DOI 10.1016/S0014-5793(03)01169-4
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   ORourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002
   Parker AR, 2003, CELL MOL LIFE SCI, V60, P2064, DOI 10.1007/s00018-003-3053-4
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593
   PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   REENAN RAG, 1992, GENETICS, V132, P975
   Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847
   Sia EA, 2000, P NATL ACAD SCI USA, V97, P250, DOI 10.1073/pnas.97.1.250
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381
   SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929
   Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917
   Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350
   TAPPER DP, 1981, J BIOL CHEM, V256, P5109
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8236
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   VANDERSTRAETEN S, 1996, THESIS CATHOLIC U LO, V0, P0
   Vongsamphanh R, 2001, MOL CELL BIOL, V21, P1647, DOI 10.1128/MCB.21.5.1647-1655.2001
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   Williamson D, 2002, NAT REV GENET, V3, P475, DOI 10.1038/nrg814
   You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i
NR 83
TC 27
Z9 36
U1 1
U2 9
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD NOV 15
PY 2004
VL 61
IS 22
BP 2799
EP 2811
DI 10.1007/s00018-004-4220-y
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 872RM
UT WOS:000225226000002
PM 15558210
DA 2024-11-01
ER

PT J
AU Janes, MS
   Hanson, BJ
   Hill, DM
   Buller, GM
   Agnew, JY
   Sherwood, SW
   Cox, WG
   Yamagata, K
   Capaldi, RA
AF Janes, MS
   Hanson, BJ
   Hill, DM
   Buller, GM
   Agnew, JY
   Sherwood, SW
   Cox, WG
   Yamagata, K
   Capaldi, RA
TI Rapid analysis of mitochondrial DNA depletion by fluorescence in situ hybridization and immunocytochemistry: Potential strategies for HIV therapeutic monitoring
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE mitochondria; oxidative phosphorylation; mitochondrial DNA; HIV; AIDS; mitochondrial disease; nucleoside reverse transcriptase inhibitor; cytochrome c oxidase; immunocytochemistry; FISH
ID reverse-transcriptase inhibitors; antiretroviral therapy; toxicity; genome; replication; mutations; myopathy; humans
AB Nucleoside reverse transcriptase inhibitors (NRTIs) have been a mainstay in the treatment of human immunodeficiency virus since the introduction of azidothymidine (AZT) in 1987. However, none of the current therapies can completely eradicate the virus, necessitating long-term use of anti-retroviral drugs to prevent viral re-growth. One of the side effects associated with long-term use of NRTIs is mitochondrial toxicity stemming from inhibition of the mitochondrial DNA (mtDNA) polymerase gamma, which leads to mtDNA depletion and consequently to mitochondrial dysfunction. Here we report the use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) to monitor mtDNA depletion in cultured fibroblasts treated with the NRTI 2',3'-dideoxycytidine (ddC). These techniques are amenable to both microscopy and flow cytometry, allowing analysis of populations of cells on a single-cell basis. We show that, as mtDNA depletion progresses, a mosaic population develops, with some cells being depleted of and others retaining mtDNA. These techniques could be useful as potential therapeutic monitors to indicate when NRTI therapy should be interrupted to prevent mitochondrial toxicity and could aid in the development of less toxic NRTIs by providing an assay suitable for pharmacodynamic evaluation of candidate molecules.
C1 Mol Probes Inc, Eugene, OR 97402 USA.
   Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
C3 Thermo Fisher Scientific; Molecular Probes, Inc.; University of Oregon
RP Mol Probes Inc, 29851 Willow Creek Rd, Eugene, OR 97402 USA.
EM janes@probes.com
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Brinkman K, 2000, CURR OPIN INFECT DIS, V13, P5, DOI 10.1097/00001432-200002000-00002
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cossarizza A, 2003, CURR OPIN INFECT DIS, V16, P5, DOI 10.1097/00001432-200302000-00002
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200
   Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25
   Gourlain K, 2003, HIV MED, V4, P287, DOI 10.1046/j.1468-1293.2003.00158.x
   HAUGLAND RP, 2000, CURRENT PROTOCOLS CE, V0, P0
   Hellerstein MK, 2003, CLIN INFECT DIS, V37, PS52, DOI 10.1086/375888
   Kukhanova M, 1998, MOL PHARMACOL, V53, P801
   Lewis W, 2003, PROG CARDIOVASC DIS, V45, P305, DOI 10.1053/pcad.2003.3b
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   Petit C, 2003, JAIDS-J ACQ IMM DEF, V33, P461, DOI 10.1097/00126334-200308010-00006
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Scheffler IE, 1999, MITOCHONDRIA, V0, P0
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Temesgen Z, 2001, EXPERT OPIN PHARMACOTHER, V2, P1239, DOI 10.1517/14656566.2.8.1239
   Walker Ulrich A, 2003, J HIV THER, V8, P32
   Yamagata K, 2002, J AM SOC NEPHROL, V13, P0, DOI 10.1097/01.ASN.0000019772.17954.F8
NR 29
TC 22
Z9 24
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD AUG 15
PY 2004
VL 52
IS 8
BP 1011
EP 1018
DI 10.1369/jhc.3a6209.2004
PG 8
WC Cell Biology
SC Cell Biology
GA 841JZ
UT WOS:000222927400003
PM 15258176
DA 2024-11-01
ER

PT J
AU Swerdlow, RH
   Khan, SM
AF Swerdlow, RH
   Khan, SM
TI A "mitochondrial cascade hypthesis" for sporadic Alzheimer's disease
SO MEDICAL HYPOTHESES
LA English
DT Review
ID cytochrome-c-oxidase; amyloid precursor protein; amyotrophic-lateral-sclerosis; respiratory-chain function; mtdna point mutations; human skeletal-muscle; parkinsons-disease; oxidative stress; hydrogen-peroxide; dna deletion
AB Alzheimer's disease (AD) includes etiologically heterogenous disorders characterized by senile or presenile dementia, extracellular amyloid protein aggregations containing an insoluble amytoid precursor protein derivative, and intracytoptasmic tau protein aggregations. Recent studies also show excess neuronal aneuptoidy, programmed cell death (PCD), and mitochondrial dysfunction. The leading AD molecular paradigm, the "amyloid cascade hypothesis", is based on studies of rare autosomal dominant variants and does not specify what initiates the common late-onset, sporadic form. We propose for late-onset, sporadic AD a "mitochondrial cascade hypothesis" that comprehensively reconciles seemingly disparate histopathologic and pathophysiologic features. In our model, the inherited, gene-determined make-up of an individual's electron transport chain sets basal rates of reactive oxygen species (ROS) production, which determines the pace at which acquired mitochondrial damage accumulates. Oxidative mitochondrial DNA, RNA, lipid, and protein damage amplifies ROS production and triggers three events: (1) a reset response in which cells respond to elevated ROS by generating the beta-sheet protein, beta amyloid, which further perturbs mitochondrial function, (2) a removal response in which compromised cells are purged via PCD mechanisms, and (3) a replace response in which neuronal progenitors unsuccessfully attempt to re-enter the cell cycle, with resultant aneuploidy, tau phosphorylation, and neurofibrillary tangle formation. In addition to defining a rote for aging in AD pathogenesis, the mitochondrial cascade hypothesis also allows and accounts for histopathologic overlap between the sporadic, late-onset and autosomal dominant, early onset forms of the disease. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA 22908 USA.
   Univ Virginia Hlth Syst, Ctr Study Neurodegenerat Dis, Charlottesville, VA 22908 USA.
   Univ Virginia Hlth Syst, Dept Neurosci, Charlottesville, VA 22908 USA.
   Gencia Corp, Charlottesville, VA 22903 USA.
C3 University of Virginia; University of Virginia; University of Virginia
RP Univ Virginia Hlth Syst, Dept Neurol, POB 800394,1 Hosp Dr, Charlottesville, VA 22908 USA.
EM rhs7e@virginia.edu
CR Alzheimer A, 1907, ALLGEMEINE ZEITSCHRIFT FUR PSYCHIATRIE UND PSYCHISCH-GERICHTLICHE MEDIZIN, V0, P146
   AMADUCCI LA, 1986, NEUROLOGY, V36, P1497, DOI 10.1212/WNL.36.11.1497
   Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   Anderton BH, 2002, MECH AGEING DEV, V123, P811, DOI 10.1016/S0047-6374(01)00426-2
   Arendt T, 2000, NEUROBIOL AGING, V21, P783, DOI 10.1016/S0197-4580(00)00216-5
   Arias C, 2002, EXP NEUROL, V176, P163, DOI 10.1006/exnr.2002.7912
   Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081
   Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817
   Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x
   Bijur GN, 1999, MOL BRAIN RES, V71, P69, DOI 10.1016/S0169-328X(99)00168-0
   Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577
   BLASS JP, 1990, ARCH NEUROL-CHICAGO, V47, P864, DOI 10.1001/archneur.1990.00530080046009
   Boller F, 1998, J NEUROL SCI, V158, P125, DOI 10.1016/S0022-510X(98)00128-2
   BOROWSKY IW, 1989, NEUROSCIENCE, V33, P253, DOI 10.1016/0306-4522(89)90204-2
   Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1
   BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617
   BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x
   BRAND FN, 1992, J CLIN EPIDEMIOL, V45, P169, DOI 10.1016/0895-4356(92)90009-C
   Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Canevari L, 1999, FEBS LETT, V457, P131, DOI 10.1016/S0014-5793(99)01028-5
   Capuano F, 1997, J BIOENERG BIOMEMBR, V29, P379, DOI 10.1023/A:1022402915431
   Capuano F, 1996, BIOCHEM MOL BIOL INT, V38, P1013
   Cardoso SM, 1999, SOCIETY FOR NEUROSCIENCE ABSTRACTS, V25, P337
   Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje
   Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4
   Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7
   Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x
   Cassarino DS, 1998, BIOCHEM BIOPH RES CO, V248, P168, DOI 10.1006/bbrc.1998.8866
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   CHOMYN A, 1994, AM J HUM GENET, V54, P966
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Chueh PJ, 2000, ANTIOXID REDOX SIGN, V2, P177, DOI 10.1089/ars.2000.2.2-177
   Coller HA, 2002, ANN NY ACAD SCI, V959, P434, DOI 10.1111/j.1749-6632.2002.tb02113.x
   CONNOLLY JA, 1977, P NATL ACAD SCI USA, V74, P2437, DOI 10.1073/pnas.74.6.2437
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Cummings JL, 2002, JAMA-J AM MED ASSOC, V287, P2335, DOI 10.1001/jama.287.18.2335
   Curti D, 1997, NEUROSCI LETT, V236, P13, DOI 10.1016/S0304-3940(97)00741-6
   Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   de Grey ADNJ, 1998, J. ANTI-AGING MED, V1, P53, DOI 10.1089/rej.1.1998.1.53
   De Sarno P, 2000, NEUROBIOL AGING, V21, P31, DOI 10.1016/S0197-4580(00)00095-6
   Delobel P, 2002, J NEUROCHEM, V83, P412, DOI 10.1046/j.1471-4159.2002.01143.x
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Dorward A, 1997, J BIOENERG BIOMEMBR, V29, P385, DOI 10.1023/A:1022454932269
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377
   Dyall SD, 2003, J BIOL CHEM, V278, P30548, DOI 10.1074/jbc.M304032200
   Edland SD, 1996, NEUROLOGY, V47, P254, DOI 10.1212/WNL.47.1.254
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Esiri MM, 2001, LANCET, V357, P169
   EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.1989.03430180093036
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Fischer O, 1907, MON PSYCHIATR NEUROL, V22, P361
   Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0
   GABUZDA D, 1994, J BIOL CHEM, V269, P13623
   Gadaleta MN, 1998, BIOCHIMIE, V80, P863, DOI 10.1016/S0300-9084(00)88881-1
   Gershon D, 1999, EXP GERONTOL, V34, P613, DOI 10.1016/S0531-5565(99)00010-8
   Ghosh SS, 1999, ANN NY ACAD SCI, V893, P176, DOI 10.1111/j.1749-6632.1999.tb07825.x
   Ginsberg MD, 2003, J MOL BIOL, V327, P885, DOI 10.1016/S0022-2836(03)00173-6
   GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0
   Greco M, 2003, FASEB J, V17, P1706, DOI 10.1096/fj.02-1009fje
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARTIGAN JA, 1998, ALZHEIMERS DIS REV, V3, P125
   Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4
   Jauniaux E, 2003, PLACENTA, V24, PS86, DOI 10.1053/plac.2002.0932
   Johansson CB, 2003, J CELL PHYSIOL, V196, P409, DOI 10.1002/jcp.10293
   JOHNSON MH, 1994, BIOESSAYS, V16, P31, DOI 10.1002/bies.950160105
   KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506
   KATZMAN R, 1976, ARCH NEUROL-CHICAGO, V33, P217, DOI 10.1001/archneur.1976.00500040001001
   Katzman R, 1978, ALZHEIMERS DISEASE: SENILE DEMENTIA AND RELATED DISORDERS, V0, P579
   Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Kowald A, 1999, EXP GERONTOL, V34, P605, DOI 10.1016/S0531-5565(99)00011-X
   Kraepelin E, 1910, PSYCHIATRIE, V0, P0
   Kwon YW, 2003, BIOL CHEM, V384, P991, DOI 10.1515/BC.2003.111
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   LARM JA, 1994, J BIOL CHEM, V269, P30097
   LAWEN A, 1994, MOL ASPECTS MED, V15, P13
   LEDESMA A, 2003, GENOME BIOL, V3, P3015
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Lovestone S, 1997, NEUROSCIENCE, V78, P309
   Mancuso M, 2003, EXP NEUROL, V182, P421, DOI 10.1016/S0014-4886(03)00092-X
   Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025
   Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0
   Mattson MP, 2002, NEUROMOL MED, V2, P215, DOI 10.1385/NMM:2:2:215
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Melov S, 1999, NEUROBIOL AGING, V20, P565, DOI 10.1016/S0197-4580(99)00092-5
   Melov S, 2000, ANN NY ACAD SCI, V908, P219
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   *MITOMAP, 2001, HUM MIT GEN DAT, V0, P0
   Morré DM, 2000, J EXP BIOL, V203, P1513
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   NASRESFAHANI MH, 1990, DEVELOPMENT, V109, P501
   NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nunomura A, 1999, J NEUROSCI, V19, P1959
   Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8
   OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z
   Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1
   PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015
   PERUSINI G, 1911, RIV ITALIANA NEUROPA, V4, P145
   Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Robinson SR, 2002, NEUROBIOL AGING, V23, P1051, DOI 10.1016/S0197-4580(01)00342-6
   ROTH GS, 1995, NAT MED, V1, P414, DOI 10.1038/nm0595-414
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105
   Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17
   Shan X, 2003, J NEUROSCI, V23, P4913
   Sheehan JP, 1997, J NEUROSCI, V17, P4612
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Shults CW, 1998, MOV DISORD S2, V13, P217
   Smith MA, 2000, ANTIOXID REDOX SIGN, V2, P413, DOI 10.1089/15230860050192198
   Snowdon DA, 2003, ANN INTERN MED, V139, P450, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00014
   SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671
   SOONG NW, 1992, NAT GENET, V2, P318
   SWEET S, 1995, CANCER RES, V55, P5164
   Swerdlow RH, 2000, AMYOTROPH LATERAL SC, V1, P185, DOI 10.1080/14660820050515179
   Swerdlow RH, 2000, J NEUROCHEM, V75, P1681, DOI 10.1046/j.1471-4159.2000.0751681.x
   Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866
   Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918
   Swerdlow RH, 2002, INT REV NEUROBIOL, V53, P341
   Swerdlow RH, 2002, ARCH PATHOL LAB MED, V126, P271
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   SWERDLOW RH, 2000, MOL MECH NEURODEGENE, V0, P233
   SWERDLOW RH, 2001, PARKINSONISM RELAT D, V7, P47
   Sylvestre J, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-7-r44
   Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8
   Taylor DR, 2002, P NATL ACAD SCI USA, V99, P3690, DOI 10.1073/pnas.072660299
   Trimarchi JR, 2000, BIOL REPROD, V62, P1866, DOI 10.1095/biolreprod62.6.1866
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Trimmer PA, 2004, NEUROBIOL DIS, V15, P29, DOI 10.1016/j.nbd.2003.09.011
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Uriel J, 1979, ADV CANCER RES, V29, P127, DOI 10.1016/S0065-230X(08)60847-7
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Veech GA, 2000, J NEUROSCI RES, V61, P693
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Webster MT, 1998, J NEURAL TRANSM, V105, P839, DOI 10.1007/s007020050098
   Wolin Michael S, 1996, MICROCIRCULATION (PHILADELPHIA), V3, P1, DOI 10.3109/10739689609146778
   WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   ZABAR Y, 2000, NEURODEGENERATIVE DE, V0, P79
   Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572
   Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549
NR 180
TC 556
Z9 659
U1 1
U2 61
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUN 15
PY 2004
VL 63
IS 1
BP 8
EP 20
DI 10.1016/j.mehy.2003.12.045
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 832VA
UT WOS:000222294200002
PM 15193340
DA 2024-11-01
ER

PT J
AU Sudo, A
   Honzawa, S
   Nonaka, I
   Goto, Y
AF Sudo, A
   Honzawa, S
   Nonaka, I
   Goto, Y
TI Leigh syndrome caused by mitochondrial DNA G13513A mutation: frequency and clinical features in Japan
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE Leigh syndrome; mitochondrial DNA; ND5 subunit gene; G13513A; WPW syndrome
ID missense mutation; overlap-syndrome; mtdna mutation; complex-i; gene; melas; disease; nd5
AB The mitochondrial DNA (mtDNA) G13513A mutation in the ND5 subunit gene has been recently reported as a common cause of some phenotypes of mitochondrial myopathy. Until now, the prevalence and characteristics of this mutation in Leigh syndrome (LS) has not been determined. We screened 84 patients with Leigh syndrome (LS) and found the mutation in six (7%) of them. The proportions of mutant mtDNA in muscles were relatively low (42-70%). The onset of symptoms for patients with this mutation was from 9 months to 5 years. It should be noted that five patients had cardiac conduction abnormalities, particularly Wolff-Parkinson-White (WPW) syndrome (three patients). This study suggests that G13513A mutation is a frequent cause of LS and that patients with this mutation may have a characteristic clinical course.
C1 NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo 1878502, Japan.
   Natl Ctr Neurol & Psychiat, Natl Ctr Hosp Mental Nervous & Muscular Disorders, Dept Child Neurol, Tokyo, Japan.
   Dokkyo Univ, Sch Med, Koshigaya Hosp, Dept Pediat, Saitama, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Dokkyo Medical University
RP NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.
EM goto@ncnp.go.jp
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   Arii J, 2000, AM J NEURORADIOL, V21, P1502
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Komaki H, 2003, MITOCHONDRION, V2, P293, DOI 10.1016/S1567-7249(03)00003-5
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   PETERS NS, 1994, EUR HEART J, V15, P981, DOI 10.1093/oxfordjournals.eurheartj.a060619
   PINCUS JH, 1972, DEV MED CHILD NEUROL, V14, P87
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   VANERVEN PMM, 1987, CLIN NEUROL NEUROSUR, V89, P217, DOI 10.1016/S0303-8467(87)80020-3
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 34
TC 58
Z9 69
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD FEB 15
PY 2004
VL 49
IS 2
BP 92
EP 96
DI 10.1007/s10038-003-0116-1
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 779FP
UT WOS:000189284900005
PM 14730434
DA 2024-11-01
ER

PT J
AU Kärppä, M
   Mahjneh, I
   Karttunen, A
   Tolonen, U
   Majamaa, K
AF Kärppä, M
   Mahjneh, I
   Karttunen, A
   Tolonen, U
   Majamaa, K
TI Muscle computed tomography patterns in patients with the mitochondrial DNA mutation 3243A&gt;G
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE myopathy; MELAS; muscle CT; myopathic pattern
ID girdle muscular-dystrophy; stroke-like episodes; neuromuscular disease; lactic-acidosis; fiber types; ct; involvement; population; myopathy; humans
AB Computed tomography provides a sensitive method for investigating skeletal muscle changes in neuromuscular diseases, but this method has not been applied to mitochondrial myopathies. We characterized the pattern of muscle involvement in patients with the 3243A>G mutation in mitochondrial DNA (mtDNA), the common MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) mutation. Twenty-four patients, age 19-73 years, with 3243A>G were examined. Clinical evaluation included assessment of muscle strength and functional capacity. All the patients underwent muscle computed tomography, and muscle samples from 17 of them were examined for the presence of ragged red fibres and for the 3243A>G heteroplasmy. Venous blood lactate at rest and serum creatine kinase were determined. Clinical myopathy was found in six patients, while nine showed mild muscle weakness and nine had normal muscle function. The upper and lower limbs were equally affected, but the proximal muscles were more severely affected than the distal ones. CT revealed abnormalities in the muscles of 13 patients (54%; 95% confidence interval, 33-76%), including the six with clinical myopathy and seven without clinical myopathy. Myopathic changes were found most frequently in the pelvic muscles, with predominant involvement of the gluteus maximus. These data show that CT reveals frequent abnormal findings in the muscle of patients with the 3243A>G mtDNA mutation.Muscle CT is a useful adjunct to clinical evaluation in these patients.
C1 Univ Oulu, Dept Neurol, Oulu 90014, Finland.
   Univ Oulu, Bioctr, Oulu 90014, Finland.
   Univ Oulu, Dept Radiol, Oulu, Finland.
   Univ Oulu, Dept Neurophysiol, Oulu, Finland.
   Pietarsaari Hosp, Dept Neurol, Pietarsaari, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu
RP Univ Oulu, Dept Neurol, POB 5000, Oulu 90014, Finland.
EM kari.majamaa@oulu.fi
CR BULCKE JA, 1979, NEURORADIOLOGY, V17, P127
   BULCKE JA, 1981, MUSCLE NERVE, V4, P67, DOI 10.1002/mus.880040112
   BULCKE JAL, 1983, RADIOLOGY, V28, P523
   CALO M, 1986, NEURORADIOLOGY, V28, P53, DOI 10.1007/BF00341766
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Harridge SDR, 1996, PFLUG ARCH EUR J PHY, V432, P913, DOI 10.1007/s004240050215
   Hauschka S, 1994, MYOLOGY, V1, P3
   HAWLEY RJ, 1984, ARCH NEUROL-CHICAGO, V41, P383, DOI 10.1001/archneur.1984.04050160045014
   HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248
   JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Mahjneh I, 2001, NEUROMUSCULAR DISORD, V11, P20, DOI 10.1016/S0960-8966(00)00157-7
   Mahjneh I, 1996, ACTA NEUROL SCAND, V94, P177, DOI 10.1111/j.1600-0404.1996.tb07050.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Marconi G, 2001, ACTA NEUROL SCAND, V104, P156, DOI 10.1034/j.1600-0404.2001.00087.x
   *MED RES COUNC, 1986, 45 MRC, V0, P0
   Mercuri E, 2002, NEUROPEDIATRICS, V33, P10, DOI 10.1055/s-2002-23593
   MORGANHUGHES JA, 1994, MYOLOGY, V0, P1610
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   SCHWARTZ MS, 1988, MUSCLE NERVE, V11, P1240, DOI 10.1002/mus.880111208
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SWASH M, 1995, MUSCLE NERVE, V18, P708, DOI 10.1002/mus.880180706
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vlak M, 2000, NEUROL SCI, V21, PS975, DOI 10.1007/s100720070013
   VLIET A M V, 1988, NEURORADIOLOGY, V30, P421
   WILBOURN AJ, 1993, J CLIN NEUROPHYSIOL, V10, P132, DOI 10.1097/00004691-199304000-00002
NR 28
TC 15
Z9 16
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD MAY 15
PY 2004
VL 251
IS 5
BP 556
EP 563
DI 10.1007/s00415-004-0363-x
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 824ED
UT WOS:000221667000007
PM 15164188
DA 2024-11-01
ER

PT J
AU Wong, LJC
AF Wong, LJC
TI Comprehensive molecular diagnosis of mitochondrial disorders - Qualitative and quantitative approach
SO MITOCHONDRIAL PATHOGENESIS: FROM GENES AND APOPTOSIS TO AGING AND DISEASE
LA English
DT Article; Proceedings Paper
DE mtDNA mutations; molecular diagnosis; mitochondrial disorder; mtDNA deletion; mitochondria
ID progressive external ophthalmoplegia; dna; mutations; deletions
AB Mitochondrial disorders can be caused by mutations in nuclear or mitochondrial encoded genes. Point mutations and large deletions in mitochondrial DNA (mtDNA) are responsible for a small portion of the molecular defects in the mitochondrial oxidative phosphorylation system. A significant number of molecular defects of respiratory chain disorders are probably due to mutations in nuclear genes. Molecular diagnosis of mitochondrial disorders has been difficult because of broad genetic and clinical heterogeneity. Mutational analysis of common point mutations of mtDNA such as A3243G, A8344G, and T8993G/C is routinely performed. However, many patients who clearly have clinical manifestations and muscle pathology consistent with oxidative phosphorylation deficiency do not have detectable common mtDNA point mutations. A more comprehensive mutation screening method, temporal temperature gradient gel electrophoresis, was used to scan for unknown mutations in the entire mitochondrial genome. Novel mutations have been discovered but only account for a small portion of patients with suspected mitochondrial RC disorders. Real-time quantitative PCR analysis was used to measure cellular mtDNA content. Abnormal levels of mtDNA were found in many patients with respiratory chain disorders. Molecular analysis revealed that mutations in the thymidine phosphorylase gene are not seen in young patients with severe mtDNA depletion who do not demonstrate clinical features of mitochondrial neurogastrointestinal encephalomyopathy. It was also noted that an increase in the size or number of mitochondria was not necessarily associated with an increase in mtDNA content. On the contrary, in some cases the mtDNA was depleted. Respiratory activity in patients with a defective mitochondrial genome due to either point mutations or deletions may be compensated by amplification of mtDNA. Therefore, a comprehensive molecular analysis of mitochondrial respiratory chain disorders should include qualitative identification of the mutation and quantitative measurement of both the degree of mutant heteroplasmy and the total amount of mtDNA.
C1 Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
C3 Georgetown University
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, M4000,3800 Reservoir Rd,NW, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR Chen TJ, 1999, CLIN CHEM, V45, P1162
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nollau P, 1997, J INT FED CLIN CHEM, V9, P162
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shoffner JM, 1995, METABOLIC MOL BASES, V7th, P1535
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wong LC, 2002, AM J HUM GENET, V71, P501
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 20
TC 15
Z9 18
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2004
VL 1011
IS 
BP 246
EP 258
DI 10.1196/annals.1293.024
PG 13
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BAE70
UT WOS:000221896100024
PM 15126301
DA 2024-11-01
ER

PT J
AU Janssen, RJRJ
   van den Heuvel, LP
   Smeitink, JAM
AF Janssen, RJRJ
   van den Heuvel, LP
   Smeitink, JAM
TI Genetic defects in the oxidative phosphorylation (OXPHOS) system
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE complex I deficiency; mitochondria; mitochondrial; medicine; NADH; ubiquinone; oxidoreductase; OXPHOS
ID cytochrome-c-oxidase; mitochondrial complex-i; progressive external ophthalmoplegia; hereditary optic neuropathy; deoxyguanosine kinase gene; deafness dystonia syndrome; stop-codon mutation; point mutation; iii deficiency; nonsense mutation
AB The oxidative phosphorylation (OXPHOS) system consists of five multiprotein complexes and two mobile electron carriers embedded in the lipid bilayer of the mitochondrial inner membrane. With the exception of complex 11 and the mobile carriers, the other parts of the OXPHOS system are under dual genetic control. Due to this bigenomic control, the inheritance of OXPHOS system defects is either maternal, in the case of mitochondrial DNA mutations, autosomal or X-linked, in the case of nuclear gene defects. In this review, our current genetic understanding of OXPHOS system enzyme deficiencies will be summarized, and future directions that the field might take to unravel so-far genetically unresolved OXPHOS system enzyme deficiencies will be described, with special emphasis on complex I biogenesis.
C1 Univ Nijmegen, Ctr Med, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Nijmegen, Netherlands.
C3 Radboud University Nijmegen
RP Univ Nijmegen, Ctr Med, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, POB 9101, Nijmegen, Netherlands.
EM j.smeitink@cukz.umcn.nl
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   Alper G, 2003, PEDIATR NEUROL, V28, P335, DOI 10.1016/S0887-8994(03)00004-3
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Astuti, 2002, AM J HUM GENET, V70, P565
   Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300
   Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174
   Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275
   BROWN MD, 1992, AM J HUM GENET, V51, P378
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   BROWN MD, 1992, GENETICS, V130, P163
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P493, DOI 10.1016/S0960-8966(00)00107-3
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.3.CO;2-C
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   DELONLAY P, 2002, HUM MOL GENET, V0, P73
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2002, ADV NEUROL, V89, P217
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053
   Dürr A, 2002, LANCET NEUROL, V1, P370, DOI 10.1016/S1474-4422(02)00162-X
   EGGELER R, 2002, J BIOL CHEM, V277, P33906
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Hanson BJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1281, DOI 10.1177/002215540205001001
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Hutchin TP, 2001, EUR J HUM GENET, V9, P56, DOI 10.1038/sj.ejhg.5200581
   Janssen R, 2002, HUM GENET, V110, P264, DOI 10.1007/s00439-001-0673-3
   JOHNS DR, 1993, BIOCHEM BIOPH RES CO, V196, P810, DOI 10.1006/bbrc.1993.2321
   JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V181, P1358, DOI 10.1016/0006-291X(91)92088-2
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Kocaefe YÇ, 2003, EUR J HUM GENET, V11, P102, DOI 10.1038/sj.ejhg.5200908
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   Küffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114
   Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Malik S, 2003, J HUM GENET, V48, P119, DOI 10.1007/s100380300018
   Mandel H, 2001, NAT GENET, V29, P491, DOI 10.1038/ng1201-491a
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   MarinGarcia J, 1996, BIOCHEM MOL BIOL INT, V40, P487
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Mongini T, 2002, CLIN NEUROPATHOL, V21, P72
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Parfait B, 1999, EUR J PEDIATR, V158, P55, DOI 10.1007/s004310051009
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2001, ANN NEUROL, V49, P797, DOI 10.1002/ana.1060
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Rötig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Scacco S, 2003, J BIOL CHEM, V278, P44161, DOI 10.1074/jbc.M307615200
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9
   Scharfe C, 2000, J MED GENET, V37, P669, DOI 10.1136/jmg.37.9.669
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Shtilbans A, 2000, J CHILD NEUROL, V15, P759, DOI 10.1177/088307380001501109
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Simon DK, 2003, NEUROGENETICS, V4, P199, DOI 10.1007/s10048-003-0150-3
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Solano A, 2001, SALUD PUBLICA MEXICO, V43, P151, DOI 10.1590/S0036-36342001000200010
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2001, NAT GENET, V29, P100
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 1999, HUM GENET, V104, P460, DOI 10.1007/s004390050988
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   Von Kleist-Retzow JC, 2001, J MED GENET, V38, P109, DOI 10.1136/jmg.38.2.109
   Wallace DC, 1999, P NATL ACAD SCI USA, V96, P1817, DOI 10.1073/pnas.96.5.1817
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
   Zeviani M, 1999, ITAL J NEUROL SCI, V20, P401
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 161
TC 34
Z9 37
U1 2
U2 6
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD MAR 15
PY 2004
VL 4
IS 2
BP 143
EP 156
DI 10.1586/14737159.4.2.143
PG 14
WC Pathology
SC Pathology
GA 804DG
UT WOS:000220278800003
PM 14995902
DA 2024-11-01
ER

PT J
AU Melone, MAB
   Tessa, A
   Petrini, S
   Lus, G
   Sampaolo, S
   di Fede, G
   Santorelli, FM
   Cotrufo, R
AF Melone, MAB
   Tessa, A
   Petrini, S
   Lus, G
   Sampaolo, S
   di Fede, G
   Santorelli, FM
   Cotrufo, R
TI Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID lactic-acidosis; strokelike episodes; clinical spectrum; melas; encephalopathy; merrf; myopathy
AB Background: A 26-year-old man presented at onset with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS) and later with a phenotype for MELAS and myoclonic epilepsy and ragged red fiber disease (MELAS/MERRF). Objective: To identify the possible defects in the mitochondrial genome in blood and muscle samples of the patient. Design: Case study of a patient clinically exhibiting strokelike episodes and then epilepsy with myoclonic features, ataxia, and dementia. Setting: Research unit of a university hospital. Main Outcome Measures: Electromyographic, morphologic, and biochemical studies of muscle and molecular analysis of blood and muscle to investigate mitochondrial DNA (mtDNA) size and quantity. Results: Morphologically, we found abnormal mitochondrial proliferation with several cytochrome-c oxidase (COX)-negative fibers in muscle biopsy specimens; the analysis of serial sections showed a decreased immunoreactivity for the mtDNA-encoded subunits COXII and, partially, COX1. Biochemically, we found a partial and isolated COX deficiency. The complete mtDNA sequence analysis identified 3 sequence changes, 2 of which were reported polymorphisms. The remaining change, a G12147A transition in the transfer RNA(His) gene, appeared to be the likely pathogenic mutation. Conclusions: Our data propose that the G12147A change, the first mutation in the transfer RNA(His) gene associated with an overlapped MELAS/MERFF phenotype, is the cause of the encephalomyopathy in this patient interfering with the overall mitochondrial protein synthesis.
C1 Univ Naples Federico II, Policlin, Div Neurol 1, Dept Neurol Sci,Sch Med, I-80131 Naples, Italy.
   IRCCS, Dept Mol Med, Rome, Italy.
C3 University of Naples Federico II
RP Melone, MAB (corresponding author), Univ Naples Federico II, Policlin, Div Neurol 1, Dept Neurol Sci,Sch Med, Edificio10,Via Sergio Pansini 5, I-80131 Naples, Italy.
EM marina.melone@unina2.it
CR BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   BYRNE E, 1988, J NEUROL SCI, V88, P327, DOI 10.1016/0022-510X(88)90229-8
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DANKS RA, 1988, AUST NZ J MED, V18, P69, DOI 10.1111/j.1445-5994.1988.tb02245.x
   Ehrig T, 2001, J MOL DIAGN, V3, P22, DOI 10.1016/S1525-1578(10)60645-9
   FUKUHARA N, 1985, ANN NEUROL, V18, P368, DOI 10.1002/ana.410180323
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P1349, DOI 10.1177/29.11.6172466
   KURIYAMA M, 1985, ANN NEUROL, V18, P625, DOI 10.1002/ana.410180525
   Maassen JA, 1996, EXP CLIN ENDOCR DIAB, V104, P205, DOI 10.1055/s-0029-1211444
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
NR 14
TC 44
Z9 52
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD FEB 15
PY 2004
VL 61
IS 2
BP 269
EP 272
DI 10.1001/archneur.61.2.269
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 772FW
UT WOS:000188831900016
PM 14967777
DA 2024-11-01
ER

PT J
AU Koç, F
   Sarica, Y
   Bozdemir, H
   Zorludemir, S
AF Koç, F
   Sarica, Y
   Bozdemir, H
   Zorludemir, S
TI A MELAS patient with an unusual finding -: Subdural hematoma
SO NEUROSURGERY QUARTERLY
LA English
DT Article
DE MELAS; clinical and histopathologic findings; subdural hematoma
ID stroke-like episodes; lactic-acidosis; mitochondrial myopathy; clinical-features; encephalopathy; mutation; encephalomyopathy; gene; dna; mr
AB Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a rare mitochondrial disorder. Seizures, headaches, nausea and vomiting, exercise intolerance, and ragged-red fibers may be seen. In most MELAS syndrome patients, a point mutation at nucleotide 3243 encoding transfer RNA for leucine has been found. A 28-year-old woman who lost consciousness was brought to emergency room. She had a history of migraine-like headaches and secondary amenorrhea for 7 years, hearing loss for 5 years, and complex partial seizures for 3 months. She had a subacute subdural hematoma of left temporo-occipital region and subacute infarcts in cortical and subcortical areas of the left temporal lobe. Based on her history, physical and neurologic examinations, neuroimaging, and histopathologic and mitochondrial DNA analyses, she was diagnosed as having MELAS syndrome. The most outstanding feature in this case was the presence of a subdural hematoma. To the best of our knowledge, this unusual finding has not been reported previously in the literature.
C1 Cukurova Univ, Sch Med, Dept Neurol, TR-01330 Adana, Turkey.
   Cukurova Univ, Sch Med, Dept Pathol, TR-01330 Adana, Turkey.
C3 Cukurova University; Cukurova University
RP Cukurova Univ, Sch Med, Dept Neurol, TR-01330 Adana, Turkey.
EM zaferkoc@superonline.com
CR ALLARD JC, 1988, AM J NEURORADIOL, V9, P1234
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   KUWABARA T, 1994, NEUROLOGY, V44, P557, DOI 10.1212/WNL.44.3_Part_1.557
   Majamaa K, 1997, NEUROLOGY, V49, P1331, DOI 10.1212/WNL.49.5.1331
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
NR 21
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1050-6438
EI 1534-4916
J9 NEUROSURG QUART
JI Neurosurg. Q.
PD JUN 15
PY 2004
VL 14
IS 2
BP 93
EP 96
DI 
PG 4
WC Neurosciences; Surgery
SC Neurosciences & Neurology; Surgery
GA 843UZ
UT WOS:000223113400004
DA 2024-11-01
ER

PT J
AU Zeviani, M
   Di Donato, S
AF Zeviani, M
   Di Donato, S
TI Mitochondrial disorders
SO BRAIN
LA English
DT Review
DE respiratory chain; oxidative phosphorylation; mitochondrial DNA mutations; nuclear DNA mutations
ID hereditary optic neuropathy; cytochrome-c-oxidase; ragged-red fibers; progressive external ophthalmoplegia; respiratory-chain deficiency; deafness dystonia syndrome; coenzyme q(10) deficiency; complex-iii deficiency; kearns-sayre syndrome; point mutation
C1 Ist Nazl Neurol C Besta, Div Mol Neurogenet, I-20133 Milan, Italy.
   Ist Nazl Neurol C Besta, Div Biochem & Genet, I-20133 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Ist Nazl Neurol C Besta, Div Mol Neurogenet, Via Celoria 11, I-20133 Milan, Italy.
EM zeviani@istituto-besta.it; didonato@istituto-besta.it
FU Telethon [GGP030039, GGP02323] Funding Source: Medline
CR Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Aung T, 2002, HUM GENET, V110, P52, DOI 10.1007/s00439-001-0645-7
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0
   BARKOVICH AJ, 1993, AM J NEURORADIOL, V14, P1119
   Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178
   Baysal BE, 2002, J MED GENET, V39, P617, DOI 10.1136/jmg.39.9.617
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   BERKOVIC SF, 1993, EPILEPSIA, V34, P0
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Buono Lawrence M, 2002, CURR OPIN OPHTHALMOL, V13, P362, DOI 10.1097/00055735-200212000-00004
   Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chalmers RM, 1996, AM J HUM GENET, V59, P103
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   CHINNERY PF, 1999, LANCET S1, V354, P17
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   de Lonlay P, 2002, HUM MOL GENET, V11, P3273, DOI 10.1093/hmg/11.26.3273
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Di Donato S, 2000, J INHERIT METAB DIS, V23, P247, DOI 10.1023/A:1005684029429
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   Dionisi-Vici C, 1998, J INHERIT METAB DIS, V21, P2, DOI 10.1023/A:1005397227996
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Finnilä S, 2003, EUR J HUM GENET, V11, P652, DOI 10.1038/sj.ejhg.5201017
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hofmann S, 1997, HUM MOL GENET, V6, P1835, DOI 10.1093/hmg/6.11.1835
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Howell N, 1998, AM J HUM GENET, V63, P1220, DOI 10.1086/302049
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   HU DN, 1991, J MED GENET, V28, P79, DOI 10.1136/jmg.28.2.79
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923
   Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200
   JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kim JY, 2002, ANN NEUROL, V51, P630, DOI 10.1002/ana.10177
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   KWITTKEN J, 1958, AM J PATHOL, V34, P185
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   LOMBES A, 1989, ANN NEUROL, V26, P20, DOI 10.1002/ana.410260104
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   MACKEY D, 1992, AM J HUM GENET, V51, P1218
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mariotti C, 2003, NEUROLOGY, V60, P1676, DOI 10.1212/01.WNL.0000055872.50364.FC
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Nijtmans LGJ, 2001, FEBS LETT, V498, P46, DOI 10.1016/S0014-5793(01)02447-4
   NIKOSKELAINEN E, 1983, ARCH OPHTHALMOL-CHIC, V101, P1059, DOI 10.1001/archopht.1983.01040020061011
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   POULTON J, 1989, LANCET, V1, P236
   Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sadun A A, 2000, TRANS AM OPHTHALMOL SOC, V98, P223
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Santorelli F M, 2001, AM HEART J, V141, PE1, DOI 10.1067/mhj.2001.112088
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   SMITH JL, 1973, ARCH OPHTHALMOL-CHIC, V90, P349
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   Tsuchiya K, 1999, ACTA NEUROPATHOL, V97, P520, DOI 10.1007/s004010051023
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
   Zhao H, 2004, AM J HUM GENET, V74, P139, DOI 10.1086/381133
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 175
TC 330
Z9 381
U1 0
U2 34
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD OCT 15
PY 2004
VL 127
IS 
BP 2153
EP 2172
DI 10.1093/brain/awh259
PG 20
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 856YQ
UT WOS:000224082400002
PM 15358637
DA 2024-11-01
ER

PT J
AU Ruppert, V
   Nolte, D
   Aschenbrenner, T
   Pankuweit, S
   Funck, R
   Maisch, B
AF Ruppert, V
   Nolte, D
   Aschenbrenner, T
   Pankuweit, S
   Funck, R
   Maisch, B
TI Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE dilated cardiomyopathy; mitochondrial DNA; mutation analysis; dideoxy fingerprinting polymorphisms
ID maternal inheritance; organization; family; heart; rna
AB Dilated cardiomyopathy (DCM) is widely accepted as a pluricausal or multifactorial disease. Because of the linkage between energy metabolism in the mitochondria and cardiac muscle contraction, it is reasonable to assume that mitochondrial abnormalities may, e responsible for some forms of DCM. We analysed the whole mitochondrial genome in a series of 45 patients with DCM for alterations and compared the findings with those of 62 control subjects. A total of 458 sequence changes could be identified. These sequence changes were distributed among the whole mitochondrial DNA (mtDNA). An increased number of novel missense mutations could be detected nearly in all genes encoding for protein subunits in DCM patients. In genes coding for NADH dehydrogenase subunits the number of mtDNA Mutations detected in patients with DCM was significantly increased (p < 0.05) compared with control subjects. Eight mutations were found to Occur in conserved amino acids in the above species. The c.5973G > A (Ala-Trp) and the c.7042T > G (Val-Asp) mutations were located in highly conserved domains of the gene coding for cytochrome c oxidase subunit. Two tRNA mutations could be detected in the mtDNA of DCM patients alone. The T-C transition at nt 15,924 is connected with respiratory enzyme deficiency, mitochondrial myopathy, and cardiomyopathy. The c.16189T > C mutation in the D-loop region that is associated with susceptibility to DCM Could be detected in 15.6% of patients as well as in 9.7% of controls. Thus, mutations altering the function of the enzyme subunits of the respiratory chain can be relevant for the pathogenesis of dilated cardiomyopathy. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Marburg, Dept Internal Med & Cardiol, Marburg, Germany.
C3 Philipps University Marburg
RP Univ Marburg, Dept Internal Med & Cardiol, Marburg, Germany.
EM ruppert@med.uni-marburg.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   CAFORIO ALP, 1994, LANCET, V344, P773, DOI 10.1016/S0140-6736(94)92339-6
   CASE JT, 1981, SOMAT CELL GENET, V7, P103, DOI 10.1007/BF01544751
   COTTON RGH, 1993, MUTAT RES, V285, P125, DOI 10.1016/0027-5107(93)90060-S
   Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002
   FELMLEE TA, 1995, J CLIN MICROBIOL, V33, P1617, DOI 10.1128/JCM.33.6.1617-1623.1995
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   KANDOLF R, 1989, SPRINGER SEMIN IMMUN, V11, P1, DOI 10.1007/BF00197080
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   Kuhl U, 1996, HEART, V75, P295, DOI 10.1136/hrt.75.3.295
   Li YY, 1997, J MOL CELL CARDIOL, V29, P2699, DOI 10.1006/jmcc.1997.0501
   Marin-Garcia J, 2001, CARDIOVASC RES, V49, P17, DOI 10.1016/S0008-6363(00)00241-8
   Nollau P, 1997, CLIN CHEM, V43, P1114
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841
   Ruppert V, 2000, HERZ, V25, P161, DOI 10.1007/s000590050002
   Santorelli F M, 2001, AM HEART J, V141, PE1, DOI 10.1067/mhj.2001.112088
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   SCHONIAN U, 1993, CLIN IMMUNOL IMMUNOP, V68, P229, DOI 10.1006/clin.1993.1123
   SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Wallace DC, 2000, AM HEART J, V139, PS70, DOI 10.1067/mhj.2000.103934
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WHY HJF, 1994, CIRCULATION, V89, P2582, DOI 10.1161/01.CIR.89.6.2582
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
NR 31
TC 38
Z9 39
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 28
PY 2004
VL 318
IS 2
BP 535
EP 543
DI 10.1016/j.bbrc.2004.04.061
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 819LD
UT WOS:000221315500031
PM 15120634
DA 2024-11-01
ER

PT J
AU Bourgeois, JM
   Tarnopolsky, MA
AF Bourgeois, JM
   Tarnopolsky, MA
TI Pathology of skeletal muscle in mitochondrial disorders
SO MITOCHONDRION
LA English
DT Article; Proceedings Paper
DE electron microscopy; light microscopy; ragged red fibers; COX negative fibers; histology; ultrastructure; paracrystalline inclusion; mitochondria
ID oculopharyngeal muscular-dystrophy; cytochrome-b gene; ragged-red fibers; dna depletion; creatine-kinase; needle-biopsy; enzyme histochemistry; exercise intolerance; mutation; myopathy
AB Muscle histology is an essential component of the diagnostic work-up for mitochondrial cytopathies and is very important in both ruling in disease as well as ruling out the disease (i.e., alternate diagnoses). A muscle biopsy method must provide tissue for histology, electron microscopy, enzymes and DNA and this can be obtained with a suction-modified 5mm needle. Proper embedding and processing is important for optimal diagnostic yield. The essential stains for mitochondrial histology remain the modified Gomori trichrome, cytochrome oxidase, succinate dehydrogenase, and NADH. Electron microscopy can be helpful in selected cases, however, the decision to perform this on all samples remains a contentious issue. Some cases of mitochondrial cytopathy may show no abnormalities on histology or electron microscopy (i.e., LHON), whereas, other conditions can mimic mitochondrial disease through secondary mitochondrial changes (i.e., inclusion body myositis). Athletes show evidence of increased mitochondrial numbers but do not normally develop ragged red fibers or paracrystalline inclusions. Aging is associated with an accumulation of mitochondrial abnormalities and is an important factor to consider in the interpretation of the sample. For example, biopsies in young children with mitochondrial disease may be normal at the histological level and otherwise healthy older adults can show mitochondrial changes such as ragged red and COX-negative fibers. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Dept Pediat & Med, Hamilton, ON L8N 3Z5, Canada.
C3 McMaster University; McMaster University
RP McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   BERGSTROM J, 1969, ACTA MED SCAND, V186, P177
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bruno C, 2003, MUSCLE NERVE, V28, P508, DOI 10.1002/mus.10429
   Calore EE, 1994, PATHOLOGICA (GENOA), V86, P649
   Campos Y, 2001, NEUROMUSCULAR DISORD, V11, P477, DOI 10.1016/S0960-8966(00)00223-6
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   DUBOWITZ V, 1965, J NEUROL NEUROSUR PS, V28, P516, DOI 10.1136/jnnp.28.6.516
   DUBOWITZ V, 1966, J NEUROL NEUROSUR PS, V29, P23, DOI 10.1136/jnnp.29.1.23
   EDWARDS R, 1980, NEW ENGL J MED, V302, P261, DOI 10.1056/NEJM198001313020504
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289
   EVANS WJ, 1982, MED SCI SPORT EXER, V14, P101
   Gambelli S, 2004, EUR NEUROL, V51, P144, DOI 10.1159/000077070
   Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1
   GREIG PD, 1985, SURG GYNECOL OBSTET, V160, P466
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   HULTMAN E, 1967, ACTA MED SCAND, V182, P109
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Lacomis D, 2000, CURR RHEUMATOL REP, V2, P225, DOI 10.1007/s11926-000-0083-x
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Lindner A, 1997, MOL CELL BIOCHEM, V174, P297, DOI 10.1023/A:1006823818118
   LYNCH GS, 1993, ACTA PHYSIOL SCAND, V148, P27, DOI 10.1111/j.1748-1716.1993.tb09528.x
   Magistris MR, 1998, MUSCLE NERVE, V21, P194, DOI 10.1002/(SICI)1097-4598(199802)21:2<194::AID-MUS6>3.0.CO;2-6
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANZ HJ, 1980, VIRCHOWS ARCH A, V386, P1, DOI 10.1007/BF00432641
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   OROURKE KS, 1994, J RHEUMATOL, V21, P413
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   PAMPHLETT R, 1985, AUST NZ J MED, V15, P199, DOI 10.1111/j.1445-5994.1985.tb04005.x
   PAUZNER R, 1991, MUSCLE NERVE, V14, P947, DOI 10.1002/mus.880141004
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694
   Tarnopolsky M, 2003, MUSCLE NERVE, V27, P359, DOI 10.1002/mus.10330
   Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Tein I, 2002, J CHILD NEUROL, V17, P0
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
NR 48
TC 70
Z9 78
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP 15
PY 2004
VL 4
IS 5-6
BP 441
EP 452
DI 10.1016/j.mito.2004.07.036
PG 12
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 885QS
UT WOS:000226172600010
PM 16120405
DA 2024-11-01
ER

PT J
AU Crimi, M
   Galbiati, S
   Sciacco, M
   Bordoni, A
   Natali, MG
   Raimondi, M
   Bresolin, N
   Comi, GP
AF Crimi, M
   Galbiati, S
   Sciacco, M
   Bordoni, A
   Natali, MG
   Raimondi, M
   Bresolin, N
   Comi, GP
TI Mitochondrial-DNA nucleotides G4298A and T10010C as pathogenic mutations: the confirmation in two new cases
SO MITOCHONDRION
LA English
DT Article
DE mitochondrial (mt)DNA; tRNA gene; encephalomyopathy and point mutation
ID c-oxidase deficiency; myoclonus epilepsy; 2nd family; gene; myopathy; cardiomyopathy; patient; ophthalmoplegia
AB Mitochondrial encephalomyopathies are highly variable clinically and at the genetic level. In practice, when the mitochondrial DNA (mtDNA) of any mitochondrial-patient is sequenced, a very high number of variations are noted. The vast majority of these differences are simply polymorphisms, that is, non-pathologic, homoplasmic sequence variations; however, when a heteroplasmic variant is detected (co-existence of two different populations in the same tissue) this is clinically significant. We identified two different heteroplasmic mutations in the mtDNA of two subjects: G4298A in the tRNA(Ala) (Alanine) gene and T10010C in the tRNA(Gly) (Glycine), both of which have been reported previously. This work confirms the pathogenicity of these mutations and helps define the correlation between genotype and phenotype. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Milan, Osped Maggiore Policlin, IRCCS, Ctr Dino Ferrari,Dipartimento Sci Neurol, I-20122 Milan, Italy.
   Univ Milan, Osped Maggiore Policlin, IRCCS, CEND,Dipartimento Sci Neurol, I-20122 Milan, Italy.
   IRCCS E Medea, Bosisio Parini, LC, Italy.
   Ist Sci San Raffaele, Milan, Italy.
   Osped Civile, Lugano, Switzerland.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Eugenio Medea; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Univ Milan, Osped Maggiore Policlin, IRCCS, Ctr Dino Ferrari,Dipartimento Sci Neurol, Via F Sforza 35, I-20122 Milan, Italy.
EM marcreamy@tiscali.it
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   Goldstein JD, 1999, PEDIATR DEVEL PATHOL, V2, P78, DOI 10.1007/s100249900094
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   IOANESCU VV, 1994, NEUROLOGY, V44, P975
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   SWEENEY MG, 1993, Q J MED, V86, P435
   Tanji K, 2000, BRAIN PATHOL, V10, P422
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
NR 21
TC 7
Z9 8
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD APR 15
PY 2004
VL 3
IS 5
BP 279
EP 283
DI 10.1016/j.mito.2004.02.004
PG 5
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 818MZ
UT WOS:000221250500003
PM 16120360
DA 2024-11-01
ER

PT J
AU Kiechl, S
   Horváth, R
   Luoma, P
   Kiechl-Kohlendorfer, U
   Wallacher-Scholz, B
   Stucka, R
   Thaler, C
   Wanschitz, J
   Suomalainen, A
   Jaksch, M
   Willeit, J
AF Kiechl, S
   Horváth, R
   Luoma, P
   Kiechl-Kohlendorfer, U
   Wallacher-Scholz, B
   Stucka, R
   Thaler, C
   Wanschitz, J
   Suomalainen, A
   Jaksch, M
   Willeit, J
TI Two families with autosomal dominant progressive external ophthalmoplegia
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID mitochondrial-dna deletions; mtdna deletions; mutations; twinkle; gene; features; diseases; polg; ant1; encephalomyopathy
AB Objectives: We report here the clinical and genetic features of two new families with autosomal dominant progressive external ophthalmoplegia (adPEO). Patients and methods: The examination of index patients included a detailed clinical characterisation, histological analysis of muscle biopsy specimens, and genetic testing of mitochondrial and nuclear DNA extracted from muscle and leucocytes. Results: Index patients in both families presented with PEO and developed other clinical disease manifestations, such as myopathy and cardiomyopathy ( patient 1) and axonal neuropathy, diabetes mellitus, hearing loss, and myopathy ( patient 2), later in the course of illness. Both patients had ragged red fibres on muscle histology. Southern blot of mtDNA from muscle of patient 2 showed multiple deletions. In this case, a novel heterozygous missense mutation F485L was identified in the nuclear encoded putative mitochondrial helicase Twinkle. The mutation co-segregated with the clinical phenotype in the family and was not detected in 150 control chromosomes. In the other index patient, sequencing of ANT1, C10orf2 ( encoding for Twinkle), and POLG1 did not reveal pathogenic mutations. Conclusions: Our cases illustrate the clinical variability of adPEO, add a novel pathogenic mutation in Twinkle ( F485L) to the growing list of genetic abnormalities in adPEO, and reinforce the relevance of other yet unidentified genes in mtDNA maintenance and pathogenesis of adPEO.
C1 Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria.
   Metab Dis Ctr Munich Schwabing, Munich, Germany.
   Acad Hosp Schwabing, Dept Clin Chem, Munich, Germany.
   Univ Helsinki, Biomedicum Helsinki, Program Neurosci, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland.
   Univ Innsbruck Hosp, Dept Neonatol, A-6020 Innsbruck, Austria.
   Acad Hosp Schwabing, Dept Pediat, Munich, Germany.
   Univ Munich, Gene Ctr, Munich, Germany.
C3 Medical University of Innsbruck; University of Helsinki; University of Helsinki; Medical University of Innsbruck; University of Munich
RP Kiechl, S (corresponding author), Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.
EM stefan.kiechl@uibk.ac.at
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   JAKSCH M, 1995, CLIN BIOCHEM, V28, P503, DOI 10.1016/0009-9120(95)00035-8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAI H, 1995, MUSCLE NERVE, V18, P753, DOI 10.1002/mus.880180712
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 21
TC 26
Z9 27
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD AUG 15
PY 2004
VL 75
IS 8
BP 1125
EP 1128
DI 10.1136/jnnp.2003.025890
PG 4
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 838QJ
UT WOS:000222727800010
PM 15258213
DA 2024-11-01
ER

PT J
AU Spiekerkoetter, U
   Bennett, MJ
   Ben-Zeev, B
   Strauss, AW
   Tein, I
AF Spiekerkoetter, U
   Bennett, MJ
   Ben-Zeev, B
   Strauss, AW
   Tein, I
TI Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein
SO MUSCLE & NERVE
LA English
DT Article
DE myoglobinuria; myopathy; peripheral neuropathy; rhabdomyolysis; TFP deficiency
ID 3-hydroxyacyl-coa dehydrogenase-deficiency; coenzyme-a dehydrogenase; acid oxidation defects; beta-oxidation; molecular characterization; alpha-subunit; dna analysis; diagnosis; phenotype; mutations
AB Mitochondrial trifunctional protein (TFP) deficiency is a rare disorder of the fatty acid beta-oxidation cycle with heterogeneous phenotypes and occurs secondary to either alpha- or beta-subunit mutations. We characterized the neuromyopathic phenotype of TFP deficiency through adolescence or adulthood in 11 patients, 8 with beta-subunit mutations and 3 with alpha-subunit mutations. Two independent clinical features occurred: infantile-onset progressive peripheral neuropathy and episodic exercise-, illness- or fasting-induced rhabdomyolysis accompanied by respiratory failure (in five patients). The combination of episodic rhabdomyolysis and peripheral neuropathy occurred in 10 of the 11 patients. The neuromyopathic phenotype is common in TFP deficiency (11 of 27 families from our cohort). Therefore, this disorder must be considered in the differential diagnosis of progressive peripheral neuropathy with or without episodic myoglobinuria.
C1 Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.
   Univ Dusseldorf, Childrens Hosp, Clin Gen Pediat, D-40225 Dusseldorf, Germany.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75230 USA.
   Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75230 USA.
   Chaim Sheba Med Ctr, Dept Pediat Neurol, IL-52621 Tel Hashomer, Israel.
   Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Dept Pediat, Toronto, ON M5G 1X8, Canada.
C3 Vanderbilt University; Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas Dallas; Chaim Sheba Medical Center; University of Toronto; Hospital for Sick Children (SickKids)
RP Spiekerkoetter, U (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, 221 Kirkland Hall, Nashville, TN 37212 USA.
CR BRACKETT JC, 1995, J CLIN INVEST, V95, P2076, DOI 10.1172/JCI117894
   Darras BT, 2000, PEDIATR NEUROL, V23, P289, DOI 10.1016/S0887-8994(00)00202-2
   den Boer MEJ, 2002, PEDIATRICS, V109, P99, DOI 10.1542/peds.109.1.99
   Ferdinandusse S, 2001, J LIPID RES, V42, P1987
   Gillingham M, 1999, J INHERIT METAB DIS, V22, P123, DOI 10.1023/A:1005437616934
   Gregersen N, 2001, HUM MUTAT, V18, P169, DOI 10.1002/humu.1174
   Hintz SR, 2002, MOL GENET METAB, V75, P120, DOI 10.1006/mgme.2001.3282
   Hurvitz H, 2000, PEDIATR NEUROL, V22, P148, DOI 10.1016/S0887-8994(99)00125-3
   Ibdah JA, 2001, J CLIN INVEST, V107, P1403, DOI 10.1172/JCI12590
   Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204
   Ibdah JA, 1998, J CLIN INVEST, V102, P1193, DOI 10.1172/JCI2091
   Ibdah JA, 2001, J PEDIATR-US, V138, P396, DOI 10.1067/mpd.2001.111503
   Isaacs JD, 1996, PEDIATR RES, V40, P393, DOI 10.1203/00006450-199609000-00005
   JOUTEL A, 1993, REV NEUROL, V149, P797
   KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302
   MAK IT, 1986, J BIOL CHEM, V261, P1153
   Matern D, 1999, PEDIATR RES, V46, P45, DOI 10.1203/00006450-199907000-00008
   OGILVIE I, 1994, NEUROLOGY, V44, P467, DOI 10.1212/WNL.44.3_Part_1.467
   Orii KE, 1997, HUM MOL GENET, V6, P1215, DOI 10.1093/hmg/6.8.1215
   SADEH M, 1990, ISRAEL J MED SCI, V26, P510
   Saudubray JM, 1999, J INHERIT METAB DIS, V22, P488
   Schaefer J, 1996, ANN NEUROL, V40, P597, DOI 10.1002/ana.410400409
   Scholte HR, 1999, NEUROMUSCULAR DISORD, V9, P313, DOI 10.1016/S0960-8966(99)00032-2
   Spiekerkoetter U, 2002, JOURNAL OF INHERITED METABOLIC DISEASE, V25, P72
   Spiekerkoetter U, 2003, HUM MUTAT, V21, P598, DOI 10.1002/humu.10211
   Tein I, 1999, NEUROLOGY, V52, P640, DOI 10.1212/WNL.52.3.640
   TEIN I, 1995, PEDIATR NEUROL, V12, P68, DOI 10.1016/0887-8994(94)00109-F
   Ushikubo S, 1996, AM J HUM GENET, V58, P979
   WANDERS RJA, 1992, BIOCHEM BIOPH RES CO, V188, P1139, DOI 10.1016/0006-291X(92)91350-Y
NR 29
TC 56
Z9 60
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0148-639X
EI 
J9 MUSCLE NERVE
JI Muscle Nerve
PD JAN 15
PY 2004
VL 29
IS 1
BP 66
EP 72
DI 10.1002/mus.10500
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 759PY
UT WOS:000187747100007
PM 14694500
DA 2024-11-01
ER

PT J
AU Van Goethem, G
   Luoma, P
   Rantamäki, M
   Al Memar, A
   Kaakkola, S
   Hackman, P
   Krahe, R
   Löfgren, A
   Martin, JJ
   De Jonghe, P
   Suomalainen, A
   Udd, B
   Van Broeckhoven, C
AF Van Goethem, G
   Luoma, P
   Rantamäki, M
   Al Memar, A
   Kaakkola, S
   Hackman, P
   Krahe, R
   Löfgren, A
   Martin, JJ
   De Jonghe, P
   Suomalainen, A
   Udd, B
   Van Broeckhoven, C
TI <i>POLG</i> mutations in neurodegenerative disorders with ataxia but no muscle involvement
SO NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; mitochondrial-dna deletions; multiple deletions; neurogastrointestinal encephalomyopathy; autosomal-dominant; polymerase-gamma; mtdna deletions; patient; cardiomyopathy; neuropathy
AB Objective: To identify POLG mutations in patients with sensory ataxia and CNS features. Methods: The authors characterized clinical, laboratory, and molecular genetic features in eight patients from five European families. The authors conducted sequencing of coding exons of POLG, C10orf2 ( Twinkle), and ANT1 and analyzed muscle mitochondrial DNA ( mtDNA), including Southern blot analysis and long-range PCR. Results: Ataxia occurred in combination with various CNS features, including myoclonus, epilepsy, cognitive decline, nystagmus, dysarthria, thalamic and cerebellar white matter lesions on MRI, and neuronal loss in discrete gray nuclei on autopsy. Gastrointestinal dysmotility, weight loss, cardiomyopathy, and valproate-induced hepatotoxicity occurred less frequently. Two patients died without preceding signs of progressive external ophthalmoplegia. In muscle, typical findings of mitochondrial disease, such as ragged red fibers and Southern blot mtDNA abnormalities, were absent. POLG mutations were present in eight patients, including two isolated cases, and one Finnish and two unrelated Belgian families contained in total six patients. All POLG mutations were recessive, occurring in a homozygous state in seven patients and in a compound heterozygous state in one patient. The novel W748S mutation was identified in five patients from three unrelated families. Conclusions: The clinical spectrum of recessive POLG mutations is expanded by sensory ataxic neuropathy, combined with variable features of involvement of CNS and other organs. Progressive external ophthalmoplegia, myopathy, ragged red fibers, and Southern blot abnormalities of muscle mitochondrial DNA also are not mandatory features associated with POLG mutations.
C1 Univ Instelling Antwerp, Dept Mol Genet, B-2610 Antwerp, Belgium.
   Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
   Univ Antwerp Hosp, Neuromuscular Reference Ctr, Antwerp, Belgium.
   Flanders Interuniv Inst Biotechnol VIB8, Dept Mol Genet, Antwerp, Belgium.
   Born Bunge Fdn, Dept Neuropathol, Antwerp, Belgium.
   Univ Helsinki, Program Neurosci, Helsinki, Finland.
   Univ Helsinki, Dept Neurol, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
   Seinajoki Cent Hosp, Dept Phys Med, Seinajoki, Finland.
   Seinajoki Cent Hosp, Dept Rehabil & Neurol, Seinajoki, Finland.
   Atkinson Morelys Hosp, Dept Neurol, London, England.
   Univ Helsinki, Dept Med Genet, Folkhalsan Inst Genet, Helsinki, Finland.
   Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, Houston, TX 77030 USA.
   Vaasa Cent Hosp, Vaasa, Finland.
   Tampere Univ Hosp, Tampere, Finland.
C3 University of Antwerp; University of Antwerp; University of Antwerp; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Seinajoki Central Hospital; Seinajoki Central Hospital; University of Helsinki; University of Texas System; UTMD Anderson Cancer Center; Vaasa Central Hospital; Tampere University; Tampere University Hospital
RP Van Goethem, G (corresponding author), Univ Instelling Antwerp, Dept Mol Genet, VIB8 Univ Pl 1, B-2610 Antwerp, Belgium.
EM gert.vangoethem@ua.ac.be
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alderborn A, 2000, GENOME RES, V10, P1249, DOI 10.1101/gr.10.8.1249
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   KAGUNI LS, 1982, P NATL ACAD SCI-BIOL, V79, P983, DOI 10.1073/pnas.79.4.983
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   MARTIN JJ, 1991, HDB CLIN NEUROLOGY, V1660, P701
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   Parton MJ, 2002, HUM MUTAT, V20, P0, DOI 10.1002/humu.9081
   Paul R, 2000, EUR J HUM GENET, V8, P331, DOI 10.1038/sj.ejhg.5200463
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 204
Z9 215
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD OCT 12
PY 2004
VL 63
IS 7
BP 1251
EP 1257
DI 10.1212/01.WNL.0000140494.58732.83
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 861HV
UT WOS:000224408000021
PM 15477547
DA 2024-11-01
ER

PT J
AU Blakely, EL
   He, L
   Taylor, RW
   Chinnery, PF
   Lightowlers, RN
   Schaefer, AM
   Turnbull, DM
AF Blakely, EL
   He, L
   Taylor, RW
   Chinnery, PF
   Lightowlers, RN
   Schaefer, AM
   Turnbull, DM
TI Mitochondrial DNA deletion in "identical'' twin brothers
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; mutation; mtdna; son
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
CR Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROWLAND LP, 1988, NEUROLOGY, V38, P1399, DOI 10.1212/WNL.38.9.1399
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Weber K, 1997, AM J HUM GENET, V60, P373
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 20
TC 48
Z9 52
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB 1
PY 2004
VL 41
IS 2
BP 
EP 
DI 10.1136/jmg.2003.011296
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 769VE
UT WOS:000188669800017
PM 14757869
DA 2024-11-01
ER

PT J
AU Tarnopolsky, MA
   Simon, DK
   Roy, BD
   Chorneyko, K
   Lowther, SA
   Johns, DR
   Sandhu, JK
   Li, Y
   Sikorska, M
AF Tarnopolsky, MA
   Simon, DK
   Roy, BD
   Chorneyko, K
   Lowther, SA
   Johns, DR
   Sandhu, JK
   Li, Y
   Sikorska, M
TI Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome <i>b</i> mutation
SO MUSCLE & NERVE
LA English
DT Article
DE creatine kinase; cybrids; exercise; dietary supplements; mitochondrial myopathy
ID magnetic-resonance spectroscopy; human mitochondrial myopathy; skeletal-muscle; oxidative stress; exercise intolerance; dna; disease; kinase; encephalomyopathy; brain
AB Mitochondrial cytopathies are associated with increased free radical generation and paracrystalline inclusions. Paracrystalline inclusions were serendipitously found in a young male athlete with a very high respiratory exchange ratio during steady-state exercise; he also had an unusually low aerobic capacity. Direct sequencing of the mitochondrial DNA (mtDNA) coding regions revealed a novel missense mutation (G15497A) resulting in a glycine-->serine conversion at a highly conserved site in the cytochrome b gene in the subject, his mother, and sister. Cybrids, prepared by fusion of the subject's platelets with either U87MG rhodegrees or SH-SY5Y rhodegrees cells, generated higher basal levels of reactive oxygen species (ROS), had a lower adenosine triphosphate (ATP) content, and were more sensitive to oxygen and glucose deprivation and peroxynitrite generation compared to control cybrids with wild-type mtDNA. Cell survival was significantly enhanced with 50 mmol/L creatine monohydrate (CM) administration. The subject was also treated with CM (10 g/d) for a period of 5 weeks and a repeat muscle biopsy showed no paracrystalline inclusions. The results suggest that the development of exercise-induced paracrystalline inclusions may be influenced by the G15497A mtDNA mutation, and that CM mitigates against the pathological consequences of this mutation.
C1 McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Beth Israel Deaconess Med Ctr, Dept Ophthalmol, Boston, MA USA.
   Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
C3 McMaster University; McMaster University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; National Research Council Canada
RP McMaster Univ, Med Ctr, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   Ashton T, 1999, J APPL PHYSIOL, V87, P2032, DOI 10.1152/jappl.1999.87.6.2032
   Barbiroli B, 1997, CELL MOL BIOL, V43, P741
   Borchert A, 1999, MUSCLE NERVE, V22, P1299
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Carter SL, 2001, CAN J PHYSIOL PHARM, V79, P386, DOI 10.1139/cjpp-79-5-386
   Chomyn A, 1996, METHODS ENZYMOL, V264, P334, DOI 10.1016/S0076-6879(96)64031-2
   EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   GREENHAFF PL, 1994, AM J PHYSIOL, V266, PE725, DOI 10.1152/ajpendo.1994.266.5.E725
   Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hultman E, 1996, J APPL PHYSIOL, V81, P232
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031
   Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164
   Mahoney DJ, 2002, CURR OPIN CLIN NUTR, V5, P619, DOI 10.1097/00075197-200211000-00004
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, PE580, DOI 10.1152/ajpendo.2000.278.4.E580
   Miller SW, 1996, J NEUROCHEM, V67, P1897
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6
   OGorman E, 1997, J CELL SCI, V110, P1403
   OGorman E, 1997, MOL CELL BIOCHEM, V174, P283, DOI 10.1023/A:1006881113149
   OHKOSHI N, 1995, MUSCLE NERVE, V18, P1265, DOI 10.1002/mus.880181108
   Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5
   PETROSKI RE, 1994, J NEUROSCI METH, V52, P23, DOI 10.1016/0165-0270(94)90051-5
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   Rowbottom DG, 1998, MED SCI SPORT EXER, V30, P1345, DOI 10.1097/00005768-199809000-00001
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Santos-Silva A, 2001, CLIN CHIM ACTA, V306, P119, DOI 10.1016/S0009-8981(01)00406-5
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Simon DK, 1999, ANNU REV MED, V50, P111
   SMEITINK J, 1992, NEUROMUSCULAR DISORD, V2, P35, DOI 10.1016/0960-8966(92)90024-Z
   Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694
   Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821
   Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Takao M, 1996, J NEUROL SCI, V139, P111
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055
   TAUBE R, 1995, MED SCI SPORTS EXERC, V27, P21
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
NR 53
TC 36
Z9 39
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD APR 15
PY 2004
VL 29
IS 4
BP 537
EP 547
DI 10.1002/mus.20020
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 808ZA
UT WOS:000220605800007
PM 15052619
DA 2024-11-01
ER

PT J
AU Park, SB
   Ma, KT
   Kook, KH
   Lee, SY
AF Park, SB
   Ma, KT
   Kook, KH
   Lee, SY
TI Kearns-Sayre syndrome - 3 case reports and review of clinical feature
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE atypical retinal pigmentary change; Kearns-Sayre syndrome; ptosis; ragged-red fiber
ID progressive external ophthalmoplegia; mitochondrial-dna deletion
AB Keams-Sayre syndrome, first described by Kearns and Sayre in 1958, is a rare disorder consisting of ptosis, limited movement of both eyes and atypical retinal pigmentary change (salt-pepper like appearance). Most cases have shown an increase in the concentration of mitochondria and ragged-red fiber under Gomori-trichrome staining on muscle biopsy. Occasionally, it is combined with other neurologic and endocrinologic symptoms such as ataxia, dementia, diabetes, and hyperaldosteronism. We recently experienced three cases of male teenaged patients who expressed the clinical features of Keams-Sayre syndrome.
C1 Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM SYLee@yumc.yonsei.ac.kr
CR Ashizawa T, 2001, ARCH NEUROL-CHICAGO, V58, P1053, DOI 10.1001/archneur.58.7.1053
   BECKERMAN BL, 1976, AM J OPHTHALMOL, V81, P89, DOI 10.1016/0002-9394(76)90197-5
   BERENBAUM F, 1990, NEUROLOGY, V40, P193, DOI 10.1212/WNL.40.1.193
   BROCKINGTON M, 1995, J NEUROL SCI, V131, P78, DOI 10.1016/0022-510X(95)00091-F
   Chabrol B, 1997, NEUROLOGY, V49, P308, DOI 10.1212/WNL.49.1.308-b
   Choi C, 2000, YONSEI MED J, V41, P676, DOI 10.3349/ymj.2000.41.5.676
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   GREGORY K, 1991, NEUROL CLIN, V9, P147
   HERZBERG NH, 1993, NEUROLOGY, V43, P218, DOI 10.1212/WNL.43.1_Part_1.218
   Ishikawa Y, 2000, J CHILD NEUROL, V15, P750, DOI 10.1177/088307380001501107
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   OTA Y, 1994, RETINA-J RET VIT DIS, V14, P270, DOI 10.1097/00006982-199414030-00015
   Simaan EM, 1999, PEDIATR NEUROL, V21, P830, DOI 10.1016/S0887-8994(99)00084-3
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 17
TC 16
Z9 19
U1 0
U2 1
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD AUG 31
PY 2004
VL 45
IS 4
BP 727
EP 735
DI 10.3349/ymj.2004.45.4.727
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 853UV
UT WOS:000223855300022
PM 15344217
DA 2024-11-01
ER

PT J
AU Kotzailias, N
   Finsterer, J
   Zellner, M
   Marsik, C
   Dukic, T
   Jilma, B
AF Kotzailias, N
   Finsterer, J
   Zellner, M
   Marsik, C
   Dukic, T
   Jilma, B
TI Platelet function in mitochondriopathy with stroke and stroke-like episodes
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE platelet function; ATP exercise; mitochondriopathy; stroke
ID function analyzer; melas syndrome; lactic-acidosis; healthy-men; mutation; exercise; aspirin; dna; thromboelastography; inflammation
AB Stroke and stroke-like episodes are frequent complications in mitochondriopathy, particulary in MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes) which is a disorder of the mitochondrial oxidative metabolism in diverse cell types. To clarify a possible pathological aspect of stroke in these patients, we investigated platelet function before and after physical exercise. Ten patients with mitochondriopathy and stroke and ten healthy sex and age matched controls were investigated in an analyst blinded, prospective cross-sectional trial. Exercise decreased intraplatelet adenosine triphosphate (ATP) concentrations by -22% from baseline in patients with mitochondriopathy (p<0.01 between groups) while exercise increased ATP-levels by 28% healthy controls (p=0.01 vs baseline). Thrombin receptor activating peptide (TRAP) stimulated P-selectin expression increased up to 50% (p<0.05) in healthy subjects following exercise compared to 39% (p>0.05) in patients with mitochondriopathy. Exercise trendwise decreased platelet plug formation under shear stress by 24% in patients as measured by the platelet function analyzer PFA-100(R). Tromboelastography showed firm thrombus formation and delayed lysis in patients following exercise. In conclusion, this trial has shown that ATP depletion during and after exercise probably accounts for a defective oxidative metabolism in platelets of patients with mitochondriopathy and stroke. This might induce decreased platelet function in these patients but fails to explain the increased stroke rate. Therefore other mechanisms seem to be etiologically involved in the pathogenesis of stroke in patients with mitochondriopathy.
C1 Univ Vienna, Sch Med, Dept Clin Pharmacol, TARGET, A-1090 Vienna, Austria.
   Neurol Hosp Rudolfstiftung, Dept Neurol, Vienna, Austria.
   Univ Vienna, Dept Surg Res, Vienna, Austria.
   Univ Vienna, Dept Neurol, Vienna, Austria.
C3 University of Vienna; Rudolfstiftung Hospital; University of Vienna; University of Vienna
RP Univ Vienna, Sch Med, Dept Clin Pharmacol, TARGET, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM nicole.hergovich@univie.ac.at
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   AKKERMAN JWN, 1982, BRIT J HAEMATOL, V51, P561, DOI 10.1111/j.1365-2141.1982.tb02819.x
   BARAK Y, 1995, ISRAEL J MED SCI, V31, P224
   CLEMETSON KJ, 1997, PLATELETS THEIR FACT, V0, P155
   Dalby MCD, 2000, PLATELETS, V11, P320
   Garcia J H, 1995, SEMIN PEDIATR NEUROL, V2, P180, DOI 10.1016/S1071-9091(05)80029-4
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x
   Hergovich N, 2000, CLIN PHARMACOL THER, V68, P435, DOI 10.1067/mcp.2000.110456
   HOLMSEN H, 1900, P1182, V0, P0
   Homoncik M, 2000, THROMB HAEMOSTASIS, V83, P316, DOI 10.1055/s-0037-1613805
   HORIGUCHI Y, 1991, JOURNAL OF DERMATOLOGY (TOKYO), V18, P295
   HUANG CC, 1995, EUR NEUROL, V35, P199, DOI 10.1159/000117128
   HUBAR JLMV, 1991, NEUROPEDIATRICS, V22, P10
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Jilma B, 1996, BRIT J HAEMATOL, V93, P432, DOI 10.1046/j.1365-2141.1996.5031040.x
   Jilma B, 2001, J LAB CLIN MED, V138, P152, DOI 10.1067/mlc.2001.117406
   Jilma B, 1997, IMMUNOBIOLOGY, V197, P505, DOI 10.1016/S0171-2985(97)80082-4
   Khurana S, 1997, J LAB CLIN MED, V130, P401, DOI 10.1016/S0022-2143(97)90040-8
   Li NL, 1999, CIRCULATION, V100, P1374, DOI 10.1161/01.CIR.100.13.1374
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa K, 1997, NEUROLOGY, V49, P1331, DOI 10.1212/WNL.49.5.1331
   Michiels JJ, 1999, CLIN APPL THROMB-HEM, V5, P247, DOI 10.1177/107602969900500408
   RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1
   Reiter R, 2003, THROMB HAEMOSTASIS, V90, P898, DOI 10.1160/TH03-04-0245
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SELAK MA, 1994, RECEPTOR, V4, P3
   Sharma SK, 1999, ANESTHESIOLOGY, V90, P385, DOI 10.1097/00000542-199902000-00009
   SMITH PR, 1994, J NEUROL SCI, V122, P80, DOI 10.1016/0022-510X(94)90055-8
   Stohlawetz P, 1999, TRANSFUSION, V39, P506, DOI 10.1046/j.1537-2995.1999.39050506.x
   Storey RF, 2001, PLATELETS, V12, P197, DOI 10.1080/09537100120058739
   THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613
   TOMASIAK M, 1987, ACTA BIOCHIM POL, V34, P269
   Tzima E, 2000, PLATELETS, V11, P245
   Valanne L, 1996, NEUROPEDIATRICS, V27, P154, DOI 10.1055/s-2007-973767
   WANG JS, 1994, CIRCULATION, V90, P2877, DOI 10.1161/01.CIR.90.6.2877
   Williams AJ, 1999, J CHILD NEUROL, V14, P518, DOI 10.1177/088307389901400807
NR 38
TC 5
Z9 5
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
PD MAR 15
PY 2004
VL 91
IS 3
BP 544
EP 552
DI 10.1160/TH03-03-0156
PG 9
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 802GF
UT WOS:000220151300018
PM 14983231
DA 2024-11-01
ER

PT J
AU Sakai, Y
   Kaga, K
   Kodama, K
   Higuchi, A
   Miyamoto, J
AF Sakai, Y
   Kaga, K
   Kodama, K
   Higuchi, A
   Miyamoto, J
TI Hearing evaluation in two sisters with a T8993G point mutation of mitochondrial DNA
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article
DE A T8993G point mutation of mitochondrial DNA; Leigh's syndrome; neurogenic muscle, weakness, ataxia and retinitis pigmentosa (NARP); sensorineural hearing loss; auditory brainstem responses
ID trna(ser(ucn)) gene; sensorineural deafness; leighs syndrome; patient; disease; family; mtdna
AB We report on two sisters with a T8993G point mutation of mitochondrial DNA, and their hearing evaluation. Considering auditory function, hearing in the elder sister remains almost normal. However, in the younger sister, the auditory brainstem response (ABR) threshold has fluctuated remarkably during a 3-year follow-up. The threshold changes of ABR in the younger sister suggest that her hearing problems may well be caused by both cochlear nerves and retrocochlear lesions. Our experience is clinically important because there have been only a few reports on hearing evaluation in patients with a T8993G point mutation of mitochondrial DNA. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Tokyo, Sch Med, Dept Otolaryngol, Bunkyo Ku, Tokyo 1138655, Japan.
   Natl Ctr Childrens Rehabilitat, Itabashi Ku, Tokyo 1730037, Japan.
   Kiyose Childrens Hosp, Dept Pediat, Tokyo 2048567, Japan.
C3 University of Tokyo
RP Sakai, Y (corresponding author), 1-35-27 Hongo,Bunkyo Ku,ATORU MASAGO 701, Tokyo 1130033, Japan.
EM xxxsakai@tivedoor.com
CR COR WRJ, 2002, GENETIC HEARING IMPA, V61, P172
   ENSINK RJH, 1996, P 2 WORKSH EUR WORK, V0, P0
   Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   KAGA M, 1987, ACTA PAEDIATRICA JAPONICA, V29, P254
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443
   REID FM, 1994, HUM MOL GENET, V3, P1435
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   SOFFNER JM, 1992, NEUROLOGY, V42, P2168
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   YOSHINAGA H, 1993, J CHILD NEUROL, V8, P129, DOI 10.1177/088307389300800204
NR 16
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND
SN 0165-5876
EI 
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD AUG 15
PY 2004
VL 68
IS 8
BP 1115
EP 1119
DI 10.1016/j.ijporl.2004.03.015
PG 5
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA 845LM
UT WOS:000223244200020
PM 15236904
DA 2024-11-01
ER

PT J
AU Karkos, PD
   Waldron, M
   Johnson, IJ
AF Karkos, PD
   Waldron, M
   Johnson, IJ
TI The MELAS syndrome. Review of the literature: the role of the otologist
SO CLINICAL OTOLARYNGOLOGY
LA English
DT Review
DE MELAS syndrome; sensorineural hearing loss; mitochondrial cytopathy
ID sensorineural hearing-loss; stroke-like episodes; mitochondrial myopathy; lactic-acidosis; cochlear implantation; mutation; encephalopathy; disease; dna; encephalomyopathy
AB The mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is a rare congenital disorder of mitochondrial DNA (mt-DNA). Patients with this syndrome may present to the otolaryngologist with sensorineural hearing loss (SNHL), which is genetic in origin. A high index of suspicion is required because this hearing loss is part of a syndrome for which early diagnosis and intervention is required.
C1 Freeman Rd Hosp, Dept Otolaryngol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle Freeman Hospital
RP Freeman Rd Hosp, Dept Otolaryngol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
EM pkarkos@aol.com
CR BINDOFF LA, 1994, DIS VOLUNTARY MUSCLE, V0, P717
   CARROLL JE, 1976, NEUROLOGY, V26, P140, DOI 10.1212/WNL.26.2.140
   Cerri C, 1983, MITOCHONDRIAL PATHOL, V0, P141
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   CHINNERY PF, 1999, LANCET S1, V354, P1721
   DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   DONOVAN TJ, 1995, ANN OTO RHINOL LARYN, V104, P786, DOI 10.1177/000348949510401007
   Edmonds JL, 2002, ARCH OTOLARYNGOL, V128, P355, DOI 10.1001/archotol.128.4.355
   FERNANDEZ C, 1974, ACTA OTO-LARYNGOL, V78, P173, DOI 10.3109/00016487409126343
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hill D, 2001, J NEUROL NEUROSUR PS, V71, P281, DOI 10.1136/jnnp.71.2.281
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Keats BJB, 2002, J COMMUN DISORD, V35, P355, DOI 10.1016/S0021-9924(02)00090-4
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Nadol JB, 2001, INT J PEDIATR OTORHI, V61, P1, DOI 10.1016/S0165-5876(01)00546-8
   Nance W E, 1980, BIRTH DEFECTS ORIG ARTIC SER, V16, P263
   NAVIAUX RK, 1999, ATLAS METABOLIC DIS, V0, P314
   OSHIMA T, 1999, ASS RES OTOLARYNGOLO, V0, P11
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385
   Rosenthal EL, 1999, AM J OTOL, V20, P187
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   SKOGLUND RR, 1979, NEUROLOGY, V29, P717, DOI 10.1212/WNL.29.5.717
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   SWIFT AC, 1988, J LARYNGOL OTOL, V102, P626, DOI 10.1017/S0022215100105912
   Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VERNHAM GA, 1994, CLIN OTOLARYNGOL, V19, P314, DOI 10.1111/j.1365-2273.1994.tb01238.x
   Warrick PD, 1997, J LARYNGOL OTOL, V111, P279, DOI 10.1017/S0022215100137089
NR 35
TC 9
Z9 13
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1749-4478
EI 1749-4486
J9 CLIN OTOLARYNGOL
JI Clin. Otolaryngol.
PD FEB 15
PY 2004
VL 29
IS 1
BP 1
EP 4
DI 10.1111/j.1365-2273.2004.00769.x
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 760TB
UT WOS:000187849600001
PM 14961844
DA 2024-11-01
ER

PT J
AU Divi, RL
   Walker, VE
   Wade, NA
   Nagashima, K
   Seilkopf, SK
   Adams, ME
   Nesel, CJ
   O'Neill, JP
   Abrams, EJ
   Poirier, MC
AF Divi, RL
   Walker, VE
   Wade, NA
   Nagashima, K
   Seilkopf, SK
   Adams, ME
   Nesel, CJ
   O'Neill, JP
   Abrams, EJ
   Poirier, MC
TI Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir
SO AIDS
LA English
DT Article
DE leukocytes; zidovudine; lamivudine; electron microscopy; PCR-chemiluminescence immunoasssay detection
ID immunodeficiency-virus type-1; uninfected infants; pregnant-women; zidovudine; toxicity; fetal; transmission; dysfunction; myopathy; hyperlactatemia
AB Objective: Although most uninfected infants born to women infected with HIV-1 show no clinical evidence of mitochondrial compromise, mitochondrial dysfunction has been reported in children born to women receiving zidovudine and/or lamivudine during pregnancy. In this pilot study we examined mitochondrial integrity in HIV-1-uninfected infants born to HIV-1-infected women receiving Combivir during pregnancy. Design: Samples of umbilical cord and cord blood were obtained from HIV-1-uninfected infants born to either HIV-1-infected women receiving Combivir therapy during pregnancy (n = 10) or HIV-1-uninfected women (n = 9). Methods: Mitochondrial morphological integrity was examined in umbilical cords (n = 16) by electron microscopy and mtDNA quantity was determined in DNA from cord blood (n = 18) and umbilical cord (n = 18) by PCR-chemiluminescence immunoassay detection. Results: In umbilical cords from six of nine infants born to HIV-1-infected mothers taking Combivir moderate to severe mitochondrial morphological damage was observed (P = 0.011), while none of seven unexposed infants showed similar damage. Compared to unexposed infants, statistically significant mtDNA depletion was observed in umbilical cord (P = 0.006) and cord blood (P = 0.003) from drug-exposed infants. Conclusions: A cohort of HIV-1-uninfected Combivir-exposed infants with no clinical symptoms showed morphological and molecular evidence of mitochondrial damage. (C) 2004 Lippincott Williams Wilkins.
C1 NCI, CDI Sect, NIH, Bethesda, MD 20892 USA.
   Lovelace Resp Res Inst, Albuquerque, NM USA.
   Albany Med Ctr, Childrens Hosp, Dept Pediat, Albany, NY USA.
   New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.
   NCI, SAIC, Frederick, MD 21701 USA.
   SKS Consulting Serv, Siler City, NC USA.
   Westat Corp, Rockville, MD USA.
   Univ Vermont, Genet Lab, Burlington, VT USA.
   Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY USA.
   Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, New York, NY 10032 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Lovelace Respiratory Research Institute; Albany Medical College; State University of New York (SUNY) System; Wadsworth Center; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Westat; University of Vermont; Columbia University; Columbia University
RP NCI, CDI Sect, NIH, Bldg 37,Rm 4032,37 Convent Dr,MSC-4255, Bethesda, MD 20892 USA.
FU NHLBI NIH HHS [R01-HL72727] Funding Source: Medline; NICHD NIH HHS [R01-HD33648] Funding Source: Medline
CR AGRESTI A, 1996, STAT SCI, V7, P131
   Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74
   Anderson J, 2002, OBSTET GYNECOL, V99, P1117
   Barret B, 2003, AIDS, V17, P1769, DOI 10.1097/00002030-200308150-00006
   Beach JW, 1998, CLIN THER, V20, P2
   Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0
   Brinkman K, 2001, AIDS, V15, P795, DOI 10.1097/00002030-200104130-00016
   Bulterys M, 2000, J ACQ IMMUN DEF SYND, V25, P261, DOI 10.1097/00126334-200011010-00009
   Caselli D, 2000, J CLIN ONCOL, V18, P3854, DOI 10.1200/JCO.2000.18.22.3854
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151
   CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1
   Dagan T, 2002, MITOCHONDRION, V1, P397, DOI 10.1016/S1567-7249(02)00003-X
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Ewings EL, 2000, J ACQ IMMUN DEF SYND, V24, P100
   Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200
   Gérard Y, 2000, AIDS, V14, P2723
   Gerschenson M, 2000, AIDS RES HUM RETROV, V16, P635, DOI 10.1089/088922200308864
   Gerschenson M, 2004, AIDS RES HUM RETROV, V20, P91, DOI 10.1089/088922204322749530
   Glantz S, 1997, PRIMER BIOSTATISTICS, V0, P0
   Hanson IC, 1999, J ACQ IMMUN DEF SYND, V20, P463, DOI 10.1097/00042560-199904150-00008
   Hollander M, 1973, NONPARAMETRIC STATISTICAL METHODS, V0, P0
   LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lipshultz SE, 2000, NEW ENGL J MED, V343, P759, DOI 10.1056/NEJM200009143431102
   Meng QX, 2000, P NATL ACAD SCI USA, V97, P12667, DOI 10.1073/pnas.220203197
   MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607
   Mofenson LM, 2002, J ACQ IMMUN DEF SYND, V30, P200, DOI 10.1097/00042560-200206010-00010
   Mofenson LM, 2000, PEDIATRICS, V106, P0, DOI 10.1542/peds.106.6.e88
   Newschaffer CJ, 2000, J ACQ IMMUN DEF SYND, V24, P249
   Olivero OA, 2002, J ACQ IMMUN DEF SYND, V29, P323
   Olivero OA, 1999, AIDS, V13, P919, DOI 10.1097/00002030-199905280-00007
   Pennell CE, 1999, AUST NZ J OBSTET GYN, V39, P227, DOI 10.1111/j.1479-828X.1999.tb03379.x
   Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010
   Shiramizu B, 2003, JAIDS-J ACQ IMM DEF, V32, P370, DOI 10.1097/00126334-200304010-00004
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   TOMELLERI G, 1992, ITAL J NEUROL SCI, V13, P723, DOI 10.1007/BF02229156
   Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159
   Veal GJ, 1996, AIDS, V10, P546, DOI 10.1097/00002030-199605000-00016
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117, DOI 10.1097/00042560-200202010-00002
   Walker VE, 2001, ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, V37, P77
   *WHO, 1900, V76, V0, P1
NR 44
TC 69
Z9 78
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD APR 30
PY 2004
VL 18
IS 7
BP 1013
EP 1021
DI 10.1097/00002030-200404300-00009
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 821OG
UT WOS:000221470100010
PM 15096804
DA 2024-11-01
ER

PT J
AU Carrozzo, R
   Rizza, T
   Lucioli, S
   Pierini, R
   Bertini, E
   Santorelli, F
AF Carrozzo, R
   Rizza, T
   Lucioli, S
   Pierini, R
   Bertini, E
   Santorelli, F
TI A mitochondrial ATPase 6 mutation is associated with Leigh syndrome in a family and affects proton flow and adenosine triphosphate output when modeled in <i>Escherichia coli</i>
SO ACTA PAEDIATRICA
LA English
DT Article; Proceedings Paper
DE ATPase 6; Escherichia coli; Leigh syndrome; mtDNA
ID atp synthase; mtdna
AB A multidisciplinary strategy was used to identify the molecular defect in a family with Leigh syndrome (LS). The prooopositus presented severe developmental delay, all ataxic-spastic gait and seizures. She died at 3.5 y of age front cardiorespiratory arrest. Postmortem examination disclosed pathological features typical of LS. A 12-y-old sister is affected with the same disease. Respiratory chain enzyme complex activities in skeletal muscle biopsy were normal. Adenosine triphosphate (ATP) synthesis during oxidative phosphorylation in skin fibroblasts mitochondria showed a severely hampered ATP production. Mitochondrial DNA sequencing revealed a new mutation in the ATPase 6 gene (T9176G). Site-directed mutagenesis in Escherichia coli strains was used to measure H+ pumping and ATP synthesis. Results were comparable to findings obtained in human cells. These data corroborate the use of E. coli strains as it feasible animal, model for functional studies in pathogenic mutations of the ATPase 6 gene.
C1 Osped Pediat Bambino Gesu, IRCCS, Dept Mol Med, I-00165 Rome, Italy.
   Osped Pediat Bambino Gesu, IRCCS, Dept Neurol, I-00165 Rome, Italy.
C3 IRCCS Bambino Gesu; IRCCS Bambino Gesu
RP Osped Pediat Bambino Gesu, IRCCS, Dept Mol Med, Piazza S Onofrio 4, I-00165 Rome, Italy.
EM fms3@na.flashnet.it
CR Capaldi RA, 2000, J EXP BIOL, V203, P29
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   DiMauro S, 1996, ANN NEUROL, V40, P5, DOI 10.1002/ana.410400104
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   HARTZOG PE, 1993, J BIOL CHEM, V268, P12250
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198
   VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347
NR 8
TC 11
Z9 12
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0803-5253
EI 1651-2227
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD MAY 15
PY 2004
VL 93
IS 
BP 65
EP 67
DI 10.0180/08035320310021309
PG 3
WC Pediatrics
SC Pediatrics
GA 819ZO
UT WOS:000221355600020
PM 15176724
DA 2024-11-01
ER

PT J
AU Sokolova, VA
   Kustova, ME
   Arbuzova, NI
   Sorokin, AV
   Moskaliova, OS
   Bass, MG
   Vasilyev, VB
AF Sokolova, VA
   Kustova, ME
   Arbuzova, NI
   Sorokin, AV
   Moskaliova, OS
   Bass, MG
   Vasilyev, VB
TI Obtaining mice that carry human mitochondrial DNA transmitted to the progeny
SO MOLECULAR REPRODUCTION AND DEVELOPMENT
LA English
DT Article
DE human mtDNA; mtDNA transfer; mitochondria microinjection; transgenic mice; maternal inheritance
ID transmitochondrial mice; maternal inheritance; mouse mtdna; cells; gene; microinjection; sequence; oocytes; zygotes; genome
AB To study human diseases associated with mutations in mitochondrial DNA one needs an animal model in which the distribution of abnormal mtDNA and its impact on the phenotype might be followed. We isolated human mitochondria from HepG2 cell culture and microinjected them into murine zygotes, upon which those were transplanted to the pseudopregnant mice. PCR with species-specific primers allowed detecting human mtDNA in the tissues of 7-13-day embryos. No serious alterations in the development of transmitochondrial embryos were noticed. Among various organs/tissues of the 13-day embryos, human mtDNA was detected only in the heart, skeletal muscles, and stomach, which is in line with its uneven distribution among the blastomeres of an early mouse embryo that we described previously. In four recipient females, the microinjected zygotes were allowed to develop to term, the four neonate males of their joint litter were sacrificed, and in three of them human mtDNA was detected in the heart, skeletal muscles, stomach, brain, testes, and bladder. Six females of that joint litter were grown and mated to intact males. In the progeny (F-1) of one of the females two mice were carrying human mtDNA in the heart, skeletal muscles, stomach, brain, lungs, uterus, ovaries, and kidneys. The study confirms the possibility to obtain transmitochondrial mice carrying human mtDNA that is transmitted to the animals of the next generation. Our results also indicate that among the organs to which human mtDNA is distributed some are more likely to receive it than others. (C) 2004 Wiley-Liss, Inc.
C1 Inst Expt Med, Dept Mol Genet, St Petersburg 197376, Russia.
C3 Institute of Experimental Medicine
RP Inst Expt Med, Dept Mol Genet, 12 Pavlov Str, St Petersburg 197376, Russia.
EM vadim@biomed.spb.su
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759
   BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7
   Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   Do JT, 2002, BIOL REPROD, V67, P555, DOI 10.1095/biolreprod67.2.555
   EBERT K M, 1989, MOLECULAR REPRODUCTION AND DEVELOPMENT, V1, P156, DOI 10.1002/mrd.1080010303
   HECHT NB, 1984, DEV BIOL, V102, P452, DOI 10.1016/0012-1606(84)90210-0
   Hiendleder S, 2003, REPROD DOMEST ANIM, V38, P290, DOI 10.1046/j.1439-0531.2003.00448.x
   Hobbs Helen H, 1992, HUMAN MUTATION, V1, P445, DOI 10.1002/humu.1380010602
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   MANIATIS T, 1982, MOL CLONING LAB MANU, V2, P9
   Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403
   Meirelles FV, 1997, GENETICS, V145, P445
   Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345
   Nagao Yasumitsu, 1998, JOURNAL OF REPRODUCTION AND DEVELOPMENT, V44, P129, DOI 10.1262/jrd.44.129
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   QUINN P, 1982, J REPROD FERTIL, V66, P161
   Rinaudo P, 1999, FERTIL STERIL, V71, P912, DOI 10.1016/S0015-0282(99)00089-8
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   Shoubridge EA, 2000, NAT GENET, V26, P132, DOI 10.1038/79832
   SMITH LC, 1993, J REPROD FERTIL, V0, P31
   TORRONI A, 1992, GENETICS, V130, P153
   Vasilyev VB, 1999, ZYGOTE, V7, P279, DOI 10.1017/S0967199499000672
   Yamaoka M, 2000, GENETICS, V155, P301
NR 34
TC 15
Z9 22
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1040-452X
EI 1098-2795
J9 MOL REPROD DEV
JI Mol. Reprod. Dev.
PD JUL 15
PY 2004
VL 68
IS 3
BP 299
EP 307
DI 10.1002/mrd.20075
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology
SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology; Reproductive Biology
GA 821WO
UT WOS:000221494000005
PM 15112322
DA 2024-11-01
ER

PT J
AU Pak, JW
   Aiken, JM
AF Pak, JW
   Aiken, JM
TI Low levels of mtDNA deletion mutations in ETS normal fibers from aged rats
SO STRATEGIES FOR ENGINEERED NEGLIGIBLE SENESCENCE: WHY GENUINE CONTROL OF AGING MAY BE FORESEEABLE
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; deletion mutations; ETS abnormality; fiber type; quantitative PCR
ID muscle-fibers; wild-type; abnormality; sarcopenia; disease
AB The objectives were (1) to determine whether deletion mutations occur in phenotypically normal type I and type 11 fibers, (2) to quantify the levels of both deletion mutant and wild-type (wt) mtDNA (nondeletion) within single normal fibers containing mutant mtDNA, and (3) to quantify the amount of wt mtDNA in genotypically and phenotypically normal type I and type 11 fibers. Deletion mutations in normal fibers are not restricted to specific fiber types, although clonal accumulation of mtDNA deletion mutations and subsequent ETS abnormalities occur exclusively in type 11 fibers.
C1 Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.
EM aiken@svm.vetmed.wisc.edu
CR Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   Mueller-Hoecker J, 1993, VIRCHOWS ARCHIV A PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, V422, P7
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
NR 9
TC 8
Z9 8
U1 0
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
EI 
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PD JUN 15
PY 2004
VL 1019
IS 
BP 289
EP 293
DI 10.1196/annals.1297.049
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Geriatrics & Gerontology; Multidisciplinary Sciences
SC Biochemistry & Molecular Biology; Cell Biology; Geriatrics & Gerontology; Science & Technology - Other Topics
GA BAN77
UT WOS:000223002700049
PM 15247031
DA 2024-11-01
ER

PT J
AU Pye, D
   Watt, DJ
   Walker, C
   Lightowlers, RN
   Turnbull, DM
AF Pye, D
   Watt, DJ
   Walker, C
   Lightowlers, RN
   Turnbull, DM
TI Identification of the RAG-1 as a suitable mouse model for mitochondrial DNA disease
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE recombinase activating gene-1; severe combined immunodeficient mouse; muscle fibres
ID myoblast transplantation; scid mice; muscle-fibers; expression
AB Previous studies have shown that transfer of human myoblasts carrying a mitochondrial DNA mutation into muscles of the severe combined immunodeficient mouse may provide an important animal model for mitochondrial myopathy. However, a major drawback of this mouse is its extreme sensitivity to ionising radiation, a pre-treatment which enhances the efficiency of myoblast transfer success. We implanted human myoblasts into the tibialis anterior muscles of another immunodeficient mouse, mutated in the recombinase activating gene-1 (RAG-1), to determine if this mouse could be an alternative to the severe combined immunodeficient for our mitochondrial myoblast transfer model. We also examined several different methods of muscle degeneration prior to myoblast transfer to determine which method resulted in the greatest amount of human tissue in implanted muscles. Our results show that the RAG-1 mouse displayed no sensitivity to the irradiation process compared to the high sensitivity in the severe combined immunodeficient mouse which resulted in early termination of the study. We also show that degeneration of host muscles by the myotoxin barium chloride (BaCl2) resulted in the greatest amount of regenerating human muscle fibres in both the severe combined immunodeficient and RAG-1 mice. In addition, the maximum amount of human fibres observed in transplanted muscles was similar in each mouse strain. The average number of fibres throughout muscles was significantly greater in severe combined immunodeficient mice injured by BaCl2, but was similar between all other muscle groups. This study suggests that the RAG-1 mouse is a suitable host for the mitochondrial myoblast transfer model and may also prove valuable for other myoblast transfer models such as muscular dystrophy. (C) 2004 Elsevier B.V. All rights reserved.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Brighton & Sussex Med Sch, Brighton BN1 9PX, E Sussex, England.
   Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
C3 Newcastle University - UK; University of Brighton; University of Sussex; Newcastle General Hospital
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
CR Clark KM, 1998, J CLIN INVEST, V102, P2090, DOI 10.1172/JCI944
   Cooper RN, 2001, HUM GENE THER, V12, P823, DOI 10.1089/104303401750148784
   Figarella-Branger D, 1999, J NEUROL SCI, V170, P149, DOI 10.1016/S0022-510X(99)00284-1
   Guigal N, 2002, J BIOL CHEM, V277, P47407, DOI 10.1074/jbc.M208048200
   HUARD J, 1994, J CLIN INVEST, V93, P586, DOI 10.1172/JCI117011
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Leriche-Guérin K, 2002, NEUROMUSCULAR DISORD, V12, P167, DOI 10.1016/S0960-8966(01)00254-1
   MCARDLE A, 1994, J APPL PHYSIOL, V76, P1274, DOI 10.1152/jappl.1994.76.3.1274
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Skuk D, 1999, J NEUROPATH EXP NEUR, V58, P921, DOI 10.1097/00005072-199909000-00003
   Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1
   Wells DJ, 1998, J PHARM SCI, V87, P763, DOI 10.1021/js970391o
   Wernig A, 2000, J PHYSIOL-LONDON, V522, P333, DOI 10.1111/j.1469-7793.2000.t01-2-00333.x
NR 15
TC 8
Z9 11
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY 15
PY 2004
VL 14
IS 5
BP 329
EP 336
DI 10.1016/j.nmd.2004.02.010
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 818YP
UT WOS:000221280700008
PM 15099593
DA 2024-11-01
ER

PT J
AU Strazielle, C
   Dumont, M
   Fukuchi, K
   Lalonde, R
AF Strazielle, C
   Dumont, M
   Fukuchi, K
   Lalonde, R
TI Transgenic mice expressing the human C99 terminal fragment of βAPP:: effects on cytochrome oxidase activity in skeletal muscle and brain
SO JOURNAL OF CHEMICAL NEUROANATOMY
LA English
DT Article
DE amyloid-beta; beta-amyloid precursor protein; inclusion body myopathy; regional brain; metabolism
ID amyloid precursor protein; inclusion-body myositis; mitochondrial-dna deletions; alzheimers-disease; intracellular accumulation; abnormality; hereditary; system; hippocampus; metabolism
AB In order to furnish a combined model of relevance to human inclusion-body myopathy and Alzheimer's disease, transgenic mice expressing human betaAPP-C99 in skeletal muscle and brain under the control of the cytomegalovirus/beta-actin promoter were produced (Tg13592). These transgenic mice develop Abeta deposits in muscles but not in brain. Cell metabolic activity was analyzed in brain regions and muscle by cytochrome oxidase (CO) histochemistry, the terminal enzyme of the electron transport chain. By comparison to age-matched controls of the C57BL/6 strain, CO activity was selectively increased in dark skeletal muscle fibers of Tg13592 mice. In addition, only increases in CO activity were obtained in those brain regions where a significant difference appeared. The CO activity of Tg13592 mice was elevated in several thalamic nuclei, including laterodorsal, ventromedial, and midline as well as submedial, intralaminar, and reticular. In contrast, the groups did,not differ in most cortical regions, except for prefrontal, secondary motor, and auditory cortices, and in most brainstem regions, except for cerebellar (fastigial and interpositus) nuclei and related areas (red and lateral vestibular nuclei). No variation in cell density and surface area appeared in conjunction with these enzymatic alterations. The overproduction of betaAPP-C99 fragments in brain without (amyloidosis did not appear to affect the metabolic activity of structures particularly vulnerable in Alzheimer's disease. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Henri Poincare, Lab Pathol Mol & Cellulair Nutr, EMI 0014, INSERM, Nancy 1, France.
   Univ Henri Poincare, Serv Microscopie Electron, Fac Med, Nancy 1, France.
   Univ Rouen, Fac Med & Pharm, INSERM, EMI 9906,IFRMP23, F-76183 Rouen, France.
   Univ Alabama Birmingham, Sch Med & Dent, Dept Genet, Birmingham, AL 35294 USA.
   CHUM St Luc, Ctr Rech Neurosci, Montreal, PQ H2X 3J4, Canada.
C3 Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Universite de Rouen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Alabama System; University of Alabama Birmingham; Universite de Montreal
RP Univ Henri Poincare, Lab Pathol Mol & Cellulair Nutr, EMI 0014, INSERM, Nancy 1, France.
EM straziel@persmail.uhp-nancy.fr
FU NINDS NIH HHS [R01 NS43947] Funding Source: Medline
CR Amaral David G, 1995, P443, V0, P0
   ASKANAS V, 1994, CURR OPIN NEUROL, V7, P448, DOI 10.1097/00019052-199410000-00013
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   Askanas V, 1998, ANN NY ACAD SCI, V841, P28, DOI 10.1111/j.1749-6632.1998.tb10908.x
   Askanas Valerie, 1998, CURRENT OPINION IN RHEUMATOLOGY, V10, P530, DOI 10.1097/00002281-199811000-00005
   Baloyannis SJ, 2000, ACTA OTO-LARYNGOL, V120, P247
   Braak H, 1999, CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM, V0, P497
   Butcher Larry L, 1995, P1003, V0, P0
   COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589
   de la Torre JC, 2000, NEUROBIOL AGING, V21, P331, DOI 10.1016/S0197-4580(00)00111-1
   FERRANDIZ ML, 1994, BRAIN RES, V644, P335, DOI 10.1016/0006-8993(94)91699-3
   Franklin KBJ, 2013, PAXINOS AND FRANKLINS THE MOUSE BRAIN IN STEREOTAXIC COORDINATES, V0, P0
   FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N
   Fukuchi K, 1996, AM J PATHOL, V149, P219
   FUKUCHI K, 1992, MOL BRAIN RES, V16, P37, DOI 10.1016/0169-328X(92)90191-D
   Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9
   FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101
   GONZALEZLIMA F, 1994, BRAIN RES, V660, P34, DOI 10.1016/0006-8993(94)90836-2
   Hermanns B, 2000, J NEUROL SCI, V179, P92, DOI 10.1016/S0022-510X(00)00395-6
   HESS HH, 1953, J BIOL CHEM, V204, P295
   Ibáñez V, 1998, NEUROLOGY, V50, P1585, DOI 10.1212/WNL.50.6.1585
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   Johnson KA, 2000, NEUROBIOL AGING, V21, P289, DOI 10.1016/S0197-4580(00)00137-8
   KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857
   Kish SJ, 1999, J NEUROCHEM, V72, P700, DOI 10.1046/j.1471-4159.1999.0720700.x
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Lalonde R, 2002, EXP GERONTOL, V37, P1401, DOI 10.1016/S0531-5565(02)00123-7
   Lalonde R, 1999, TEC BEHAV N, V0, P627
   Li QX, 1999, J NEUROCHEM, V72, P2479, DOI 10.1046/j.1471-4159.1999.0722479.x
   Liu QL, 2003, J APPL PHYSIOL, V95, P2285, DOI 10.1152/japplphysiol.00638.2003
   Lodi R, 1998, BRAIN, V121, P2119, DOI 10.1093/brain/121.11.2119
   McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Nagy Z, 1999, ACTA NEUROPATHOL, V97, P346, DOI 10.1007/s004010050997
   Nair HP, 1999, DEV BRAIN RES, V118, P197, DOI 10.1016/S0165-3806(99)00149-2
   NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   PETTEGREW JW, 1994, NEUROBIOL AGING, V15, P117, DOI 10.1016/0197-4580(94)90152-X
   Price Joseph L, 1995, P629, V0, P0
   Rapoport SI, 1999, ANN NY ACAD SCI, V893, P138, DOI 10.1111/j.1749-6632.1999.tb07823.x
   READER TA, 1999, NEUROMETH, V33, P1
   Reiman EM, 2000, NEUROREPORT, V11, P987, DOI 10.1097/00001756-200004070-00018
   Rubertone Joseph A, 1995, P773, V0, P0
   Ruigrok Tom JH, 1995, P277, V0, P0
   SANDHU FA, 1991, J BIOL CHEM, V266, P21331
   Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0
   Selkoe DJ, 1999, NATURE, V399, PA23, DOI 10.1038/399a023
   Sjöbeck M, 2001, DEMENT GERIATR COGN, V12, P211, DOI 10.1159/000051260
   Strazielle C, 2003, NEUROSCIENCE, V118, P1151, DOI 10.1016/S0306-4522(03)00037-X
   Strazielle C, 1998, EXP BRAIN RES, V121, P35, DOI 10.1007/s002210050434
   Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001
   WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5
   WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3
   Zhang CY, 1999, J NEUROCYTOL, V28, P525, DOI 10.1023/A:1007053204929
NR 54
TC 6
Z9 7
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0891-0618
EI 1873-6300
J9 J CHEM NEUROANAT
JI J. Chem. Neuroanat.
PD JUL 15
PY 2004
VL 27
IS 4
BP 237
EP 246
DI 10.1016/j.jchemneu.2004.03.009
PG 10
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 842TE
UT WOS:000223026300002
PM 15261330
DA 2024-11-01
ER

PT J
AU Oshima, Y
   Kuroda, Y
   Kunishige, M
   Matsumoto, T
   Mitsui, T
AF Oshima, Y
   Kuroda, Y
   Kunishige, M
   Matsumoto, T
   Mitsui, T
TI Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells
SO MUSCLE & NERVE
LA English
DT Article
DE apoptosis; corticosteroid myopathy; dexamethasone; mitochondrial membrane potentials; reactive oxygen species; superoxide dismutase
ID skeletal-muscle; steroid myopathy; dna deletions; apoptosis; rat; accumulation; differentiation; proliferation; respiration; expression
AB We analyzed the effects of corticosteroid on mitochondrial membrane potentials (DeltaPsi(m)), generation of reactive oxygen species (ROS), and apoptosis in a human rhabdomyosarcoma cell line, RD, and a dopaminergic neuroblastoma cell line, SH-SY5Y. The cell lines were cultured in the presence or absence of dexamethasone and superoxide dismutase (SOD) for up to 1 week. Dexamethasone treatment increased DeltaPsi(m), ROS generation, and apoptosis in proliferating RD cells. Treatment with SOD attenuated ROS generation and apoptosis, but not DeltaPsi(m) The increase in DeltaPsi(m) seemed to be the primary effect of dexamethasone on proliferating RD cells, which is probably mediated by mitochondrial transcription. In differentiated RD cells, but not differentiated SH-SY5Y cells, dexamethasone treatment showed a delayed effect of interfering with the DeltaPsi(m) and increasing ROS generation and apoptosis. Since these changes disappeared in the presence of SOD, dexamethasone primarily induced ROS generation, resulting in apoptosis. We speculate that this mechanism provides the basis of a pathophysiological model of corticosteroid myopathy.
C1 Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan.
C3 Tokushima University
RP Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM tmitsui@clin.med.tokushima-u.ac.jp
CR Azuma H, 1997, BLOOD, V89, P183, DOI 10.1182/blood.V89.1.183.183_183_190
   Bravard A, 1999, FREE RADICAL BIO MED, V26, P1027, DOI 10.1016/S0891-5849(98)00299-8
   BRAVARD A, 1994, INT J CANCER, V59, P843, DOI 10.1002/ijc.2910590622
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087
   ENGEL AG, 1966, MAYO CLIN PROC, V41, P785
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X
   KAMINSKI HJ, 1994, MYOLOGY, V0, P1726
   MALANDRINI A, 1995, EUR NEUROL, V35, P182, DOI 10.1159/000117123
   MAROLDA M, 1991, ITAL J NEUROL SCI, V12, P409
   MCINTOSH MK, 1992, COMPR BIOCH PHYSL A, V104, P147
   MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Mitsui T, 2002, J NEUROL, V249, P1004, DOI 10.1007/s00415-002-0774-5
   Mitsui T, 2002, ACTA NEUROPATHOL, V104, P260, DOI 10.1007/s00401-002-0553-5
   MITSUI T, 1996, J NEUROL SCI, V136, P111
   Murthy CRK, 2001, J NEUROSCI RES, V66, P282, DOI 10.1002/jnr.1222
   Poluha W, 1996, MOL CELL BIOL, V16, P1335
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769
   TRITSCHLER HJ, 1993, NEUROLOGY, V43, P280, DOI 10.1212/WNL.43.2.280
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   VANITALLIE CM, 1992, ENDOCRINOLOGY, V130, P567, DOI 10.1210/en.130.2.567
   VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55
   VIGNOS PJ, 1973, J LAB CLIN MED, V81, P365
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Yowe DL, 1998, GENE, V209, P23, DOI 10.1016/S0378-1119(97)00628-8
   Zhang CF, 1997, BIOCHEM BIOPH RES CO, V230, P630, DOI 10.1006/bbrc.1996.6020
NR 31
TC 44
Z9 46
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL 15
PY 2004
VL 30
IS 1
BP 49
EP 54
DI 10.1002/mus.20036
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 835NW
UT WOS:000222491500006
PM 15221878
DA 2024-11-01
ER

PT J
AU Moslemi, AR
   Lindberg, C
   Toft, J
   Holme, E
   Kollberg, G
   Oldfors, A
AF Moslemi, AR
   Lindberg, C
   Toft, J
   Holme, E
   Kollberg, G
   Oldfors, A
TI A novel mutation in the mitochondrial tRNA<SUP>Phe</SUP> gene associated with mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE myopathy; cytochrome c oxidase deficiency; tRNA; mutation; mtDNA
ID point mutation; muscle disease; dna; encephalomyopathy; sequence; fibers
AB We report a novel heteroplasmic T-->C mutation at nt position 582 within the mitochondrial tRNA(Phe) gene of a 70-year-old woman with mitochondrial myopathy. No other family members were affected, suggesting that our patient was a sporadic case. The muscle showed frequent ragged red fibers and 43% cytochrome c oxidase deficient fibers. The mutation alters a conserved base pairing in the aminoacyl acceptor stem. The mutation load was 70% in muscle homogenate and varied from 0 to 95% in individual muscle fiber segments. Cytochrome c oxidase-negative fibers showed significantly higher levels of mutated mtDNA (>75%) than Cytochrome c oxidase-positive fibers (<55%). This mutation adds to the previously described four pathogenic mutations in the tRNA(Phe) gene. (C) 2003 Elsevier B.V. All rights reserved.
C1 Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
   S Elfsborg Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@path.gu.se
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   *EM U, 2002, MIT HUM MIT GEN DAT, V0, P0
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Moslemi AR, 2000, CARDIOLOGY, V94, P68, DOI 10.1159/000007049
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
NR 20
TC 16
Z9 18
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN 15
PY 2004
VL 14
IS 1
BP 46
EP 50
DI 10.1016/S0960-8966(03)00168-8
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 756CL
UT WOS:000187448200007
PM 14659412
DA 2024-11-01
ER

PT J
AU Martin-Kleiner, I
   Pape-Medvidovic, E
   Pavlic-Renar, I
   Metelko, Z
   Kusec, R
   Gabrilovac, J
   Boranic, M
AF Martin-Kleiner, I
   Pape-Medvidovic, E
   Pavlic-Renar, I
   Metelko, Z
   Kusec, R
   Gabrilovac, J
   Boranic, M
TI A pilot study of mitochondrial DNA point mutation A3243G in a sample of Croatian patients having type 2 diabetes mellitus associated with maternal inheritance
SO ACTA DIABETOLOGICA
LA English
DT Article
DE diabetes type 2; MELAS syndrome; mito-chondrial DNA; mutation A3243G
ID clinical-features; deafness; subtype; insulin; phenotype; genotype; genetics; blood
AB In this work, patients having type 2 diabetes mellitus and diabetic mothers were tested for the presence of mitochondrial DNA point mutation A3243G. This mutation is associated with the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes), diabetes and deafness. Twenty-two diabetic persons were screened. DNA was isolated from peripheral blood lymphocytes and from swabs of oral mucosa. The mitochondrial DNA point mutation A3243G was detected using PCR-RFLP test. The mutation was detected in oral mucosal DNA of two patients (but not from lymphocyte DNA). One patient was a man with hearing and visual impairments and proteinuria: the other was a woman having proteinuria but no hearing impairment. The mutation was not detectable in oral mucosal DNA from the control persons: 20 diabetic patients having diabetic fathers and 22 healthy, nondiabetic volunteers. The incidence of mitochondrial DNA point mutation A3243G in this study of Croatian diabetic patients is in line with data in the literature.
C1 Rudjer Boskovic Inst, Div Mol Med, HR-10002 Zagreb, Croatia.
   Univ Zagreb, Vuk Vrhovac Univ Clin, Zagreb, Croatia.
   Univ Zagreb, Univ Hosp Merkur, Inst Clin Chem, Dept Internal Med, Zagreb, Croatia.
C3 Rudjer Boskovic Institute; University of Zagreb; University of Zagreb
RP Rudjer Boskovic Inst, Div Mol Med, POB 180, HR-10002 Zagreb, Croatia.
EM kleiner@irb.hr
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U
   CHINNERY PF, 1999, LANCET S1, V354, P17
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DILENA BA, 1983, CLIN CHEM, V29, P1533
   FEINGENBAUM A, 1996, AM J MED GENET, V62, P404
   Fischel-Ghodsian N, 1998, P SOC EXP BIOL MED, V218, P1
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   Iwase M, 2001, DIABETES RES CLIN PR, V54, P215, DOI 10.1016/S0168-8227(01)00295-9
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kiechle FL, 1999, ANN CLIN LAB SCI, V29, P59
   Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7
   LIVESEY JH, 1980, CLIN BIOCHEM, V13, P151, DOI 10.1016/S0009-9120(80)91040-1
   Maassen JA, 1996, DIABETOLOGIA, V39, P375
   Maassen JA, 1997, HORM METAB RES, V29, P50, DOI 10.1055/s-2007-978984
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mravak-Stipetic M, 1998, J ORAL PATHOL MED, V27, P1, DOI 10.1111/j.1600-0714.1998.tb02081.x
   Perucca-Lostanlen D, 2000, BIOCHEM BIOPH RES CO, V277, P771, DOI 10.1006/bbrc.2000.3751
   RENDELL M, 1983, ACTA DIABETOL LAT, V20, P105, DOI 10.1007/BF02624911
   SHIMOJO N, 1989, CLIN CHEM, V35, P1992
   Tawata M, 2000, DIABETES, V49, P1269, DOI 10.2337/diabetes.49.7.1269
   THART LM, 1994, DIABETOLOGIA, V37, P1169
   Trinder P, 1969, JOURNAL OF CLINICAL PATHOLOGY, V22, P158, DOI 10.1136/jcp.22.2.158
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Vucic M, 1999, CLINICAL CHEMISTRY AND LABORATORY MEDICINE, V37, P0
   Zambelli A, 1999, CLIN BIOCHEM, V32, P81, DOI 10.1016/S0009-9120(98)00102-7
   Zeviani M, 1997, MOL HUM REPROD, V3, P133, DOI 10.1093/molehr/3.2.133
NR 28
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0940-5429
EI 1432-5233
J9 ACTA DIABETOL
JI Acta Diabetol.
PD DEC 15
PY 2004
VL 41
IS 4
BP 179
EP 184
DI 10.1007/s00592-004-0163-x
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 886CU
UT WOS:000226205300007
PM 15660201
DA 2024-11-01
ER

PT J
AU Kirino, Y
   Yasukawa, T
   Ohta, S
   Akira, S
   Ishihara, K
   Watanabe, K
   Suzuki, T
AF Kirino, Y
   Yasukawa, T
   Ohta, S
   Akira, S
   Ishihara, K
   Watanabe, K
   Suzuki, T
TI Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
ID stroke-like episodes; transfer rnaleu(uur) gene; cells lacking mtdna; lactic-acidosis; protein-synthesis; point mutation; transcription termination; bovine mitochondria; elongation-factors; melas mutation
AB Point mutations in the mitochondrial (mt) tRNA(Leu(UUR)) gene are responsible for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), a subgroup of mitochondrial encephalomyopathic diseases. We previously showed that mt tRNA(Leu(UUR)) with an A3243G or T3271C mutation derived from patients with MELAS are deficient in a normal taurine-containing modification (taum(5)U; 5-taurinomethyluridine) at the anticodon wobble position. To examine decoding disorder of the mutant tRNA due to the wobble modification deficiency independent of the pathogenic point mutation itself, we used a molecular surgery technique to construct an mt tRNA(Leu(UUR)) molecule lacking the taurine modification but without the pathogenic mutation. This "operated" mt tRNA(Leu(UUR)) without the taurine modification showed severely reduced UUG translation but no decrease in UUA translation. We thus concluded that the UUG codon-specific translational defect of the mutant mt tRNAs(Leu(UUR)) is the primary cause of MELAS at the molecular level. This result could explain the complex 1 deficiency observed clinically in MELAS.
C1 Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Bunkyo Ku, Tokyo 1138656, Japan.
   Inst Dev & Aging Sci, Grad Sch Med, Nippon Med Sch, Dept Biochem & Cell Biol, Kanagawa 2118533, Japan.
   Nippon Med Coll, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138603, Japan.
C3 University of Tokyo; University of Tokyo; Nippon Medical School; Nippon Medical School
RP Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM ts@chembio.t.u-tokyo.ac.jp
CR Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529
   Bjork Glenn R, 1995, P165, V0, P0
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GARDNER RS, 1962, P NATL ACAD SCI USA, V48, P2087, DOI 10.1073/pnas.48.12.2087
   GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   JOHNS DR, 1991, LANCET, V337, P927, DOI 10.1016/0140-6736(91)90272-Q
   Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066
   KEITH G, 1974, BIOCHEMISTRY-US, V13, P3601, DOI 10.1021/bi00714a031
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   KOGA Y, 1988, ANN NEUROL, V24, P749, DOI 10.1002/ana.410240609
   KUMAZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1090, P167, DOI 10.1016/0167-4781(91)90097-6
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0
   Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200
   Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3
   RAVEL JM, 1971, METHODS ENZYMOLOGY C, V20, P306
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105
   SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122
   Takai K, 2003, NUCLEIC ACIDS RES, V31, P6383, DOI 10.1093/nar/gkg839
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2002, MITOCHONDRION, V2, P129, DOI 10.1016/S1567-7249(02)00033-8
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   YOKOGAWA T, 1989, NUCLEIC ACIDS RES, V17, P2623, DOI 10.1093/nar/17.7.2623
   Yokoyama Shigeyuki, 1995, P207, V0, P0
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 52
TC 220
Z9 245
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 19
PY 2004
VL 101
IS 42
BP 15070
EP 15075
DI 10.1073/pnas.0405173101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 865FT
UT WOS:000224688700019
PM 15477592
DA 2024-11-01
ER

PT J
AU Spinazzola, A
   Carrara, F
   Mora, M
   Zeviani, M
AF Spinazzola, A
   Carrara, F
   Mora, M
   Zeviani, M
TI Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with the 5698G→A mitochondrial DNA mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE chronic progressive external ophthalmoplegia; mitochondrial myopathy; mtDNA; point mutation; tRNA
AB We describe a second patient carrying the 5698G --> A transition in the mitochondrial DNA gene encoding tRNA(Asn) who has an apparently isolated mitochondrial myopathy with chronic progressive external opthalmoplegia. A muscle biopsy showed the presence of ragged-red and COX-negative fibres. Analysis of the mutation load on single muscle fibres showed significant segregation of the 569SG --> A with COX-depleted fibres. These results indicate that the 5698G --> A is pathogenic. (C) 2004 Elsevier B.V. All rights reserved.
C1 Natl Neurol Inst C Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, I-21033 Milan, Italy.
   Natl Neurol Inst C Besta, Unit Neuromuscular Disorders, I-21033 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Natl Neurol Inst C Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Via Temolo 4, I-21033 Milan, Italy.
EM zeviani@tin.it
FU Telethon [GGP030039] Funding Source: Medline
CR DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
NR 5
TC 11
Z9 11
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC 15
PY 2004
VL 14
IS 12
BP 815
EP 817
DI 10.1016/j.nmd.2004.09.002
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 881CR
UT WOS:000225841500007
PM 15564038
DA 2024-11-01
ER

PT J
AU Lorenc, A
   Bryk, J
   Bartnik, E
AF Lorenc, A
   Bryk, J
   Bartnik, E
TI Mitochondrial DNA in tumors
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article; Proceedings Paper
DE cancer; mitochondria; mtDNA
ID red fibers merrf; complex-ii gene; mtdna mutations; colorectal tumors; protein-synthesis; point mutation; high-frequency; human-cells; cancer; myopathy
AB Mitochondria, cellular powerhouses, play a central role in apoptosis. In addition, they are suspected to contribute to aging. There is also increasing evidence that abnormalities in mitochondrial function help cancer development. Changes in mitochondrial transcription and oxidative phosphorylation pathways are observed in many types of cancer. Somatic mutations and quantitative changes in mitochondrial DNA were found in tumors, suggesting that alterations in mitochondrial DNA and the resulting respiratory deficiency play a role in carcinogenesis. It was postulated they could be useful as cancer markers. Mitochondria with abnormal functions are suitable targets for anticancer drugs.
C1 Univ Warsaw, Dept Genet, PL-02106 Warsaw, Poland.
   Postgrad Sch Mol Med, Warsaw, Poland.
   Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland.
C3 University of Warsaw; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences
RP Univ Warsaw, Dept Genet, Pawinskiego 5A, PL-02106 Warsaw, Poland.
EM ebartnik@ibb.waw.pl
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carew Jennifer S, 2002, MOL CANCER, V1, P9, DOI 10.1186/1476-4598-1-9
   Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189
   CHESTER KA, 1990, J PATHOL, V162, P309, DOI 10.1002/path.1711620406
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Gimm O, 2000, CANCER RES, V60, P6822
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
   HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159
   HOLME E, 1993, AM J HUM GENET, V52, P551
   Jerónimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646
   JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V
   Jones JB, 2001, CANCER RES, V61, P1299
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Liu VWS, 2001, CANCER RES, V61, P5998
   Lorenc A, 2003, MITOCHONDRION, V3, P119, DOI 10.1016/S1567-7249(03)00106-5
   LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Máximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8
   McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   MORAIS R, 1994, CANCER RES, V54, P3889
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nomoto S, 2002, CLIN CANCER RES, V8, P481
   Parrella P, 2001, CANCER RES, V61, P7623
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Pulselli R, 1996, ANTICANCER RES, V16, P419
   Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015
   Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920
   SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056
   Takao M, 1996, J NEUROL SCI, V139, P111
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O, 1930, METABOLISM TUMOURS, V0, P0
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112
   Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537
NR 50
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1537-6516
EI 1537-6524
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD JAN-APR 15
PY 2004
VL 14
IS 1-2
BP 85
EP 90
DI 10.1080/15376520490257563
PG 6
WC Toxicology
SC Toxicology
GA 757FU
UT WOS:000187551000017
PM 20021129
DA 2024-11-01
ER

PT J
AU Korhonen, JA
   Pham, XH
   Pellegrini, M
   Falkenberg, M
AF Korhonen, JA
   Pham, XH
   Pellegrini, M
   Falkenberg, M
TI Reconstitution of a minimal mtDNA replisome <i>in vitro</i>
SO EMBO JOURNAL
LA English
DT Article
DE DNA polymerase gamma; mitochondrion; mtSSB; TWINKLE
ID human mitochondrial-dna; polymerase-gamma; binding protein; accessory subunit; helicase activity; crystal-structure; replication; strand; transcription; bacteriophage-t7
AB We here reconstitute a minimal mammalian mitochondrial DNA (mtDNA) replisome in vitro. The mtDNA polymerase (POLgamma) cannot use double-stranded DNA (dsDNA) as template for DNA synthesis. Similarly, the TWINKLE DNA helicase is unable to unwind longer stretches of dsDNA. In combination, POLgamma and TWINKLE form a processive replication machinery, which can use dsDNA as template to synthesize single-stranded DNA (ssDNA) molecules of about 2kb. The addition of the mitochondrial ssDNA-binding protein stimulates the reaction further, generating DNA products of about 16kb, the size of the mammalian mtDNA molecule. The observed DNA synthesis rate is 180 base pairs (bp)/min, corresponding closely to the previously calculated value of 270 bp/min for in vivo DNA replication. Our findings provide the first biochemical evidence that TWINKLE is the helicase at the mitochondrial DNA replication fork. Furthermore, mutations in TWINKLE and POLgamma cause autosomal dominant progressive external ophthalmoplegia (adPEO), a disorder associated with deletions in mitochondrial DNA. The functional interactions between TWINKLE and POLgamma thus explain why mutations in these two proteins cause an identical syndrome.
C1 Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.
C3 Karolinska Institutet
RP Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.
EM maria.falkenberg-gustafsson@mednut.ki.se
CR Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267
   Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181
   Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   CRUTE JJ, 1991, J BIOL CHEM, V266, P4484
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   ENGLER MJ, 1983, J BIOL CHEM, V258, P1165
   Falkenberg M, 1998, J BIOL CHEM, V273, P32154, DOI 10.1074/jbc.273.48.32154
   Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200
   Fernández-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6
   HUBER HE, 1987, J BIOL CHEM, V262, P16224
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.bi.63.070194.002523
   Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821
   MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195
   ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   TAPPER DP, 1981, J BIOL CHEM, V256, P5109
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481
NR 30
TC 300
Z9 353
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD JUN 16
PY 2004
VL 23
IS 12
BP 2423
EP 2429
DI 10.1038/sj.emboj.7600257
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 842WT
UT WOS:000223035900010
PM 15167897
DA 2024-11-01
ER

PT J
AU Saada-Reisch, A
AF Saada-Reisch, A
TI Deoxyribonucleoside kinases in mitochondrial DNA depletion
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA depletion; thymidine kinase 2; deoxyguanosine kinase; respiratory chain; myopathy; hepatocerebral; deoxyribonucleoside; deoxyribonucleotide
ID thymidine kinase; mtdna depletion; gene; mutations; myopathy; cell; replication; metabolism; expression; mechanism
AB Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a heterogeneous group of mitochondrial disorders, manifested by a decreased mtDNA copy number and respiratory chain dysfunction. Primary MDS are inherited autosomally and may affect a single organ or multiple tissues. Mutated mitochondrial deoxyribonucleoside kinases; deoxyguanosine kinase (dGK) and thymidine kinase 2 (TK2), were associated with the hepatocerebral and myopathic forms of MDS respectively. dGK and TK2 are key enzymes in the mitochondrial nucleotide salvage pathway, providing the mitochondria with deoxyribonucleotides (dNP) essential for mtDNA synthesis. Although the mitochondrial dNP pool is physically separated from the cytosolic one, dNP's may still be imported through specific transport. Non-replicating tissues, where cytosolic dNP supply is down regulated, are thus particularly vulnerable to dGK and TK2 deficiency. The overlapping substrate specificity of deoxycytidine kinase (dCK) may explain the relative sparing of muscle in dGK deficiency, while low basal TK2 activity render this tissue susceptible to TK2 deficiency. The precise pathophysiological mechanisms of mtDNA depletion due to dGK and TK2 deficiencies remain to be determined, though recent findings confirm that it is attributed to imbalanced dNTP pools.
C1 Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Shaare Zedek Med Ctr, Metab Dis Unit, POB Reisch 3235, IL-91031 Jerusalem, Israel.
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   KARLSSON A, 2003, JOINT 11 INT 9 EUR S, V0, P0
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lewis W, 2003, AM J PHYSIOL-HEART C, V284, PH1, DOI 10.1152/ajpheart.00814.2002
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, CLIN CHEM LAB MED, V41, P845, DOI 10.1515/CCLM.2003.128
   Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4
   Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   van der Wilt CL, 2003, EUR J CANCER, V39, P691, DOI 10.1016/S0959-8049(02)00813-4
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146
NR 34
TC 15
Z9 18
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PD OCT 15
PY 2004
VL 23
IS 8-9
BP 1205
EP 1215
DI 10.1081/NCN-200027480
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 871EY
UT WOS:000225113700028
PM 15571232
DA 2024-11-01
ER

PT J
AU Wanrooij, S
   Luoma, P
   van Goethem, G
   van Broeckhoven, C
   Suomalainen, A
   Spelbrink, JN
AF Wanrooij, S
   Luoma, P
   van Goethem, G
   van Broeckhoven, C
   Suomalainen, A
   Spelbrink, JN
TI Twinkle and POLG defects enhance age-dependent accumulation of mutations in the control region of mtDNA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID progressive external ophthalmoplegia; human mitochondrial-dna; large-scale deletions; polymerase gamma-a; d-loop region; autosomal-dominant; multiple deletions; neurogastrointestinal encephalomyopathy; thymidine phosphorylase; point mutations
AB Autosomal dominant and/or recessive progressive external ophthalmoplegia (ad/arPEO) is associated with mtDNA mutagenesis. It can be caused by mutations in three nuclear genes, encoding the adenine nucleotide translocator 1, the mitochondrial helicase Twinkle or DNA polymerase gamma (POLG). How mutations in these genes result in progressive accumulation of multiple mtDNA deletions in post- mitotic tissues is still unclear. A recent hypothesis suggested that mtDNA replication infidelity could promote slipped mispairing, thereby stimulating deletion formation. This hypothesis predicts that mtDNA of ad/arPEO patients will contain frequent mutations throughout; in fact, our analysis of muscle from ad/arPEO patients revealed an age-dependent, enhanced accumulation of point mutations in addition to deletions, but specifically in the mtDNA control region. Both deleted and non-deleted mtDNA molecules showed increased point mutation levels, as did mtDNAs of patients with a single mtDNA deletion, suggesting that point mutations do not cause multiple deletions. Deletion breakpoint analysis showed frequent breakpoints around homopolymeric runs, which could be a signature of replication stalling. Therefore, we propose replication stalling as the principal cause of deletion formation.
C1 Inst Med Technol, Tampere, Finland.
   Tampere Univ Hosp, Tampere, Finland.
   Univ Helsinki, Biomed Helsinki, Programme Neurosci, Helsinki, Finland.
   Univ Helsinki, Biomed Helsinki, Dept Neurol, Helsinki, Finland.
   Univ Antwerp, Born Bunge Fdn, B-2020 Antwerp, Belgium.
   Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium.
C3 Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; University of Antwerp; Flanders Institute for Biotechnology (VIB); University of Antwerp
RP Inst Med Technol, Tampere, Finland.
EM lthasp@uta.fi
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   Chinnery PF, 2003, NEUROLOGY, V61, P878, DOI 10.1212/WNL.61.7.878
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717
   Gordenin DA, 1998, MUTAT RES-FUND MOL M, V400, P45, DOI 10.1016/S0027-5107(98)00047-5
   Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5
   Liu HT, 2000, J VIROL, V74, P11681, DOI 10.1128/JVI.74.24.11681-11689.2000
   LUOMA P, 2004, IN PRESS LANCET, V0, P0
   MADSEN CS, 1993, MOL CELL BIOL, V13, P2162, DOI 10.1128/MCB.13.4.2162
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oshima J, 2002, CANCER RES, V62, P547
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SACCONE C, 1987, J MOL EVOL, V26, P205, DOI 10.1007/BF02099853
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Solano A, 2003, J MED GENET, V40, P0, DOI 10.1136/jmg.40.7.e86
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
NR 60
TC 98
Z9 110
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 15
PY 2004
VL 32
IS 10
BP 3053
EP 3064
DI 10.1093/nar/gkh634
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 830JQ
UT WOS:000222118600017
PM 15181170
DA 2024-11-01
ER

PT J
AU Luoma, P
   Melberg, A
   Rinne, JO
   Kaukonen, JA
   Nupponen, NN
   Chalmers, RM
   Oldfors, A
   Rautakorpi, I
   Peltonen, L
   Majamaa, K
   Somer, H
   Suomalainen, A
AF Luoma, P
   Melberg, A
   Rinne, JO
   Kaukonen, JA
   Nupponen, NN
   Chalmers, RM
   Oldfors, A
   Rautakorpi, I
   Peltonen, L
   Majamaa, K
   Somer, H
   Suomalainen, A
TI Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations:: clinical and molecular genetic study
SO LANCET
LA English
DT Article
ID progressive external ophthalmoplegia; autosomal-dominant; multiple deletions; mtdna deletions; polg mutations; disease; features; disorders; encephalomyopathy; hypogonadism
AB Background Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA. Mitochondrial dysfunction is also suspected to participate in the pathogenesis of Parkinson's disease. However, no primary gene defects affecting mitochondrial proteins causing mendelian transmission of parkinsonism have been characterised. We aimed to analyse the gene sequence of POLG in patients with progressive external ophthalmoplegia and their healthy relatives. Methods In seven families of various ethnic origins we assessed patients with progressive external ophthalmoplegia and unaffected individuals by clinical, biochemical, morphological, and molecular genetic characterisation and positron emission tomography (PET). Findings We recorded mutations in POLG in members of all seven families. Clinical assessment showed significant cosegregation of parkinsonism with POLG mutations (p<0.0001), and PET findings were consistent with dopaminergic neuron loss. Post-mortem examination in two individuals showed loss of pigmented neurons and pigment phagocytosis in substantia nigra without Lewy bodies. Furthermore, most women with progressive external ophthalmoplegia had early menopause before age 35 years. The POLG gene defect resulted in secondary accumulation of mtDNA deletions in patients' tissues. Interpretation Dysfunction of mitochondrial POLG causes a severe progressive multisystem disorder including parkinsonism and premature menopause, which are not typical of mitochondrial disease. Cosegregation of parkinsonism and POLG mutations in our families suggests that when defective, this gene can underlie mendelian transmission of parkinsonism. Relevance to practice Awareness that mitochondrial POLG mutations can underlie parkinsonism is important for clinicians working in diagnosis of movement disorders, as well as for studies of the genetics of Parkinson's disease. Further, progressive external ophthalmoplegia with muscle weakness and neuropathy can mask symptoms of parkinsonism, and clinicians should pay special attention to detect and treat parkinsonism in those individuals.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Dept Oncol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Helsinki, Finland.
   Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland.
   Univ Helsinki, Dept Med Genet, Helsinki, Finland.
   Univ Uppsala Hosp, Dept Neurosci & Neurol, Uppsala, Sweden.
   Univ Turku, Turku PET Ctr, Turku, Finland.
   Inst Neurol, Univ Dept Clin Neurol, London WC1N 3BG, England.
   Gothenburg Univ, Sahlgrens Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Cent Hosp Lapland, Dept Neurol, Rovaniemi, Finland.
   Univ Oulu, Bioctr, Oulu, Finland.
   Univ Oulu, Dept Neurol, Oulu, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki; Uppsala University; Uppsala University Hospital; University of Turku; University of London; University College London; Sahlgrenska University Hospital; University of Gothenburg; University of Oulu; University of Oulu
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Room C522B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
CR Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   CHECCARELLI N, 1994, J NEUROL SCI, V123, P74, DOI 10.1016/0022-510X(94)90206-2
   de Rijk MC, 2000, NEUROLOGY, V54, P0
   Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Guttman M, 2003, MOVEMENT DISORD, V18, P313, DOI 10.1002/mds.10333
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rinne JO, 1999, SYNAPSE, V31, P119, DOI 10.1002/(SICI)1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4
NR 40
TC 441
Z9 487
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 4
PY 2004
VL 364
IS 9437
BP 875
EP 882
DI 10.1016/S0140-6736(04)16983-3
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 851KY
UT WOS:000223685200034
PM 15351195
DA 2024-11-01
ER

PT J
AU Shanske, S
   Wong, LJC
AF Shanske, S
   Wong, LJC
TI Molecular analysis for mitochondrial DNA disorders
SO MITOCHONDRION
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; mitochondrial disorders; molecular analysis : DNA diagnosis
ID progressive external ophthalmoplegia; kearns-sayre-syndrome; tissue distribution; point mutations; deletion; disease; mtdna; woman; transmission; diagnosis
AB In this article, we review the current methodologies used for the molecular diagnosis of mitochondrial DNA defects. Definition of mitochondrial disorders at the molecular level has been difficult because of both clinical and genetic heterogeneity. Direct DNA analysis for common point mutations and large mtDNA deletions is readily performed and can be done routinely. However, a large number of patients who have the clinical manifestations and muscle pathology findings consistent with mitochondrial DNA disorders do not have detectable common mutations. Additional mutation screening methods are required for the detection of rare and previously undescribed mutations in the mitochondrial genome. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Georgetown University; Columbia University
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, POB 571477,3800 Reservoir Rd,NW,Room M4000, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Boles RG, 1997, LANCET, V350, P1299, DOI 10.1016/S0140-6736(05)62477-4
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   Chinnery PF, 1998, LANCET, V351, P448, DOI 10.1016/S0140-6736(05)78396-3
   DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DIMAURO S, 2003, MOL GENETIC BASIS NE, V0, P189
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gourlain K, 2003, HIV MED, V4, P287, DOI 10.1046/j.1468-1293.2003.00158.x
   Graff C, 2000, PRENATAL DIAG, V20, P426, DOI 10.1002/(SICI)1097-0223(200005)20:5<426::AID-PD845>3.3.CO;2-B
   Hirano M, 2003, MOL GENETIC BASIS NE, V0, P197
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   KADOWAKI T, 1995, MUSCLE NERVE, V0, PS137
   Lacbawan F, 2000, AM J MED GENET, V95, P266, DOI 10.1002/1096-8628(20001127)95:3<266::AID-AJMG13>3.3.CO;2-S
   LARSSON NG, 1992, AM J HUM GENET, V50, P360
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LIANG MH, 2000, AM J MED GENET, V7, P385
   Michikawa Y, 1997, NUCLEIC ACIDS RES, V25, P2455, DOI 10.1093/nar/25.12.2455
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   SERVIDEI S, 2003, NEUROMUSCULAR DISORD, V13, P685
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHANSKE S, 2004, IN PRESS AM J MED GE, V0, P0
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   SUOMALAINEN A, 1992, J NEUROL SCI, V111, P222, DOI 10.1016/0022-510X(92)90074-U
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WARTELL RM, 1990, NUCLEIC ACIDS RES, V18, P2699, DOI 10.1093/nar/18.9.2699
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Wong LC, 2002, AM J HUM GENET, V71, P501
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2003, J MED GENET, V40, P0
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 54
TC 29
Z9 31
U1 2
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP 15
PY 2004
VL 4
IS 5-6
BP 403
EP 415
DI 10.1016/j.mito.2004.07.026
PG 13
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 885QS
UT WOS:000226172600007
PM 16120402
DA 2024-11-01
ER

PT J
AU Hansson, A
   Hance, N
   Dufour, E
   Rantanen, A
   Hultenby, K
   Clayton, DA
   Wibom, R
   Larsson, NG
AF Hansson, A
   Hance, N
   Dufour, E
   Rantanen, A
   Hultenby, K
   Clayton, DA
   Wibom, R
   Larsson, NG
TI A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
ID dna gene-expression; failing heart; knockout mice; enzyme; muscle; diseases; phosphofructokinase; differentiation; cardiomyopathy; maintenance
AB We performed global gene expression analyses in mouse hearts with progressive respiratory chain deficiency and found a metabolic switch at an early disease stage. The tissue-specific mitochondrial transcription factor A (Tfam) knockout mice of this study displayed a progressive heart phenotype with depletion of mtDNA and an accompanying severe decline of respiratory chain enzyme activities along with a decreased mitochondrial ATP production rate. These characteristics were observed after 2 weeks of age and became gradually more severe until the terminal stage occurred at 10-12 weeks of age. Global gene expression analyses with microarrays showed that a metabolic switch occurred early in the progression of cardiac mitochondrial dysfunction. A large number of genes encoding critical enzymes in fatty acid oxidation showed decreased expression whereas several genes encoding glycolytic enzymes showed increased expression. These alterations are consistent with activation of a fetal gene expression program, a well-documented phenomenon in cardiac disease. An increase in mitochondrial mass was not observed until the disease had reached an advanced stage. In contrast to what we have earlier observed in respiratory chain-deficient skeletal muscle, the increased mitochondrial biogenesis in respiratory chain-deficient heart muscle did not increase the overall mitochondrial ATP production rate. The observed switch in metabolism is unlikely to benefit energy homeostasis in the respiratory chain-deficient hearts and therefore likely aggravates the disease. It can thus be concluded that at least some of the secondary gene expression alterations in mitochondrial cardiomyopathy do not compensate but rather directly contribute to heart failure progression.
C1 Karolinska Univ Hosp, Karolinska Inst, Dept Med Nutr & Biosci, Novum, S-14186 Huddinge, Sweden.
   Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Novum, S-14186 Huddinge, Sweden.
   Karolinska Univ Hosp, Karolinska Inst, Clin Res Ctr, Novum, S-14186 Huddinge, Sweden.
   Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
C3 Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Howard Hughes Medical Institute
RP Karolinska Univ Hosp, Karolinska Inst, Dept Med Nutr & Biosci, Novum, S-14186 Huddinge, Sweden.
EM nils-goran.larsson@mednut.ki.se
CR ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555
   BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x
   BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x
   Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0
   DIMAURO S, 1983, ANN NEUROL, V13, P11, DOI 10.1002/ana.410130104
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297
   Förster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299
   Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955
   Graff C, 2002, BEST PRACT RES CL OB, V16, P715, DOI 10.1053/beog.2002.0315
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   KELLY DP, 1989, J BIOL CHEM, V264, P18921
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6
   Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x
   Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467
   Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121
   MANSOUR TE, 1965, J BIOL CHEM, V240, P2165
   OPIE LH, 1967, BIOCHEM J, V103, P391, DOI 10.1042/bj1030391
   Razeghi P, 2001, CIRCULATION, V104, P2923, DOI 10.1161/hc4901.100526
   Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Silva JP, 2002, BBA-BIOENERGETICS, V1555, P106, DOI 10.1016/S0005-2728(02)00263-3
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   WANKERL M, 1995, J MOL MED-JMM, V73, P487
   Weibel ER, 1979, STEREOLOGICAL METHOD, V1, P0
   Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
NR 35
TC 174
Z9 188
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 2
PY 2004
VL 101
IS 9
BP 3136
EP 3141
DI 10.1073/pnas.0308710100
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 800ZD
UT WOS:000220065300087
PM 14978272
DA 2024-11-01
ER

PT J
AU Szigeti, K
   Wong, LJC
   Perng, CL
   Saifi, GM
   Eldin, K
   Adesina, AM
   Cass, DL
   Hirano, M
   Lupski, JR
   Scaglia, F
AF Szigeti, K
   Wong, LJC
   Perng, CL
   Saifi, GM
   Eldin, K
   Adesina, AM
   Cass, DL
   Hirano, M
   Lupski, JR
   Scaglia, F
TI MNGIE with lack of skeletal muscle involvement and a novel <i>TP</i> splice site mutation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID thymidine phosphorylase-deficiency; mitochondrial-dna; gene-mutations; disorders; defects; growth
AB Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive multisystem disorder caused by thymidine phosphorylase (TP) deficiency, resulting in severe gastrointestinal dysmotility and skeletal muscle abnormalities. A patient is reported with a classical MNGIE clinical presentation but without skeletal muscle involvement at morphological, enzymatic, or mitochondrial DNA level, though gastrointestinal myopathy was present. MNGIE was diagnosed by markedly raised plasma thymidine and reduced thymidine phosphorylase activity. Molecular genetic analysis showed a homozygous novel splice site mutation in TP. On immunohistochemical studies there was marked TP expression in the CNS, in contrast to what has been observed in rodents. It is important to examine the most significantly affected tissue and to measure TP activity and plasma thymidine in order to arrive at an accurate diagnosis in this condition.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Texas Childrens Hosp, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Georgetown University; Columbia University
RP Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,Rm604B, Houston, TX 77030 USA.
EM jlupski@bcm.tmc.edu
CR den Dunnen JT, 2000, HUM MUTAT, V15, P7
   ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4
   Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Kocaefe YÇ, 2003, EUR J HUM GENET, V11, P102, DOI 10.1038/sj.ejhg.5200908
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   MIYADERA K, 1995, CANCER RES, V55, P1687
   MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   Rick SW, 1999, PROTEINS, V37, P242, DOI 10.1002/(SICI)1097-0134(19991101)37:2<242::AID-PROT9>3.0.CO;2-5
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 17
TC 35
Z9 37
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB 1
PY 2004
VL 41
IS 2
BP 125
EP 129
DI 10.1136/jmg.2003.013789
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 769VE
UT WOS:000188669800008
PM 14757860
DA 2024-11-01
ER

PT J
AU Scaglia, F
   Towbin, JA
   Craigen, WJ
   Belmont, JW
   Smith, EO
   Neish, SR
   Ware, SM
   Hunter, JV
   Fernbach, SD
   Vladutiu, GD
   Wong, LJC
   Vogel, H
AF Scaglia, F
   Towbin, JA
   Craigen, WJ
   Belmont, JW
   Smith, EO
   Neish, SR
   Ware, SM
   Hunter, JV
   Fernbach, SD
   Vladutiu, GD
   Wong, LJC
   Vogel, H
TI Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease
SO PEDIATRICS
LA English
DT Article
DE mitochondrial encephalomyopathies; mitochondrial cardiomyopathies; modified Walker criteria; morbidity; survival rate
ID respiratory-chain disorders; complex-i deficiency; barth syndrome; cardiomyopathy; dna; encephalomyopathy; children; myopathy; childhood; mutations
AB Objectives. The aim of this study was to elucidate the frequency of major clinical manifestations in children with mitochondrial disease and establish their clinical course, prognosis, and rates of survival depending on their clinical features. Methods. We performed a retrospective review of the medical records of 400 patients who were referred for evaluation of mitochondrial disease. By use of the modified Walker criteria, only patients who were assigned a definite diagnosis were included in the study. Results. A total of 113 pediatric patients with mitochondrial disease were identified. A total of 102 (90%) patients underwent a muscle biopsy as part of the diagnostic workup. A significant respiratory chain ( RC) defect, according to the diagnostic criteria, was found in 71% of the patients who were evaluated. In this cohort, complex I deficiency (32%) and combined complex I, III, and IV deficiencies (26%) were the most common causes of RC defects, followed by complex IV (19%), complex III (16%), and complex II deficiencies (7%). Pathogenic mitochondrial DNA abnormalities were found in 11.5% of the patients. A substantial fraction (40%) of patients with mitochondrial disorders exhibited cardiac disease, diagnosed by Doppler echocardiography; however, the majority (60%) of patients had predominant neuromuscular manifestations. No correlation between the type of RC defect and the clinical presentation was observed. Overall, the mean age at presentation was 40 months. However, the mean age at presentation was 33 months in the cardiac group and 44 months in the noncardiac group. Twenty-six (58%) patients in the cardiac group exhibited hypertrophic cardiomyopathy, 29% had dilated cardiomyopathy, and the remainder (13%) had left ventricular noncompaction. Patients with cardiomyopathy had an 18% survival rate at 16 years of age. Patients with neuromuscular features but no cardiomyopathy had a 95% survival at the same age. Conclusions. This study gives strong support to the view that in patients with RC defects, cardiomyopathy is more common than previously thought and tends to follow a different and more severe clinical course. Although with a greater frequency than previously reported, mitochondrial DNA mutations were found in a minority of patients, emphasizing that most mitochondrial disorders of childhood follow a Mendelian pattern of inheritance.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Texas Childrens Hosp, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
   SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14260 USA.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; State University of New York (SUNY) System; University at Buffalo, SUNY; Georgetown University; Stanford University
RP Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
EM fscaglia@bcm.tmc.edu
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Applegarth DA, 2000, PEDIATRICS, V105, Part. no., DOI 10.1542/peds.105.1.e10
   BENECKE R, 1992, ANN NEUROL, V32, P683, DOI 10.1002/ana.410320512
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   BERNSEN PLJA, 1991, ARCH NEUROL-CHICAGO, V48, P334, DOI 10.1001/archneur.1991.00530150106028
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   Bleyl SB, 1997, AM J HUM GENET, V61, P868, DOI 10.1086/514879
   CASAZZA F, 1998, G ITAL CARDIOL, V18, P615
   Chinnery PF, 1997, QJM-INT J MED, V90, P657, DOI 10.1093/qjmed/90.11.657
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   Edmonds JL, 2002, ARCH OTOLARYNGOL, V128, P355, DOI 10.1001/archotol.128.4.355
   GOLD M, 1994, INT J PEDIATR OTORHI, V30, P91, DOI 10.1016/0165-5876(94)90191-0
   Holmgren D, 2003, EUR HEART J, V24, P280, DOI 10.1016/S0195-668X(02)00387-1
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   KARTSOUNIS LD, 1992, ARCH NEUROL-CHICAGO, V49, P158, DOI 10.1001/archneur.1992.00530260058020
   KELLEY RI, 1991, J PEDIATR-US, V119, P738, DOI 10.1016/S0022-3476(05)80289-6
   King T E, 1967, METHODS IN ENZYMOLOGY EDS, V10, P275, DOI 10.1016/0076-6879(67)10055-4
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Lincke CR, 1996, NEUROPEDIATRICS, V27, P216, DOI 10.1055/s-2007-973792
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Momiyama Y, 1999, JPN CIRC J, V63, P130, DOI 10.1253/jcj.63.130
   Munnich A, 1996, EUR J PEDIATR, V155, P262
   Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112
   Nissenkorn A, 2000, J CHILD NEUROL, V15, P44, DOI 10.1177/088307380001500110
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Pignatelli RH, 2003, CIRCULATION, V108, P2672, DOI 10.1161/01.CIR.0000100664.10777.B8
   ROBINSON BH, 1993, BIOCHIM BIOPHYS ACTA, V1182, P231, DOI 10.1016/0925-4439(93)90064-8
   Rubio-Gozalbo ME, 2000, HUM MUTAT, V15, P522, DOI 10.1002/1098-1004(200006)15:6<522::AID-HUMU4>3.0.CO;2-Y
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573
   Srere PA, 1969, METHOD ENZYMOL, V13, P3, DOI 10.1016/0076-6879(69)13005-0
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   Thorburn D R, 2000, HUM REPROD, V15 Suppl 2, P57
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Towbin JA, 1999, CURR OPIN CARDIOL, V14, P250, DOI 10.1097/00001573-199905000-00010
   Turconi AC, 1999, J NEUROL SCI, V170, P57, DOI 10.1016/S0022-510X(99)00199-9
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   von Kleist-Retzow JC, 1998, AM J HUM GENET, V63, P428, DOI 10.1086/301957
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   WONG LJC, 2003, J MED GENET, V40, P0
   Yonetan T, 1967, METHODS ENZYMOL, V0, P332
NR 49
TC 335
Z9 367
U1 0
U2 13
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD OCT 15
PY 2004
VL 114
IS 4
BP 925
EP 931
DI 10.1542/peds.2004-0718
PG 7
WC Pediatrics
SC Pediatrics
GA 859DI
UT WOS:000224242200024
PM 15466086
DA 2024-11-01
ER

PT J
AU Nakada, K
   Sato, A
   Sone, H
   Kasahara, A
   Ikeda, K
   Kagawa, Y
   Yonekawa, H
   Hayashi, J
AF Nakada, K
   Sato, A
   Sone, H
   Kasahara, A
   Ikeda, K
   Kagawa, Y
   Yonekawa, H
   Hayashi, J
TI Accumulation of pathogenic ΔmtDNA induced deafness but not diabetic phenotypes in mito-mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondria; mitochondrial diseases; respiration defects; mitochondrial DNA; pathogenic deletion mutant mitochondrial DNA; mitochondrial diabetes; deafness; disease model mouse; mito-mice
ID mitochondrial-dna deletions; insulin-secretion; protein-synthesis; point mutation; mouse mtdna; human brain; hela-cells; mellitus; gene; myopathy
AB Mito-mice carrying various proportions of deletion mutant mtDNA (DeltamtDNA) were generated by introduction of the DeltamtDNA from cultured cells into fertilized eggs of C57BL/6.1 (136) strain mice. Great advantages of mito-mice are that they share exactly the same nuclear-genome background, and that their genetic variations are restricted to proportions of pathogenic DeltamtDNA. Since accumulation of DeltamtDNA to more than 75% induced respiration defects, the disease phenotypes observed exclusively in mito-mice carrying more than 75% DeltamtDNA should be due to accumulated DeltamtDNA. In this study, we focused on the expressions of hearing loss and diabetic phenotypes, since these common age-associated abnormalities have sometimes been reported to be inherited maternally and to be associated with pathogenic mutant mtDNAs. The results showed that accumulation of exogenously introduced DeltamtDNA was responsible for hearing loss, but not for expression of diabetic phenotypes in mito-mice. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan.
   Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan.
   Kagawa Nutr Univ, High Technol Res Ctr, Sakado, Saitama 3500288, Japan.
   Juntendo Univ, Sch Med, Dept Otorhinolaryngol, Bunkyo Ku, Tokyo 1138421, Japan.
C3 University of Tsukuba; University of Tsukuba; Tokyo Metropolitan Institute of Medical Science; Kagawa Nutrition University; Juntendo University
RP Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greeley SAW, 2002, NAT MED, V8, P399, DOI 10.1038/nm0402-399
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923
   JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shitara H, 1998, GENETICS, V148, P851
   Shoubridge EA, 2000, NAT GENET, V26, P132, DOI 10.1038/79832
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194
   SOONG NW, 1992, NAT GENET, V2, P318
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   TULINIUS MH, 1995, EUR J PEDIATR, V154, P35, DOI 10.1007/BF01972970
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9
NR 38
TC 34
Z9 35
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 8
PY 2004
VL 323
IS 1
BP 175
EP 184
DI 10.1016/j.bbrc.2004.08.073
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 855HY
UT WOS:000223965300027
PM 15351718
DA 2024-11-01
ER

PT J
AU Kumaran, S
   Subathra, M
   Balu, M
   Panneerselvam, C
AF Kumaran, S
   Subathra, M
   Balu, M
   Panneerselvam, C
TI Age-associated decreased activities of mitochondrial electron transport chain complexes in heart and skeletal muscle: role of L-carnitine
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE aging; mitochondria; electron transport chain; carnitine
ID dna deletions; oxidase activity; rat-heart; brain; supplementation; decline; stress; damage
AB The mitochondrial respiratory chain is a powerful source of reactive oxygen species (ROS), considered as the pathogenic agent of many diseases and aging. L-Carnitine (4-N-trimethylammonium-3-hydroxybutric acid) plays an important role in transport of fatty acid from cytoplasm to mitochondria for energy production. Previous studies in our laboratory reported L-carnitine as a free radical scavenger in aged rats. In the present study we focused the effect of L-carnitine on the activities of electron transport chain in young and aged rats. The activities of electron transport chain complexes were found to be significantly decreased in aged rats when compared to young control rats. Supplementation of carnitine to young and aged rats for 14 and 21 days improved the electron transport chain complexes levels in aged rats when compared with young rats in duration dependent manner. No significant changes were observed in young rats. Our result suggested that L-carnitine improved the activities of electron transport chain enzymes there by improving the energy status in aged rats. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Dr AL Mudaliar Post Grad Inst Basic Med Sci, Dept Med Biochem, Madras 600113, Tamil Nadu, India.
RP Dr AL Mudaliar Post Grad Inst Basic Med Sci, Dept Med Biochem, Taramani Campus, Madras 600113, Tamil Nadu, India.
EM panneerselvam@eth.net
CR Barja G, 2000, AGING CLIN EXP RES, V12, P342, DOI 10.1007/BF03339859
   Beal MF, 2000, BRAIN, V123, P1291, DOI 10.1093/brain/123.7.1291
   BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B
   BRICHMACHIN M, 1993, MITOCHRONDRIAL DYSFU, V0, P51
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Drouet M, 1999, EXP GERONTOL, V34, P843, DOI 10.1016/S0531-5565(99)00058-3
   Ernster L, 1967, METHODS ENZYMOLOGY, V10, P86
   Filburn CR, 1996, MECH AGEING DEV, V87, P35, DOI 10.1016/0047-6374(96)01696-X
   Hagen TM, 2002, ANN NY ACAD SCI, V959, P491, DOI 10.1111/j.1749-6632.2002.tb02119.x
   HSIEH RH, 1994, BIOCHEM MOL BIOL INT, V32, P1009
   Iossa S, 2002, J NUTR, V132, P636, DOI 10.1093/jn/132.4.636
   Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2
   Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425
   PAPA S, 2002, FRONTIERS CELLULAR B, V0, P0
   Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0
   Ragan CI, 1987, MITOCHONDRIA PRACTIC, V0, P79
   Rani PJA, 2001, EXP GERONTOL, V36, P1713, DOI 10.1016/S0531-5565(01)00116-4
   REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372
   Sandhu SK, 2003, BIOGERONTOLOGY, V4, P19, DOI 10.1023/A:1022473219044
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Singh RJ, 2002, J LAB CLIN MED, V140, P380, DOI 10.1067/mlc.2002.129505
   SLATER EC, 1952, BIOCHEM J, V52, P185, DOI 10.1042/bj0520185
   SOHAL RS, 1993, FREE RADICAL BIO MED, V14, P583, DOI 10.1016/0891-5849(93)90139-L
   TAGLIALATELA G, 1994, EXP GERONTOL, V29, P55, DOI 10.1016/0531-5565(94)90062-0
   TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B
   Vijg Jan, 1999, BIOCHIMICA ET BIOPHYSICA ACTA, V1423, PR1, DOI 10.1016/S0304-419X(98)00028-6
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V61, P1175
   Wharton DC, 1967, METHODS ENZYMOL, V10, P245, DOI 10.1016/0076-6879(67)10048-7
NR 33
TC 51
Z9 61
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JUN 30
PY 2004
VL 148
IS 1-2
BP 11
EP 18
DI 10.1016/j.cbi.2003.10.010
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 838WW
UT WOS:000222745100002
PM 15223352
DA 2024-11-01
ER

PT J
AU Cheng, G
   Merriam, AP
   Gong, B
   Leahy, P
   Khanna, S
   Porter, JD
AF Cheng, G
   Merriam, AP
   Gong, B
   Leahy, P
   Khanna, S
   Porter, JD
TI Conserved and muscle-group-specific gene expression patterns shape postnatal development of the novel extraocular muscle phenotype
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE skeletal muscle; hindlimb; microarray; allotype
ID avian craniofacial muscles; deficient mdx mice; skeletal-muscle; fiber types; myosin expression; neuromuscular-junction; calcium homeostasis; muscular-dystrophy; mitochondrial-dna; binding protein
AB Current models in skeletal muscle biology do not fully account for the breadth, causes, and consequences of phenotypic variation among skeletal muscle groups. The muscle allotype concept arose to explain frank differences between limb, masticatory, and extraocular (EOM) muscles, but there is little understanding of the developmental regulation of the skeletal muscle phenotypic range. Here, we used morphological and DNA microarray analyses to generate a comprehensive temporal profile for rat EOM development. Based upon coordinate regulation of morphologic/gene expression traits with key events in visual, vestibular, and oculomotor system development, we propose a model that the EOM phenotype is a consequence of extrinsic factors that are unique to its local environment and sensory-motor control system, acting upon a novel myoblast lineage. We identified a broad spectrum of differences between the postnatal transcriptional patterns of EOM and limb muscle allotypes, including numerous transcripts not traditionally associated with muscle fiber/group differences. Several transcription factors were differentially regulated and may be responsible for signaling muscle allotype specificity. Significant differences in cellular energetic mechanisms defined the EOM and limb allotypes. The allotypes were divergent in many other functional transcript classes that remain to be further explored. Taken together, we suggest that the EOM allotype is the consequence of tissue-specific mechanisms that direct expression of a limited number of EOM-specific transcripts and broader, incremental differences in transcripts that are conserved by the two allotypes. This represents an important first step in dissecting allotype-specific regulatory mechanisms that may, in turn, explain differential muscle group sensitivity to a variety of metabolic and neuromuscular diseases.
C1 Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Visual Sci Res Ctr, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA.
   Univ Hosp Cleveland, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University Hospitals of Cleveland
RP Case Western Reserve Univ, Dept Neurol, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM john.porter@case.edu
FU NCI NIH HHS [P30-CA-43703] Funding Source: Medline; NEI NIH HHS [R01-EY-12779, R01-EY-015306, P30-EY-11371, R01-EY-09834] Funding Source: Medline
CR Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J
   Andrade FH, 2003, J APPL PHYSIOL, V95, P692, DOI 10.1152/japplphysiol.00358.2003
   Briggs MM, 2000, J EXP BIOL, V203, P2485
   BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010
   Brueckner JK, 1998, J APPL PHYSIOL, V85, P584, DOI 10.1152/jappl.1998.85.2.584
   Brueckner JK, 1996, J MUSCLE RES CELL M, V17, P297
   Brueckner JK, 1999, CELL TISSUE RES, V295, P477, DOI 10.1007/s004410051253
   BURKE RE, 1971, SCIENCE, V174, P709, DOI 10.1126/science.174.4010.709
   Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001
   CELIO MR, 1982, NATURE, V297, P504, DOI 10.1038/297504a0
   Cheng G, 2003, INVEST OPHTH VIS SCI, V44, P3842, DOI 10.1167/iovs.03-0170
   Cheng G, 2002, INVEST OPHTH VIS SCI, V43, P1048
   COULY GF, 1992, DEVELOPMENT, V114, P1
   Degenhardt K, 2001, DEV BIOL, V231, P175, DOI 10.1006/dbio.2000.0131
   Delp MD, 1996, J APPL PHYSIOL, V80, P261, DOI 10.1152/jappl.1996.80.1.261
   Dietrich S, 1999, CELL TISSUE RES, V296, P175, DOI 10.1007/s004410051278
   Dietrich S, 1998, DEVELOPMENT, V125, P2235
   Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001
   Gage PJ, 1999, DEVELOPMENT, V126, P4643
   HANSON J, 1980, ACTA PHYSIOL SCAND, V108, P61, DOI 10.1111/j.1748-1716.1980.tb06500.x
   HAUNERLAND NH, 1994, COMP BIOCHEM PHYS B, V109, P199, DOI 10.1016/0305-0491(94)90003-5
   Hoefler G, 1997, BIOCHIMIE, V79, P163, DOI 10.1016/S0300-9084(97)81509-X
   HOH JFY, 1988, J MUSCLE RES CELL M, V9, P59
   HOH JFY, 1989, CELLULAR MOL BIOL MU, V0, P15
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng015
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   JACOBY J, 1990, J MUSCLE RES CELL M, V11, P25, DOI 10.1007/BF01833323
   KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W
   Kaminski HJ, 1996, INVEST OPHTH VIS SCI, V37, P345
   Kaminski HJ, 2003, ANN NY ACAD SCI, V998, P362, DOI 10.1196/annals.1254.043
   KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418
   KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407
   KELLY AM, 1978, DEV BIOL, V65, P1, DOI 10.1016/0012-1606(78)90174-4
   KELLY AM, 1969, J CELL BIOL, V42, P135, DOI 10.1083/jcb.42.1.135
   Khanna S, 2003, FASEB J, V17, P1370, DOI 10.1096/fj.02-1108fje
   Khanna S, 2003, INVEST OPHTH VIS SCI, V44, P1918, DOI 10.1167/iovs.02-0890
   KHURANA TS, 1995, J EXP MED, V182, P467, DOI 10.1084/jem.182.2.467
   Kitamura K, 1999, DEVELOPMENT, V126, P5749
   Lu JR, 2002, SCIENCE, V298, P2378, DOI 10.1126/science.1078273
   LUFF AR, 1971, J CELL BIOL, V51, P369, DOI 10.1083/jcb.51.2.369
   Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892
   MASCARELLO F, 1992, ANAT EMBRYOL, V185, P143
   McLoon LK, 1996, INVEST OPHTH VIS SCI, V37, P318
   Mitchell PO, 2002, CLIN ORTHOP RELAT R, V0, PPS197, DOI 10.1097/01.blo.0000031981.92980.01
   Mootoosamy RC, 2002, DEVELOPMENT, V129, P573
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   NAG AC, 1982, J EMBRYOL EXP MORPH, V71, P171
   Noden DM, 1999, DEV DYNAM, V216, P96, DOI 10.1002/(SICI)1097-0177(199910)216:2<96::AID-DVDY2>3.3.CO;2-Y
   NODEN DM, 1986, DEV BIOL, V116, P347, DOI 10.1016/0012-1606(86)90138-7
   PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61
   PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013
   Porter JD, 1998, CELL TISSUE RES, V292, P495, DOI 10.1007/s004410051078
   Porter JD, 1999, BIOCHEM BIOPH RES CO, V257, P678, DOI 10.1006/bbrc.1999.0536
   Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1
   Porter JD, 2001, P NATL ACAD SCI USA, V98, P12062, DOI 10.1073/pnas.211257298
   Porter JD, 2003, J EXP BIOL, V206, P3101, DOI 10.1242/jeb.00511
   PORTER JD, 1993, DEV BIOL, V160, P39, DOI 10.1006/dbio.1993.1284
   PORTER JD, 1992, INVEST OPHTH VIS SCI, V33, P657
   PORTER JD, 1993, ACTA ANAT, V147, P197
   Porter JD, 2003, FASEB J, V17, P893, DOI 10.1096/fj.02-0810fje
   Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197
   Porter JD, 1998, J CELL SCI, V111, P1801
   PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4
   Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263
   Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30
   PORTER JD, 2003, PERSPECTIVES GENE EX, V0, P221
   Ragusa RJ, 1996, J NEUROL SCI, V139, P180
   Ramoni MF, 2002, P NATL ACAD SCI USA, V99, P9121, DOI 10.1073/pnas.132656399
   RUBINSTEIN NA, 1981, J CELL BIOL, V90, P128, DOI 10.1083/jcb.90.1.128
   RUSHBROOK JI, 1994, J MUSCLE RES CELL M, V15, P505, DOI 10.1007/BF00121157
   Schäfer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843
   Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9
   Spangenburg EE, 2003, ACTA PHYSIOL SCAND, V178, P413, DOI 10.1046/j.1365-201X.2003.01158.x
   Spencer R F, 1988, REV OCULOMOT RES, V2, P33
   Summerbell D, 2000, DEVELOPMENT, V127, P3745
   TERMIN A, 1989, HISTOCHEMISTRY, V92, P453, DOI 10.1007/BF00524756
   TRAINOR PA, 1995, DEVELOPMENT, V121, P2569
   TSUZUKI S, 1995, NEUROSCI RES, V23, P389, DOI 10.1016/0168-0102(95)00966-W
   Tzahor E, 2003, GENE DEV, V17, P3087, DOI 10.1101/gad.1154103
   WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618
NR 81
TC 28
Z9 29
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
EI 1531-2267
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD JUL 8
PY 2004
VL 18
IS 2
BP 184
EP 195
DI 10.1152/physiolgenomics.00222.2003
PG 12
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA 841LQ
UT WOS:000222931700005
PM 15138310
DA 2024-11-01
ER

PT J
AU Lev, D
   Nissenkorn, A
   Leshinsky-Silver, E
   Sadeh, M
   Zeharia, A
   Garty, BZ
   Blieden, L
   Barash, V
   Lerman-Sagie, T
AF Lev, D
   Nissenkorn, A
   Leshinsky-Silver, E
   Sadeh, M
   Zeharia, A
   Garty, BZ
   Blieden, L
   Barash, V
   Lerman-Sagie, T
TI Clinical presentations of mitochondrial cardiomyopathies
SO PEDIATRIC CARDIOLOGY
LA English
DT Article
DE hypertrophic cardiomyopathy; dilated cardiomyopathy; mitochondrial DNA
ID respiratory-chain; dysfunction; disorders; childhood
AB To determine the clinical manifestations and interfamilial variability of patients diagnosed with a mitochondrial cardiomyopathy, we reviewed the charts of 14 patients with cardiomyopathy out of 59 patients with mitochondrial disorders who attended the mitochondrial disease clinic at Wolfson Medical Center from 1996 to 2001. All patients underwent a metabolic evaluation including blood lactate, pyruvate, carnitine, and amino acids and urine organic acids. Respiratory chain enzymes were assessed in 10 patients. The mitochondrial DNA (mtDNA) was assessed for mutations. The age at presentation ranged between 6 months and 24 years. Six of the patients died, 5 from heart failure. The cardiomyopathy was hypertrophic in 10 and dilated in 4. Conduction and rhythm abnormalities were present in 6. Eleven patients had family members with mitochondrial disorders. All the patients had additional involvement of one or more systems. Seven patients exhibited a deficiency of a respiratory chain enzyme in the muscle. The MELAS mtDNA point mutation (3243) was found in one patient. Blood lactic acid levels were increased in 5. Brain MRI abnormalities were observed in 4. ConclusionsMitochondrial dysfunction frequently affects the heart and may cause both hypertrophic and dilated cardiomyopathy. The cardiomyopathy is usually a part of a multisystem involvement and may rarely be isolated. The course may be stable for many years, but rapid deterioration may occur. Understanding the biochemical and genetic features of these diseases will enable us to comprehend the clinical heterogeneity of these disorders.
C1 Mitochondrial Dis Clin, Wolfson Med Ctr, Metab Neurogenet Serv, IL-58100 Holon, Israel.
   Wolfson Med Ctr, Genet Mol Lab, IL-58100 Holon, Israel.
   Wolfson Med Ctr, Inst Phys Hyg, IL-58100 Holon, Israel.
   Wolfson Med Ctr, Dept Neurol, IL-58100 Holon, Israel.
   Schneider Med Ctr Israel, Dept Pediat D, Petah Tiqwa, Israel.
   Sackler Sch Med, Tel Aviv, Israel.
   Schneider s Childrens Med Ctr Israel, Dept Pediat B, Petah Tiqwa, Israel.
   Schneider s Childrens Med Ctr Israel, Pediat Cardiol Unit, Petah Tiqwa, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Biochem, Jerusalem, Israel.
C3 Tel Aviv University; Hebrew University of Jerusalem; Hadassah University Medical Center
RP Mitochondrial Dis Clin, Wolfson Med Ctr, Metab Neurogenet Serv, IL-58100 Holon, Israel.
EM dorlev@post.tau.ac.il
CR BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   Bonnet D, 1998, EUR HEART J, V19, P790, DOI 10.1053/euhj.1997.0818
   Caruso U, 1996, J INHERIT METAB DIS, V19, P143, DOI 10.1007/BF01799415
   CLARKE LA, 1992, PEDIATR CLIN N AM, V39, P319
   DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886
   DiMauro S, 1998, CURR OPIN CARDIOL, V13, P190
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   GUENTHARD J, 1995, ARCH DIS CHILD, V72, P223, DOI 10.1136/adc.72.3.223
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Lerman-Sagie T, 2001, J INHERIT METAB DIS, V24, P28, DOI 10.1023/A:1005642302316
   Marin-Garcia J, 1999, PEDIATRICS, V103, P456, DOI 10.1542/peds.103.2.456
   Marin-Garcia J, 2000, J INHERIT METAB DIS, V23, P625, DOI 10.1023/A:1005638231195
   MarinGarcia J, 1997, PEDIATR CARDIOL, V18, P251, DOI 10.1007/s002469900169
   MarinGarcia J, 1996, PEDIATR CARDIOL, V17, P387, DOI 10.1007/s002469900084
   Munnich A, 1996, EUR J PEDIATR, V155, P262
   Nissenkorn A, 1999, ARCH DIS CHILD, V81, P209, DOI 10.1136/adc.81.3.209
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   RUSTIN P, 1994, J PEDIATR-US, V124, P224, DOI 10.1016/S0022-3476(94)70308-6
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Santorelli F M, 2001, AM HEART J, V141, PE1, DOI 10.1067/mhj.2001.112088
   SHOFFNER JM, 1990, ADV HUM GENET, V19, P267
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   TULINIUS MH, 1991, J PEDIATR-US, V119, P251, DOI 10.1016/S0022-3476(05)80735-8
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   WALLACE DC, 2000, AM HEART J 3, V139, P0
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   ZEVIANI M, 1995, MUSCLE NERVE, V0, PS170
NR 29
TC 57
Z9 69
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0172-0643
EI 1432-1971
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
PD SEP-OCT 15
PY 2004
VL 25
IS 5
BP 443
EP 450
DI 10.1007/s00246-003-0490-7
PG 8
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA 861ZR
UT WOS:000224459200001
PM 15185043
DA 2024-11-01
ER

PT J
AU Lodi, R
   Rajagopalan, B
   Blamire, AM
   Crilley, JG
   Styles, P
   Chinnery, PF
AF Lodi, R
   Rajagopalan, B
   Blamire, AM
   Crilley, JG
   Styles, P
   Chinnery, PF
TI Abnormal cardiac energetics in patients carrying the A3243G mtDNA mutation measured in vivo using phosphorus MR spectroscopy
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article
DE magnetic resonance spectroscopy; metabolism; cardiomyopathy
ID left-ventricular mass; stroke-like episodes; mitochondrial myopathy; lactic-acidosis; melas; cardiomyopathy; epidemiology; hypertrophy; dysfunction; deficiency
AB Cardiomyopathy is a frequent cause of morbidity and mortality in patients carrying the A3243G transition in the mitochondrial DNA (mtDNA) tRNALeu(UUR) gene, the most common heteroplasmic single mtDNA defect. We used phosphorus magnetic resonance spectroscopy (P-31-MRS) to look for evidence of an in vivo bioenergetics defect in patients carrying the A3243G mtDNA mutation with and without echocardiographic signs of left ventricle hypertrophy (LVH). Eight patients, three with LVH, carrying the A3243G mtDNA mutation and 10 healthy subjects underwent one-dimensional chemical shift imaging P-31-MRS. In the patients, mean cardiac phosphocreatine to adenosine triphosphate ratio (PCr/ATP) (1.55 +/- 0.58) was significantly reduced compared to the control group (2.34 +/- 0.14; P<0.001). Cardiac PCr/ATP was within the normal range only in one case that showed normal echocardiography. Our results point to a central role of bioenergetics deficit in the development of cardiac hypertrophy in patients with the A3243G mtDNA mutation. Impaired cardiac energy metabolism in patients with normal echocardiography suggests that the enhancement of mitochondrial function may be beneficial not only to patients with cardiac hypertrophy but also to those patients carrying the mutation in the absence of signs of cardiac hypertrophy and/or dysfunction but with cardiac bioenergetics deficit. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Bologna, Policlin S Orsola, Dipartimento Med Clin & Biotechnol Applicata D Ca, I-40138 Bologna, Italy.
   Univ Oxford, Dept Biochem, MRC Biochem & Clin Magnet Resonance Unit, Oxford, England.
   Oxford Radcliffe Hosp, Oxford, England.
   Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Oxford; University of Oxford; Newcastle University - UK
RP Univ Bologna, Policlin S Orsola, Dipartimento Med Clin & Biotechnol Applicata D Ca, Via Massarenti 9, I-40138 Bologna, Italy.
EM raffaele.lodi@unibo.it
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7
   Barbiroli B, 1999, J CEREBR BLOOD F MET, V19, P528, DOI 10.1097/00004647-199905000-00007
   Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215
   Blamire AM, 1999, MAGN RESON MED, V41, P198, DOI 10.1002/(SICI)1522-2594(199901)41:1<198::AID-MRM28>3.0.CO;2-H
   BOTTOMLEY PA, 1994, MAGNET RESON MED, V32, P137, DOI 10.1002/mrm.1910320120
   Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Crilley JG, 2000, J AM COLL CARDIOL, V36, P1953, DOI 10.1016/S0735-1097(00)00960-8
   DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z
   Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704
   Lerman-Sagie T, 2001, J INHERIT METAB DIS, V24, P28, DOI 10.1023/A:1005642302316
   Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492
   Lodi R, 2001, CARDIOVASC RES, V52, P111, DOI 10.1016/S0008-6363(01)00357-1
   Lodi R, 2001, ANN NEUROL, V49, P590
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa-Voltti Kirsi, 2002, BMC CARDIOVASC DISORD, V2, P12
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   RABINOWITZ M, 1974, CIRC RES, V35, P3
   RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   Slotboom J, 1998, MAGNET RESON MED, V39, P899, DOI 10.1002/mrm.1910390607
   VEECH RL, 1979, J BIOL CHEM, V254, P6538
   Wikstrand J, 1997, J HYPERTENS, V15, P811, DOI 10.1097/00004872-199715080-00003
NR 34
TC 24
Z9 24
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD JUL 9
PY 2004
VL 1657
IS 2-3
BP 146
EP 150
DI 10.1016/j.bbabio.2004.05.003
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 838ST
UT WOS:000222734200007
PM 15238271
DA 2024-11-01
ER

PT J
AU Lenaz, G
   Baracca, A
   Carelli, V
   D'Aurelio, M
   Sgarbi, G
   Solaini, G
AF Lenaz, G
   Baracca, A
   Carelli, V
   D'Aurelio, M
   Sgarbi, G
   Solaini, G
TI Bioenergetics of mitochondrial diseases associated with mtDNA mutations
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE mitochondrial cytopathy; LHON; NARP; complex I; ATP synthase; cytochrome oxidase subunit III
ID cytochrome-c-oxidase; hereditary optic neuropathy; dna t8993g mutation; subunit-iii; complex-i; rhodobacter-sphaeroides; proton uptake; d-pathway; oxygen; site
AB This mini-review summarizes our present view of the biochemical alterations associated with mitochondrial DNA (mtDNA) point mutations. Mitochondrial cytopathies caused by mutations of mtDNA are well-known genetic and clinical entities, but the biochemical pathogenic mechanisms are often obscure. Leber's hereditary optic neuropathy (LHON) is due to three main mutations in genes for complex I subunits. Even if the catalytic activity of complex I is maintained except in cells carrying the 3460/ND1 mutation, in all cases there is a change in sensitivity to complex I inhibitors and an impairment of mitochondrial respiration, eliciting the possibility of generation of reactive oxygen species (ROS) by the complex. eurogenic muscle weakness, Ataxia and Retinitis Pigmentosa (HARP), is due to a mutation in the ATPase-6 gene. In NARP patients ATP synthesis is strongly depressed to an extent proportional to the mutation load; nevertheless, ATP hydrolysis and ATP-driven proton translocation are not affected. It is suggested that the NARP mutation affects the ability of the enzyme to couple proton transport to ATP synthesis. A point mutation in subunit III of cytochrome c oxidase is accompanied by a syndrome resembling MELAS: however, no major biochemical defect is found, if we except an enhanced production of ROS. The mechanism of such enhancement is at present unknown. In this review, we draw attention to a few examples in which the overproduction of ROS might represent a common step in the induction of clinical phenotypes and/or in the progression of several human pathologies associated with mtDNA point mutations. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Bologna, Dipartimento Biochim, I-40126 Bologna, Italy.
   Univ Bologna, Dipartimento Sci Neurol, I-40126 Bologna, Italy.
   Univ Pisa, Scuola Super & Perfezionamento S Anna, I-56127 Pisa, Italy.
C3 University of Bologna; University of Bologna; University of Pisa; Scuola Superiore Sant'Anna
RP Univ Bologna, Dipartimento Biochim, Via Irnerio 48, I-40126 Bologna, Italy.
EM lenaz@biocfarm.unibo.it
FU Telethon [GGP02323] Funding Source: Medline
CR Baracca A, 2003, BBA-BIOENERGETICS, V1606, P137, DOI 10.1016/S0005-2728(03)00110-5
   Baracca A, 2000, J BIOL CHEM, V275, P4177, DOI 10.1074/jbc.275.6.4177
   Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188
   Brown MD, 1999, J NEUROL SCI, V165, P1, DOI 10.1016/S0022-510X(99)00087-8
   Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.3.CO;2-C
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Carelli V, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2nd, P115
   COCK HR, 1995, AM J HUM GENET, V57, P1501
   ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6
   Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   Ghelli A, 1997, MOL ASPECTS MED, V18, P0
   Gilderson G, 2003, BIOCHEMISTRY-US, V42, P7400, DOI 10.1021/bi0341298
   HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x
   Hanson BJ, 2001, J BIOL CHEM, V276, P16296, DOI 10.1074/jbc.M011162200
   Hoffbuhr KC, 2000, J BIOL CHEM, V275, P13994, DOI 10.1074/jbc.275.18.13994
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KLEISTRETZOW JC, 2003, EXP PHYSIOL, V88, P155
   Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121
   Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957
   Lenaz G, 2001, FEBS LETT, V509, P151, DOI 10.1016/S0014-5793(01)03172-6
   Lincoln AJ, 2003, ARCH BIOCHEM BIOPHYS, V416, P81, DOI 10.1016/S0003-9861(03)00202-9
   Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x
   Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x
   MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Mather MW, 1998, FEBS LETT, V433, P93, DOI 10.1016/S0014-5793(98)00891-6
   McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372
   Meunier B, 2001, BIOCHEM J, V354, P407, DOI 10.1042/0264-6021:3540407
   Mills DA, 2003, BIOCHEMISTRY-US, V42, P7410, DOI 10.1021/bi0341307
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 44
TC 84
Z9 92
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 0006-3002
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD JUL 23
PY 2004
VL 1658
IS 1-2
BP 89
EP 94
DI 10.1016/j.bbabio.2004.03.013
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 845KA
UT WOS:000223240100013
PM 15282179
DA 2024-11-01
ER

PT J
AU Hao, R
   Yao, YN
   Zheng, YG
   Xu, MG
   Wang, ED
AF Hao, R
   Yao, YN
   Zheng, YG
   Xu, MG
   Wang, ED
TI Reduction of mitochondrial tRNA <SUP>Leu</SUP>(UUR) aminoacylation by some MELAS-associated mutations
SO FEBS LETTERS
LA English
DT Article
DE human mitochondrion; MELAS-related mutation; tRNA(Leu)(UUR); aminoacylation
ID lactic-acidosis; episodes melas; trna(leu(uur)) mutation; point mutation; encephalopathy; myopathy; synthetase; gene; polymerase; cells
AB The mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome (MELAS) is a rare congenital disorder of mitochondrial DNA. Five single nucleotide substitutions within the human mitochondrial tRNA (Leu)(UUR) gene have been reported to be associated with MELAS. Here, we provide in vitro evidence that the aminoacylation capacities of these five hmtRNA (Leu)(UUR) transcripts are reduced to different extents relative to the wild-type hmtRNA (Leu)(UUR) transcript. A thermal denaturation experiment showed that the A3243G and T3291C mutants, which were the least charged by LeuRS, have fragile structures. In addition, the T3291C mutant can inhibit aminoacylation of the wild-type hmtRNA (Leu)(UUR), indicating that it may act as an inhibitor in the mitochondrial heteroplasmic environment. (C) 2004 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
C1 Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Beijing 100864, Peoples R China.
   Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences
RP Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Beijing 100864, Peoples R China.
EM edwang@sibs.ac.cn
CR Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Enríquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207
   Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Li Y, 1999, PROTEIN EXPRES PURIF, V16, P355, DOI 10.1006/prep.1999.1083
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Piechota Janusz, 2001, JOURNAL OF APPLIED GENETICS, V42, P351
   PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304
   QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Sohm N, 2004, J MOL BIOL, V339, P17, DOI 10.1016/j.jmb.2004.03.066
   SOLL D, 1990, EXPERIENTIA, V46, P1089
   Takai D, 1999, J BIOL CHEM, V274, P11199, DOI 10.1074/jbc.274.16.11199
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Yao YN, 2003, PROTEIN EXPRES PURIF, V30, P112, DOI 10.1016/S1046-5928(03)00097-4
   Yao YN, 2003, FEBS LETT, V534, P139, DOI 10.1016/S0014-5793(02)03833-4
NR 30
TC 23
Z9 28
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
EI 
J9 FEBS LETT
JI FEBS Lett.
PD DEC 3
PY 2004
VL 578
IS 1-2
BP 135
EP 139
DI 10.1016/j.febslet.2004.11.004
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 878MI
UT WOS:000225650500025
PM 15581630
DA 2024-11-01
ER

PT J
AU Samuels, DC
   Schon, EA
   Chinnery, PF
AF Samuels, DC
   Schon, EA
   Chinnery, PF
TI Two direct repeats cause most human mtDNA deletions
SO TRENDS IN GENETICS
LA English
DT Article
ID human mitochondrial-dna; progressive external ophthalmoplegia; kearns-sayre syndrome; recombination; replication; sequences; region; model; duplication; myopathy
AB Mitochondrial DNA (mtDNA) deletions are a common cause of human mitochondrial disease and also occur as part of normal aging. However, it is unknown how the deletions actually occur. To gain further insight, we studied the sequences that flank 263 different human mtDNA deletions. The distribution of deletion breakpoints did not correspond to the basic parameters of wild-type mtDNA that are thought to predispose to deletion formation. But there was a striking correspondence to the position of two 13-bp direct repeats beginning at nucleotides 8470 and 13447. The vast majority of different mtDNA deletions appear to be related to these two repeats, suggesting a common mechanism related to mtDNA replication.
C1 Newcastle Univ, Sch Med, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
   Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10031 USA.
   Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10031 USA.
C3 Newcastle University - UK; Virginia Polytechnic Institute & State University; Columbia University; Columbia University
RP Newcastle Univ, Sch Med, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU NICHD NIH HHS [HD 32062] Funding Source: Medline; NINDS NIH HHS [NS 39854, NS 28828] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   Barrientos A, 1996, AM J HUM GENET, V58, P963
   BAUMER A, 1994, AM J HUM GENET, V54, P618
   BLOK RB, 1995, HUM GENET, V95, P75
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BUROKER NE, 1990, GENETICS, V124, P157
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   de Massy B, 2003, TRENDS GENET, V19, P514, DOI 10.1016/S0168-9525(03)00201-4
   DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   Eisenbarth I, 2000, AM J HUM GENET, V67, P873, DOI 10.1086/303085
   Fullerton SM, 2001, MOL BIOL EVOL, V18, P1139, DOI 10.1093/oxfordjournals.molbev.a003886
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Lakshmipathy U, 1999, NUCLEIC ACIDS RES, V27, P1198, DOI 10.1093/nar/27.4.1198
   LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5
   LARSSON NG, 1992, BIOCHIM BIOPHYS ACTA, V1139, P311, DOI 10.1016/0925-4439(92)90106-W
   LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   Marzuki S, 1997, J NEUROL SCI, V145, P155, DOI 10.1016/S0022-510X(96)00241-9
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MIYABAYASHI S, 1991, J INHERIT METAB DIS, V14, P805, DOI 10.1007/BF01799954
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, MOL CELL BIOL, V11, P1631, DOI 10.1128/MCB.11.3.1631
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Negrier MLM, 1998, AM J HUM GENET, V63, P1227, DOI 10.1086/302045
   NELSON I, 1989, CR HEBD ACAD SCI, V1, P403
   Rocher C, 2002, MOL GENET METAB, V76, P123, DOI 10.1016/S1096-7192(02)00024-0
   Saiwaki T, 2000, J CLIN PATHOL-MOL PA, V53, P333, DOI 10.1136/mp.53.6.333
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Servidei Serenella, 2003, NEUROMUSCUL DISORD, V13, P848
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Solano A, 2003, J MED GENET, V40, P0, DOI 10.1136/jmg.40.7.e86
   TRINH TQ, 1993, GENETICS, V134, P409
   WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 142
Z9 165
U1 0
U2 5
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0168-9525
EI 1362-4555
J9 TRENDS GENET
JI Trends Genet.
PD SEP 15
PY 2004
VL 20
IS 9
BP 393
EP 398
DI 10.1016/j.tig.2004.07.003
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 852AC
UT WOS:000223726600001
PM 15313545
DA 2024-11-01
ER

PT J
AU Crimi, M
   Papadimitriou, A
   Galbiati, S
   Palamidou, P
   Fortunato, F
   Bordoni, A
   Papandreou, U
   Papadimitriou, D
   Hadjigeorgiou, GM
   Drogari, E
   Bresolin, N
   Comi, GP
AF Crimi, M
   Papadimitriou, A
   Galbiati, S
   Palamidou, P
   Fortunato, F
   Bordoni, A
   Papandreou, U
   Papadimitriou, D
   Hadjigeorgiou, GM
   Drogari, E
   Bresolin, N
   Comi, GP
TI A new mitochondrial DNA mutation in ND3 gene causing severe Leigh syndrome with early lethality
SO PEDIATRIC RESEARCH
LA English
DT Article
ID complex-i deficiency; missense mutation; disease; patient
AB We describe a new mitochondrial DNA mutation in a male infant who presented clinical and magnetic resonance imaging features of Leigh syndrome and died at the age of 9 mo. The patient's development was reportedly normal in the first months of life. At the age of 5 mo, he presented severe generalized hypotonia, nystagmus, and absent eye contact. Laboratory examination showed increased lactate and pyruvate in both serum and cerebrospinal fluid. Brain magnetic resonance imaging revealed multiple necrotic lesions in the basal ganglia, brain stem, and thalamus. Muscle histopathology was unremarkable, whereas respiratory chain enzyme analysis revealed a severe complex I deficiency. The patient died after an acidotic coma at age 9 mo. Sequence analysis of the entire mtDNA disclosed a new T10158C mutation with variable tissue heteroplasm (muscle: 83%; blood: 48%). The mutation was undetectable in the blood of his unaffected mother. The transition changes a serine residue into a proline, in a highly conserved region of the NADH dehydrogenase subunit 3 (ND3). This is the first description of a mitochondrial ND3 gene in Leigh syndrome with early lethality.
C1 Univ Milan, IRCCS Osped Maggiore Policlin, Ctr Exxellenza Malattie Neurodegenerat, Dept Neurol Sci,Ctr Dino Ferrari, I-20122 Milan, Italy.
   Res Cross Hosp, Athens 11526, Greece.
   Univ Thessaly, Larisa 41222, Greece.
   Univ Athens, St Sophias Childrens Hosp, Dept Pediat 1, Athens, Greece.
   IRCCS Eugenio Medea, I-23842 Bosisio Parini, LC, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Thessaly; National & Kapodistrian University of Athens; IRCCS Eugenio Medea
RP Univ Milan, Dipartimento Sci Neurol, Via F Sforza 35, I-20122 Milan, Italy.
EM neurogene@policlinico.mi.it
FU Telethon [GTF02008] Funding Source: Medline
CR Bar-Meir M, 2001, J PEDIATR-US, V139, P868, DOI 10.1067/mpd.2001.118885
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Crimi Marco, 2002, HUM MUTAT, V20, P409, DOI 10.1002/humu.9079
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   VANERVEN PMM, 1987, ARCH NEUROL-CHICAGO, V44, P775, DOI 10.1001/archneur.1987.00520190079019
   VANERVEN PMM, 1986, NEUROPEDIATRICS, V17, P28, DOI 10.1055/s-2008-1052495
   Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6
   WALLACE DC, 2003, MITOMAP HUMAN MITOCH, V0, P0
NR 20
TC 61
Z9 68
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD MAY 15
PY 2004
VL 55
IS 5
BP 842
EP 846
DI 10.1203/01.PDR.0000117844.73436.68
PG 5
WC Pediatrics
SC Pediatrics
GA 813VK
UT WOS:000220934400018
PM 14764913
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Haller, RG
AF Taivassalo, T
   Haller, RG
TI Implications of exercise training in mtDNA defects - use it or lose it?
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE mitochondrial myopathy; mtDNA defect; exercise intolerance; treatment; endurance and resistance training; satellite cell
ID cytochrome-c-oxidase; transcription factor-a; human skeletal-muscle; mitochondrial-dna; contractile activity; satellite cells; point mutation; oxygen-uptake; older men; adaptations
AB Whether regular exercise is beneficial or should be avoided is a question currently unsettled in patients with heteroplasmic mitochondrial DNA (mtDNA) disorders of skeletal muscle. Deleterious effects of habitual physical inactivity superimposed upon impaired mitochondrial oxidative phosphorylation may contribute to varying degrees of exercise intolerance in these patients. Endurance exercise training is widely known to improve exercise capacity in healthy subjects and various chronic-disease patient populations. Although we have shown that beneficial physiological and biochemical responses to training increase exercise tolerance in patients with mtDNA defects, knowledge of the muscle adaptive response to endurance training within the setting of mitochondrial heteroplasmy remains limited. In order to determine advisability of endurance training as therapy, it remains to be established whether potential endurance training-induced increases in mutant mtDNA levels may be offset by increases in absolute wild-type mtDNA levels, and whether chronic inactivity leads to a selective downregulation of wild-type mtDNA. Resistance training utilizes a different adaptive exercise approach to induce the transfer of normal mitochondrial templates from satellite cells to mature muscle fibers of patients with sporadic mtDNA disorders. The efficacy and safety of this approach needs to be further established. Our current inability to clearly advise patients to "use it or lose it'' underscores the immediate urgency of studying the effects of exercise on skeletal muscle of patients with heteroplasmic mtDNA defects. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Texas, SW Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX 75231 USA.
   Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75231 USA.
   Dallas VA Med Ctr, Dallas, TX USA.
C3 University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas
RP Taivassalo, T (corresponding author), Univ Texas, SW Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, 7232 Greenville Ave,Suite 435, Dallas, TX 75231 USA.
EM tanjataivassalo@texashealth.org
CR Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505
   BISCHOFF R, 1994, MYOGENESIS, V2, P97
   BOOTH FW, 1977, J BIOL CHEM, V252, P416
   CHEEK DB, 1985, EARLY HUM DEV, V12, P211, DOI 10.1016/0378-3782(85)90144-6
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857
   Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   Essig D A, 1996, EXERC SPORT SCI REV, V24, P289
   FAULKNER JA, 1977, MED SCI SPORT EXER, V9, P148
   Flück M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   HALLER RG, 1983, NEUROLOGY, V33, P1283, DOI 10.1212/WNL.33.10.1283
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   HALLER RG, 1994, MYOLOGY BASIC CLIN, V2, P807
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   HENRIKSSON J, 1992, DIABETES CARE, V15, P1701, DOI 10.2337/diacare.15.11.1701
   Heslop L, 2000, J CELL SCI, V113, P2299
   Hikida RS, 2000, J GERONTOL A-BIOL, V55, PB347, DOI 10.1093/gerona/55.7.B347
   Hood D A, 2000, EXERC SPORT SCI REV, V28, P68
   HOUSTON ME, 1986, BIOCH EXERCISE, V4, P63
   Ivey FM, 2000, J GERONTOL A-BIOL, V55, PM641, DOI 10.1093/gerona/55.11.M641
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   KLAUSEN K, 1981, ACTA PHYSIOL SCAND, V113, P9, DOI 10.1111/j.1748-1716.1981.tb06854.x
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   MCCOMAS AJ, 1994, MED SCI SPORT EXER, V26, P1498
   MITCHELL JH, 1971, NEW ENGL J MED, V284, P1018, DOI 10.1056/NEJM197105062841809
   MOORE RL, 1987, J APPL PHYSIOL, V63, P1719, DOI 10.1152/jappl.1987.63.5.1719
   Mujika I, 2001, MED SCI SPORT EXER, V33, P1297, DOI 10.1097/00005768-200108000-00009
   NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004
   Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032
   Roth SM, 2001, J GERONTOL A-BIOL, V56, PB240, DOI 10.1093/gerona/56.6.B240
   Sale DG, 1998, MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, V20, P135
   SALTIN B, 1980, FED PROC, V39, P1506
   Saltin B, 1983, COMPREHENSIVE PHYSIOLOGY, V0, P555
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2002, MED SCI SPORTS EXERC, V34, P0
   TESCH PA, 1989, J APPL PHYSIOL, V83, P67
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 53
TC 36
Z9 37
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD DEC 6
PY 2004
VL 1659
IS 2-3
BP 221
EP 231
DI 10.1016/j.bbabio.2004.09.007
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 882KT
UT WOS:000225938500016
PM 15576055
DA 2024-11-01
ER

PT J
AU Urata, M
   Wada, Y
   Kim, SH
   Chumpia, W
   Kayamori, Y
   Hamasaki, N
   Kang, DC
AF Urata, M
   Wada, Y
   Kim, SH
   Chumpia, W
   Kayamori, Y
   Hamasaki, N
   Kang, DC
TI High-sensitivity detection of the A3243G mutation of mitochondrial DNA by a combination of allele-specific PCR and peptide nucleic acid-directed PCR clamping
SO CLINICAL CHEMISTRY
LA English
DT Article
ID diabetes-mellitus; muscle; accumulation; sequences; features; network; mtdna; blood; cell
AB Background: The A3243G mutation of mitochondrial DNA (mtDNA) is involved in many common diseases, including diabetes mellitus and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS). For detection of this mutation, allele-specific PCR is highly sensitive but requires strict control of PCR conditions; it thus is not adequate for a routine clinical test. We aimed to develop a routinely available PCR method for quantitative detection of low-level heteroplasmy of the A3243G mutation. Methods: Quantitative allele-specific PCR for the A3243G mutation was performed in the presence of peptide nucleic acid (PNA), in which PNA is complementary to the wild-type mtDNA, with one primer having a 3' end matched to nucleotide position 3243 of the mutant. Results: With our method, amplification of wild-type mtDNA was suppressed 7000-fold compared with amplification of the mutant mtDNA under a broad range of conditions: DNA, 5-100 ng; annealing temperature, 61-66 degreesC; and PNA, 1.5-3.5 mumol/L. Hence, 0.1% heteroplasmy of the A3243G mutation can be reliably quantified by this method. Blood samples form 40 healthy volunteers showed <0.06% heteroplasmy, suggesting that 0.1% is diagnostically significant. Conclusions: PNA maintains the specificity of allele-specific PCR over a wide range of conditions, which is important for routine clinical testing. (C) 2004 American Association for Clinical Chemistry.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan.
   Daegue Univ, Dept Biol Educ, Kyungsan, South Korea.
   Mahidol Univ, Inst Sci & Technol Res & Dev, Thalassemia Res Ctr, Nakhon Pathom, Thailand.
C3 Kyushu University; Mahidol University
RP Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM kang@mailserver.med.kyushu-u.ac.jp
CR Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   Kong QP, 2003, AM J HUM GENET, V73, P671, DOI 10.1086/377718
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Nomiyama T, 2002, DIABETOLOGIA, V45, P1577, DOI 10.1007/s00125-002-0893-7
   Puomila A, 2002, J NEUROL SCI, V205, P41, DOI 10.1016/S0022-510X(02)00276-9
   Rotig A, 1996, DIABETES METAB, V22, P291
   SMITH ML, 1997, J CLIN ENDOCR METAB, V82, P2816
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   Suzuki Y, 1997, J NEUROL SCI, V145, P49, DOI 10.1016/S0022-510X(96)00239-0
   Urata M, 1998, CLIN CHEM, V44, P2088
   Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 26
TC 28
Z9 36
U1 0
U2 4
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD NOV 15
PY 2004
VL 50
IS 11
BP 2045
EP 2051
DI 10.1373/clinchem.2004.033761
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 865QL
UT WOS:000224717500016
PM 15364886
DA 2024-11-01
ER

PT J
AU Okun, MS
   Bhatti, MT
AF Okun, MS
   Bhatti, MT
TI SANDO: Another presentation of mitochondrial disease
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
ID neuropathy
AB PURPOSE: To describe a unique mitochondrial syndrome that may present with the combination of ocular manifestations, sensory symptoms, and speech dysfunction. DESIGN: Case report. METHODS: Case report and review of the literature. RESULTS: A 43-year-old man presented with a Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis (SANDO). Nerve conduction studies showed a sensory ganglionopathy. Skeletal muscle biopsy revealed ragged red fibers, and polymerase chain reaction analysis of the tissue demonstrated multiple mitochondrial DNA deletions. CONCLUSION: Mitochondrial disease should be considered in cases of external ophthalmoplegia, especially if a sensory ganglionopathy and dysarthria are present.
C1 Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida
RP Bhatti, MT (corresponding author), Univ Florida, Coll Med, Dept Ophthalmol, Box 100284, Gainesville, FL 32610 USA.
EM tbhatti@eye.ufl.edu
CR BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   COLAN RV, 1980, ANN NEUROL, V8, P441, DOI 10.1002/ana.410080419
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Newman NJ, 1992, OPHTHALMOL CLIN N AM, V5, P405
NR 4
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY 15
PY 2004
VL 137
IS 5
BP 951
EP 953
DI 10.1016/j.ajo.2003.10.046
PG 3
WC Ophthalmology
SC Ophthalmology
GA 820KA
UT WOS:000221386400030
PM 15126171
DA 2024-11-01
ER

PT J
AU Graziewicz, MA
   Longley, MJ
   Bienstock, RJ
   Zeviani, M
   Copeland, WC
AF Graziewicz, MA
   Longley, MJ
   Bienstock, RJ
   Zeviani, M
   Copeland, WC
TI Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID multiple deletions; escherichia-coli; klenow fragment; gamma-a; mutations; alignment; binding; mtdna; identification; replication
AB Progressive external ophthalmoplegia (PEO) is a mitochondrial disorder associated with mutations in the POLG gene encoding the mitochondrial DNA polymerase (pol gamma). Four autosomal dominant mutations that cause PEO encode the amino acid substitutions G923D, R943H, Y955C and A957S in the polymerase domain of pol gamma. A homology model of the pol gamma catalytic domain in complex with DNA was developed to investigate the effects of these mutations. Two mutations causing the most severe disease phenotype, Y955C and R943H, change residues that directly interact with the incoming dNTP. Polymerase mutants exhibit 0.03 - 30% wild-type polymerase activity and a 2- to 35-fold decrease in nucleotide selectivity in vitro. The reduced selectivity and catalytic efficiency of the autosomal dominant PEO mutants predict in vivo dysfunction, and the extent of biochemical defects correlates with the clinical severity of the disease.
C1 NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA.
   NIEHS, Comp Sci Lab, NIH, Res Triangle Pk, NC 27709 USA.
   Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland.
   Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, I-20126 Milan, Italy.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0
   POLESKY AH, 1990, J BIOL CHEM, V265, P14579
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 36
TC 108
Z9 123
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD AUG 15
PY 2004
VL 11
IS 8
BP 770
EP 776
DI 10.1038/nsmb805
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 841LF
UT WOS:000222930600022
PM 15258572
DA 2024-11-01
ER

PT J
AU Walsh, EJ
   Souza, S
   Gerschenson, M
   Shikuma, C
   Chow, D
AF Walsh, EJ
   Souza, S
   Gerschenson, M
   Shikuma, C
   Chow, D
TI HIV disease progression and limited antiretroviral treatment options for a HIV-1 infected individual with myoclonic epilepsy associated with ragged red fibers
SO MITOCHONDRION
LA English
DT Article
DE highly active antiretroviral therapy; nucleoside reverse transcriptase inhibitors; protease inhibitors
ID mitochondrial toxicity; antiviral drugs; mutation; merrf
AB We describe a 50-year-old Caucasian man with a family history of myoclonic epilepsy associated with ragged red fibers (MERRF) and a diagnosis of Human Immunodeficiency Virus (HIV). The patient had multiple risk factors for contracting HIV and was being followed in our clinic at the time of his diagnosis. Initial testing following seroconversion revealed a baseline CD4 + T-lymphocyte count of 652 x 10(6) cells/1 and a HIV-1 RNA of 14,781 copies/ml. He reported exercise intolerance and had mild neurologic deficits, which worsened around the time of HIV seroconversion. These symptoms led to his subsequent diagnosis of MERRF by the detection of the A8344G point mutation in the tRNA(Lys) gene of mitochondrial DNA (mtDNA). The baseline estimated proportion of mutant genome was 39%. He showed a rapid course of HIV disease progression with a CD4 + T-lymphocyte nadir of 174 x 10(6) cells/1 associated with a HIV-1 RNA of 238,178 copies/ml, within 17 months following HIV seroconversion. To avoid further mitochondrial insult, which could result from the use of a standard nucleoside reverse transcriptase inhibitor-containing regimen, a protease inhibitor regimen consisting of hard-gel saquinavir (Invirase((TM))), and lopinavir/ritonavir (Kaletra((TM))) was chosen for this patient. The patient's CD4+ T-lymphocyte count increased to 282 x 10(6) cells/1 and his viral load became undetectable 7 months following the initiation of antiretroviral therapy. His neurologic symptoms did not worsen on this antiretroviral regimen. When initiating HIV therapy in individuals with metabolic myopathies related to mitochondrial dysfunction, it may be important to design an antiviral regimen that minimizes mitochondrial damage, yet effectively maintains durable viral suppression. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Hawaii Manoa, Leohi Hosp, John A Burns Sch Med, Hawaii AIDS Clin Res Program, Honolulu, HI 96816 USA.
C3 University of Hawaii System; University of Hawaii Manoa
RP Univ Hawaii Manoa, Leohi Hosp, John A Burns Sch Med, Hawaii AIDS Clin Res Program, 3675 Kilauea Ave,Young Bldg 5th Floor, Honolulu, HI 96816 USA.
EM dominicc@hawaii.edu
FU NCRR NIH HHS [U54 RR014607-05, P20 RR011091-11, G12 RR003061-20] Funding Source: Medline
CR Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Dagan T, 2002, MITOCHONDRION, V1, P397, DOI 10.1016/S1567-7249(02)00003-X
   Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001
   GERSCHENSON M, 2004, IN PRESS MITOCHONDRI, V0, P0
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Santorelli FM, 1998, ANN NEUROL, V44, P962, DOI 10.1002/ana.410440616
   Shikuma Cecilia M, 2001, CURR INFECT DIS REP, V3, P553, DOI 10.1007/s11908-001-0094-4
   SHOFFNER JM, 1992, AM J HUM GENET, V51, P1179
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 13
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUL 15
PY 2004
VL 4
IS 2-3
BP 169
EP 173
DI 10.1016/j.mito.2004.05.013
PG 5
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 865ZU
UT WOS:000224743500009
PM 16120382
DA 2024-11-01
ER

PT J
AU Jacobs, LJAM
   Jongbloed, RJE
   Wijburg, FA
   de Klerk, JBC
   Geraedts, JPM
   Nijland, JG
   Scholte, HR
   de Coo, IFM
   Smeets, HJM
AF Jacobs, LJAM
   Jongbloed, RJE
   Wijburg, FA
   de Klerk, JBC
   Geraedts, JPM
   Nijland, JG
   Scholte, HR
   de Coo, IFM
   Smeets, HJM
TI Pearson syndrome and the role of deletion dimers and duplications in the mtDNA
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID mitochondrial-dna deletion; marrow-pancreas-syndrome; diabetes-mellitus; rearrangements; myopathy
AB Pearson syndrome is an often fatal multisystem disease associated with mitochondrial DNA rearrangements. Here we report a patient with a novel mtDNA deletion of 3.4 kb ranging from nucleotides 6097 to 9541 in combination with deletion dimers. The mutation percentage in different tissues <LF>(blood, muscle and liver) varied between 64% and 95%. After a remission period of about a year, the patient suddenly died at the age of 3 years owing to a severe lactic acidosis. A second patient with a previously reported deletion of 8 kb and a milder phenotype was found to have mitochondrial duplications and died at the age of 10 years. From these data and data from previous reports, we hypothesize that duplications might be beneficial in the clinical course of the disease and in life expectancy.
C1 Univ Maastricht, Dept Genet & Cell Biol, Res Inst Growth & Dev GROW, NL-6200 MD Maastricht, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Paediat, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Biochem, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Neurol, Rotterdam, Netherlands.
C3 Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Univ Maastricht, Dept Genet & Cell Biol, Res Inst Growth & Dev GROW, POB 616, NL-6200 MD Maastricht, Netherlands.
EM bert.smeets@molcelb.unimaas.nl
CR BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   DIMAURO, 1993, MOL GENETIC BASIS NE, V0, P665
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   Hsieh RH, 2002, FERTIL STERIL, V77, P1012, DOI 10.1016/S0015-0282(02)02994-1
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   *MITOMAP, 2001, MITOMAP HUM MIT GEN, V0, P0
   Muraki K, 2001, AM J MED GENET, V98, P205, DOI 10.1002/1096-8628(20010122)98:3<205::AID-AJMG1077>3.0.CO;2-P
   OTA Y, 1994, RETINA-J RET VIT DIS, V14, P270, DOI 10.1097/00006982-199414030-00015
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1994, NAT GENET, V8, P313, DOI 10.1038/ng1294-313
   POULTON J, 1995, MUSCLE NERVE S, V3, P154
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   SAMBROOK J, 1998, MOL CLONING LAB MANU, V0, P0
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   TANAKA M, 1989, BIOCHEM BIOPH RES CO, V164, P156, DOI 10.1016/0006-291X(89)91696-3
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
NR 24
TC 20
Z9 20
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD JUN 15
PY 2004
VL 27
IS 1
BP 47
EP 55
DI 10.1023/B:BOLI.0000016601.49372.18
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 774YG
UT WOS:000189013500005
PM 14970745
DA 2024-11-01
ER

PT J
AU Pineda, M
   Solano, A
   Artuch, R
   Andreu, AL
   Playan, A
   Vilaseca, MA
   Colomer, J
   Briones, P
   Casademont, J
   Montoya, J
AF Pineda, M
   Solano, A
   Artuch, R
   Andreu, AL
   Playan, A
   Vilaseca, MA
   Colomer, J
   Briones, P
   Casademont, J
   Montoya, J
TI Peripheral neuropathy with ataxia in childhood as a result of the G8363A mutation in mitochondrial DNA
SO PEDIATRIC RESEARCH
LA English
DT Article
ID sensory neuropathy; myoclonus epilepsy; respiratory-chain; trna(lys); gene
AB Peripheral neuropathy has been identified in children with mitochondrial encephalomyopathies but not as a main clinical landmark. Here we report the clinical, electrophysiologic, biochemical, and genetic findings in a family who harbors the G8363A mutation in the tRNALys gene of mitochondrial DNA. Affected individuals presented with peripheral neuropathy and ataxia as the main clinical sign. Additional involvement included muscle weakness and multiple lipomatosis. Other common clinical characteristics associated with the G8363A mutation, such as cardiomyopathy and myoclonus epilepsy, were not observed. These findings suggest that a mitochondrial disease should be considered in the differential diagnosis of children with heredoataxic syndrome and peripheral neuropathy of unknown origin.
C1 Clin Hosp Sant Joan Deu, Serv Neuropediat, Unitat Integrada, Barcelona 08950, Spain.
   Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, E-50013 Zaragoza, Spain.
   Univ Barcelona, Hosp Gen Valle Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain.
   CSIC, Inst Bioquim Clin, Barcelona 08280, Spain.
   Clin Hosp Sant Joan Deu, Serv Bioquim & Med Interna, Unitat Integrada, Barcelona 08950, Spain.
C3 University of Zaragoza; University of Barcelona; Hospital Universitari Vall d'Hebron; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)
RP Clin Hosp Sant Joan Deu, Serv Neuropediat, Unitat Integrada, Passeig St,Joan Deu 2, Barcelona 08950, Spain.
EM pineda@hsjdben.org
CR Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   ARTUCH R, 1995, EUR J CLIN CHEM CLIN, V33, P529
   Artuch R, 2000, CLIN BIOCHEM, V33, P481, DOI 10.1016/S0009-9120(00)00137-5
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Casali C, 1999, NEUROLOGY, V52, P1103, DOI 10.1212/WNL.52.5.1103
   FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4
   Gámez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   HARDING AE, 1993, ADV NEUROL, V61, P1
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   MIZUSAWA H, 1991, REV NEUROL, V147, P501
   OUVRIER RA, 1999, PERIPHERAL NEUROPATH, V0, P188
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Rubio-Gozalbo ME, 2000, NEUROPEDIATRICS, V31, P114, DOI 10.1055/s-2000-7491
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Shtilbans A, 2000, J CHILD NEUROL, V15, P759, DOI 10.1177/088307380001501109
   SUBRAMONY SH, 1995, J CHILD NEUROL, V10, P353, DOI 10.1177/088307389501000503
   Suzuki Y, 2002, DIABETES CARE, V25, P407, DOI 10.2337/diacare.25.2.407
   vanDomburg PHMF, 1996, BRAIN, V119, P997, DOI 10.1093/brain/119.3.997
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
NR 21
TC 9
Z9 10
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD JUL 15
PY 2004
VL 56
IS 1
BP 55
EP 59
DI 10.1203/01.PDR.0000130475.20571.98
PG 5
WC Pediatrics
SC Pediatrics
GA 831WE
UT WOS:000222226400010
PM 15128915
DA 2024-11-01
ER

PT J
AU Miller, C
   Saada, A
   Shaul, N
   Shabtai, N
   Ben-Shalom, E
   Shaag, A
   Hershkovitz, E
   Elpeleg, O
AF Miller, C
   Saada, A
   Shaul, N
   Shabtai, N
   Ben-Shalom, E
   Shaag, A
   Hershkovitz, E
   Elpeleg, O
TI Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID subunit; complement; myopathy; s16; dna
AB The mitochondrial respiratory chain comprises 85 subunits, 13 of which are mitochondrial encoded. The synthesis of these 13 proteins requires many nuclear-encoded proteins that participate in mitochondrial DNA replication, transcript production, and a distinctive mitochondrial translation apparatus. We report a patient with agenesis of corpus callosum, dysmorphism, and fatal neonatal lactic acidosis with markedly decreased complex I and IV activity in muscle and liver and a generalized mitochondrial translation defect identified in pulse-label experiments. The defect was associated with marked reduction of the 12S rRNA transcript level likely attributed to a nonsense mutation in the MRPS16 gene. A new group of mitochondrial respiratory chain disorders is proposed, resulting from mutations in nuclear encoded components of the mitochondrial translation apparatus.
C1 Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
   Ben Gurion Univ Negev, Soroka Med Ctr, Fac Med, Dept Pediat, IL-84105 Beer Sheva, Israel.
   Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem
RP Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
EM elpeleg@cc.huji.ac.il
CR Allard P, 2000, STRUCT FOLD DES, V8, P875, DOI 10.1016/S0969-2126(00)00177-5
   Bonnefoy E, 1997, EUR J BIOCHEM, V247, P852, DOI 10.1111/j.1432-1033.1997.t01-1-00852.x
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   CHOMYN A, 1996, METHOD ENZYMOL, V264, P196
   DENNIS PP, 1975, J BACTERIOL, V121, P994, DOI 10.1128/JB.121.3.994-999.1975
   DOOIJEWAARD G, 1976, BIOCHIM BIOPHYS ACTA, V440, P1, DOI 10.1016/0005-2728(76)90109-2
   HOPPEL C, 1969, ARCH BIOCHEM BIOPHYS, V135, P173, DOI 10.1016/0003-9861(69)90528-1
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200
   Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Toivonen JM, 2001, GENETICS, V159, P241
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
NR 16
TC 178
Z9 201
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD NOV 15
PY 2004
VL 56
IS 5
BP 734
EP 738
DI 10.1002/ana.20282
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 869FR
UT WOS:000224969300020
PM 15505824
DA 2024-11-01
ER

PT J
AU Akman, CI
   Sue, CM
   Shanske, S
   Tanji, K
   Bonilla, E
   Ojaimi, J
   Krishna, S
   Schubert, R
   DiMauro, S
AF Akman, CI
   Sue, CM
   Shanske, S
   Tanji, K
   Bonilla, E
   Ojaimi, J
   Krishna, S
   Schubert, R
   DiMauro, S
TI Mitochondrial DNA deletion in a child with megaloblastic anemia and recurrent encephalopathy
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID marrow-pancreas syndrome; kearns-sayre syndrome; pearson marrow; mtdna; encephalomyopathy; genome
AB A 3 1/2-year-old boy presented with megaloblastic anemia and recurrent episodes of severe lactic acidosis and coma. At age 4 years, he developed sepsis and died; postmortem examination failed to show any gross abnormality in any tissue. Biochemical analysis of muscle showed decreased activities for all respiratory chain enzymes except complex II. Muscle histochemistry revealed diffuse cytochrome c oxidase deficiency. Southern blot analysis of mitochondrial DNA from muscle, liver, and blood showed a heteroplasmic single mitochindrial DNA deletion of 2.4 kb, which removed the genes for cytochrome c oxidase I and II and the transfer ribonucleic acid genes for serine and aspartic acid. Single large-scale deletions in mitochondrial DNA have been associated with Pearson's syndrome, Kearns-Sayre syndrome, and progressive external ophthalmoplegia. This patient's presentation is unusual and suggests an overlap between Pearson's syndrome and Kearns-Sayre syndrome.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   SUNY Brooklyn, Hlth Sci Ctr, Dept Neurol, Brooklyn, NY USA.
   SUNY Brooklyn, Hlth Sci Ctr, Div Pediat Neurol, Brooklyn, NY USA.
C3 Columbia University; State University of New York (SUNY) System; SUNY Downstate Health Sciences University; State University of New York (SUNY) System; SUNY Downstate Health Sciences University
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR CORMIER V, 1991, AM J HUM GENET, V48, P643
   CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5
   DEVRIES DD, 1992, NEUROMUSCULAR DISORD, V2, P185, DOI 10.1016/0960-8966(92)90005-Q
   DiMauro S, 1998, BBA-BIOENERGETICS, V1366, P199, DOI 10.1016/S0005-2728(98)00113-3
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Muraki K, 1997, J INHERIT METAB DIS, V20, P697, DOI 10.1023/A:1005378527077
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320
   SUPERTIFURGA A, 1993, EUR J PEDIATR, V152, P44, DOI 10.1007/BF02072515
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 17
TC 10
Z9 10
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD APR 15
PY 2004
VL 19
IS 4
BP 258
EP 261
DI 10.1177/088307380401900403
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 820VZ
UT WOS:000221419000003
PM 15163090
DA 2024-11-01
ER

PT J
AU D'Souza, GGM
   Weissig, V
AF D'Souza, GGM
   Weissig, V
TI Approaches to mitochondrial gene therapy
SO CURRENT GENE THERAPY
LA English
DT Review
ID peptide nucleic-acid; mammalian-cells; ornithine transcarbamylase; rna/dna oligonucleotides; restriction-endonuclease; dqasome/dna complexes; nucleotide exchange; cationic bolasm; targeted delivery; dna heteroplasmy
AB Since their discovery during the end of the 80's the number of diseases found to be associated with defects in the mitochondrial genome has grown significantly. Organs affected by mutations in mitochondrial DNA (mtDNA) include in decreasing order of vulnerability the brain, skeletal muscle, heart, kidney and liver. Hence neuromuscular and neurodegenerative diseases represent the two largest groups of mtDNA diseases. Despite major advances in understanding mtDNA defects at the genetic and biochemical level, there is however no satisfactory treatment available to the vast majority of patients. This is largely due to the fact that most of these patients have respiratory chain defects, i.e. defects that involve the final common pathway of oxidative metabolism, making it impossible to bypass the defect by administering alternative metabolic carriers of energy. Conventional biochemical treatment having reached an impasse, the exploration of gene therapeutic approaches for patients with mtDNA defects is warranted. For now mitochondrial gene therapy appears to be only theoretical and speculative. Any possibility for gene replacement is dependent on the development of an efficient mitochondrial transfection vector. In this review we describe the current state of the development of mitochondria-specific DNA delivery systems. We summarize our own efforts in exploring the properties of dequalinium and other similar cationic bolaamphiphiles with delocalized charge centers, for the design of a vector suited for the transport of DNA to mitochondria in living cells. Further, we outline some unique hurdles that need to be overcome if the development of such delivery systems is to progress.
C1 Northeastern Univ, Dept Pharmaceut Sci, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
C3 Northeastern University
RP D'Souza, GGM (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
EM dsouza.g@ncu.edu
CR Allen JF, 2003, PHILOS T R SOC B, V358, P19, DOI 10.1098/rstb.2002.1191
   Attardi Giuseppe M, 2001, SCIENTIFICWORLDJOURNAL, V1, P76, DOI 10.1100/tsw.2001.133
   Bandyopadhyay P, 1999, J BIOL CHEM, V274, P10163, DOI 10.1074/jbc.274.15.10163
   Bigger BW, 2001, J BIOL CHEM, V276, P23018, DOI 10.1074/jbc.M010873200
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Butow R A, 1996, METHODS ENZYMOL, V264, P265, DOI 10.1016/S0076-6879(96)64026-9
   BUTOW RA, 1990, TRENDS BIOCHEM SCI, V15, P465, DOI 10.1016/0968-0004(90)90299-Q
   Chen ZY, 2001, BIOCHEM BIOPH RES CO, V285, P188, DOI 10.1006/bbrc.2001.5156
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Chrzanowska-Lightowlers ZM, 1999, GENE, V230, P241, DOI 10.1016/S0378-1119(99)00082-7
   Collombet JM, 1997, J BIOL CHEM, V272, P5342, DOI 10.1074/jbc.272.8.5342
   DSouza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168-3659(03)00297-9
   de Grey ADNJ, 2000, TRENDS BIOTECHNOL, V18, P394, DOI 10.1016/S0167-7799(00)01476-1
   De Vivo Darryl C, 1993, P39, V0, P0
   Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230
   Entelis NS, 1998, P NATL ACAD SCI USA, V95, P2838, DOI 10.1073/pnas.95.6.2838
   Entelis NS, 2001, J BIOL CHEM, V276, P45642, DOI 10.1074/jbc.M103906200
   Flierl A, 2003, MOL THER, V7, P550, DOI 10.1016/S1525-0016(03)00037-6
   GERGORIADIS G, 2000, TARGETING DRUGS STRA, V0, P0
   Geromel V, 2001, ANTISENSE NUCLEIC A, V11, P175, DOI 10.1089/108729001300338708
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   HARDING AE, 1991, TRENDS NEUROSCI, V14, P132, DOI 10.1016/0166-2236(91)90081-5
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 2002, METHODS, V26, P358, DOI 10.1016/S1046-2023(02)00042-7
   JACOBS HT, 1991, J MOL EVOL, V32, P333, DOI 10.1007/BF02102192
   James AM, 2003, EUR J BIOCHEM, V270, P2827, DOI 10.1046/j.1432-1033.2003.03660.x
   JAUSLIN ML, 2003, FASEB J, V0, P0
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954
   Kagawa Y, 2001, ADV DRUG DELIVER REV, V49, P107, DOI 10.1016/S0169-409X(01)00129-6
   Kagawa Y, 1997, GENE THER, V4, P6, DOI 10.1038/sj.gt.3300347
   Kazakova HA, 1999, FEBS LETT, V442, P193, DOI 10.1016/S0014-5793(98)01653-6
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kren BT, 2003, DNA REPAIR, V2, P531, DOI 10.1016/S1568-7864(03)00022-3
   Kren BT, 2002, GENE THER, V9, P686, DOI 10.1038/sj.gt.3301762
   Kren BT, 2002, METHOD ENZYMOL, V346, P14
   Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626
   LACORAZZA HD, 1995, GENE THER, V2, P22
   Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Mukhopadhyay A, 2003, J BIOL CHEM, V278, P13712, DOI 10.1074/jbc.M212743200
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8
   NAGLEY P, 1989, TRENDS BIOCHEM SCI, V14, P31, DOI 10.1016/0968-0004(89)90087-X
   Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   Owen R, 2000, HUM GENE THER, V11, P2067, DOI 10.1089/104303400750001381
   Owen R, 2001, ANTIOXID REDOX SIGN, V3, P451, DOI 10.1089/15230860152409086
   Papa S, 1996, MOL ASPECTS MED, V17, P513
   Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   ROLLAND A, 1999, ADV GENE DELIVERY, V0, P0
   Ross GF, 2003, BIOCONJUGATE CHEM, V14, P962, DOI 10.1021/bc034050f
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519
   Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5
   SCHEFFLER IE, 1999, EVOLUTIONARY ORIGIN, V0, P7
   SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10
   Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x
   SOBOL RE, 1995, INTERNET BOOK GENE T, V0, P0
   SOLIGNAC M, 1983, P NATL ACAD SCI-BIOL, V80, P6942, DOI 10.1073/pnas.80.22.6942
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   SULLIVAN S, 2003, LIPSOMES PRACTICAL A, V0, P0
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor D, 2000, IEEE INTELL SYST APP, V15, P2
   Taylor RW, 2000, NEUROL SCI, V21, PS909, DOI 10.1007/s100720070002
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Taylor RW, 2001, ADV DRUG DELIVER REV, V49, P121, DOI 10.1016/S0169-409X(01)00130-2
   Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536
   VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Weissig V, 2000, DRUG DELIV, V7, P1, DOI 10.1080/107175400266722
   Weissig V, 2001, STP PHARMA SCI, V11, P91
   Weissig V, 2001, ADV DRUG DELIVER REV, V49, P127, DOI 10.1016/S0169-409X(01)00131-4
   Weissig V, 2001, J CONTROL RELEASE, V75, P401, DOI 10.1016/S0168-3659(01)00392-3
   Weissig V, 2001, J DRUG TARGET, V9, P1
   Wheeler VC, 1996, GENE, V169, P251, DOI 10.1016/0378-1119(95)00812-8
   Wheeler VC, 1997, GENE, V198, P203, DOI 10.1016/S0378-1119(97)00315-6
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   Yoon YG, 2003, NUCLEIC ACIDS RES, V31, P1407, DOI 10.1093/nar/gkg228
   ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997
   Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91
   Zimmer KP, 1999, MOL MED, V5, P244, DOI 10.1007/BF03402122
   Zullo SJ, 2001, SEMIN NEUROL, V21, P327, DOI 10.1055/s-2001-17949
NR 94
TC 25
Z9 32
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PD SEP 15
PY 2004
VL 4
IS 3
BP 317
EP 328
DI 
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 864CW
UT WOS:000224611800008
PM 15384945
DA 2024-11-01
ER

PT J
AU Joseph, AM
   Rungi, AA
   Robinson, BH
   Hood, DA
AF Joseph, AM
   Rungi, AA
   Robinson, BH
   Hood, DA
TI Compensatory responses of protein import and transcription factor expression in mitochondrial DNA defects
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE mitochondrial biogenesis; skeletal muscle; rho(-) cells; mitochondrial disease; peroxisome proliferator-activated receptor-gamma coactivator-1 alpha
ID abnormal calcium homeostasis; contractile activity; thyroid-hormone; mammalian-cells; intermembrane space; ethidium-bromide; muscle-cells; hela-cells; nuclear; fibroblasts
AB Defects in mitochondrial DNA (mtDNA) evoke distinctive responses in the nuclear genome, leading to altered mitochondrial biogenesis. We used C2C12 cells depleted of mtDNA (rho(-) cells) and fibroblasts from a mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS) patient to examine adaptations of the protein import machinery and transcription factors involved in mitochondrial biogenesis. In rho(-) cells, Tom20 and Tim23 protein levels were reduced by 25% and 59%, whereas mtHSP70 was induced by twofold relative to control cells. These changes were accompanied by a 21% increase in enhanced yellow fluorescent protein (EYFP) import into mitochondria in rho(-) cells (P < 0.05). In contrast, in MELAS cells mtHSP70 was elevated by 70%, whereas Tom20 and Tom34 protein levels were increased by 45% and 112% relative to control values. EYFP import was not altered in MELAS cells. In rho(-) cells, protein levels of the transcription factors nuclear respiratory factor-1 (NRF-1) and transcription factor A (Tfam) declined by 33% and 54%, whereas no change was observed for the coactivator peroxisome proliferator receptor-gamma coactivator-1 alpha (PGC-1 alpha). In contrast, Tfam was increased by 40% in MELAS cells. Rho(-) cells displayed reduced oxygen consumption ((V) over dot o(2)) and ATP levels, along with a twofold increase in lactate levels (P < 0.05). In electrically stimulated C2C12 cells, 109%, 78%, 60%, and 67% increases were observed in mtDNA, (V) over dot o(2), cytochrome-c oxidase (COX) activity, and Tom34 levels, respectively (P < 0.05). Our findings suggest that compensatory adaptations occurred to maintain normal rates of protein import in response to mtDNA defects and support a role for contractile activity in reducing pathophysiology associated with mtDNA depletion. Because the expression of nuclear-encoded transcription factors and protein import machinery components was dependent on the type of mtDNA defect, these findings suggest involvement of distinct signaling cascades, each dependent on the type of mitochondrial defect, resulting in divergent changes in nuclear gene expression patterns.
C1 York Univ, Dept Biol, N York, ON M3J 1P3, Canada.
   York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
   Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
C3 York University - Canada; York University - Canada; University of Toronto; Hospital for Sick Children (SickKids)
RP York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.
EM dhood@yorku.ca
CR Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Boudreau-Larivière C, 2000, AM J PHYSIOL-REG I, V278, PR140, DOI 10.1152/ajpregu.2000.278.1.R140
   Chewawiwat N, 1999, J BIOCHEM, V125, P721, DOI 10.1093/oxfordjournals.jbchem.a022342
   Colavecchia M, 2003, AM J PHYSIOL-ENDOC M, V284, PE29, DOI 10.1152/ajpendo.00294.2002
   Connor MK, 2001, J BIOL CHEM, V276, P15898, DOI 10.1074/jbc.M100272200
   Craig EE, 1998, AM J PHYSIOL-CELL PH, V275, PC1508, DOI 10.1152/ajpcell.1998.275.6.C1508
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1
   GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grey JY, 2000, AM J PHYSIOL-CELL PH, V279, PC1393, DOI 10.1152/ajpcell.2000.279.5.C1393
   Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200
   Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9
   HUCKRIEDE A, 1994, BBA-MOL BASIS DIS, V1227, P200, DOI 10.1016/0925-4439(94)90096-5
   Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001
   Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510
   Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, PC1669, DOI 10.1152/ajpcell.00409.2002
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534
   LI K, 1995, AM J PHYSIOL-CELL PH, V269, PC1265, DOI 10.1152/ajpcell.1995.269.5.C1265
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   Murakami T, 1998, BBA-GEN SUBJECTS, V1381, P113, DOI 10.1016/S0304-4165(98)00018-X
   Rungi AA, 2002, BBA-MOL BASIS DIS, V1586, P146, DOI 10.1016/S0925-4439(01)00072-2
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, PC1380, DOI 10.1152/ajpcell.1998.274.5.C1380
   Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wasniewska M, 2001, BIOCHEM BIOPH RES CO, V283, P687, DOI 10.1006/bbrc.2001.4834
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459
NR 40
TC 60
Z9 74
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD APR 1
PY 2004
VL 286
IS 4
BP C867
EP C875
DI 10.1152/ajpcell.00191.2003
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 800MR
UT WOS:000220032900017
PM 14656719
DA 2024-11-01
ER

PT J
AU Thambisetty, M
   Newman, NJ
AF Thambisetty, M
   Newman, NJ
TI Diagnosis and management of MELAS
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE encephalopathy; gene therapy; heteroplasmy; MELAS; ragged red fibers; stroke
ID stroke-like episodes; mitochondrial trna(leu(uur)) mutation; magnetic-resonance-spectroscopy; a3243g point mutation; kearns-sayre syndrome; red fibers merrf; lactic-acidosis; prenatal-diagnosis; overlap syndrome; mtdna mutation
AB Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) Is the most common maternally Inherited mitochondrial disease. An A-->G mutation in the transfer RNA(Leu(UUR)) gene at position 3243 of the mitochondrial DNA accounts for most MELAS cases. The transient nature of the stroke-like episodes is reflected In abnormalities on neuroimaging. The cardinal laboratory abnormalities Include elevated serum lactate during the acute episodes and respiratory enzyme defects in skeletal muscle. Muscle biopsy also helps confirm the diagnosis by Identifying abnormal proliferation of mitochondria. Although current treatment options for MELAS are largely supportive, several therapeutic approaches have been attempted with limited success. Genetic counseling is an Important component of patient management In MELAS. Newer reproductive technologies hold promise for reducing the recurrence of MELAS in subsequent generations. Advances in research Into gene therapy offer hope of treatment for the future.
C1 Emory Univ, Ctr Eye, Neuroopthalmol Unit, Atlanta, GA 30322 USA.
   Kings Coll London, Inst Psychiat, Sect Old Age Psychiat, London SE5 8AF, England.
   Kings Coll London, Inst Psychiat, Dept Neurol, London SE5 8AF, England.
C3 Emory University; University of London; King's College London; University of London; King's College London
RP Emory Univ, Ctr Eye, Neuroopthalmol Unit, 1365-B Clifton Rd NE, Atlanta, GA 30322 USA.
EM ophinjn@emory.edu
FU NEI NIH HHS [P30-EYO] Funding Source: Medline
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ABE K, 1991, ACTA NEUROL SCAND, V83, P356, DOI 10.1111/j.1600-0404.1991.tb03962.x
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Biousse V, 2001, SEMIN NEUROL, V21, P275, DOI 10.1055/s-2001-17945
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Briones P, 2001, EUR J PAEDIATR NEUROL, V5, P127, DOI 10.1053/ejpn.2001.0483
   Calvani M, 1993, P173, V0, P0
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   DiMauro S, 2000, NEUROL SCI, V21, P0
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   Filippi M, 2003, LANCET NEUROL, V2, P337, DOI 10.1016/S1474-4422(03)00408-3
   GODA S, 1987, J NEUROL, V234, P62, DOI 10.1007/BF00314013
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1991, ANN NEUROL, V30, P299
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kuroda Y, 1997, J PEDIATR-US, V131, P450, DOI 10.1016/S0022-3476(97)80075-3
   Latkany P, 1999, AM J OPHTHALMOL, V128, P112, DOI 10.1016/S0002-9394(99)00057-4
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Lescuyer P, 2003, PROTEOMICS, V3, P157, DOI 10.1002/pmic.200390024
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   MATSUOKA T, 1991, J NEUROL SCI, V106, P193, DOI 10.1016/0022-510X(91)90257-8
   MATTHEWS PM, 1991, NEUROLOGY, V41, P1043, DOI 10.1212/WNL.41.7.1043
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Nakada K, 2001, SEMIN CELL DEV BIOL, V12, P459, DOI 10.1006/scdb.2001.0283
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohkoshi N, 1998, J MED, V29, P13
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Oppenheim C, 2000, J NEUROL NEUROSUR PS, V69, P248, DOI 10.1136/jnnp.69.2.248
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Ruitenbeek W, 1996, J INHERIT METAB DIS, V19, P581, DOI 10.1007/BF01799118
   SAIJO T, 1991, NEUROPEDIATRICS, V22, P166, DOI 10.1055/s-2008-1071436
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Schaefer PW, 2001, J NEUROIMAGING, V11, P369, DOI 10.1111/j.1552-6569.2001.tb00065.x
   Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113
   SCHOFFNER JM, 1997, CURRENT THERAPY NEUR, V0, P332
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Shanske Sara, 1997, CURRENT OPINION IN RHEUMATOLOGY, V9, P496, DOI 10.1097/00002281-199711000-00004
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   STACPOOLE PW, 1988, ANN INTERN MED, V108, P58, DOI 10.7326/0003-4819-108-1-58
   STACPOOLE PW, 1992, DIABETES CARE, V15, P785, DOI 10.2337/diacare.15.6.785
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 2000, NEUROL SCI, V21, PS909, DOI 10.1007/s100720070002
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Thambisetty M, 2002, NEUROLOGIST, V8, P302, DOI 10.1097/00127893-200209000-00003
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   YAMAMOTO T, 1984, NEUROLOGY, V34, P1456, DOI 10.1212/WNL.34.11.1456
   YANG CY, 1995, CLIN ENDOCRINOL, V43, P235, DOI 10.1111/j.1365-2265.1995.tb01922.x
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
   Yorifuji T, 1996, J MED GENET, V33, P621, DOI 10.1136/jmg.33.7.621
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 100
TC 36
Z9 45
U1 0
U2 8
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD SEP 15
PY 2004
VL 4
IS 5
BP 631
EP 644
DI 10.1586/14737159.4.5.631
PG 14
WC Pathology
SC Pathology
GA 853KD
UT WOS:000223825500008
PM 15347257
DA 2024-11-01
ER

PT J
AU Tarnopolsky, MA
   Bourgeois, JM
   Fu, MH
   Kataeva, G
   Shah, J
   Simon, DK
   Mahoney, D
   Johns, D
   MacKay, N
   Robinson, BH
AF Tarnopolsky, MA
   Bourgeois, JM
   Fu, MH
   Kataeva, G
   Shah, J
   Simon, DK
   Mahoney, D
   Johns, D
   MacKay, N
   Robinson, BH
TI Novel SCO2 mutation (G1521A) presenting as a spinal muscular atrophy type I phenotype
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE mitochondrial disease; Werdnig-Hoffman; nuclear mutation; cytochrome oxidase deficiency
ID c-oxidase deficiency; hypertrophic cardiomyopathy; mitochondrial-dna; gene; features; protein; mngie
AB Rare cases of suspected spinal muscular atrophy (SMA) have been found to have cytochrome c oxidase (COX) deficiency. To date, four cases with SMA features have been reported in children with mutations in the synthesis of cytochrome oxidase 2 (SCO2) gene. We report a male neonate who was born hypotonic, with persistent lactic acidosis, spontaneous activity with EMG testing, development of respiratory distress in the first few hours of life, and died at 30 days of age with progressive cardiomyopathy. Testing for survival motor neurone (smn) and NAIP deletions were negative and a skeletal muscle biopsy showed neurogenic features with severe reductions of COX enzymatic and histochemical staining intensity. Postmortem muscle, heart, and liver biopsies showed severe, moderate, and mild reductions in COX activity, respectively, with parallel findings in the protein content for the mitochondrial DNA (COII) and nuclear DNA (COIV) encoded subunits. DNA sequencing of exon 2 of the SCO2 gene revealed compound heterozygosity with mutations at G1541A (common mutation, E140K) and also at a novel site in the copper binding region (G1521A in the current case (converting a highly conserved cysteine to serine (C133S)); mother heterozygous for G1521A; and father heterozygous for G1541A). This case provides strong support that SCO2 mutations can result in neonatal hypotonia with an SMA 1 phenotype. SCO2 mutations should be screened in suspected SMA cases with normal smn mutation analysis and any one of; cardiomyopathy, lactic acidosis, or COX deficiency in muscle. (C) 2003 Wiley-Liss, Inc.
C1 McMaster Univ, Med Ctr, Dept Neurol, Hamilton, ON L8N 3Z5, Canada.
   Univ Toronto, Dept Biochem, Toronto, ON, Canada.
   Univ Toronto, Dept Pediat, Toronto, ON, Canada.
   Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada.
   Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
   McMaster Univ, Inst Mol Biol & Biotechnol MOBIX & Pediat, Hamilton, ON, Canada.
   McMaster Univ, Inst Mol Biol & Biotechnol MOBIX, Hamilton, ON, Canada.
   McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   McMaster Univ, Dept Phys Med & Rehabil, Hamilton, ON, Canada.
C3 McMaster University; University of Toronto; University of Toronto; University of Toronto; Hospital for Sick Children (SickKids); Harvard University; Beth Israel Deaconess Medical Center; McMaster University; McMaster University; McMaster University; McMaster University
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Med Ctr, Dept Neurol, Rm 4U4,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
CR Akita Y, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU15>3.0.CO;2-B
   Carter SL, 2001, CAN J PHYSIOL PHARM, V79, P386, DOI 10.1139/cjpp-79-5-386
   Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110
   Dickinson EK, 2000, J BIOL CHEM, V275, P26780
   HIRUTA Y, 1995, INTERNAL MED, V34, P670, DOI 10.2169/internalmedicine.34.670
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, PE580, DOI 10.1152/ajpendo.2000.278.4.E580
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Rubio-Gozalbo ME, 1999, NEUROLOGY, V52, P383, DOI 10.1212/WNL.52.2.383
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Simon DK, 1999, ANNU REV MED, V50, P111
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055
NR 20
TC 43
Z9 47
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0148-7299
EI 
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD MAR 15
PY 2004
VL 125A
IS 3
BP 310
EP 314
DI 10.1002/ajmg.a.20466
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 779TK
UT WOS:000189316800016
PM 14994243
DA 2024-11-01
ER

PT J
AU Bai, RK
   Wong, LJC
AF Bai, RK
   Wong, LJC
TI Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: A single-step approach
SO CLINICAL CHEMISTRY
LA English
DT Article
ID blood; cells
AB Background: The A3243G mitochondrial tRNA leu(UUR) point mutation causes mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, the most common mitochondrial DNA (mtDNA) disorder, and is also found in patients with maternally inherited diabetes and deafness syndrome (MIDD). To correlate disease manifestation with mutation loads, it is necessary to measure the percentage of the A3243G mtDNA mutation. Methods: To reliably quantify low proportions of the mutant mtDNA, we developed a real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay. We validated the method with experimental samples containing known proportions of mutant A3243G mtDNA generated by mixing known amounts of cloned plasmid DNA containing either the wild-type or the mutant sequences. Results: A correlation coefficient of 0.9995 between the expected and observed values for the proportions of mutant A3243G in the experimental samples was found. Evaluation of a total of 36 patient DNA samples demonstrated consistent results between PCR-restriction fragment length polymorphism (RFLP) analysis and real-time ARMS-qPCR. However, the latter method was much more sensitive for detecting low percentages of mutant heteroplasmy. Three samples contained allele-specific oligonucleotide-detectable but RFLP-undetectable mutations. Conclusions: The real-time ARMS-qPCR method provides rapid, reliable, one-step quantitative detection of heteroplasmic mutant mtDNA. (C) 2004 American Association for Clinical Chemistry.
C1 Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
C3 Georgetown University
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, M4000,3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DIMAURO S, 2003, MOL GENETIC BASIS NE, V0, P189
   Hammond EL, 2003, J CLIN VIROL, V27, P97, DOI 10.1016/S1386-6532(02)00134-8
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Nomiyama T, 2002, DIABETOLOGIA, V45, P1577, DOI 10.1007/s00125-002-0893-7
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2003, J MED GENET, V40, P0
NR 20
TC 127
Z9 156
U1 0
U2 32
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JUN 15
PY 2004
VL 50
IS 6
BP 996
EP 1001
DI 10.1373/clinchem.2004.031153
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 827BR
UT WOS:000221873800003
PM 15073091
DA 2024-11-01
ER

PT J
AU Deschauer, M
   Krasnianski, A
   Zierz, S
   Taylor, RW
AF Deschauer, M
   Krasnianski, A
   Zierz, S
   Taylor, RW
TI False-positive diagnosis of a single, large-scale mitochondrial DNA deletion by Southern blot analysis: The role of neutral polymorphisms
SO GENETIC TESTING
LA English
DT Article
ID progressive external ophthalmoplegia; kearns-sayre syndrome; mtdna control region; mutations; myopathy; muscle; heteroplasmy; neuropathy; disorder; disease
AB Single, large-scale deletions of mitochondrial DNA ( mtDNA) are a common finding in the molecular investigation of patients with suspected mitochondrial disorders and are typically detected by Southern blot analysis of muscle DNA that has been linearized by a single cutter enzyme ( BamHI or PvuII). We describe our investigations of a 47-year-old woman with exercise intolerance, myalgia, and ptosis who underwent a muscle biopsy for a suspected mitochondrial genetic abnormality. Southern blot analysis after digestion of muscle DNA with BamHI revealed the apparent presence of two mtDNA species, indicative of a heteroplasmic deletion of 2.0 - 2.5 kb in length involving approximately 50% of all molecules. Contrary to this observation, long-range polymerase chain reaction (PCR) amplified only wild-type mtDNA. Sequence analysis revealed that the patient harbored two previously recognized control region polymorphisms, a homoplasmic 16390G > A variant that introduces a new BamHI site and a heteroplasmic 16390G > A change that abolishes this site, thus explaining the initial false-positive testing for a heteroplasmic mtDNA deletion. Our findings highlight the potential problems associated with the diagnosis of mitochondrial genetic disease and emphasize the need to confirm positive cases of mtDNA deletions using more than one enzyme or an independent method such as long-range PCR amplification.
C1 Univ Halle Wittenberg, Neurol Klin & Poliklin, Dept Neurol, D-06097 Halle Saale, Germany.
   Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK
RP Deschauer, M (corresponding author), Univ Halle Wittenberg, Neurol Klin & Poliklin, Dept Neurol, Ernst Grube Str 40, D-06097 Halle Saale, Germany.
EM marcus.deschauer@medizin.uni-halle.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BENDALL KE, 1995, AM J HUM GENET, V57, P248
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 2000, AM J HUM GENET, V66, P1589, DOI 10.1086/302910
   JOHNS DR, 1993, AM J HUM GENET, V53, P916
   Kirby DM, 1998, MOL DIAGN, V3, P211, DOI 10.1016/S1084-8592(98)80042-8
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   White SL, 1998, MOL DIAGN, V3, P113, DOI 10.1016/S1084-8592(98)80059-3
   Yamamoto M, 1996, MUSCLE NERVE, V19, P928
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 24
TC 8
Z9 9
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1090-6576
EI 
J9 GENET TEST
JI Genet. Test.
PD DEC 15
PY 2004
VL 8
IS 4
BP 395
EP 399
DI 10.1089/gte.2004.8.395
PG 5
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 888ZU
UT WOS:000226413900006
PM 15684869
DA 2024-11-01
ER

PT J
AU Valentino, ML
   Barboni, P
   Ghelli, A
   Bucchi, L
   Rengo, C
   Achilli, A
   Torroni, A
   Lugaresi, A
   Lodi, R
   Barbiroli, B
   Dotti, MT
   Federico, A
   Baruzzi, A
   Carelli, V
AF Valentino, ML
   Barboni, P
   Ghelli, A
   Bucchi, L
   Rengo, C
   Achilli, A
   Torroni, A
   Lugaresi, A
   Lodi, R
   Barbiroli, B
   Dotti, MT
   Federico, A
   Baruzzi, A
   Carelli, V
TI The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID magnetic-resonance spectroscopy; mitochondrial-dna mutations; mtdna mutations; skeletal-muscle; european mtdna; vivo; haplogroups; expression; sequence; disease
AB A novel mitochondrial DNA (mtDNA) transition (3733G-->A) inducing the E143 K amino acid change at a very conserved site of the NADH dehydrogenase subunit 1 (ND1) was identified in a family with six maternally related individuals with Leber's hereditary optic neuropathy (LHON) and in an unrelated sporadic case, all negative for known mutations and presenting with the canonical phenotype. The transition was not detected in 1,082 control mtDNAs and was heteroplasmic in several individuals from both pedigrees. In addition, the mtDNAs of the two families were found to belong to different haplogroups (H and X), thus confirming that the 3733G-->A mutation occurred twice independently. Phosphorus magnetic resonance spectroscopy disclosed an in vivo brain and skeletal muscle energy metabolism deficit in the four examined patients. Muscle biopsy from two patients showed slight mitochondrial proliferation with abnormal mitochondria. Biochemical investigations in platelets showed partially insensitive complex 1 to rotenone inhibition. We conclude that the 3733G-->A transition is a novel cause of LHON and, after those at positions 3460 and 4171, is the third ND1 mutation to be identified in multiple unrelated families. This finding shows that, in addition to ND6, the ND1 subunit gene is also a mutational hot spot for LHON.
C1 Univ Bologna, Dipartimento Sci Neurol, I-40123 Bologna, Italy.
   Univ Bologna, Ctr Oftalmol, I-40126 Bologna, Italy.
   Univ Bologna, Dipartimento Biol Evoluzionist Sperimentale, I-40126 Bologna, Italy.
   Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy.
   Univ G dAnnunzio, Dipartimento Oncol & Neurosci, Chieti, Italy.
   Univ Bologna, Dipartimento Med Clin & Biotecnol Applicata D Cam, I-40126 Bologna, Italy.
   Univ Siena, Dipartimento Sci Neurol Comportamento, I-53100 Siena, Italy.
C3 University of Bologna; University of Bologna; University of Bologna; University of Pavia; G d'Annunzio University of Chieti-Pescara; University of Bologna; University of Siena
RP Univ Bologna, Dipartimento Sci Neurol, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
EM carelli@neuro.unibo.it
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ARNOLD DL, 1984, MAGNET RESON MED, V1, P307, DOI 10.1002/mrm.1910010303
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brown MD, 1999, J NEUROL SCI, V165, P1, DOI 10.1016/S0022-510X(99)00087-8
   Brown MD, 2001, HUM GENET, V109, P33, DOI 10.1007/s004390100538
   BROWN MD, 1992, GENETICS, V130, P163
   Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2
   Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.3.CO;2-C
   Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2nd, P115
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0
   ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6
   Fauser S, 2002, BIOCHEM BIOPH RES CO, V295, P342, DOI 10.1016/S0006-291X(02)00672-1
   Fauser Sascha, 2002, OPHTHALMIC GENET, V23, P191, DOI 10.1076/opge.23.3.191.7881
   FEDERICO A, 1988, J INHERIT METAB DIS, V11, P193, DOI 10.1007/BF01804233
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   GHELLI A, 1994, THESIS U BOLOGNA BOL, V0, P0
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Howell N, 1998, AM J HUM GENET, V62, P196, DOI 10.1086/301675
   Howell N, 1999, INT REV CYTOL, V186, P49
   HOWELL N, 1991, AM J HUM GENET, V48, P935
   HUOPONEN K, 1993, HUM GENET, V92, P379, DOI 10.1007/BF01247339
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   IOTTI S, 1993, NMR BIOMED, V6, P248, DOI 10.1002/nbm.1940060404
   Kim JY, 2002, ANN NEUROL, V51, P630, DOI 10.1002/ana.10177
   Kivisild T, 2002, MOL BIOL EVOL, V19, P1737, DOI 10.1093/oxfordjournals.molbev.a003996
   Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896
   Lodi R, 1997, ANN NEUROL, V42, P573, DOI 10.1002/ana.410420407
   Lodi R, 2002, J NEUROL NEUROSUR PS, V72, P805, DOI 10.1136/jnnp.72.6.805
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Matsumoto M, 1999, OPHTHALMIC GENET, V20, P153, DOI 10.1076/opge.20.3.153.2281
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   Reidla M, 2003, AM J HUM GENET, V73, P1178, DOI 10.1086/379380
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 42
TC 92
Z9 100
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD NOV 15
PY 2004
VL 56
IS 5
BP 631
EP 641
DI 10.1002/ana.20236
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 869FR
UT WOS:000224969300005
PM 15505787
DA 2024-11-01
ER

PT J
AU Kaufmann, P
   Shungu, DC
   Sano, MC
   Jhung, S
   Engelstad, K
   Mitsis, E
   Mao, X
   Shanske, S
   Hirano, M
   DiMauro, S
   De Vivo, DC
AF Kaufmann, P
   Shungu, DC
   Sano, MC
   Jhung, S
   Engelstad, K
   Mitsis, E
   Mao, X
   Shanske, S
   Hirano, M
   DiMauro, S
   De Vivo, DC
TI Cerebral lactic acidosis correlates with neurological impairment in MELAS
SO NEUROLOGY
LA English
DT Article
ID ischemic cell-damage; stroke-like episodes; ragged-red fibers; mitochondrial myopathy; hippocampal-neurons; brain; mutation; glia; encephalomyopathy; encephalopathy
AB Objective: To evaluate the role of chronic cerebral lactic acidosis in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes ( MELAS). Methods: The authors studied 91 individuals from 34 families with MELAS and the A3243G point mutation and 15 individuals from two families with myoclonus epilepsy and ragged red fibers ( MERRF) and the A8344G mutation. Subjects were divided into four groups. Paternal relatives were studied as controls ( Group 1). The maternally related subjects were divided clinically into three groups: asymptomatic ( no clinical evidence of neurologic disease) ( Group 2), oligosymptomatic ( neurologic symptoms but without the full clinical picture of MELAS or MERRF) ( Group 3), and symptomatic ( fulfilling MELAS or MERRF criteria) ( Group 4). The authors performed a standardized neurologic examination, neuropsychological testing, MRS, and leukocyte DNA analysis in all subjects. Results: The symptomatic and oligosymptomatic MELAS subjects had significantly higher ventricular lactate than the other groups. There was a significant correlation between degree of neuropsychological and neurologic impairment and cerebral lactic acidosis as estimated by ventricular MRS lactate levels. Conclusions: High levels of ventricular lactate, the brain spectroscopic signature of MELAS, are associated with more severe neurologic impairment.
C1 Columbia Univ, Neurol Inst, New York, NY 10032 USA.
   Columbia Univ, Dept Pediat, New York, NY 10027 USA.
   Columbia Univ, Dept Radiol, New York, NY USA.
   Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia University
RP Columbia Univ, Neurol Inst, 710 W 168th St, New York, NY 10032 USA.
EM dcd1@columbia.edu
CR Anderson RE, 1999, STROKE, V30, P160, DOI 10.1161/01.STR.30.1.160
   BALENTINE JD, 1987, ACTA NEUROPATHOL, V73, P233, DOI 10.1007/BF00686616
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   De Vivo D C, 2001, CURR NEUROL NEUROSCI REP, V1, P203
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   DUYN JH, 1993, RADIOLOGY, V188, P277, DOI 10.1148/radiology.188.1.8511313
   GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Himmelseher S, 1998, CRIT CARE MED, V26, P2029, DOI 10.1097/00003246-199812000-00035
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80
   Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   NEDERGAARD M, 1991, J NEUROSCI, V11, P2489
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   PALJARVI L, 1984, ACTA NEUROPATHOL, V64, P89, DOI 10.1007/BF00695571
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PETITO CK, 1987, J CEREBR BLOOD F MET, V7, P625, DOI 10.1038/jcbfm.1987.115
   Phillis JW, 1999, NEUROSCI LETT, V272, P195, DOI 10.1016/S0304-3940(99)00584-4
   REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Sano M, 1998, ANN NEUROL, V44, P576
   Shanske Sara, 2003, NEUROLOGY, V60, P0
   SHOFFNER JM, 1990, CELL, V43, P1200
   SHUNGU DC, 2002, P INT SOC MAGN RESON, V10, P695
   STAUB F, 1993, J NEUROL SCI, V119, P79, DOI 10.1016/0022-510X(93)90194-4
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N
NR 29
TC 139
Z9 183
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD APR 27
PY 2004
VL 62
IS 8
BP 1297
EP 1302
DI 10.1212/01.WNL.0000120557.83907.A8
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 815UM
UT WOS:000221067200010
PM 15111665
DA 2024-11-01
ER

PT J
AU Burger, PA
   Steinborn, R
   Walzer, C
   Petit, T
   Mueller, M
   Schwarzenberger, F
AF Burger, PA
   Steinborn, R
   Walzer, C
   Petit, T
   Mueller, M
   Schwarzenberger, F
TI Analysis of the mitochondrial genome of cheetahs (<i>Acinonyx jubatus</i>) with neurodegenerative disease
SO GENE
LA English
DT Article
DE mitochondrial DNA; heteroplasmy; mitochondrial disease; myelopathy; real-time PCR; single nucleotide polymorphism
ID paternal inheritance; nuclear genome; control region; dna; sequence; encephalomyelopathy; heteroplasmy; myelopathy; mutations; muscle
AB The complete mitochondrial genome of Acinonyx jubatus was sequenced and mitochondrial DNA (mtDNA) regions were screened for polymorphisms as candidates for the cause of a neurodegenerative demyelinating disease affecting captive cheetahs. The mtDNA reference sequences were established on the basis of the complete sequences of two diseased and two nondiseased animals as well as partial sequences of 26 further individuals. The A. jubatus mitochondrial genome is 17,047-bp long and shows a high sequence similarity (91%) to the domestic cat. Based on single nucleotide polymorphisms (SNPs) in the control region (CR) and pedigree information, the 18 myelopathic and 12 non-myelopathic cheetahs included in this study were classified into haplotypes I, II and III. In view of the phenotypic comparability of the neurodegenerative disease observed in cheetahs and human mtDNA-associated diseases, specific coding regions including the tRNAs leucine UUR, lysine, serine UCN, and partial complex I and V sequences were screened. We identified a heteroplasmic and a homoplasmic SNP at codon 507 in the subunit 5 (MTND5) of complex I. The heteroplasmic haplotype I-specific valine to methionine substitution represents a nonconservative amino acid change and was found in 11 myelopathic and eight non-myelopathic cheetahs with levels ranging from 29% to 79%. The homoplasmic conservative amino acid substitution valine to alanine was identified in two myelopathic animals of haplotype II. In addition, a synonymous SNP in the codon 76 of the MTND4L gene was found in the single haplotype III animal. The amino acid exchanges in the MTND5 gene were not associated with the occurrence of neurodegenerative disease in captive cheetahs. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Vet Med, Dept Nat Sci, Inst Biochem, A-1210 Vienna, Austria.
   Univ Vet Med, Clin Dept Anim Breeding & Reprod, Genet Inst, A-1210 Vienna, Austria.
   Zoo Salzburg, A-5081 Anif, Austria.
   Zoo Palmyre, F-17570 Les Mathes, France.
C3 University of Veterinary Medicine Vienna; University of Veterinary Medicine Vienna
RP Univ Vet Med, Dept Nat Sci, Inst Biochem, Veterinaerpl 1, A-1210 Vienna, Austria.
EM Franz.Schwarzenberger@vu-wien.ac.at
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7
   Brenner O, 1997, ACTA NEUROPATHOL, V94, P390, DOI 10.1007/s004010050724
   Burger G, 2003, TRENDS GENET, V19, P709, DOI 10.1016/j.tig.2003.10.012
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Dayhoff MO, 1978, ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, V0, P345
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Driscoll CA, 2002, GENOME RES, V12, P414, DOI 10.1101/gr.185702
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Fleischer S, 1974, METHODS ENZYMOL, V31, P6
   Freeman AR, 2001, HEREDITY, V86, P355, DOI 10.1046/j.1365-2540.2001.00840.x
   Jellinger KA, 2003, J NEURAL TRANSM-SUPP, V0, P101
   Kotsch V, 2002, WIEN TIERARZTL MONAT, V89, P341
   Lopez JV, 1996, GENOMICS, V33, P229, DOI 10.1006/geno.1996.0188
   MARKERKRAUS L, 2001, 2000 2001 INT CHEETA, V0, P0
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Munson L, 1999, J ZOO WILDLIFE MED, V30, P342
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   PALMER AC, 1995, J SMALL ANIM PRACT, V36, P57, DOI 10.1111/j.1748-5827.1995.tb02822.x
   Ramakrishna C, 2002, J IMMUNOL, V168, P1204, DOI 10.4049/jimmunol.168.3.1204
   ROBERT N, 2003, ANN P AM ASS ZOO VET, V0, P139
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Steinborn R, 2000, NAT GENET, V25, P255, DOI 10.1038/77000
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   TOENNIESSEN JG, 1995, COMP CONT EDUC PRACT, V17, P271
   Tourmen Y, 2002, GENOMICS, V80, P71, DOI 10.1006/geno.2002.6798
   Walzer C, 2003, J ZOO WILDLIFE MED, V34, P36, DOI 10.1638/1042-7260(2003)34[0036:IAOMIC]2.0.CO;2
   WALZER C, 1998, P EURO ASS ZOO WILDL, V2, P267
   XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7
NR 32
TC 21
Z9 28
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD AUG 18
PY 2004
VL 338
IS 1
BP 111
EP 119
DI 10.1016/j.gene.2004.05.020
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 850EI
UT WOS:000223593600012
PM 15302412
DA 2024-11-01
ER

PT J
AU Hirano, M
   Martí, R
   Spinazzola, A
   Nishino, I
   Nishigaki, Y
AF Hirano, M
   Martí, R
   Spinazzola, A
   Nishino, I
   Nishigaki, Y
TI Thymidine phosphorylase deficiency causes MNGIE:: An autosomal recessive mitochondrial disorder
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
DE mitochondria; mitochondrial DNA; MNGIE; thymidine phosphorylase; thymidine and deoxyuridine
ID neurogastrointestinal encephalomyopathy mngie; deoxynucleotide carrier; multiple deletions; dna; depletion; kinase; toxicity; gene; mutations; fidelity
AB Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in the gene encoding thymidine phosphorylase (TP). The disease is characterized clinically by impaired eye movements, gastrointestinal dysmotility, cachexia, peripheral neuropathy, myopathy, and leukoencephalopathy. Molecular genetic studies of MNGIE patients' tissues have revealed multiple deletions, depletion, and site-specific point mutations of mitochondrial DNA. TP is a cytosolic enzyme required for nucleoside homeostasis. In MNGIE, TP activity is severely reduced and consequently levels of thymidine and deoxyuridine in plasma are dramatically elevated. We have hypothesized that the increased levels of intracellular thymidine and deoxyuridine cause imbalances of mitochondrial nucleotide pools that, in turn, lead to the mtDNA abnormalities. MNGIE was the first molecularly characterized genetic disorder caused by abnormal mitochondrial nucleoside/nucleotide metabolism. Future studies are likely to reveal further insight into this expanding group of diseases.
C1 Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Hosp Santo Crew, Dept Neurol, Barcelona, Spain.
   Natl Neurol Inst Carlo Besta, Div Mol Neurogenet, Milan, Italy.
   Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Tokyo, Japan.
C3 Columbia University; Fondazione IRCCS Istituto Neurologico Carlo Besta; National Center for Neurology & Psychiatry - Japan
RP Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
FU NICHD NIH HHS [R01HD37529] Funding Source: Medline; NINDS NIH HHS [P01NS11766] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2
   Brown NS, 1998, BIOCHEM J, V334, P1
   Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7
   CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   ELKOUNI MH, 1993, CANCER RES, V53, P3687
   Focher F, 2001, CURR CANCER DRUG TAR, V1, P141, DOI 10.2174/1568009013334232
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT I, 1988, NATURE, V331, P34
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KUNKEL TA, 1986, J BIOL CHEM, V261, P160
   Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Teitelbaum JE, 2002, J PEDIATR GASTR NUTR, V35, P377, DOI 10.1097/00005176-200209000-00029
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 39
TC 20
Z9 23
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PD OCT 15
PY 2004
VL 23
IS 8-9
BP 1217
EP 1225
DI 10.1081/NCN-200027485
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 871EY
UT WOS:000225113700029
PM 15571233
DA 2024-11-01
ER

PT J
AU Compston, A
AF Compston, A
TI 'The marvellous harmony of the nervous parts': The origins of multiple sclerosis
SO CLINICAL MEDICINE
LA English
DT Article
DE epidemiology; genetics; MHC; mitochondrial haplogroups; multiple sclerosis; neuromyelitis optica; optico-spinal; TH1; TH2; William Croone
ID mitochondrial-dna mutations; no pathogenic mutations; neuromyelitis-optica; association; mechanisms; infection; axons
AB Working in the 1660s, William Croone wrote on the nature of connections between nerve and muscle. A previously unknown copy of his essay, wrongly attributed to Thomas Willis, has recently come to light. Croone left the challenges of clinical neurology to his successors. The story of multiple sclerosis begins early in the nineteenth century. Despite much information on the aetiology and pathogenesis, the origins of that disease remain obscure. Here, the hypothesis is advanced - based on the epidemiology, clinical neurology, immunology and genetics of demyelinating disease, linked to European history and population genetics - that multiple sclerosis evolved from a related disorder, neuromyelitis optica (or Devic's disease). Genetic drift and stratification altered the immune response to a common pathogen and changed the disease, phenotype. Against this background, the sustained epidemic of multiple sclerosis arose when cultural changes led to a subtle but crucial alteration in the age at which genetically vulnerable individuals are exposed to Epstein Barr infection.
C1 Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England.
C3 University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital
RP Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Hills Rd, Cambridge CB2 2QQ, England.
CR Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853
   Cabre P, 2001, NEUROLOGY, V56, P507, DOI 10.1212/WNL.56.4.507
   Cock H, 1997, J NEUROL NEUROSUR PS, V62, P85, DOI 10.1136/jnnp.62.1.85
   COMPSTON DAS, 1986, BRAIN, V109, P325, DOI 10.1093/brain/109.2.325
   COSNETT JE, 1981, MED HYPOTHESES, V7, P61, DOI 10.1016/0306-9877(81)90022-0
   Cree BAC, 2002, SEMIN NEUROL, V22, P105, DOI 10.1055/s-2002-36534
   CROONE W, 1900, V1667, V0, P45
   DEAN G, 1994, J NEUROL NEUROSUR PS, V57, P1064, DOI 10.1136/jnnp.57.9.1064
   DEVIC E, 1894, B MED LYON, V35, P18
   Firth D, 1948, THE CASE OF AUGUSTUS D ESTE, V0, P0
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HEYER E, 1995, AM J HUM GENET, V56, P1450
   Hwang JM, 2001, OPHTHALMOLOGICA, V215, P398, DOI 10.1159/000050896
   JAIN S, 1985, NEUROEPIDEMIOLOGY, V4, P96, DOI 10.1159/000110220
   John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781
   Kalman B, 1997, MULT SCLER, V2, P279
   Kalman B, 2002, ANN NEUROL, V51, P661, DOI 10.1002/ana.10166
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121
   Kenealy SJ, 2003, J NEUROIMMUNOL, V143, P7, DOI 10.1016/j.jneuroim.2003.08.005
   Kira J, 2003, LANCET NEUROL, V2, P117, DOI 10.1016/S1474-4422(03)00308-9
   KURZKE JF, 1968, J NEUROL SCI, V6, P463
   Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835
   Le Souëf PN, 2000, LANCET, V356, P242
   Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
   Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151
   MARTYN CN, 1993, J NEUROL NEUROSUR PS, V56, P167, DOI 10.1136/jnnp.56.2.167
   MayrWohlfart U, 1996, ACTA NEUROL SCAND, V94, P167, DOI 10.1111/j.1600-0404.1996.tb07048.x
   McGeoch DJ, 2001, PHILOS T ROY SOC B, V356, P421, DOI 10.1098/rstb.2000.0775
   Mirsattari SM, 2001, NEUROLOGY, V56, P317, DOI 10.1212/WNL.56.3.317
   Mitra DK, 1997, CLIN IMMUNOL IMMUNOP, V82, P60, DOI 10.1006/clin.1996.4282
   Modi G, 2001, J NEUROL NEUROSUR PS, V70, P500, DOI 10.1136/jnnp.70.4.500
   Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055
   NISHIMURA M, 1995, NEUROLOGY, V45, P1333, DOI 10.1212/WNL.45.7.1333
   OKINAKA S, 1958, NEUROLOGY, V8, P756, DOI 10.1212/WNL.8.10.756
   OSUNTOKUN BO, 1973, TROPICAL NEUROLOGY, V0, P161
   Papais-Alvarenga RM, 2002, J NEUROL NEUROSUR PS, V73, P429, DOI 10.1136/jnnp.73.4.429
   POSER CM, 1994, ANN NEUROL, V36, PS231, DOI 10.1002/ana.410360810
   Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149
   Reynier P, 1999, EUR J HUM GENET, V7, P404, DOI 10.1038/sj.ejhg.5200293
   Richards M, 1996, AM J HUM GENET, V59, P185
   RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319
   Roberts D F, 1986, ANTHROPOL ANZ, V44, P93
   SHIBASAKI H, 1981, J NEUROL SCI, V49, P253, DOI 10.1016/0022-510X(81)90083-6
   Smith KJ, 2001, ANN NEUROL, V49, P470
   SUTHERLAND JM, 1956, BRAIN, V79, P635, DOI 10.1093/brain/79.4.635
   Sykes B, 1999, PHILOS T ROY SOC B, V354, P131, DOI 10.1098/rstb.1999.0366
   TAN CT, 1988, ARCH NEUROL-CHICAGO, V45, P624, DOI 10.1001/archneur.1988.00520300042016
   VRIES RRPD, 1979, J IMMUNOGENET, V6, P271
   Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2
   Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003
   Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107
   Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031
   YU YL, 1989, BRAIN, V112, P1445, DOI 10.1093/brain/112.6.1445
NR 60
TC 20
Z9 24
U1 0
U2 1
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD JUL-AUG 15
PY 2004
VL 4
IS 4
BP 346
EP 354
DI 10.7861/clinmedicine.4-4-346
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 852DJ
UT WOS:000223735100012
PM 15372896
DA 2024-11-01
ER

PT J
AU McDonnell, MT
   Schaefer, AM
   Blakely, EL
   McFarland, R
   Chinnery, PF
   Turnbull, DM
   Taylor, RW
AF McDonnell, MT
   Schaefer, AM
   Blakely, EL
   McFarland, R
   Chinnery, PF
   Turnbull, DM
   Taylor, RW
TI Noninvasive diagnosis of the 3243A&gt;G mitochondrial DNA mutation using urinary epithelial cells
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; MELAS; 3243A > G mutation; noninvasive diagnosis
ID mtdna mutation; melas; gene; a3243g; blood; decrease; adult; merrf; load
AB The 3243A>G mutation is one of the most frequently observed mutations of mitochondrial DNA (mtDNA), and is associated with numerous clinical presentations including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO) and diabetes and deafness. The routine diagnosis of the 3243A>G mutation in blood is difficult as mutation levels are known to decrease in this tissue over time, while in some patients it may be absent. We have directly compared the levels of the 3243A>G mutation in skeletal muscle, blood and urinary epithelial cells in 18 patients and observed a striking correlation between the mutation load in postmitotic muscle and urinary epithelium, a mitotic tissue. These data strongly support the use of urinary epithelial cells as the tissue of choice in the noninvasive diagnosis of the 3243A>G mutation.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
CR Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 1997, LANCET, V350, P560, DOI 10.1016/S0140-6736(97)05005-8
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   KOTSIMBOS N, 1994, HUM MUTAT, V4, P132, DOI 10.1002/humu.1380040207
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   tHart LM, 1996, HUM MUTAT, V7, P193
NR 20
TC 74
Z9 80
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP 15
PY 2004
VL 12
IS 9
BP 778
EP 781
DI 10.1038/sj.ejhg.5201216
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 847OD
UT WOS:000223403900014
PM 15199381
DA 2024-11-01
ER

PT J
AU Michaelides, M
   Moore, AT
AF Michaelides, M
   Moore, AT
TI The genetics of strabismus
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Review
ID progressive external ophthalmoplegia; kearns-sayre-syndrome; mitochondrial-dna deletions; extraocular-muscles type-2; duanes retraction syndrome; superior oblique palsy; congenital fibrosis; mobius-syndrome; chromosome-translocation; retinitis-pigmentosa
AB Strabismus ( misalignment of the eyes; also known as "squint'') comprises a common heterogeneous group of disorders characterised by a constant or intermittent ocular deviation often associated with amblyopia (uniocular failure of normal visual development) and reduced or absent binocular vision. The associated poor cosmetic appearance may also interfere with social and psychological development. Extensive twin and family studies suggest a significant genetic component to the aetiology of strabismus. The complexity of the molecular basis of strabismus is now beginning to be elucidated with the identification of genetic loci and disease causing genes. Currently greater insights have been gained into the incomitant subtype ( differing magnitude of ocular misalignment according to direction of gaze), whereas less is known about the pathogenesis of the more common childhood concomitant strabismus. It is hoped that a greater understanding of the molecular genetics of these disorders will lead to improved knowledge of disease mechanisms and ultimately to more effective treatment. The aim of this paper is to review current knowledge of the molecular genetics of both incomitant and concomitant strabismus.
C1 UCL, Inst Ophthalmol, London EC1V 9EL, England.
   Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust
RP UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM tony.moore@ucl.ac.uk
CR Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821
   ALDRICH MS, 1987, NEUROLOGY, V37, P1369, DOI 10.1212/WNL.37.8.1369
   Alexandrakis G, 2001, OPHTHALMOL CLIN NORTH AM, V14, P407, DOI 10.1016/S0896-1549(05)70238-8
   Appukuttan B, 1999, AM J HUM GENET, V65, P1639, DOI 10.1086/302656
   ASTLE WF, 1985, ARCH OPHTHALMOL-CHIC, V103, P532
   Bhola RM, 2001, EYE, V15, P479, DOI 10.1038/eye.2001.159
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Botelho PJ, 1996, OPHTHALMOLOGY, V103, P1508, DOI 10.1016/S0161-6420(96)30475-2
   Calabrese G, 2000, EUR J HUM GENET, V8, P319, DOI 10.1038/sj.ejhg.5200461
   CHEW CKS, 1995, AM J OPHTHALMOL, V119, P807, DOI 10.1016/S0002-9394(14)72795-3
   CHEW E, 1994, ARCH OPHTHALMOL-CHIC, V112, P1349, DOI 10.1001/archopht.1994.01090220099030
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   CRONE RA, 1956, ARCH OPHTHALMOL-CHIC, V55, P455, DOI 10.1001/archopht.1956.00930030459002
   CULLEN P, 1993, AM J MED GENET, V47, P925, DOI 10.1002/ajmg.1320470623
   CURRIE S, 1970, BRAIN, V93, P193, DOI 10.1093/brain/93.1.193
   DEGOUL F, 1991, J NEUROL SCI, V101, P168, DOI 10.1016/0022-510X(91)90042-6
   Doherty EJ, 1999, INVEST OPHTH VIS SCI, V40, P1687
   DONAHUE SP, 1993, OPHTHALMIC PAED GEN, V14, P17, DOI 10.3109/13816819309087618
   ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69
   Engle EC, 1997, ANN NEUROL, V41, P314, DOI 10.1002/ana.410410306
   Engle EC, 2002, BMC GENET, V3, P0, DOI 10.1186/1471-2156-3-3
   Evans JC, 2000, HUM GENET, V106, P636, DOI 10.1007/s004390050036
   Fujiwara H, 2003, ACTA MED OKAYAMA, V57, P109
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOWAN M, 1968, BR ORTHOPTIC J, V25, P91
   GRAHAM PA, 1974, BRIT J OPHTHALMOL, V58, P224, DOI 10.1136/bjo.58.3.224
   Grutzner I P, 1970, SURV OPHTHALMOL, V14, P441
   Gutowski N J, 2003, NEUROMUSCUL DISORD, V13, P573, DOI 10.1016/S0960-8966(03)00043-9
   HAKIM RB, 1992, ARCH OPHTHALMOL-CHIC, V110, P1459, DOI 10.1001/archopht.1992.01080220121033
   Hansrote S, 2002, J NEUROL SCI, V197, P63, DOI 10.1016/S0022-510X(02)00048-5
   HARRIS DJ, 1986, OPHTHALMOLOGY, V93, P88
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOTCHKISS MG, 1980, ARCH OPHTHALMOL-CHIC, V98, P870, DOI 10.1001/archopht.1980.01020030864013
   HU DN, 1987, J MED GENET, V24, P584, DOI 10.1136/jmg.24.10.584
   Isenberg S, 1983, J PEDIATR OPHTHALMOL STRABISMUS, V20, P235
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   KATZ NNK, 1981, J PEDIAT OPHTH STRAB, V18, P32
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Kremer H, 1996, HUM MOL GENET, V5, P1367, DOI 10.1093/hmg/5.9.1367
   Lammens M, 1998, CLIN GENET, V54, P136
   Lee A G, 2001, STRABISMUS, V9, P137, DOI 10.1076/stra.9.3.137.6758
   Mackey DA, 2002, HUM GENET, V110, P510, DOI 10.1007/s00439-002-0707-5
   Matsuo T, 2002, JPN J OPHTHALMOL, V46, P59, DOI 10.1016/S0021-5155(01)00465-8
   Matsuo T, 2001, J PEDIAT OPHTH STRAB, V38, P78, DOI 10.11618/adhesion.38.78
   Maumenee I H, 1986, TRANS AM OPHTHALMOL SOC, V84, P85
   Mohney BG, 1998, OPHTHALMOLOGY, V105, P846, DOI 10.1016/S0161-6420(98)95024-2
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nakano M, 2001, NAT GENET, V29, P315, DOI 10.1038/ng744
   Nishikawa M, 1997, CLIN GENET, V51, P122
   OKeefe M, 2001, BRIT J OPHTHALMOL, V85, P357, DOI 10.1136/bjo.85.3.357
   Parikh V, 2003, P NATL ACAD SCI USA, V100, P12283, DOI 10.1073/pnas.2035118100
   PAUL TO, 1994, OPHTHALMIC GENET, V15, P1, DOI 10.3109/13816819409056905
   Pizzuti A, 2002, INVEST OPHTH VIS SCI, V43, P3609
   Podgor MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P739, DOI 10.1001/archopht.1996.01100130731018
   PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8
   RAMSAY J, 1980, BRIT J OPHTHALMOL, V64, P518, DOI 10.1136/bjo.64.7.518
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   RESKENIELSEN E, 1976, ACTA OPHTHALMOL, V54, P553
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   SHAULY Y, 1993, J PEDIATR OPHTHALMOL, V30, P178
   SLEE JJ, 1991, J MED GENET, V28, P413, DOI 10.1136/jmg.28.6.413
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sudarshan A, 1985, PEDIATR NEUROL, V1, P180, DOI 10.1016/0887-8994(85)90061-X
   Taira Y, 2003, JPN J OPHTHALMOL, V47, P208, DOI 10.1016/S0021-5155(02)00685-8
   TOWFIGHI J, 1979, ACTA NEUROPATHOL, V48, P11, DOI 10.1007/BF00691785
   Van Der Zwaag B, 2002, J MED GENET, V39, PE30, DOI 10.1136/jmg.39.6.e30
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Versteegh FGA, 2000, CLIN DYSMORPHOL, V9, P135, DOI 10.1097/00019605-200009020-00013
   Verzijl HTFM, 1999, AM J HUM GENET, V65, P752, DOI 10.1086/302539
   VINCENT C, 1994, HUM MOL GENET, V3, P1859, DOI 10.1093/hmg/3.10.1859
   Wackerhagen MV, 1986, AM ORTHOPT J, V36, P113
   Wang SM, 1998, AM J HUM GENET, V63, P517, DOI 10.1086/301980
   Wang Zhao-xia, 2003, ZHONGHUA YI XUE YI CHUAN XUE ZA ZHI, V20, P273
   Wilmore HP, 2000, HUM GENET, V106, P269, DOI 10.1007/s004390051037
   WORTHAM E, 1988, AM J OPHTHALMOL, V105, P562
   Yamada K, 2003, NAT GENET, V35, P318, DOI 10.1038/ng1261
   Yu CBO, 2002, BRIT J OPHTHALMOL, V86, P854, DOI 10.1136/bjo.86.8.854
   ZITER FA, 1977, ARCH NEUROL-CHICAGO, V34, P437, DOI 10.1001/archneur.1977.00500190071011
NR 83
TC 31
Z9 32
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP 15
PY 2004
VL 41
IS 9
BP 641
EP 646
DI 10.1136/jmg.2004.021667
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 850TJ
UT WOS:000223635200001
PM 15342692
DA 2024-11-01
ER

PT J
AU Kornblum, C
   Kunz, WS
   Klockgether, T
   Roggenkämper, P
   Schröder, R
AF Kornblum, C
   Kunz, WS
   Klockgether, T
   Roggenkämper, P
   Schröder, R
TI Diagnostic value of mitochondrial DNA analysis in chronic progressive external ophthalmoplegia (CPEO)
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE CPEO; mitochondrial DNA deletion; diplopia
ID deletions; diseases; disorders; features; defects; muscle
AB Background: Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial cytopathy presenting with ptosis and external ophthalmoparesis. Mitochondrial disorders are characterized by a broad clinical spectrum and genetic background with marked genotype/phenotype variability. The routine diagnostic work-up usually includes clinical and laboratory examinations as well as histological and histochemical analysis of skeletal muscle biopsy. In our case only an additional molecular biological examination allowed the diagnosis of CPEO. Patient and Methods: We report a 35-year-old woman with a 7-years history of slowly progressive diplopia due to impaired ocular motility and bilateral ptosis. We performed ophthalmological and neurological examinations, laboratory testing, lower limb skeletal muscle biopsy including histological and histochemical investigations, biochemical analysis of respiratory chain enzymes in skeletal muscle homogenate and molecular genetic testing of skeletal muscle DNA. Results: Although clinical, laboratory, histological and biochemical analyses did not give any hints suggesting a mitochondrial cytopathy, molecular genetic testing of total DNA from skeletal muscle tissue by Southern blot analysis finally revealed a 3.8 kb mitochondrial DNA deletion with a degree of heteroplasmy of 45%. Conclusions: In patients with unexplained binocular diplopia, oculo-motor deficits and/or acquired ptosis, an underlying mitochondrial cytopathy should be considered. Even in the case of inconspicuous skeletal muscle histology and biochemistry, molecular genetic testing of skeletal muscle DNA is advisable in order to establish the diagnosis.
C1 Univ Bonn, Neurol Klin & Poliklin, Fak Med, D-53105 Bonn, Germany.
   Univ Bonn, Fak Med, Klin & Poliklin Epileptol, D-5300 Bonn, Germany.
   Univ Bonn, Fak Med, Klin & Poliklin Augenheilkunde, D-5300 Bonn, Germany.
C3 University of Bonn; University of Bonn; University of Bonn
RP Kornblum, C (corresponding author), Univ Bonn, Neurol Klin & Poliklin, Fak Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM cornelia.kornblum@ukb.uni-bonn.de
CR Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   DiMauro S, 2001, SEMIN NEUROL, V21, P251, DOI 10.1055/s-2001-17942
   DUBOVITZ V, 1985, MUSCLE BIOPSY, V0, P0
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   OKULLA T, 2004, IN PRESS GRAEF ARCH, V0, P0
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Simon DK, 1999, ANNU REV MED, V50, P111
   Sommer F, 2003, KLIN MONATSBL AUGENH, V220, P315, DOI 10.1055/s-2003-39428
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 14
TC 6
Z9 7
U1 0
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD DEC 15
PY 2004
VL 221
IS 12
BP 1057
EP 1061
DI 10.1055/s-2004-813830
PG 5
WC Ophthalmology
SC Ophthalmology
GA 886SW
UT WOS:000226249900009
PM 15599814
DA 2024-11-01
ER

PT J
AU Christensen, ER
   Stegger, M
   Jensen-Fangel, S
   Laursen, AL
   Ostergaard, L
AF Christensen, ER
   Stegger, M
   Jensen-Fangel, S
   Laursen, AL
   Ostergaard, L
TI Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: A randomized, double-blind, placebo-controlled pilot study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID reverse-transcriptase inhibitors; subcutaneous fat; nucleoside; toxicity; therapy; infection; myopathy; depletion; disorder; damage
AB Background. Mitochondrial toxicity can be induced by reverse-transcriptase inhibitors, and an association between levels of mitochondrial DNA (mtDNA) per cell and lipodystrophy, peripheral neuropathy, and HIV infection per se has been suggested. Studies aimed at increasing the oxidative capacity in HIV-infected patients have been sparse. Methods. Levels of mtDNA in fat and peripheral blood mononuclear cells (PBMCs) from 25 HIV infected patients and 10 healthy control subjects were studied with real-time PCR analysis. A placebo-controlled and doubleblind design was used to assign individuals to receive either 100 mg of coenzyme Q twice daily for 3 months or a matching placebo regimen. Levels of mtDNA and other parameters were assessed before and after the intervention period. Results. The mean number of mtDNA copies per cell was lower in fat tissue obtained from patients with peripheral neuropathy (1547 mtDNA copies/cell; P = .045), patients with lipodystrophy (1732 mtDNA copies/cell; P = .003) and in HIV patients with no complications associated with highly active antiretroviral therapy (2935 mtDNA copies/cell; P = .078), compared with healthy control subjects (6198 mtDNA copies/cell). No clear difference was seen in mtDNA content in PBMCs. Coenzyme Q therapy improved the general condition of patients (P = .005) and caused a reversible increase in peripheral neuropathy pain (P = .048). Compared with placebo, treatment with coenzyme Q did not result in changes in mtDNA levels in fat cells or in PBMCs after the treatment period. Conclusions. Levels of mtDNA in fat tissue, but not in PBMCs, were associated with peripheral neuropathy and lipodystrophy. High-dose coenzyme Q therapy increased well-being in asymptomatic HIV-infected patients and those with lipodystrophy, as well as in control subjects, but aggravated pain in patients with peripheral neuropathy.
C1 Aarhus Univ Hosp, Skejby Sygehus, Dept Infect Dis, Res Unit Q, DK-8200 Aarhus N, Denmark.
C3 Aarhus University
RP Aarhus Univ Hosp, Skejby Sygehus, Dept Infect Dis, Res Unit Q, DK-8200 Aarhus N, Denmark.
EM eva.rabing@studmed.au.dk
CR Belloso WH, 2003, JAIDS-J ACQ IMM DEF, V32, P104, DOI 10.1097/00126334-200301010-00015
   Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8
   Bril V, 2002, DIABETIC MED, V19, P661, DOI 10.1046/j.1464-5491.2002.00759.x
   Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4
   Carter V M, 2001, HIV MED, V2, P174, DOI 10.1046/j.1468-1293.2001.00073.x
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Dalakas MC, 2001, J PERIPHER NERV SYST, V6, P14, DOI 10.1046/j.1529-8027.2001.006001014.x
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   GALLI M, 2003, PROGR ABSTR 40 INT C, V0, P0
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Kakuda TN, 1999, AIDS, V13, P2311, DOI 10.1097/00002030-199911120-00019
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002
   Masini A, 1999, J NEUROL SCI, V166, P131, DOI 10.1016/S0022-510X(99)00126-4
   Miller Alan L, 2003, ALTERN MED REV, V8, P7
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Polo R, 2003, JAIDS-J ACQ IMM DEF, V34, P32, DOI 10.1097/00126334-200309010-00004
   Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   SIMPSON DM, 1995, J ACQ IMMUN DEF SYND, V9, P153
   van der Valk M, 2001, AIDS, V15, P847, DOI 10.1097/00002030-200105040-00005
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
   Walker Ulrich A, 2003, J HIV THER, V8, P32
   White AJ, 2001, SEX TRANSM INFECT, V77, P158, DOI 10.1136/sti.77.3.158
NR 27
TC 23
Z9 25
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2004
VL 39
IS 9
BP 1371
EP 1379
DI 10.1086/424881
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JG
UT WOS:000227491800014
PM 15494915
DA 2024-11-01
ER

